

- Aalders, JG, 1381  
 Abak, T, 35P(ab)  
 Abbo, M, 139P(ab)  
 Abdel-Dayem, HM, 23P(ab), 97P(ab), 108P(ab), 109P(ab), 255P(ab), 654, 1357  
 Abdul-Karmin, F, 95P(ab)  
 Abe, T, 1518  
 Abe, Y, 214P(ab)  
 Abella-Columna, E, 122P(ab), 134P(ab), 135P(ab)  
 Abi-Dargham, A, 13P(ab), 55P(ab), 82P(ab), 207P(ab)  
 Abitbol, C, 28P(ab)  
 Abrams, D, 124P(ab)  
 Abu-Judeh, H, 97P(ab)  
 Abu-Judeh, HH, 629, 654, 1357  
 Aburano, T, 57P(ab), 86P(ab), 126P(ab), 156P(ab), 157P(ab)  
 Acampa, W, 17P(ab), 101P(ab), 634  
 Acio, E, 116P(ab)  
 Acton, PD, 82P(ab), 83P(ab), 204P(ab)  
 Adachi, I, 201P(ab)  
 Adalet, I, 1897  
 Adam, G, 249P(ab), 815  
 Adam, MJ, 231P(ab)  
 Adams, BK, 272P(ab)  
 Adams, HR, 36P(ab), 135P(ab), 136P(ab)  
 Adams, S, 66P(ab), 1155  
 Adams, WD, 182P(ab)  
 Adelson, PD, 211P(ab)  
 Adelstein, SJ, 18N(5), 111P(ab), 183P(ab), 186P(ab), 245P(ab), 1148  
 Adelwöhrer, C, 1508  
 Adityanjee, 207P(ab)  
 Adler, LP, 95P(ab), 123P(ab)  
 Adnot, S, 90P(ab)  
 Afonso, Y, 137P(ab)  
 Afriyie, MO, 263P(ab)  
 Agarwal, MS, 270P(ab)  
 Agnew, JE, 85P(ab), 129P(ab), 193P(ab)  
 Agostini, D, 1129, 1841  
 Agrawal, S, 219P(ab)  
 Agresti, R, 4, 254P(ab)  
 Aguadé-Bruix, S, 751  
 Ahlberg, AW, 76P(ab), 2019  
 Ahmed, K, 53P(ab), 236P(ab), 663  
 Ahmed, SS, 4P(ab)  
 Ahn, BC, 253P(ab), 1401  
 Ahn, HS, 267P(ab)  
 Aiello, V, 57P(ab)  
 Aigbirhio, FI, 231P(ab)  
 Aigner, RM, 790, 2153  
 Aihara, Y, 153P(ab)  
 Ainslie, J, 11P(ab)  
 Akabani, G, 1376  
 Akagi, N, 191P(ab), 216P(ab), 242P(ab)  
 Akaki, S, 529, 2095  
 Akamune, A, 166P(ab)  
 Akhurst, T, 67P(ab), 134P(ab), 135P(ab), 253P(ab)  
 Akiyama, H, 129P(ab)  
 Akkoclu, A, 2116  
 Akpinar, O, 2116  
 Aktas, A, 197P(ab)  
 Alagöl, F, 1897  
 Alauddin, MM, 131P(ab), 230P(ab), 232P(ab)  
 Alavi, A, 5P(ab), 6P(ab), 10P(ab), 33P(ab), 46P(ab), 55P(ab), 56P(ab), 71P(ab), 81P(ab), 95P(ab), 126P(ab), 146P(ab), 164P(ab), 180P(ab), 181P(ab), 198P(ab), 201P(ab), 206P(ab), 210P(ab), 214P(ab), 221P(ab), 231P(ab), 249P(ab), 255P(ab), 265P(ab), 268P(ab), 274P(ab), 1363, 2069, 2087  
 Alavi, J, 146P(ab), 255P(ab)  
 Alay, R, 57P(ab)  
 Albert, MS, 965  
 Alberti, D, 57P(ab)  
 Alberts, AS, 2110  
 Albin, RL, 15P(ab), 125P(ab), 202P(ab), 210P(ab)  
 Aldershile, J, 89P(ab)  
 Alderson, PO, 543  
 Alexander, C, 1551  
 Alexandrides, T, 1433  
 Alexoff, D, 238P(ab)  
 Alger, JR, 211P(ab)  
 Ali, A, 1335  
 Allemann, L, 118P(ab)  
 Allen, L, 1388  
 Allen, S, 73P(ab)  
 Allen-Auerbach, M, 60P(ab), 90P(ab), 94P(ab)  
 Allgayer, B, 1398  
 Allman, K, 361, 1095  
 Almeida, MATM, 221P(ab)  
 Almeida, P, 61P(ab), 168P(ab)  
 Almoguera, I, 624  
 Al-Nafisi, N, 258P(ab)  
 Aloj, L, 67P(ab), 80P(ab), 98P(ab), 251P(ab), 786  
 Alomk, PJ, 155P(ab)  
 Alonso, O, 137P(ab)  
 Alper, E, 1191  
 Alpert, NM, 46P(ab), 66P(ab), 89P(ab), 167P(ab), 168P(ab), 195P(ab), 203P(ab), 205P(ab), 238P(ab)  
 Al-Sugair, A, 108P(ab), 109P(ab)  
 Altchoefer, C, 263  
 Al-Tikriti, M, 136P(ab)  
 Alvarez, I, 15  
 Alyafei, S, 53P(ab), 236P(ab), 663  
 Al-Zaabi, K, 28P(ab)  
 Amador, JF, 242P(ab)  
 Amano, S, 53P(ab), 663, 1424  
 Amanullah, A, 116P(ab)  
 Ambrose, JA, 18P(ab)  
 Ametamey, SM, 118P(ab)  
 Amin, K, 43P(ab)  
 Amin, R, 276P(ab)  
 Amoachi, GS, 34P(ab)  
 Amols, H, 48P(ab)  
 Andersen, T, 222P(ab)  
 Anderson, B, 24P(ab)  
 Anderson, CJ, 63P(ab), 91P(ab), 104P(ab), 105P(ab), 1944  
 Anderson, DM, 190P(ab)  
 Ando, A, 161P(ab)  
 Ando, T, 1424  
 Andreato, M, 9P(ab), 52P(ab), 92P(ab)  
 Andreas, J, 83P(ab)  
 Andreff, M, 246P(ab)  
 Angelberger, P, 39P(ab), 77P(ab), 223P(ab), 246P(ab), 1570, 1575, 1907, 1928, 2090  
 Angermann, C, 153P(ab)  
 Angrist, B, 100P(ab)
- Aninipot, R, 245P(ab)  
 Anjilvel, S, 55P(ab), 167P(ab)  
 Annala, AJ, 278P(ab)  
 Antebi, E, 1802  
 Antevska, E, 1605  
 Antin, JH, 187P(ab)  
 Antonietti, T, 156P(ab)  
 Antonini, A, 1521  
 Antonyshyn, OM, 98P(ab)  
 Aoki, E, 163P(ab)  
 Aoki, J, 53P(ab), 541  
 Aoki, S, 1630  
 Aoyagi, K, 53P(ab), 663  
 Aoyama, T, 59P(ab)  
 Apostolopoulos, DJ, 1433  
 Apparu, M, 50P(ab)  
 Appel, RG, 1454  
 Araha, Y, 214P(ab)  
 Arahi, T, 266  
 Araki, T, 266  
 Arano, Y, 217P(ab), 220P(ab), 224P(ab), 244P(ab)  
 Arashiro, K, 156P(ab)  
 Arata, LK, 38P(ab)  
 Araujo, LI, 46P(ab), 120P(ab), 180P(ab), 221P(ab), 232P(ab), 2069  
 Arbab, AS, 266  
 Areeda, J, 62P(ab), 103P(ab)  
 Arikan, Z, 304  
 Armstrong, JA, 28P(ab)  
 Arnello, F, 2015(lc)  
 Arnold, S, 26P(ab), 27P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab), 109P(ab), 654  
 Athanasoulis, T, 156P(ab)  
 Atik, E, 57P(ab)  
 Atkins, FA, 1617  
 Atsumi, H, 582  
 Attay, S, 255P(ab)  
 Aubert, B, 1590  
 Aubier, M, 44P(ab)  
 Auer, C, 109P(ab)  
 Auerbach, M, 162P(ab)  
 Aull, S, 978  
 Aurell, M, 1297  
 Aurengo, A, 735  
 Aurisch, R, 118P(ab), 2141  
 Austin, G, 203P(ab)  
 Avril, N, 1398  
 Awasthi, VD, 58P(ab), 125P(ab), 1089  
 Axworthy, D, 71P(ab), 91P(ab)  
 Ayabe, K, 247P(ab), 248P(ab)  
 Ayesha, A, 1810  
 Azeka, E, 57P(ab)  
 Azmoodeh, M, 54P(ab)  
 Azuma, N, 157P(ab)  
 Baas, P, 1074  
 Baba, K, 259P(ab)  
 Babatasi, G, 1129, 1841  
 Babich, JW, 58P(ab), 66P(ab), 195P(ab), 220P(ab), 223P(ab), 233P(ab), 238P(ab), 239P(ab), 240P(ab), 266P(ab), 267P(ab)  
 Bacharach, SL, 46P(ab), 80P(ab), 98P(ab), 103P(ab), 141P(ab), 160P(ab), 179P(ab)  
 Bachelot, I, 1172  
 Bacher-Stier, C, 87P(ab), 104P(ab)  
 Bachman, W, 75P(ab), 139P(ab)  
 Backfrieder, W, 167P(ab), 1166  
 Backhaus, M, 265P(ab)  
 Backlin, C, 982  
 Badawi, RD, 178P(ab)  
 Bader, JB, 1551  
 Bading, JR, 131P(ab), 232P(ab)  
 Bachre, M, 108P(ab)  
 Baert, L, 269P(ab)  
 Baghaei, H, 93P(ab)  
 Bahk, Y-W, 33P(ab), 130, 1444  
 Bai, C, 120P(ab), 124  
 Baidoo, KE, 7P(ab)  
 Baidoo, N, 186P(ab)  
 Bailey, AG, 98P(ab)  
 Bailey, DL, 73P(ab)  
 Baille, G, 928(lc)  
 Baiocchi, P, 875  
 Bajaafar, F, 1452  
 Bakale, G, 95P(ab)  
 Bakheet, SMB, 234, 1452  
 Bakker, W, 39P(ab), 63P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Arocha, LAT, 1918  
 Arroliga, A, 43P(ab)  
 Arslan, N, 199P(ab)  
 Arwert, F, 262P(ab)  
 Asada, N, 1179  
 Asenbaum, S, 613  
 Ashburn, W, 23P(ab), 132P(ab), 139P(ab)  
 Ashburner, J, 1696  
 Ashby, CR, 99P(ab)  
 Ashida, A, 201P(ab)  
 Atalay, Y, 1703  
 Atasever, T, 304  
 Atavci, S, 1  
 Atay, S, 23P(ab), 97P(ab

- Beijnen, JH, 30P(ab)  
 Bekdik, CF, 199P(ab), 1021  
 Belaklief, A, 209P(ab), 1521  
 Belezzuoli, E, 132P(ab)  
 Bell, RA, 7P(ab)  
 Bellegrun, A, 150P(ab)  
 Bellemann, ME, 165P(ab),  
     166P(tab)  
 Beller, GA, 115P(ab), 160P(ab)  
 Bellmas, L, 140P(ab)  
 Belmatoug, N, 44P(ab)  
 Benali, H, 61P(ab), 179P(ab)  
 Bénard, F, 33P(ab), 56P(ab),  
     81P(ab), 126P(ab), 146P(ab),  
     164P(ab), 210P(ab), 255P(ab),  
     2087  
 Benazzouz, F, 1214  
 Bencherif, B, 40P(ab), 99P(ab),  
     207P(ab)  
 Bender, H, 135P(ab), 151P(ab),  
     269P(ab), 1551, 1903  
 Bendtrem, B, 61P(ab), 71P(ab),  
     168P(ab), 205P(ab), 229P(ab)  
 Bengel, F, 56P(ab), 128P(ab),  
     161P(ab)  
 Ben-Haim, S, 16P(ab), 59P(ab)  
 Benkelfat, C, 83P(ab)  
 Benkert, O, 83P(ab)  
 Bennett, JA, 222P(ab)  
 Bennett, S, 7P(ab)  
 Bennink, R, 269P(ab)  
 Benoit, T, 152P(ab)  
 Bense, S, 110P(ab)  
 Bentti, R, 58P(ab), 218P(ab)  
 Bentourkia, M, 57P(ab), 97P(ab)  
 Benz, P, 83P(ab)  
 Berdichevsky, D, 168P(ab)  
 Berent, S, 96P(ab)  
 Berg, GEB, 357, 2195(le)  
 Berger, HG, 1030  
 Berger, MS, 440  
 Bergman, AM, 146P(ab)  
 Bergman, J, 141P(ab)  
 Bergmann, H, 167P(ab),  
     198P(ab)  
 Bergmans, P, 1143, 1879  
 Bergström, E, 982  
 Bergström, M, 982, 1273  
 Bergström-Pettermann, E, 1273  
 Berk, AJ, 35P(ab), 53P(ab),  
     2003  
 Berman, DS, 3P(ab), 62P(ab),  
     87P(ab), 101P(ab), 102P(ab),  
     103P(ab), 104P(ab), 115P(ab),  
     116P(ab), 154P(ab), 253P(ab)  
 Berman, R, 40P(ab)  
 Bernard, B, 39P(ab), 63P(ab),  
     233P(ab), 261P(ab)  
 Bernard, E, 27P(ab), 311  
 Bernard, EJ, 1428, 1983  
 Bernard, HF, 62P(ab), 264P(ab)  
 Bernard, X, 74P(ab)  
 Bernardini, GL, 149P(ab)  
 Bernier, B, 240P(ab)  
 Bernier, H, 17P(ab)  
 Bernstein, MP, 99P(ab)  
 Bernstein, T, 214P(ab)  
 Béron-Gaillard, N, 825  
 Berridge, MS, 1972, 2048  
 Berrocal, JO, 1830(le)  
 Berrouschot, J, 213P(ab)  
 Berry, CR, 47P(ab)  
 Berry, G, 8P(ab), 160P(ab)  
 Bertelli, P, 215P(ab), 822  
 Bertelsen, H, 37P(ab)  
 Berthele, A, 26P(ab)
- Berthold, T, 111P(ab)  
 Besnard, JC, 49P(ab)  
 Betocchi, S, 1869  
 Bettinardi, V, 171P(ab)  
 Bettman, L, 104, 1614  
 Beyea, D, 271P(ab)  
 Bhargava, KK, 30P(ab), 33P(ab),  
     197P(ab), 266P(ab)  
 Bhatnagar, A, 71P(ab), 126P(ab),  
     146P(ab), 249P(ab), 1617  
 Bhuiya, T, 263P(ab)  
 Bianco, RA, 634  
 Bicik, I, 1892  
 Bier, D, 263P(ab)  
 Biersack, H-J, 105P(ab),  
     135P(ab), 143P(ab), 151P(ab),  
     212P(ab), 241P(ab), 269P(ab),  
     1551, 1903  
 Bigliani, V, 82P(ab)  
 Bigner, DD, 77P(ab), 105P(ab)  
 Bihl, H, 66P(ab), 125P(ab)  
 Biko, J, 20P(ab)  
 Bikov, S, 244P(ab)  
 Bilanuk, L, 56P(ab)  
 Bilger, K, 164P(ab), 169P(ab)  
 Billen, J, 269P(ab)  
 Biniakiewicz, DS, 216P(ab),  
     219P(ab), 659  
 Binkert, B, 113P(ab)  
 Binns, DS, 11P(ab), 249P(ab)  
 Birdwell, R, 24P(ab)  
 Birrell, A, 227P(ab)  
 Bischof, C, 39P(ab), 77P(ab),  
     223P(ab), 1928  
 Bischof Delaloye, A, 15P(ab),  
     150P(ab)  
 Bishop, HA, 19P(ab), 80P(ab),  
     123P(ab)  
 Bishop, M, 11P(ab)  
 Bisi, G, 384  
 Bisson, G, 1441  
 Bittini, A, 624  
 Björnsson, EH, 640  
 Black, PM, 1148  
 Blackmore, DG, 154P(ab)  
 Blanckaert, N, 269P(ab)  
 Blankenberg, F, 8P(ab),  
     160P(ab)  
 Blanksma, PK, 161P(ab), 1312  
 Blasberg, RG, 130P(ab),  
     236P(ab), 237P(ab), 879  
 Blasini, R, 1307  
 Blasl, C, 1066  
 Blaufox, MD, 250P(ab), 522,  
     1297  
 Bleichrodt, R, 302P(ab)  
 Blend, MJ, 276P(ab)  
 Blockmans, D, 267P(ab)  
 Boccaletto, F, 516  
 Bockisch, A, 110P(ab),  
     156P(ab), 185P(ab), 268P(ab),  
     533, 1536  
 Boddington, S, 204P(ab)  
 Bodré, F, 70P(ab)  
 Bodere, FK, 246P(ab)  
 Boecker, H, 111P(ab)  
 Bochme, B, 199P(ab)  
 Boerman, OC, 7P(ab), 30P(ab),  
     47P(ab), 78P(ab), 119,  
     195P(ab), 242P(ab), 244P(ab),
- 246P(ab), 247P(ab), 264P(ab),  
 265P(ab), 266P(ab), 267P(ab),  
 268P(ab), 2167, 2172  
 Boersma, LJ, 1074  
 Bogatzky, J, 151P(ab), 269P(ab)  
 Bogdanov, M, 54P(ab)  
 Boggs, J, 1388  
 Bogni, A, 4  
 Bohnen, NI, 15P(ab), 125P(ab),  
     202P(ab), 210P(ab)  
 Bohuslavizki, KH, 38P(ab), 224,  
     1237, 1913  
 Boissier, B, 1214  
 Bok, B, 185P(ab)  
 Bokemeyer, C, 67P(ab)  
 Bol, A, 97P(ab), 1655  
 Bolch, WE, 84P(ab), 183P(ab)  
 Bollow, D, 265P(ab)  
 Boltzmann, L, 198P(ab)  
 Bom, HS, 184P(ab)  
 Bom, S-S, 91  
 Bomanji, JB, 1743  
 Bombardieri, E, 4, 254P(ab),  
     1586  
 Bonab, AA, 66P(ab), 167P(ab),  
     195P(ab), 207P(ab), 238P(ab)  
 Bonaduce, D, 101P(ab)  
 Bonasera, TA, 982  
 Bonavia, GH, 220P(ab)  
 Bonavina, L, 58P(ab)  
 Bonfanti, A, 40P(ab)  
 Bonfils, E, 109P(ab)  
 Böni, R, 94P(ab)  
 Böning, G, 411  
 Bonnin, F, 185P(ab)  
 Booij, J, 13P(ab), 1143, 1879  
 Boonen, C, 218P(ab)  
 Boonstra, H, 1381  
 Borchardt, PE, 476  
 Borek, PP, 61P(ab)  
 Borgers, M, 142P(ab)  
 Borges-Neto, S, 75P(ab),  
     76P(ab), 140, 161P(ab)  
 Borghei, AR, 2003  
 Bormans, G, 142P(ab)  
 Bornman, PC, 272P(ab)  
 Boroujerdi, M, 159P(ab)  
 Bosch, J-P, 950  
 Bosson, J-L, 2193(le)  
 Bousseyt, A, 78P(ab), 1850  
 Bottlaender, M, 21P(ab),  
     71P(ab), 72P(ab), 168P(ab),  
     205P(ab), 238P(ab)  
 Bottoncetti, A, 208P(ab)  
 Botvinick, EH, 139P(ab)  
 Boubaker, A, 15P(ab), 150P(ab)  
 Bouchareb, Y, 160P(ab)  
 Bouchet, LG, 84P(ab), 183P(ab)  
 Bouhou, J, 1937  
 Boulfelf, J, 234P(ab)  
 Bourguet, P, 900  
 Bourque, CR, 217P(ab)  
 Boutefnouchet, A, 170P(ab)  
 Bouvard, G, 1129, 1841  
 Bouwens, LR, 176P(ab)  
 Bowen, WD, 227P(ab)  
 Bowsher, JE, 79P(ab)  
 Boy, C, 22P(ab), 188P(ab),  
     230P(ab)  
 Boyd, JH, 122P(ab), 256P(ab)  
 Bozik, M, 211P(ab)  
 Bozorgi, F, 113, 1458  
 Boztepe, H, 1897  
 Braams, JW, 1476  
 Brady, F, 237P(ab), 239P(ab)  
 Brambilla, C, 70P(ab)
- Brambs, H-J, 81P(ab)  
 Brandau, W, 23, 226P(ab)  
 Brandt, T, 110P(ab)  
 Brandt-Mainz, K, 1536  
 Brans, B, 176P(ab)  
 Brassard, A, 1621  
 Brasseur, N, 165P(ab)  
 Braune, S, 224  
 Bray, LA, 91P(ab)  
 Braymer, W, 180P(ab)  
 Brazaitis, M, 32P(ab)  
 Breakefield, XO, 236P(ab)  
 Brechbiel, MW, 91P(ab),  
     223P(ab), 232P(ab), 829  
 Brechtelsbauer, D, 212P(ab)  
 Brecht-Krauss, D, 33P(ab), 2145  
 Breedon, W, 49P(ab)  
 Breeman, W, 39P(ab), 62P(ab),  
     63P(ab), 233P(ab), 261P(ab),  
     264P(ab)  
 Breitz, HB, 71P(ab), 1746  
 Bremmer, S, 2055  
 Bremner, JD, 175P(ab),  
     202P(ab), 209P(ab)  
 Brenner, R, 211P(ab)  
 Brenner, W, 38P(ab), 224, 1237,  
     1913  
 Bresnahan, DR, 116P(ab)  
 Bresolin, N, 218P(ab)  
 Brew, BJ, 298  
 Bridewell, R, 32P(ab)  
 Brigger, P, 46P(ab), 103P(ab)  
 Bright, SJ, 63P(ab)  
 Brill, AB, 671  
 Brinkman-Medema, R, 836  
 Brissot, P, 900  
 Brix, G, 165P(ab), 166P(ab)  
 Brondum, DM, 107P(ab)  
 Brodie, JD, 99P(ab)  
 Brody, AL, 41P(ab)  
 Broekhuizen-de Gast, HS,  
     196P(ab)  
 Broussard, WF, 191P(ab)  
 Browne, RJ, 1647P(ab)  
 Brown, AM, 49P(ab)  
 Brown, G, 237P(ab), 239P(ab)  
 Brown, JK, 98P(ab)  
 Brown, ML, 1111, 1114, 1302  
 Brown, MT, 1376  
 Brown, P, 259P(ab)  
 Brown, R, 196P(ab)  
 Brown, WD, 1884  
 Brownell, A-L, 54P(ab)  
 Brücke, T, 613  
 Bruckner, J, 95P(ab), 190P(ab)  
 Brummer, ME, 107P(ab)  
 Brunelli, C, 396  
 Brunetti, A, 786  
 Bruni, WL, 61P(ab), 62P(ab)  
 Brunner, C, 39P(ab)  
 Bruno, A, 218P(ab)  
 Bryan, JA, 71P(ab), 1617  
 Bryan, TA, 132P(ab)  
 Bryant, TA, 1857  
 Buchner, E, 1638  
 Buchriegel, C, 221P(ab)  
 Buchsbaum, DJ, 63P(ab),  
     224P(ab), 1243  
 Buck, A, 106P(ab), 111P(ab),  
     277P(ab), 1892  
 Bucky, L, 10P(ab)  
 Budinger, TF, 93P(ab),  
     171P(ab), 190P(ab), 208P(ab),  
     228P(ab), 233P(ab)  
 Buell, U, 81P(ab), 147,  
     249P(ab), 304P(ab), 402, 815
- Buettner, TL, 105P(ab)  
 Buffaz, P-D, 2193P(ab)  
 Bugaj, J, 39P(ab)  
 Bui, S, 94P(ab), 254P(ab)  
 Buijs, WCAM, 2167  
 Bull, J, 244P(ab)  
 Büll, U, 157P(ab)  
 Bullmore, E, 204P(ab)  
 Bültmann, B, 19P(ab)  
 Buonocore, E, 52P(ab)  
 Burch, WM, 1647P(ab)  
 Burchert, W, 125P(ab), 202P(ab)  
 Burger, C, 106P(ab), 123P(ab),  
     277P(ab)  
 Burgers, JK, 650  
 Burke, JF, 195P(ab)  
 Burkhardt, H, 1638  
 Burleigh, BD, 77  
 Burmester, G-R, 265P(ab)  
 Burns, HD, 1209  
 Burroni, L, 215P(ab), 822  
 Burton, J, 71P(ab)  
 Busatto, GF, 83P(ab), 204P(ab)  
 Buscombe, JR, 129P(ab),  
     138P(ab), 150P(ab), 193P(ab)  
 Bushnell, D, 113P(ab), 194P(ab)  
 Buskard, T, 180P(ab)  
 Bussière, F, 73P(ab)  
 Buvat, I, 61P(ab), 73P(ab),  
     141P(ab), 179P(ab), 1590  
 Buxton, DB, 272  
 Byrd, D, 24P(ab)  
 Byrne, C, 180P(ab)  
 Cacciabuado, JM, 756  
 Caday, CG, 184P(ab)  
 Cadiot, G, 2194P(ab)  
 Cadorette, J, 165P(ab)  
 Cai, J, 608  
 Cai, S, 67P(ab)  
 Caillat-Vigneron, N, 2195P(ab)  
 Calderon, C, 1254  
 Caldwell, CB, 99P(ab)  
 Caldwell, JH, 1327  
 Caldwell, MA, 139P(ab)  
 Cali, G, 117P(ab)  
 Callahan, R, 266P(ab)  
 Callahan, RJ, 144P(ab), 239P(ab)  
 Callans, L, 10P(ab)  
 Calne, DB, 792  
 Calnon, DA, 115P(ab)  
 Calza, P, 24P(ab), 2080  
 Camarano, GP, 374P(ab)  
 Camargo, PR, 57P(ab)  
 Camici, PG, 1696  
 Camp, VM, 35P(ab)  
 Campbell, JN, 207P(ab)  
 Campbell, SK, 52P(ab)  
 Campini, R, 154P(ab)  
 Campisi, R, 3P(ab), 89P(ab),  
     162P(ab)  
 Candell-Riera, J, 751  
 Canela, T, 751  
 Canelo, R, 70P(ab)  
 Caner, B, 199P(ab)  
 Canfi, A, 191P(ab)  
 Cangiano, T, 150P(ab)  
 Canpinar, H, 1191  
 Cantez, S, 1897  
 Cantin, J, 459  
 Canzi, C, 58P(ab), 61P(ab)  
 Capa, G, 2116  
 Capitelli, P, 484  
 Cappiello, A, 202P(ab)  
 Capponnetto, S, 396  
 Caputo, G, 108P(ab)

- Caraco, C. 67P(ab), 251P(ab),  
     634  
 Carbonnelle, E. 50P(ab)  
 Carey, JE. 1230  
 Cargnel, S. 261  
 Carlson, B. 250P(ab)  
 Carlson, KJ. 1684  
 Carlson, RA. 174P(ab)  
 Carmona, A. 28P(ab)  
 Carnell, D. 260P(ab)  
 Carniato, A. 516  
 Carpenter, L. 40P(ab)  
 Carpenter, A. 1441  
 Carpinelli, A. 30P(ab)  
 Carr, JG. 61P(ab)  
 Carrasquillo, JA. 76P(ab),  
     80P(ab), 98P(ab), 221P(ab),  
     232P(ab), 236P(ab), 272P(ab),  
     829  
 Carreras, JL. 624  
 Carretta, RF. 923  
 Carroll, FI. 12P(ab)  
 Carroll, RG. 1388  
 Carson, JM. 46P(ab), 103P(ab),  
     141P(ab)  
 Carson, RE. 36P(ab), 55P(ab),  
     85P(ab), 135P(ab), 136P(ab)  
 Carter, CS. 205P(ab)  
 Carter, EA. 58P(ab), 195P(ab),  
     266P(ab)  
 Casadio, C. 70P(ab)  
 Casati, R. 218P(ab)  
 Case, JA. 101P(ab), 181P(ab)  
 Casey, M. 92P(ab)  
 Casey, ME. 9P(ab), 133P(ab)  
 Casier, K. 189P(ab), 198P(ab),  
     1563  
 Castaigne, A. 90P(ab)  
 Castell, J. 950  
 Castellani, M. 117P(ab), 1012,  
     1586  
 Castell-Conesa, J. 751  
 Castiglioni, I. 171P(ab)  
 Castronovo, F. 187P(ab)  
 Catsafados, E. 96P(ab)  
 Cave, A. 93P(ab)  
 Caveliers, V. 1672, 1850  
 Ceballos-Baumann, A. 111P(ab)  
 Celler, A. 65P(ab), 2183  
 Cerqueira, MD. 918  
 Cerri, GG. 57P(ab)  
 Cesarman, G. 247P(ab)  
 Cessna, JT. 575(lc)  
 Chae, SC. 31P(ab)  
 Chai, JH. 212P(ab)  
 Chakdar, S. 64P(ab)  
 Challa, S. 893  
 Chalon, S. 49P(ab), 118P(ab),  
     120P(ab), 238P(ab)  
 Chaly, T. 209P(ab), 1521  
 Champailleur, A. 17P(ab)  
 Champlin, RE. 186P(ab)  
 Chan, GL-Y. 792, 1714  
 Chandra, P. 45P(ab), 87P(ab),  
     101P(ab)  
 Chandrea, S. 212P(ab)  
 Chang, CJ. 129P(ab)  
 Chang, C-S. 1449  
 Chang, F. 56, 241P(ab)  
 Chang, J-K. 2128  
 Chang, TC. 193P(ab)  
 Chang, W. 1335  
 Chang, Y-C. 1711  
 Chang, YS. 235P(ab), 255P(ab)  
 ChangLai, S-P. 769, 773, 1354,  
     1707, 1798
- Channing, MA. 136P(ab),  
     230P(ab)  
 Chap, L. 254P(ab)  
 Chapman, SA. 21P(ab)  
 Chapman, WC. 81P(ab)  
 Charbonnier, B. 275P(ab)  
 Charkes, ND. 2196(lc)  
 Charney, DS. 21P(ab), 40P(ab),  
     72P(ab), 123P(ab), 136P(ab),  
     202P(ab), 209P(ab), 1500  
 Chastré, J. 29P(ab)  
 Chatal, JF. 70P(ab), 246P(ab),  
     1172  
 Chatal, J-F. 1608  
 Chatterjee, VK. 263P(ab)  
 Chatzioannou, A. 133P(ab),  
     278P(ab)  
 Chatzioannou, AF. 9P(ab)  
 Chatzioannou, SN. 88P(ab)  
 Cheesman, EH. 217P(ab)  
 Chefer, SI. 207P(ab)  
 Chéhadé, F. 1100  
 Chen, A. 166P(ab)  
 Chen, CC. 238, 923  
 Chen, E. 212P(ab)  
 Chen, EQ. 148P(ab)  
 Chen, G-H. 1449  
 Chen, J. 222P(ab), 274P(ab)  
 Chen, JQ. 77P(ab)  
 Chen, K. 19P(ab), 161P(ab), 272  
 Chen, M-N. 243P(ab), 1752  
 Chen, P. 35P(ab)  
 Chen, S-D. 1449  
 Chen, T. 137P(ab), 258P(ab),  
     1752  
 Chen, WL. 88P(ab)  
 Chen, YC. 74P(ab)  
 Chen, YCI. 54P(ab)  
 Cheng, A. 1273  
 Cheng, D. 168P(ab)  
 Cheng, FP. 205P(ab)  
 Chenggazi, V. 173P(ab), 174P(ab)  
 Chenoufi, N. 900  
 Cheon, GJ. 59P(ab), 60P(ab)  
 Cherry, S. 35P(ab)  
 Cherry, SR. 9P(ab), 10P(ab),  
     50P(ab), 93P(ab), 133P(ab),  
     170P(ab), 278P(ab), 729,  
     1951, 2003  
 Chester, KA. 47  
 Chi, C-S. 1752  
 Chi, DY. 229P(ab)  
 Chiarello, M. 1869  
 Chicco, P. 44P(ab), 361, 1095  
 Chieng, P-U. 769, 773, 1354,  
     1707, 1798  
 Chierichetti, F. 261  
 Chiesa, C. 4  
 Chin, BB. 149P(ab), 152P(ab),  
     194P(ab)  
 Chin, L. 229P(ab)  
 Chin, LK. 35P(ab)  
 Chinol, M. 70P(ab), 221P(ab),  
     245P(ab)  
 Chiron, C. 27P(ab)  
 Chiron, F. 146P(ab)  
 Chisin, R. 264P(ab)  
 Chiu, N-T. 129P(ab), 1711, 2128  
 Cho, BY. 257P(ab), 261P(ab)  
 Cho, JH. 235P(ab)  
 Cho, K. 149P(ab)  
 Cho, MJ. 41P(ab)  
 Cho, YK. 31P(ab)  
 Choc, YS. 12P(ab), 54P(ab),  
     65P(ab), 154P(ab), 229P(ab),  
     252P(ab)
- Choi, BIW. 85P(ab)  
 Choi, C-W. 195P(ab), 257P(ab)  
 Choi, JY. 65P(ab), 154P(ab),  
     252P(ab)  
 Choi, P. 192P(ab)  
 Choi, SR. 220P(ab)  
 Choi, Y. 12P(ab), 34P(ab),  
     54P(ab), 65P(ab), 154P(ab),  
     229P(ab), 252P(ab)  
 Chou, JY. 67P(ab)  
 Chou, KL. 187P(ab)  
 Chou, Y-H. 2061  
 Chowdhury, S. 243P(ab), 912  
 Christensen, C. 259P(ab)  
 Christian, BT. 167P(ab),  
     207P(ab), 214P(ab)  
 Christian, CL. 1280  
 Christian, PE. 124, 182P(ab),  
     192P(ab)  
 Christie, DRH. 95  
 Chu, DJZ. 2097  
 Chu, W-J. 148P(ab), 149P(ab)  
 Chudnovsky, A. 221  
 Chugani, DC. 124P(ab),  
     137P(ab)  
 Chugani, HT. 124P(ab),  
     200P(ab)  
 Chun, KA. 31P(ab), 150P(ab),  
     253P(ab), 1401  
 Chun, KJ. 19P(ab)  
 Chun, MS. 85P(ab)  
 Chung, J-K. 41P(ab), 59P(ab),  
     60P(ab), 103P(ab), 130P(ab),  
     201P(ab), 211P(ab), 212P(ab),  
     213P(ab), 234P(ab), 235P(ab),  
     250P(ab), 255P(ab), 257P(ab),  
     261P(ab), 267P(ab), 303P(ab)  
 Chung, ML. 271P(ab)  
 Chung, S-K. 33P(ab), 130, 1444  
 Chyatte, D. 148P(ab)  
 Cichon, G. 125P(ab)  
 Cideciyan, AV. 163P(ab)  
 Cieuta, C. 27P(ab)  
 Cintorino, M. 215(lc), 822  
 Ciocia, G. 1012  
 Cirak, KA. 2116  
 Cittanti, C. 204P(ab)  
 Civelek, AC. 194P(ab)  
 Claessens, RAMJ. 119  
 Clark, C. 1363  
 Clark, CM. 210P(ab)  
 Clark, J. 203P(ab)  
 Clark, RD. 119P(ab)  
 Clarke, HS. 86P(ab)  
 Clarkson, E. 93P(ab)  
 Clausen, M. 1237, 1913  
 Clauss, RP. 1596  
 Claussen, C. 122P(ab), 147P(ab)  
 Claveau-Tremblay, R. 1621  
 Cleveland, W. 201P(ab)  
 Clifton, PM. 108  
 Clinthorne, NH. 51P(ab),  
     132P(ab), 173P(ab)  
 Clough, D. 55P(ab)  
 Clouse, JC. 11N(7)  
 Coates, G. 258P(ab)  
 Cockeram, A. 271P(ab)  
 Coenen, HH. 21P(ab), 22P(ab),  
     131P(ab), 188P(ab), 230P(ab),  
     1596  
 Cognneau, M. 1655  
 Cohen, A. 134P(ab), 253P(ab)  
 Cohen, H. 1214  
 Cohen, I. 3P(ab), 87P(ab),  
     101P(ab), 103P(ab), 154P(ab),  
     253P(ab)
- Cohen, M. 86  
 Cohen, P. 173P(ab)  
 Cohen, R. 45P(ab)  
 Colamussi, P. 204P(ab)  
 Colas-Linhart, N. 185P(ab)  
 Colby, R. 190P(ab)  
 Colcher, D. 11S  
 Cole, RL. 128P(ab)  
 Colella, AC. 875  
 Coleman, RE. 47P(ab), 76P(ab),  
     92P(ab), 107P(ab), 108P(ab),  
     109P(ab), 121P(ab), 140,  
     161P(ab), 257P(ab), 365, 856,  
     1105, 1376  
 Coles, AJ. 263P(ab)  
 Collier, BD. 5P(ab), 25P(ab),  
     217P(ab)  
 Collier, TL. 227P(ab)  
 Collignon, M-A. 5P(ab),  
     275P(ab)  
 Colahan, HA. 425  
 Colombo, C. 40P(ab)  
 Colombo, FR. 218P(ab)  
 Colombo, N. 243P(ab)  
 Colon, AR. 200P(ab)  
 Comans, EFI. 302P(ab)  
 Compston, A. 263P(ab)  
 Conrad, K. 1778  
 Conard, B. 109P(ab), 111P(ab)  
 Conrad, EU. 95P(ab), 190P(ab)  
 Conrad, M. 113P(ab), 130P(ab),  
     189P(ab), 262P(ab), 1248  
 Consigny, PM. 64P(ab)  
 Constable, RT. 61P(ab)  
 Conti, PS. 131P(ab), 230P(ab),  
     232P(ab)  
 Contreras, SJ. 1778  
 Conway, JH. 98P(ab)  
 Conway, JJ. 1254  
 Conwell, R. 23P(ab)  
 Ciocia, G. 1012  
 Cook, CU. 1148  
 Cook, G. 73P(ab)  
 Cook, GJR. 99  
 Cook, RC. 192P(ab)  
 Cook, SA. 148P(ab)  
 Cooper, M. 207P(ab)  
 Cooper, PW. 99P(ab)  
 Cooper, S. 192P(ab)  
 Cooper, TB. 207P(ab)  
 Copeland, DL. 149P(ab)  
 Copeland, SA. 211P(ab)  
 Copello, F. 96P(ab)  
 Copin, D. 75P(ab)  
 Coppens, A. 57P(ab), 97P(ab)  
 Corbett, JR. 73P(ab), 74P(ab)  
 Corcuff, B. 1172  
 Cordero, H. 102P(ab)  
 Cordes, M. 954  
 Cordobes, MD. 1214  
 Cornel, JH. 18P(ab), 60P(ab),  
     1481, 1662  
 Corsello, SM. 1202  
 Corsi, M. 68P(ab), 212P(ab)  
 Corsiglia, L. 396  
 Corstens, FHM. 7P(ab), 30P(ab),  
     47P(ab), 78P(ab), 119,  
     195P(ab), 242P(ab), 244P(ab),  
     246P(ab), 247P(ab), 264P(ab),  
     265P(ab), 266P(ab), 267P(ab),  
     268P(ab), 2167, 2172  
 Cortadellas, J. 751  
 Cortelli, P. 210P(ab)
- Cortés, A. 178P(ab), 203P(ab)  
 Cosgriff, P. 17P(ab)  
 Costa, DC. 83P(ab), 124P(ab),  
     204P(ab)  
 Coulon, C. 72P(ab), 238P(ab)  
 Coursey, BM. 575(lc)  
 Covelli, EM. 802  
 Cowan, RJ. 1454  
 Craen, M. 198P(ab)  
 Craig, JC. 27P(ab), 1428  
 Crane, PD. 217P(ab), 218P(ab)  
 Crankshaw, CL. 13P(ab). 77  
 Cremer, M. 230P(ab)  
 Cremerius, U. 81P(ab), 147,  
     249P(ab), 304P(ab), 815  
 Cremonesi, M. 24P(ab), 70P(ab),  
     221P(ab), 2080  
 Crestani, B. 44P(ab)  
 Crippa, F. 4, 254P(ab)  
 Crippa, R. 30P(ab)  
 Crisp, J. 27P(ab)  
 Cristel, ME. 91P(ab), 1944  
 Crocker, A. 215P(ab)  
 Croft, L. 76P(ab)  
 Cronin, BF. 255P(ab)  
 Crouzel, C. 21P(ab), 72P(ab),  
     229P(ab)  
 Cua, D. 24P(ab)  
 Cullom, SJ. 101P(ab), 181P(ab)  
 Culver-Schultz, C. 259P(ab)  
 Cumming, P. 43P(ab)  
 Cummings, D. 659  
 Cuocolo, A. 17P(ab), 101P(ab),  
     802, 1869  
 Cupps, B. 4P(ab)  
 Curcio, MJ. 223P(ab)  
 Curiel, DT. 63P(ab)  
 Currat, C. 70P(ab)  
 Cutler, CS. 91P(ab)  
 Cutler, PD. 1944  
 Cutrone, JA. 449  
 Cwikla, JB. 138P(ab)  
 Cyr, GM. 76P(ab)  
 Czech, T. 978  
 Czerniecki, B. 10P(ab)  
 Czernin, J. 3P(ab), 9P(ab),  
     60P(ab), 68P(ab), 69P(ab),  
     89P(ab), 90P(ab), 94P(ab),  
     162P(ab), 248P(ab), 254P(ab),  
     272  
 Czerny, C. 1907  
 Czerwiec, FS. 238  
 Dachille, MA. 205P(ab),  
     211P(ab)  
 Dadparvar, S. 273P(ab)  
 Dac, MW. 139P(ab)  
 Daghigian, F. 51P(ab),  
     171P(ab)  
 D'Agnolo, A. 138P(ab)  
 Dahl, R. 209P(ab)  
 Dahlbom, M. 9P(ab), 52P(ab),  
     69P(ab), 165P(ab), 167P(ab)  
 Dahlbom, MN. 1302  
 Dahlheimer, JL. 13P(ab), 77  
 Dahman, BA. 183P(ab),  
     245P(ab)  
 Dähne, I. 1138  
 Dai, D. 48P(ab), 142P(ab)  
 Daley, LJ. 132P(ab), 175P(ab)  
 Daly, JL. 277P(ab)  
 Damann, F. 122P(ab)  
 Damen, EMF. 1074  
 Dams, ETM. 7P(ab), 30P(ab),  
     119, 195P(ab), 242P(ab),  
     264P(ab), 267P(ab), 2172

- Danforth, DN, 80P(ab), 98P(ab)  
 Dangas, G, 18P(ab)  
 D'Angelo, A, 30P(ab)  
 D'Angelo, MG, 218P(ab)  
 Daniel, GB, 1286  
 Daniels, RV, 21P(ab)  
 Dannals, B, 207P(ab)  
 Dannals, RF, 21P(ab), 40P(ab),  
   48P(ab), 72P(ab), 99P(ab),  
   100P(ab), 119P(ab), 137P(ab),  
   196P(ab), 207P(ab), 229P(ab),  
   1209  
 Dannenberg, C, 32P(ab),  
   213P(ab)  
 Danno, N, 220P(ab)  
 Dansereau, RN, 38P(ab),  
   222P(ab)  
 Daou, D, 44P(ab), 140P(ab)  
 Daoud, D, 1614  
 Darcourt, J, 73P(ab)  
 D'Arcy, BJ, 90P(ab)  
 Darlas, Y, 1129  
 Darrelmann, M, 270P(ab)  
 Das, B, 42P(ab)  
 Dasgupta, A, 43P(ab)  
 DaSilva, JN, 71P(ab), 119P(ab),  
   236P(ab)  
 Datz, FL, 192P(ab)  
 Daube-Witherspoon, ME,  
   80P(ab), 98P(ab), 133P(ab),  
   179P(ab)  
 Dautet, H, 92P(ab)  
 Daver, A, 1546  
 Davids, E, 83P(ab)  
 Dávila-García, M, 48P(ab)  
 Davila-Roman, VG, 4P(ab)  
 Davis, CM, 46P(ab), 103P(ab)  
 Davis, E, 8P(ab), 160P(ab)  
 Davis, J, 106P(ab)  
 Davis, M, 14N(9)  
 De Backer, G, 155P(ab)  
 De Backer, J, 155P(ab)  
 De Baere, E, 189P(ab)  
 de Beco, V, 1214  
 De Belen, EC, 41P(ab)  
 De Boni, D, 137P(ab)  
 De Brackeleer, M, 1621  
 De Braud, F, 70P(ab)  
 de Bruin, E, 261P(ab)  
 de Bruin, K, 13P(ab)  
 De Cesare, A, 160P(ab)  
 De Cicco, C, 24P(ab), 70P(ab),  
   243P(ab), 245P(ab), 2080  
 De Coster, P, 74P(ab), 75P(ab),  
   164P(ab)  
 De Geeter, F, 1850  
 de Groot, T, 218P(ab)  
 de Herder, WW, 19P(ab)  
 de Hullu, JA, 1381  
 de Jong, HWAM, 170P(ab)  
 de Jong, M, 39P(ab), 62P(ab),  
   63P(ab), 233P(ab), 261P(ab),  
   264P(ab)  
 de Landsheere, CM, 260P(ab)  
 de Leij, FMH, 836  
 De Liso, A, 218P(ab)  
 De Luca, G, 1869  
 De Mulder, PHM, 247P(ab)  
 De Reuck, J, 307, 495  
 De Ridder, L, 189P(ab)  
 De Rooij, L, 183P(ab)  
 De Rosario, J, 173P(ab)  
 De Sadeleer, C, 16P(ab),  
   189P(ab), 198P(ab), 1563  
 De Sanctis, V, 4  
 De Scheerder, I, 142P(ab)  
 De Sonza, B, 786  
 De Sousa, MC, 1590  
 De Sutter, J, 155P(ab)  
 de Swart, J, 19P(ab)  
 De Volder, AG, 57P(ab),  
   97P(ab)  
 De Vos, F, 307  
 de Vries, DJ, 97P(ab), 169P(ab)  
 de Vries, EGE, 130P(ab), 1736  
 de Weijert, MCA, 78P(ab)  
 De Winter, H, 189P(ab)  
 Dean, RT, 225P(ab)  
 DeBruin, S, 178P(ab)  
 DeBruyne, FMJ, 244P(ab),  
   246P(ab), 247P(ab)  
 Deckart, HF, 259P(ab)  
 Decker, C, 202P(ab)  
 Decker, P, 151P(ab)  
 Decoo, D, 307  
 Decoster, M, 269P(ab)  
 Defabritiis, A, 87P(ab)  
 Defrise, M, 78P(ab)  
 Degen, K, 82P(ab)  
 Degirmenci, B, 23P(ab),  
   109P(ab), 587, 2116  
 DeGrado, TR, 47P(ab),  
   107P(ab), 1684, 1690  
 Degueldre, C, 778  
 Dchdashti, F, 1302  
 Dei, S, 45P(ab), 193P(ab)  
 Deisenhammer, E, 1508  
 DeJesus, OT, 1884  
 deKernion, J, 150P(ab)  
 Del Fiore, G, 260P(ab), 778  
 Del Guerra, A, 133P(ab)  
 Del Sole, A, 40P(ab)  
 Delahay, J, 1084  
 Delahaye, N, 29P(ab), 44P(ab),  
   104P(ab), 140P(ab), 142P(ab)  
 Delaloye, J-F, 150P(ab)  
 Deland, D, 484  
 Delbeke, D, 81P(ab), 108P(ab)  
 Delforge, J, 65P(ab), 71P(ab),  
   142P(ab), 205P(ab)  
 Delgado, L, 137P(ab)  
 Delledonne, V, 4, 254P(ab)  
 Deloar, HM, 187P(ab)  
 DeLong, DM, 161P(ab)  
 Delpassand, ES, 278P(ab)  
 DeMan, P, 61P(ab), 62P(ab),  
   417  
 Demidchik, EP, 20P(ab)  
 DeNardo, DA, 112P(ab)  
 DeNardo, GL, 112P(ab),  
   185P(ab), 186P(ab), 243P(ab),  
   246P(ab), 269P(ab), 842,  
   1223, 2105  
 DeNardo, SJ, 112P(ab),  
   185P(ab), 186P(ab), 243P(ab),  
   246P(ab), 269P(ab), 667, 842,  
   1223, 2105  
 Dence, C, 145P(ab)  
 Denet, S, 1172  
 Denison, GL, 128P(ab)  
 Denny, W, 239P(ab)  
 DeNovo, RC, 1286  
 DeLuca, G, 1869  
 DeMulder, PHM, 247P(ab)  
 DeReuck, J, 307, 495  
 De Ridder, L, 189P(ab)  
 DeRooij, L, 183P(ab)  
 DeRosario, J, 173P(ab)  
 DeSadeleer, C, 16P(ab),  
   189P(ab), 198P(ab), 1563  
 DeSanctis, V, 4  
 De Scheerder, I, 142P(ab)  
 Desvignes, P, 73P(ab)  
 Deterding, T, 35P(ab)  
 Deters, E, 109P(ab)  
 Deutsch, G, 96P(ab), 148P(ab),  
   149P(ab), 216P(ab)  
 Deutsch, KF, 77  
 Deverre, JR, 229P(ab)  
 Devito, A, 449  
 Devizzi, L, 1586  
 Devous, MD Sr., 24N(4), 285,  
   923  
 Devys, A, 1608  
 Dewanjee, MK, 265P(ab)  
 Dewaraja, Y, 97P(ab), 112P(ab)  
 DeWeese, TL, 149P(ab)  
 Dewey, SL, 12P(ab), 54P(ab),  
   99P(ab)  
 Dey, D, 196P(ab)  
 Dey, HM, 132P(ab), 159P(ab),  
   175P(ab), 176P(ab)  
 Dezutter, N, 218P(ab)  
 Dhar, SC, 87P(ab), 102P(ab),  
   154P(ab)  
 Dhawan, V, 209P(ab), 1521  
 Dhekne, RD, 20P(ab), 88P(ab),  
   276P(ab)  
 Di Bella, EVR, 64P(ab), 124,  
   144P(ab), 182P(ab)  
 Di Chiro, G, 786  
 Di Domenico, G, 133P(ab)  
 Di Giambardino, L, 229P(ab)  
 Di Paola, M, 1590  
 Di Paola, R, 61P(ab), 179P(ab)  
 Diamond, J, 76P(ab), 154P(ab)  
 Diaz, M, 533  
 DiCarli, M, 200P(ab)  
 Diederichs, CD, 113P(ab)  
 Diederichs, CG, 81P(ab), 1030  
 Diefenbach, K, 268P(ab)  
 Diegeler, A, 32P(ab)  
 Diehl, B, 26P(ab), 27P(ab)  
 Diehl, J-L, 5P(ab)  
 Dierckx, RA, 155P(ab),  
   176P(ab), 189P(ab), 198P(ab),  
   199P(ab), 307, 495, 1563  
 Dicterich, M, 110P(ab)  
 Dietelberg, AG, 15P(ab)  
 DiFilippo, F, 132P(ab)  
 Diggles, L, 139P(ab), 449  
 Dikic, B, 50P(ab)  
 Diksic, M, 43P(ab), 83P(ab),  
   136P(ab)  
 Dillehay, GL, 1111  
 Dilsizian, V, 46P(ab), 103P(ab),  
   141P(ab), 160P(ab)  
 Dilworth, JP, 193P(ab)  
 Dimitrakopoulou-Strauss, A,  
   53P(ab), 465, 1197  
 Dimitrov, I, 6P(ab)  
 Dinanian, S, 142P(ab)  
 Ding, Y-S, 12P(ab), 42P(ab),  
   43P(ab), 238P(ab)  
 Dinges, HP, 236  
 Dinkelborg, LM, 1819  
 Dione, DP, 61P(ab), 62P(ab),  
   417  
 DiPalma, JS, 200P(ab)  
 Dirschinger, J, 139P(ab)  
 Discipolo, A, 802  
 Dittmann, H, 19P(ab), 147P(ab)  
 Dittrich, I, 224  
 Divgi, CR, 42, 484, 1776  
 Dobbeleir, A, 155P(ab), 1845  
 Dobko, T, 792  
 Dogan, AS, 166P(ab)  
 Dogan, S, 72P(ab)  
 Doherty, C, 147  
 Dohmen, BM, 19P(ab), 67P(ab),  
   122P(ab), 147P(ab), 190P(ab)  
 Doi, K, 201P(ab), 269P(ab)  
 Doll, J, 465  
 Dollé, F, 21P(ab), 72P(ab),  
   229P(ab)  
 Dombret, MC, 44P(ab)  
 Domingues, C, 543  
 Dominguez, P, 624  
 Donahay, T, 1468  
 Donald, PJ, 122P(ab)  
 Dondi, M, 86P(ab), 87P(ab),  
   1297  
 Dopfer, R, 1033  
 Dopichaj-Menge, U, 196P(ab)  
 Dorbala, S, 45P(ab), 87P(ab),  
   101P(ab)  
 Dorner, G, 1928  
 Dorney, S, 311  
 Doshi, NK, 170P(ab), 278P(ab),  
   1951  
 Doss, AL, 115P(ab)  
 İnanır, S, 1, 28  
 Doting, E, 1381  
 Dottorini, ME, 1202  
 Douyet, DJ, 792  
 Dougherty, DA, 121P(ab)  
 Dougherty, DD, 203P(ab)  
 Dragotakes, SC, 239P(ab)  
 Drent, M, 1605  
 Dresel, S, 6P(ab), 7P(ab),  
   82P(ab), 214P(ab), 221P(ab),  
   268P(ab), 1138, 2069  
 Drew, BJ, 139P(ab)  
 Driedger, AA, 168P(ab),  
   258P(ab)  
 Drum, DE, 1114  
 Drumm, D, 829  
 Drzegza, A, 26P(ab), 27P(ab)  
 D'Souza, CD, 82P(ab)  
 Duatti, A, 218P(ab)  
 Dubois Randé, JL, 90P(ab)  
 Dubovsky, EV, 15P(ab), 1257,  
   1297  
 Elahi, N, 1021  
 Elder, D, 10P(ab)  
 Elezi, S, 139P(ab)  
 El-Galley, R, 86P(ab)  
 Elgazzar, AH, 28P(ab)  
 Elger, CE, 212P(ab)  
 Elhendy, A, 1481, 1662  
 Eliashev, SD, 68P(ab)  
 Ell, PJ, 82P(ab), 83P(ab),  
   204P(ab), 1743  
 Elliott, WM, 16P(ab)  
 Ellis, GK, 146P(ab)  
 Ellis, PR, 191P(ab)  
 Elmaleh, DR, 240P(ab),  
   267P(ab)  
 Elmer, L, 210P(ab)  
 Elsinga, PH, 117P(ab)  
 El-Zeftawy, HA, 23P(ab),  
   97P(ab), 109P(ab), 255P(ab)  
 El-Zeftawy, HM, 654  
 Emans, SJ, 203P(ab)  
 Emond, P, 49P(ab), 118P(ab)  
 Enas, JD, 208P(ab), 228P(ab)  
 Encke, A, 1155  
 Endo, K, 53P(ab), 152P(ab),  
   153P(ab), 234P(ab), 236P(ab),  
   498, 541, 663, 1424  
 Endo, T, 2095  
 Endres, CJ, 55P(ab), 135P(ab)  
 Engel, J, 68P(ab)  
 Engelbach, M, 268P(ab)  
 English, C, 792  
 Enomoto, M, 156P(ab)

- Ensing, K. 117P(ab)  
 Enterline, DS. 647  
 Entman, ML. 48P(ab)  
 Epelbaum, R. 10P(ab), 11P(ab)  
 Ephron, V. 244P(ab), 273P(ab)  
 Epstein, AL. 222P(ab), 247P(ab)  
 Erami-Aredon, SS. 209P(ab)  
 Erbel, R. 156P(ab)  
 Erdi, YE. 174P(ab),  
     278P(ab)P(tab)  
 Ergün, EL. 1021  
 Eriks, E. 130P(ab)  
 Eriksson, L. 9P(ab), 52P(ab),  
     133P(tab)  
 Erion, J. 39P(ab), 63P(ab)  
 Erlandsson, K. 552  
 Ernst, M. 689  
 Ernst, R. 114P(ab)  
 Erwin, WD. 145P(ab)  
 Eschmann, SM. 1033  
 Escobedo, D. 1388  
 Eshima, D. 7P(ab), 215P(ab),  
     267P(ab)  
 Eshima, L. 271P(ab)  
 Eskin, JD. 173P(ab)  
 Eskola, O. 1320  
 Espasandin, J. 137P(ab)  
 Esselstyn, CW. 263P(ab)  
 Essner, R. 94P(ab), 1185  
 Esteban, JM. 2097  
 Estes, J. 21S  
 Estok, L. 1366  
 Evans, AC. 110P(ab), 205P(ab),  
     904  
 Evans, JF. 1989  
 Everaert, H. 88P(ab)  
 Ewert, R. 118P(ab)  
 Eyster, D. 32P(ab)  
 Ezquerra, NF. 146P(ab)  
 Ezuddin, SH. 201P(ab)  
 Ezzedine, B. 214P(ab)  
  
 Faber, TL. 107P(ab), 110P(ab),  
     146P(ab)  
 Fagret, D. 50P(ab), 70P(ab)  
 Fahey, FH. 10N(9). 24P(ab)  
 Faintuch, BL. 221P(ab)  
 Fajardo-Mostenne, PA. 152P(ab)  
 Fajman, WJ. 276P(ab)  
 Fallani, F. 87P(ab)  
 Fang, B. 244P(ab)  
 Fanti, S. 86P(ab), 87P(ab),  
     210P(ab)  
 Faraggi, M. 29P(ab), 44P(ab),  
     104P(ab), 140P(ab)  
 Farahati, J. 20P(ab), 259P(ab),  
     260P(ab)  
 Farde, L. 72P(ab), 118P(ab),  
     120P(ab), 136P(ab), 208,  
     237P(ab), 1965, 2061  
 Farncombe, T. 65P(ab)  
 Farnsworth, RH. 1280  
 Farquhar, TH. 9P(ab), 133P(ab)  
 Farrell, E. 248P(ab)  
 Farris, JS. 277P(ab)  
 Fashimbauer, P. 944  
 Fass, J. 81P(ab)  
 Faßbender, T. 111P(ab)  
 Fassotte, MF. 147P(ab),  
     254P(ab)  
 Fast, E. 90P(ab)  
 Fasth, K-J. 1273  
 Fauconnier, T. 7P(ab)  
 Faulhaber, PF. 250P(ab)  
 Fawwaz, RA. 2017(1c)  
 Fazekas, F. 790, 1363
- Fazio, F. 30P(ab), 40P(ab),  
     171P(ab), 243P(ab)  
 Felder, CA. 42P(ab), 100P(ab)  
 Feldman, JM. 647  
 Felix, R. 954  
 Fenichel, S. 190P(ab)  
 Fendrick, AM. 707  
 Ferlin, G. 261  
 Ferrand, SK. 46P(ab), 103P(ab)  
 Ferrari, C. 1012  
 Ferrari, M. 221P(ab)  
 Ferraro-Borgida, M. 76P(ab)  
 Ferrière, G. 57P(ab)  
 Fertil, B. 735  
 Fessler, JA. 73P(ab), 74P(ab)  
 Feuerstein, I. 32P(ab)  
 Feuillan, PP. 238  
 Feustel, P. 222P(ab)  
 Feyerabend, B. 1237  
 Ficaro, EP. 73P(ab), 74P(ab),  
     411  
 Fiche, M. 1608  
 Fijiwara, Y. 158P(ab)  
 Filesi, M. 1542  
 Filez, F. 134P(ab)  
 Filippo, P. 384  
 Fillet, G. 147P(ab), 254P(ab)  
 Fimmers, R. 1903  
 Fine, EJ. 522, 1297  
 Finestone, H. 6P(ab), 114P(ab),  
     608  
 Fini, A. 261  
 Finke, C. 1551  
 Finkelman, C. 268P(ab)  
 Finley, PA. 21P(ab), 48P(ab),  
     229P(ab)  
 Finn, RD. 51P(ab), 67P(ab),  
     130P(ab), 134P(ab), 135P(ab),  
     174P(ab), 188P(ab), 223P(ab),  
     236P(ab), 237P(ab)  
 Fiorani, P. 875  
 Fiorelli, A. 57P(ab)  
 Fiorenza, M. 221P(ab)  
 Fioretti, PM. 18P(ab), 60P(ab),  
     155P(ab), 1481  
 Firouzbakht, ML. 241P(ab)  
 Fischman, AJ. 46P(ab), 58P(ab),  
     66P(ab), 89P(ab), 144P(ab),  
     167P(ab), 195P(ab), 203P(ab),  
     214P(ab), 220P(ab), 223P(ab),  
     233P(ab), 238P(ab), 239P(ab),  
     240P(ab), 266P(ab), 267P(ab)  
 Fisher, D. 91P(ab)  
 Fisher, DR. 1746  
 Fisher, PE. 47P(ab)  
 Fisher, S. 215  
 Fisher, SJ. 4P(ab), 186P(ab)  
 Fissekis, JD. 232P(ab)  
 Fitz Gerald, JD. 1647(1e)  
 Fitzgerald, J. 267P(ab)  
 Fitzpatrick, J. 271P(ab)  
 Flamen, P. 134P(ab), 267P(ab)  
 Fleming, JS. 17P(ab), 98P(ab),  
     745  
 Flesch, M. 227P(ab)  
 Fletcher, JW. 23N(6). 122P(ab),  
     248P(ab), 256P(ab),  
     277P(ab)P(tab), 1297  
 Flores, LG. 49P(ab), 138P(ab)  
 Flugelman, MY. 59P(ab)  
 Focșescanu, M. 6P(ab)  
 Foged, C. 55P(ab), 2061  
 Fogelman, I. 99  
 Folks, RD. 115P(ab)  
 Folks, RF. 146P(ab)  
 Folwaczny, C. 272P(ab)
- Fommei, E. 1297  
 Fong, Y. 134P(ab), 253P(ab)  
 Ford, M. 27P(ab)  
 Ford, PV. 88P(ab)  
 Foroutan, Y. 139P(ab)  
 Forsgren, M. 2055  
 Forster, J. 191P(ab)  
 Foster, NL. 96P(ab)  
 Foulon, CF. 105P(ab)  
 Foulon, W. 2194(1e)  
 Fowler, JS. 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab), 100P(ab), 238P(ab),  
     241P(ab)  
 Fradet, G. 192P(ab)  
 Fraile, M. 950  
 Fraker, D. 10P(ab), 95P(ab),  
     2087  
 Franceschini, R. 208P(ab)  
 Franceski, D. 12P(ab)  
 Francis, IR. 21S, 112P(ab), 707  
 Francis, TJR. 425  
 Francken, GA. 118P(ab)  
 Frangin, Y. 49P(ab), 120P(ab),  
     238P(ab)  
 Frank, R. 229P(ab)  
 Franke, W-G. 199P(ab),  
     246P(ab), 270P(ab), 271P(ab)  
 Franken, PR. 78P(ab), 88P(ab),  
     155P(ab), 1672, 1845, 1850  
 Franssen, EJF. 130P(ab), 699,  
     1736  
 Franzius, C. 114P(ab)  
 Fraxedas, R. 15  
 Freed, ME. 689  
 Freedman, M. 1511  
 Freedman, RS. 476  
 Freeman, LM. 19P(ab)  
 Freeman, SD. 440  
 Freeman, SJ. 346  
 Freifelder, R. 50P(ab), 171P(ab)  
 Freimuth, P. 222P(ab)  
 Freitag, K. 1398  
 Freitas, JE. 2012  
 French, S. 449  
 Frenkel, A. 10P(ab), 11P(ab),  
     104  
 Freshman, J. 240P(ab)  
 Freund, J. 298  
 Frey, EC. 120P(ab), 121P(ab),  
     170P(ab), 177P(ab), 179P(ab)  
 Frey, GD. 20N(4)  
 Frey, KA. 15P(ab), 96P(ab),  
     125P(ab), 202P(ab), 210P(ab),  
     211P(ab), 375(1e)  
 Friberg, L. 24N(4). 89P(ab)  
 Frieder, S. 95P(ab)  
 Fried, I. 68P(ab)  
 Friedland, RP. 2048  
 Friedman, HS. 104P(ab)  
 Friedman, JD. 3P(ab), 87P(ab),  
     101P(ab), 102P(ab), 103P(ab),  
     104P(ab), 154P(ab), 253P(ab)  
 Friedman, M. 189P(ab)  
 Frigerio, L. 243P(ab)  
 Fritzberg, AR. 20N(2). 91P(ab)  
 Froidveaux, S. 63P(ab)  
 Front, A. 59P(ab)  
 Front, D. 10P(ab), 11P(ab), 104,  
     1614  
 Frost, JJ. 3P(ab), 19P(ab),  
     40P(ab), 99P(ab), 207P(ab)  
 Frouin, F. 160P(ab)  
 Frouin, V. 160P(ab)  
 Fruchtman, S. 76P(ab)  
 Fuchs, PN. 207P(ab)
- Fueger, GF. 2153  
 Fuh, MT. 194P(ab), 270P(ab)  
 Fujibayashi, Y. 53P(ab),  
     90P(ab), 158P(ab), 204P(ab),  
     245, 251P(ab), 1132, 2178  
 Fujii, C. 178P(ab)  
 Fujii, H. 102P(ab), 252P(ab)  
 Fujii, K. 760  
 Fujii, R. 325  
 Fujimori, K. 158P(ab)  
 Fujimoto, M. 1681  
 Fujimoto, T. 195P(ab)  
 Fujino, S. 59P(ab)  
 Fujioka, H. 166P(ab)  
 Fujioka, Y. 244P(ab)  
 Fujita, J. 1626  
 Fujita, M. 13P(ab), 26P(ab),  
     72P(ab), 82P(ab), 123P(ab),  
     158P(ab), 202P(ab), 208P(ab),  
     1132  
 Fujita, T. 156P(ab), 163P(ab)  
 Fujiwara, M. 89P(ab)  
 Fujiwara, S. 582  
 Fujiwara, T. 98P(ab), 187P(ab),  
     195P(ab), 1219  
 Fukuchi, K. 140P(ab), 152P(ab),  
     162P(ab), 1348, 1676, 1862,  
     2084  
 Fukuchi, M. 157P(ab)  
 Fukuda, H. 203, 1219  
 Fukui, M. 213P(ab), 760, 974  
 Fukumoto, M. 191P(ab),  
     216P(ab), 242P(ab)  
 Fukumura, T. 213P(ab),  
     258P(ab), 760, 974  
 Fukunaga, T. 1002  
 Fukushi, K. 95P(ab)  
 Fukuzawa, S. 127P(ab)  
 Fulham, MJ. 786  
 Fulton, RR. 176P(ab)  
 Fumey, R. 90P(ab)  
 Furlan, AJ. 148P(ab)  
 Furudate, M. 127P(ab)  
 Furuchi, K. 163P(ab)  
 Furukawa, M. 716  
 Fuseau, C. 71P(ab), 72P(ab),  
     238P(ab)  
 Futami, S. 138P(ab)  
 Futatsubashi, M. 171P(ab),  
     172P(ab), 198  
 Futatsuya, R. 436  
 Gabel, M. 216P(ab)  
 Gacinovic, S. 82P(ab), 83P(ab),  
     124P(ab), 204P(ab)  
 Gadner, H. 29P(ab)  
 Gachle, GG. 117P(ab)  
 Gage, HD. 206P(ab)  
 Gagermeier, E. 214P(ab)  
 Gagnon, A. 2019  
 Gagnon, JH. 146P(ab)  
 Gail, R. 21P(ab)  
 Gaitini, D. 10P(ab), 11P(ab)  
 Galassi, R. 87P(ab)  
 Gali, H. 225P(ab)  
 Galimberti, V. 24P(ab), 2080  
 Galinier, E. 120P(ab)  
 Galle, P. 1100  
 Galleguillos, C. 57P(ab)  
 Galli, L. 40P(ab)  
 Gallowitsch, HJ. 215(1e), 236,  
     870  
 Galpern, WR. 54P(ab)  
 Galt, JR. 276P(ab)  
 Galvan, G. 798  
 Galynker, II. 608
- Gambetta, R. 60P(ab)  
 Gambhir, SS. 9P(ab), 10P(ab),  
     17N(1). 35P(ab), 53P(ab),  
     60P(ab), 68P(ab), 69P(ab),  
     94P(ab), 168P(ab), 211P(ab),  
     248P(ab), 278P(ab), 591, 729,  
     2003  
 Gangwar, PK. 270P(ab)  
 Gansow, OA. 829  
 Garcia, D. 154P(ab)  
 Garcia, EV. 107P(ab), 115P(ab),  
     146P(ab), 163P(ab), 918  
 Garcia-Burillo, A. 751, 950  
 Garcés, M. 137P(ab)  
 Gardin, I. 27P(ab)  
 Gardner, PM. 5P(ab), 25P(ab)  
 Garfinkle, WB. 275P(ab)  
 Garg, PK. 136P(ab), 159P(ab)  
 Gariépy, J. 1036  
 Garino, J. 33P(ab)  
 Gariépy, J. 77P(ab)  
 Garlick, PB. 93P(ab)  
 Garty, I. 244P(ab)  
 Gasparini, M. 1586  
 Gates, M. 108P(ab)  
 Gates, VL. 186P(ab), 259P(ab),  
     1230  
 Gatley, SJ. 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 100P(ab),  
     222P(ab)  
 Gaussen, A. 825  
 Gautherot, E. 246P(ab), 1608,  
     1937  
 Gauthier, T. 15P(ab)  
 Gayed, I. 20P(ab)  
 Geagan, MJ. 50P(ab)  
 Gebauer, K. 849  
 Gebhard, MW. 2027  
 Gebski, V. 95  
 Geerlings, MW. 223P(ab)  
 Gefter, W. 6P(ab)  
 Geide, A. 224  
 Geldof, AA. 183P(ab), 262P(ab)  
 Geleinse, ML. 1662  
 Genin, R. 104P(ab)  
 Gennari, R. 245P(ab)  
 George, J. 74P(ab), 75P(ab),  
     164P(ab)  
 Georgi, P. 213P(ab)  
 Georgiou, MF. 163P(ab), 1910  
 Georgitis, WJ. 1460  
 Gerali, S. 156P(ab)  
 Gerber, BL. 1655  
 Gerlach, L. 166P(ab)  
 Germann, C. 1418  
 Germano, G. 62P(ab), 87P(ab),  
     101P(ab), 103P(ab), 104P(ab),  
     253P(ab)  
 Gershenson, DM. 191P(ab)  
 Gerson, MC. 216P(ab), 219P(ab)  
 Gerundini, P. 58P(ab), 61P(ab),  
     117P(ab), 218P(ab), 1586  
 Gesty, J. 114P(ab)  
 Geurin, WP. 243P(ab)  
 Gewirtz, H. 46P(ab), 89P(ab)  
 Geyer, BC. 227P(ab)  
 Geyskes, G. 1297  
 Ghaemi, M. 148P(ab)  
 Ghali, SK. 339  
 Ghesani, M. 189P(ab), 192P(ab)  
 Ghezzi, C. 50P(ab)  
 Ghia, K. 74P(ab)  
 Gianelli, MV. 96P(ab)  
 Giannakenas, C. 1433  
 Gianolli, L. 171P(ab)  
 Gibbons, RJ. 62P(ab)

- Gibert, C. 29P(ab)  
 Giblin, MF. 77P(ab)  
 Gibson, RE. 1209  
 Gielow, P. 125P(ab)  
 Gifford, AN. 12P(ab)  
 Gifford, HC. 9P(ab), 79P(ab).  
 169P(ab)  
 Giganti, M. 133P(ab), 204P(ab)  
 Gil, JC. 57P(ab)  
 Gil, R. 82P(ab)  
 Gilardi, MC. 171P(ab)  
 Gildehaus, FJ. 14P(ab)  
 Gilland, DR. 92P(ab), 365, 856.  
 1105  
 Gillin, AG. 227P(ab)  
 Gillum, T. 214P(ab)  
 Gindi, GR. 121P(ab)  
 Gionfriddo, MA. 723  
 Giordani, B. 96P(ab)  
 Giorgetti, A. 396  
 Giorgi, MCP. 57P(ab)  
 Gips, S. 59P(ab), 1614  
 Gitelman, DR. 205P(ab)  
 Giubbini, R. 115P(ab), 154P(ab)  
 Giuliani, DC. 547  
 Giusto, F. 516  
 Gjedde, AH. 43P(ab), 110P(ab).  
 176  
 Glanister, DD. 190P(ab)  
 Glaser, C. 1166  
 Glaser, D. 33P(ab)  
 Glaspy, JA. 254P(ab), 431  
 Glass, EC. 1185  
 Glatting, G. 33P(ab), 81P(ab).  
 84P(ab), 181P(ab), 1030, 2145  
 Gledd, KN. 48P(ab)  
 Glover, DK. 160P(ab)  
 Glowiczki, P. 1635  
 Glowniak, JV. 259P(ab)  
 Gludovacz, D. 223P(ab)  
 Go, R. 43P(ab), 148P(ab).  
 212P(ab)  
 Gobbo, C. 40P(ab)  
 Gobi, J. 143P(ab)  
 Gockerman, JP. 647  
 Goddard, A. 202P(ab)  
 Goddu, SM. 84P(ab), 547  
 Goerges, R. 262P(ab)  
 Goetze, M. 70P(ab)  
 Goff, WB. 128P(ab)  
 Gohari, A. 19P(ab)  
 Goins, B. 58P(ab), 125P(ab).  
 1089  
 Gold, B. 191P(ab)  
 Gold, CA. 2012  
 Gold, DV. 247P(ab)  
 Goldenberg, C. 113P(ab)  
 Goldenberg, DM. 34, 71P(ab).  
 105P(ab), 112P(ab), 113P(ab).  
 150P(ab), 223P(ab), 235P(ab).  
 245P(ab), 247P(ab)  
 Goldfarb, CR. 6P(ab), 19P(ab).  
 114P(ab)  
 Goldman, D. 100P(ab)  
 Goldman, ME. 18P(ab)  
 Goldman, MS. 275P(ab)  
 Goldman, S. 276P(ab)  
 Goldsmith, SJ. 11N(12).  
 20P(ab), 77P(ab), 171P(ab)  
 Golish, SR. 168P(ab)  
 Gomez, D. 77P(ab)  
 Gomez, I. 236, 870  
 Gonzalez, JM. 751  
 Gonzalez, P. 57P(ab), 264P(ab)  
 Goodbody, AE. 267P(ab).  
 271P(ab)
- Goodman, LR. 5P(ab)  
 Goodman, MM. 35P(ab)  
 Goodwin, DA. 436, 1813, 2077  
 Goodwin, S. 19P(ab)  
 Goodwin, WJ. 243  
 Gopinath, S. 1810  
 Gordon, CM. 203P(ab)  
 Gordon, EM. 230P(ab)  
 Gordon, I. 490  
 Gordon, L. 58P(ab)  
 Goren, D. 99P(ab)  
 Gorenberg, M. 28P(ab)  
 Gorey, JG. 42P(ab), 100P(ab)  
 Görges, R. 185P(ab), 268P(ab).  
 533  
 Goris, ML. 71P(ab), 178P(ab).  
 721  
 Gorman, J. 82P(ab)  
 Gorman, JD. 128P(ab)  
 Gorman, RF. 929(lc)  
 Gormley, JE. 23P(ab)  
 Goto, R. 203  
 Goto, Y. 1676  
 Goulios, C. 1007  
 Govindan, SV. 105P(ab).  
 223P(ab)  
 Grace, E. 203P(ab)  
 Grachev, ID. 168P(ab)  
 Graeber, G. 80P(ab)  
 Graeff, H. 1398  
 Graham, BB. 1805  
 Graham, MM. 440, 1043, 1757.  
 1805  
 Graham, W. 220P(ab), 233P(ab).  
 266P(ab), 267P(ab)  
 Graham-Coco, W. 223P(ab)  
 Gralow, JR. 146P(ab)  
 Grambow, H. 259P(ab)  
 Grana, C. 24P(ab), 70P(ab).  
 243P(ab), 2080  
 Granerus, G. 1297  
 Grangeat, P. 168P(ab)  
 Grant, SJ. 207P(ab)  
 Gratz, S. 34P(ab), 70P(ab).  
 113P(ab), 130P(ab), 189P(ab).  
 262P(ab), 1248  
 Graves, CM. 271P(ab)  
 Graves, MW. 271P(ab)  
 Greco, M. 4, 254P(ab)  
 Green, LA. 10P(ab), 729, 2003  
 Green, MA. 91P(ab), 142P(ab).  
 191P(ab), 232P(ab), 1579,  
 1958  
 Green, MV. 272P(ab)  
 Greenberg, CR. 124P(ab)  
 Greenspan, BS. 1111  
 Greenwald, E. 236P(ab)  
 Greer, KL. 121P(ab), 227P(ab).  
 365, 1105  
 Gref, M. 2131  
 Gregoire, MC. 160P(ab)  
 Gregorius, GK. 166  
 Gremillet, E. 17P(ab)  
 Greschniok, A. 19P(ab)  
 Grierson, JR. 22P(ab), 190P(ab).  
 228P(ab), 229P(ab), 1418,  
 1757  
 Griffith, J. 75P(ab)  
 Griffiths, GL. 34, 78P(ab).  
 105P(ab), 223P(ab), 235P(ab).  
 245P(ab)  
 Griffiths, MR. 298  
 Grillo-López, AJ. 69P(ab).  
 185P(ab)  
 Grimm, W. 268P(ab)  
 Grivet-Fojaja, MR. 802
- Groch, MW. 145P(ab), 179P(ab)  
 Grodzki, M. 277P(ab)  
 Groen, HJM. 1736  
 Groh, T. 263P(ab)  
 Grollier, G. 1129, 1841  
 Grond, M. 148P(ab)  
 Grönroos, T. 254P(ab)  
 Grootoonk, S. 93P(ab)  
 Gropler, RJ. 4P(ab), 32P(ab).  
 145P(ab)  
 Groschar, D. 16P(ab), 28P(ab)  
 Gross, DR. 265P(ab)  
 Gross, MD. 109P(ab), 707  
 Grosse-Ruyken, M. 230P(ab)  
 Grossman, Z. 257P(ab)  
 Groth, S. 2131  
 Gruender, G. 83P(ab)  
 Gruenewald, SM. 95  
 Gründer, W. 1638  
 Grüning, T. 271P(ab)  
 Grünwald, F. 151P(ab).  
 212P(ab), 1551, 1903  
 Gualtieri, E. 37P(ab)  
 Guan, DHX. 745  
 Gubernick, JA. 275P(ab)  
 Guc, D. 1191  
 Güçüyener, K. 1703  
 Guelfguat, M. 114P(ab)  
 Guenther, I. 21P(ab), 72P(ab)  
 Guhlke, S. 48P(ab), 105P(ab).  
 143P(ab), 241P(ab)  
 Guhlmann, CA. 33P(ab).  
 81P(ab), 113P(ab), 190P(ab).  
 2145  
 Guidalotti, PL. 86P(ab)  
 Guillong, E. 94P(ab)  
 Guilloteau, D. 49P(ab).  
 118P(ab), 120P(ab), 238P(ab)  
 Guirgues, AF. 275P(ab)  
 Gulec, SA. 243, 1388  
 Gullberg, GT. 78P(ab).  
 120P(ab), 124, 144P(ab), 166,  
 177P(ab), 182P(ab), 1344  
 Gumerlock, PH. 842  
 Gunderman, R. 1081  
 Gündüz, U. 1191  
 Gunn, RN. 64P(ab)  
 Günther, G. 2055  
 Gunther, I. 71P(ab)  
 Gustafsson, GR. 640  
 Gustafsson, GR. 640  
 Guttmann, M. 209P(ab)  
 Gutwillig, B. 144P(ab)  
 Ha, HJ. 229P(ab)  
 Haaparanta, M. 141P(ab), 1320  
 Haas, F. 159P(ab)  
 Haase, U. 128P(ab), 139P(ab)  
 Habbema, JDF. 39P(ab)  
 Haber, SB. 218P(ab)  
 Haberl, M. 197P(ab)  
 Haberkorn, U. 165P(ab).  
 166P(ab), 227P(ab), 259P(ab).  
 1418  
 Habraken, JBA. 1879  
 Hachamovitch, R. 3P(ab).  
 87P(ab), 101P(ab), 102P(ab).
- Hahn, K. 14P(ab), 82P(ab).  
 114P(ab), 124P(ab), 153P(ab).  
 262P(ab), 272P(ab), 849, 1138  
 Hahn, LJ. 169P(ab)  
 Haim, N. 10P(ab), 11P(ab)  
 Ha-Kawa, SK. 1463  
 Halabi, G. 15P(ab)  
 Halama, JR. 38P(ab)  
 Halicolar, H. 2116  
 Halkar, RK. 276P(ab), 374(lc)  
 Hall, H. 237P(ab)  
 Halldin, C. 55P(ab), 72P(ab).  
 118P(ab), 120P(ab), 136P(ab).  
 208, 237P(ab), 1965, 2061  
 Halon, DA. 59P(ab)  
 Halpern, S. 132P(ab)  
 Halpick, J. 213P(ab)  
 Ham, HR. 16P(ab), 216(lc).  
 1646(lc), 2015(lc)  
 Hamabe, A. 127P(ab)  
 Hamada, M. 1486  
 Hamada, S. 1676, 2084  
 Hamanaka, Y. 129P(ab)  
 Hamblen, SM. 109P(ab).  
 257P(ab)  
 Hamböke, A-SE. 155P(ab), 1845  
 Hamill, TG. 1209  
 Hamilton, G. 77P(ab), 223P(ab)  
 Hamlin, DK. 91P(ab), 228P(ab)  
 Hammami, MM. 1452  
 Hamoir, E. 260P(ab)  
 Hanke, H. 1819  
 Hannequin, PP. 175P(ab), 555  
 Hanrath, P. 402  
 Hansen, CL. 46P(ab), 102P(ab)  
 Hansen, HJ. 78P(ab), 105P(ab).  
 113P(ab), 223P(ab), 235P(ab)  
 Hansen, L. 217P(ab)  
 Hanson, MW. 76P(ab).  
 161P(ab), 647, 1376  
 Hara, T. 52P(ab), 240P(ab), 990  
 Harada, K. 217P(ab)  
 Harada, T. 178P(ab)  
 Haraki, T. 59P(ab)  
 Harapanhalli, RS. 111P(ab)  
 Harder, W. 236  
 Hardoff, R. 1614  
 Harisch, C. 954  
 Harkness, BA. 24P(ab)  
 Harmer, C. 260P(ab)  
 Harrington, RD. 190P(ab)  
 Harrington, WN. 346  
 Harris, AR. 215P(ab)  
 Harris, TD. 215P(ab), 217P(ab)  
 Harrop, R. 65P(ab), 2183  
 Hartcke, HT. 1778  
 Harte, RJA. 1370  
 Hartley, CJ. 48P(ab)  
 Hartshorne, MF. 38P(ab)  
 Hartwig, W. 58P(ab)  
 Harvey, DC. 41P(ab)  
 Harwood, SJ. 671  
 Hasani, A. 193P(ab)  
 Hasegawa, A. 153P(ab)  
 Hasegawa, BH. 98P(ab), 562  
 Hasegawa, S. 152P(ab)  
 Haseman, MK. 134P(ab).  
 135P(ab), 653  
 Hashikawa, K. 961, 1348  
 Hashimoto, A. 1492  
 Hashimoto, J. 102P(ab)
- Hashimoto, M. 1875  
 Hatakeyama, S. 156P(ab)  
 Hatano, H. 127P(ab)  
 Hatano, K. 214P(ab), 230P(ab)  
 Hatazawa, J. 182P(ab), 302.  
 1789  
 Hatori, T. 153P(ab)  
 Hattori, N. 88P(ab), 141P(ab).  
 148P(ab), 157P(ab), 390, 938.  
 1835  
 Hatzifotiadis, D. 156P(ab)  
 Hauesinger, K. 257P(ab)  
 Haunso, S. 89P(ab)  
 Hauser, H. 1769  
 Hauser, M. 56P(ab)  
 Havlik, E. 246P(ab), 1928, 2090  
 Hawk, TC. 257P(ab)  
 Hawkins, RA. 20P(ab)  
 Hawman, EG. 79P(ab)  
 Hawman, P. 2183  
 Hayabuchi, N. 320, 473, 1518  
 Hayase, N. 191P(ab)  
 Hayashi, N. 123P(ab), 251P(ab).  
 453, 2121  
 Hayashida, K. 408, 2084  
 Hayes, SW. 102P(ab), 154P(ab)  
 Haynes, NG. 142P(ab)  
 Haynie, T. 20P(ab)  
 Hayran, M. 1191  
 Hazan, E. 587  
 Hazenberg, BPC. 699  
 Haznedar, R. 1  
 Hazra, DK. 270P(ab)  
 He, Z-X. 253P(ab)  
 Heald, DL. 1972  
 Heath, GA. 1647(lc)  
 Heckers, S. 168P(ab)  
 Hedberg, E. 1273  
 Heerd, S. 268P(ab)  
 Heichel, T. 53P(ab)  
 Heidbreder, E. 86P(ab)  
 Heidendaal, GAK. 1605  
 Heilmann, JJ. 275P(ab)  
 Heinle, SK. 140  
 Heinz, A. 42P(ab), 100P(ab)  
 Heinzel-Wieland, R. 1638  
 Heiss, P. 238P(ab), 1762  
 Heiss, W-D. 133P(ab), 148P(ab)  
 Heit, JA. 218P(ab)  
 Hejna, M. 1570  
 Helfenbein, J. 120P(ab).  
 238P(ab)  
 Heller, EN. 417  
 Heller, GV. 32P(ab), 76P(ab).  
 153P(ab), 2019  
 Heller, S. 522  
 Hellman, RS. 5P(ab), 217P(ab)  
 Hellwig, D. 107P(ab), 147  
 Helsabeck, C. 10P(ab)  
 Hemelaar, JTGM. 13P(ab)  
 Hemidan, A. 1452  
 Heminway, S. 215P(ab)  
 Hendel, RC. 153P(ab), 179P(ab)  
 Henderson, D. 237P(ab).  
 239P(ab)  
 Henderson, MA. 11P(ab)  
 Hendrikse, NH. 130P(ab)  
 Henke, K. 111P(ab)  
 Henkin, RE. 38P(ab), 1649(lc)  
 Hennig, M. 63P(ab)  
 Henry, TR. 107P(ab), 110P(ab)  
 Henze, E. 38P(ab), 1237, 1913  
 Henzlova, M. 18P(ab), 76P(ab).  
 154P(ab)  
 Heo, J. 116P(ab), 2019  
 Heppeler, A. 63P(ab)

- Herbster, A. 205P(ab)  
 Herman, SD. 153P(ab)  
 Hermann, GA. 273P(ab), 1260  
 Hermansen, F. 1696  
 Herment, A. 160P(ab)  
 Hermsen, M. 262P(ab)  
 Herold, C. 2090  
 Herrero, P. 32P(ab), 145P(ab)  
 Herrlinger, U. 236P(ab)  
 Herrmann, G. 1155  
 Herrmann, R. 70P(ab), 879  
 Herschman, HR. 10P(ab),  
   35P(ab), 53P(ab), 729, 2003  
 Herscovitch, P. 85P(ab),  
   135P(ab), 136P(ab)  
 Hertel, A. 66P(ab), 94P(ab),  
   1155  
 Hervé, P. 1986  
 Herz, LH. 107P(ab)  
 Herz, M. 73P(ab)  
 Herzog, H. 22P(ab), 188P(ab),  
   230P(ab)  
 Hess, J. 56P(ab)  
 Hesse, B. 89P(ab)  
 Hesse, S. 213P(ab)  
 Heydari, N. 83P(ab)  
 Heyman, S. 55P(ab), 56P(ab),  
   201P(ab), 865  
 Hichwa, RD. 203P(ab), 239P(ab)  
 Hicks, RJ. 11P(ab), 249P(ab)  
 Hiddemann, W. 70P(ab)  
 Hierholzer, J. 954  
 Higashi, K. 9, 247P(ab),  
   248P(ab), 1016  
 Higashi, N. 2161  
 Higashi, T. 224P(ab), 250P(ab),  
   252P(ab), 1727  
 Higginbotham, C. 215P(ab),  
   222P(ab), 225P(ab)  
 Higley, D. 42P(ab)  
 Higuchi, T. 233P(ab), 234P(ab),  
   541, 663  
 Hilger, CS. 1819  
 Hillier, S. 223P(ab), 233P(ab),  
   266P(ab)  
 Hilson, AJW. 85P(ab), 129P(ab),  
   138P(ab), 150P(ab)  
 Himi, T. 89P(ab), 1123  
 Hindié, E. 1100  
 Hines, H. 37P(ab), 108P(ab),  
   133P(ab)  
 Hinkle, GH. 650  
 Hinnen, F. 21P(ab), 229P(ab)  
 Hirai, J. 59P(ab)  
 Hirai, T. 158P(ab), 1132  
 Hirakawa, K. 26P(ab)  
 Hiraki, Y. 200P(ab), 529, 2095  
 Hiramatsu, T. 106P(ab)  
 Hirani, E. 237P(ab)  
 Hirano, T. 541  
 Hiraoka, M. 252P(ab)  
 Hirasawa, K. 127P(ab)  
 Hirawat, S. 146P(ab)  
 Hiromatsu, Y. 320  
 Hiroto, N. 1875  
 Hirose, Y. 408  
 Hirsch, C. 262P(ab)  
 Hirsch, W. 275P(ab)  
 Hisada, K. 126P(ab)  
 Hitzenmann, RJ. 54P(ab),  
   100P(ab)  
 Hiwada, K. 1486  
 Hnatowich, DJ. 56, 219P(ab),  
   241P(ab)  
 Ho, B. 267P(ab)  
 Ho, K-C. 677  
 Ho, W-L. 1752  
 Ho, Y-J. 1354  
 Hobson, D. 124P(ab)  
 Hoekstra, HJ. 810, 1027, 1736  
 Hockstra, OS. 302P(ab)  
 Hoess, C. 1398  
 Hofer, S. 879  
 Hoffend, J. 153P(ab)  
 Hoffman, EJ. 9P(ab)  
 Hoffman, JM. 35P(ab),  
   107P(ab), 110P(ab)  
 Hoffman, TJ. 77P(ab), 215P(ab),  
   222P(ab), 225P(ab)  
 Hoffmann, J. 122P(ab)  
 Hofland, LJ. 39P(ab), 62P(ab),  
   264P(ab)  
 Hofmann, GO. 114P(ab)  
 Hofstrand, PD. 35P(ab),  
   229P(ab)  
 Hogarty, A. 201P(ab)  
 Hoh, CK. 9P(ab), 60P(ab),  
   68P(ab), 69P(ab), 90P(ab),  
   94P(ab), 145P(ab), 150P(ab),  
   165P(ab), 167P(ab), 254P(ab),  
   278P(ab)P(ab), 431, 729, 1302  
 Hohenberger, P. 465, 1197  
 Holden, JE. 792, 1684, 1690,  
   1884  
 Holder, LE. 195P(ab)  
 Holgate, ST. 98P(ab)  
 Hollema, H. 1381  
 Hollinger, EF. 1335  
 Holló, A. 27P(ab)  
 Holm, S. 131P(ab)  
 Holman, BL. 923, 965  
 Holoye, P. 244P(ab)  
 Holschbach, M. 22P(ab),  
   131P(ab), 188P(ab), 230P(ab),  
   1596  
 Holt, DP. 165P(ab), 239P(ab)  
 Homayounfar, T. 262P(ab)  
 Homma, Y. 1784  
 Hommel, G. 533  
 Hommer, D. 100P(ab)  
 Honda, N. 45P(ab), 193P(ab)  
 Honda, T. 250P(ab), 1727  
 Hong, MK. 250P(ab)  
 Hong, SB. 69P(ab)  
 Hong, SC. 69P(ab)  
 Hong, SW. 195P(ab)  
 Hopkins, K. 173P(ab), 174P(ab)  
 Hör, G. 66P(ab), 94P(ab),  
   134P(ab), 1155  
 Hori, M. 1348  
 Horikawa, E. 195P(ab)  
 Hornick, JL. 222P(ab)  
 Horowitz, M. 108  
 Horti, A. 209P(ab)  
 Hosencfeld, J. 238P(ab)  
 Hoshizaki, H. 153P(ab)  
 Hoskinson, M. 154P(ab)  
 Hirasawa, K. 127P(ab)  
 Hirawat, S. 146P(ab)  
 Hiromatsu, Y. 320  
 Hiroto, N. 1875  
 Hirose, Y. 408  
 Hirsch, C. 262P(ab)  
 Hirsch, W. 275P(ab)  
 Hisada, K. 126P(ab)  
 Hitzenmann, RJ. 54P(ab),  
   100P(ab)  
 Hiwada, K. 1486  
 Hnatowich, DJ. 56, 219P(ab),  
   241P(ab)  
 Ho, B. 267P(ab)  
 Ho, K-C. 677  
 Houston, S. 99  
 Houston, T. 90P(ab)  
 Houston, TK. II. 1454  
 Houstoulaki, E. 1433  
 Hove, JD. 89P(ab), 168P(ab),  
   591  
 Howarth, D. 1635  
 Howell, RW. 84P(ab), 183P(ab),  
   547  
 Howman-Giles, RB. 27P(ab),  
   311, 1428, 1983, 2195(lc)  
 Hoyes, KP. 895  
 Hoyt, G. 160P(ab)  
 Hsiao, IT. 121P(ab)  
 Hsieh, B-T. 1752  
 Hsieh, JC. 205P(ab)  
 Hsu, L. 265P(ab)  
 Hsu, MG. 197P(ab)  
 Hsu, P. 154P(ab)  
 Hu, J. 61P(ab), 62P(ab)  
 Hu, P. 222P(ab), 247P(ab)  
 Hua, C. 51P(ab), 132P(ab),  
   173P(ab)  
 Huang, C-C. 1711  
 Huang, DF. 205P(ab)  
 Huang, HF. 197P(ab)  
 Huang, S-C. 9P(ab), 41P(ab),  
   42P(ab), 65P(ab), 145P(ab),  
   211P(ab), 272, 278P(ab)  
 Huang, WS. 194P(ab), 197P(ab),  
   270P(ab), 271P(ab)  
 Huang, X-F. 6P(ab), 7P(ab)  
 Huang, Y. 119P(ab)  
 Hubb, A. 116P(ab)  
 Hubner, KF. 52P(ab), 249P(ab)  
 Hübner, R-H. 1237  
 Hübsch, P. 1575  
 Huch, RA. 1892  
 Hudkins, K. 173P(ab)  
 Huesman, RH. 93P(ab),  
   144P(ab), 171P(ab), 228P(ab)  
 Hüfner, M. 189P(ab)  
 Huglo, D. 1172  
 Hugo, H-H. 38P(ab), 1913  
 Hugonnard, P. 168P(ab)  
 Huitink, JM. 1481  
 Hume, SP. 49P(ab), 237P(ab)  
 Humen, DP. 154P(ab), 579  
 Hamm, JL. 51P(ab), 67P(ab),  
   174P(ab), 188P(ab),  
   278P(ab)P(ab), 484  
 Humphrey, W. 233P(ab)  
 Hundeshagen, H. 202P(ab)  
 Hung, D-Z. 769  
 Hung, JC. 241P(ab), 243P(ab),  
   912  
 Hunt, KJ. 95P(ab), 190P(ab)  
 Hunter, DH. 143P(ab), 218P(ab)  
 Hunter, J. 56P(ab)  
 Hurley, JR. 20P(ab), 522  
 Hurtado, T. 172P(ab)  
 Hurwitz, GA. 155P(ab), 339  
 Hosoda, S. 1117  
 Hosokawa, R. 141P(ab),  
   158P(ab), 938, 1132  
 Hosono, M. 45P(ab), 193P(ab),  
   1608  
 Hospers, GAP. 130P(ab)  
 Hosten, N. 954  
 Hostettler, ED. 34P(ab)  
 Hötte, P. 189P(ab)  
 Hou, C. 215P(ab)  
 Hou, N. 201P(ab)  
 Houle, S. 64P(ab), 71P(ab),  
   119P(ab), 209P(ab), 236P(ab)  
 Houston, A. 17P(ab)  
 Houston, AS. 425  
 Houston, S. 99  
 Houston, T. 90P(ab)  
 Houston, TK. II. 1454  
 Houstoulaki, E. 1433  
 Hove, JD. 89P(ab), 168P(ab),  
   591  
 Howarth, D. 1635  
 Howell, RW. 84P(ab), 183P(ab),  
   547  
 Howman-Giles, RB. 27P(ab),  
   311, 1428, 1983, 2195(lc)  
 Hoyes, KP. 895  
 Hoyt, G. 160P(ab)  
 Hsiao, IT. 121P(ab)  
 Hsieh, B-T. 1752  
 Hsieh, JC. 205P(ab)  
 Hsu, L. 265P(ab)  
 Hsu, MG. 197P(ab)  
 Hsu, P. 154P(ab)  
 Hu, J. 61P(ab), 62P(ab)  
 Hu, P. 222P(ab), 247P(ab)  
 Hua, C. 51P(ab), 132P(ab),  
   173P(ab)  
 Huang, C-C. 1711  
 Huang, DF. 205P(ab)  
 Huang, HF. 197P(ab)  
 Huang, S-C. 9P(ab), 41P(ab),  
   42P(ab), 65P(ab), 145P(ab),  
   211P(ab), 272, 278P(ab)  
 Huang, WS. 194P(ab), 197P(ab),  
   270P(ab), 271P(ab)  
 Huang, X-F. 6P(ab), 7P(ab)  
 Huang, Y. 119P(ab)  
 Hubb, A. 116P(ab)  
 Hubner, KF. 52P(ab), 249P(ab)  
 Hübner, R-H. 1237  
 Hübsch, P. 1575  
 Huch, RA. 1892  
 Hudkins, K. 173P(ab)  
 Huesman, RH. 93P(ab),  
   144P(ab), 171P(ab), 228P(ab)  
 Hüfner, M. 189P(ab)  
 Huglo, D. 1172  
 Hugo, H-H. 38P(ab), 1913  
 Hugonnard, P. 168P(ab)  
 Huitink, JM. 1481  
 Hume, SP. 49P(ab), 237P(ab)  
 Humen, DP. 154P(ab), 579  
 Hamm, JL. 51P(ab), 67P(ab),  
   174P(ab), 188P(ab),  
   278P(ab)P(ab), 484  
 Humphrey, W. 233P(ab)  
 Hundeshagen, H. 202P(ab)  
 Hung, D-Z. 769  
 Hung, JC. 241P(ab), 243P(ab),  
   912  
 Hunt, KJ. 95P(ab), 190P(ab)  
 Hunter, DH. 143P(ab), 218P(ab)  
 Hunter, J. 56P(ab)  
 Hurley, JR. 20P(ab), 522  
 Hurtado, T. 172P(ab)  
 Hurwitz, GA. 155P(ab), 339  
 Hosoda, S. 1117  
 Hosokawa, R. 141P(ab),  
   158P(ab), 938, 1132  
 Hosono, M. 45P(ab), 193P(ab),  
   1608  
 Hospers, GAP. 130P(ab)  
 Hosten, N. 954  
 Hostettler, ED. 34P(ab)  
 Hötte, P. 189P(ab)  
 Hou, C. 215P(ab)  
 Hou, N. 201P(ab)  
 Houle, S. 64P(ab), 71P(ab),  
   119P(ab), 209P(ab), 236P(ab)  
 Houston, A. 17P(ab)  
 Houston, AS. 425
- Hwang, YS. 212P(ab)  
 Hyder, F. 26P(ab)  
 Hyun, M. 117P(ab)  
 Ibanez, V. 65P(ab)  
 Ichihara, T. 176P(ab), 177P(ab),  
   178P(ab), 334  
 Ichise, M. 14P(ab), 72P(ab),  
   123P(ab), 209P(ab), 503, 923,  
   1511  
 Ichiya, Y. 137P(ab), 258P(ab),  
   760  
 Ichiyanagi, K. 59P(ab), 716  
 Ida, K. 2095  
 Ida, M. 147P(ab), 252P(ab)  
 Ido, A. 157P(ab)  
 Ido, T. 195P(ab), 325  
 Iguchi, N. 1117  
 Iida, H. 129P(ab), 141P(ab), 181,  
   182P(ab), 1789  
 Iida, Y. 226P(ab)  
 Ikeda, T. 1681  
 Ikeoka, K. 157P(ab)  
 Ikezoc, J. 166P(ab)  
 Illes, DL. 271P(ab)  
 Ilgan, S. 210P(ab), 233P(ab),  
   234P(ab)  
 Imahori, Y. 325  
 Imamura, M. 250P(ab), 1727  
 Imamura, T. 1875  
 Imazeki, K. 1002  
 Imbriaco, M. 253P(ab)  
 Imran, MB. 203, 1219  
 Inagaki, M. 127P(ab)  
 Inanir, S. 116  
 Ingram, DK. 207P(ab)  
 Innis, RB. 13P(ab), 14P(ab),  
   21P(ab), 26P(ab), 37P(ab),  
   40P(ab), 72P(ab), 82P(ab),  
   123P(ab), 136P(ab), 202P(ab),  
   208P(ab), 209P(ab), 1500,  
   1719  
 Inobe, Y. 157P(ab)  
 Inokuma, T. 250P(ab), 1727  
 Inoue, S. 1117  
 Inoue, T. 53P(ab), 152P(ab),  
   153P(ab), 166P(ab), 234P(ab),  
   236P(ab), 541, 663, 1424  
 Inoue, Y. 1784  
 Inouye, T. 178P(ab)  
 Inubushi, M. 88P(ab), 141P(ab),  
   157P(ab), 172P(ab), 390, 938,  
   1835  
 Iosilevsky, G. 104, 1614  
 Irie, T. 95P(ab)  
 Irngartinger, G. 53P(ab), 465  
 Irwig, LM. 1428  
 Irwin, AG. 85P(ab)  
 Isacson, O. 54P(ab)  
 Ishi, K. 293  
 Ishi, Y. 245  
 Ishibashi, M. 320, 473, 1518  
 Ishida, M. 1348  
 Ishida, Y. 140P(ab), 162P(ab),  
   1676, 1862, 2084  
 Ishigaki, T. 161P(ab), 162P(ab)  
 Ishihara, H. 252P(ab)  
 Ishihara, M. 149P(ab)  
 Ishii, K. 163P(ab), 376(lc), 1875  
 Ishii, S. 131P(ab), 498  
 Ishii, Y. 53P(ab), 123P(ab),  
   158P(ab), 164P(ab), 204P(ab),  
   213P(ab), 251P(ab), 453, 2121  
 Ishikawa, K. 931(lc)  
 Ishikawa, Y. 86P(ab), 126P(ab),  
   140P(ab)  
 Jansen, HML. 495

- Janssen, AGM, 13P(ab), 124P(ab), 1143, 1879
- Jarritt, P, 17P(ab)
- Jaszczak, RJ, 79P(ab), 121P(ab), 227P(ab), 365, 856, 1105
- Jatene, M, 57P(ab)
- Jatlow, PA, 13P(ab)
- Javaid, A, 75P(ab), 76P(ab)
- Jeanguillaume, C, 1100
- Jeannotte, S, 1441
- Jeffery, JR, 199P(ab)
- Jeffrey, S, 24P(ab)
- Jeng, CY, 194P(ab)
- Jenkins, BG, 54P(ab)
- Jenner, DA, 11P(ab)
- Jensen, M, 131P(ab)
- Jentzen, W, 185P(ab)
- Jeon, DG, 195P(ab)
- Jeon, P, 629
- Jeong, HJ, 184P(ab)
- Jeong, JM, 234P(ab), 235P(ab), 250P(ab), 255P(ab), 261P(ab), 267P(ab), 303P(ab)
- Jermann, E, 63P(ab), 143P(ab), 221P(ab)
- Jerusalem, G, 147P(ab), 254P(ab)
- Jha, B, 38P(ab)
- Jiang, C, 247P(ab)
- Jimenez, C, 32P(ab)
- Jimenez-Hoyuela, J, 2087
- Jinnouchi, S, 49P(ab), 138P(ab)
- Jivan, S, 172P(ab), 173P(ab)
- Jobert, A, 229P(ab)
- Jofré, MJ, 264P(ab)
- Joh, CW, 85P(ab)
- Johanns, J, 96P(ab)
- John, CS, 227P(ab)
- Johnson, CA, 179P(ab)
- Johnson, J, 90P(ab)
- Johnson, JA, 272
- Johnson, KA, 965
- Johnson, LL, 4P(ab), 1468
- Johnson, R, 197P(ab)
- Johnson, RR, 173P(ab)
- Johnson, RW, 159P(ab)
- Johnson, TK, 172P(ab), 276P(ab), 277P(ab)
- Johnson, VE, 121P(ab)
- Joja, I, 529
- Jonas, D, 6P(ab), 114P(ab)
- Jones, AG, 187P(ab)
- Jones, BJ, 1405
- Jones, DW, 42P(ab), 100P(ab)
- Jones, K, 965
- Jones, LA, 91P(ab), 104P(ab), 1944
- Jones, P, 101P(ab)
- Jones, RH, 140
- Jones, SB, 128P(ab)
- Jones, TD, 1223
- Jonson, SD, 34P(ab), 36P(ab)
- Jonsson, C, 106P(ab)
- Jordaens, L, 155P(ab)
- Joshi, R, 130P(ab), 236P(ab), 237P(ab)
- Joshua, AV, 10P(ab)
- Josserand, V, 50P(ab)
- Jousse, F, 80P(ab), 98P(ab)
- Judy, K, 255P(ab)
- Judy, P, 79P(ab)
- Juhlin, C, 982
- Jundt, G, 1980
- Jungehülsing, M, 256P(ab)
- Juni, JE, 923
- Juptner, M, 110P(ab)
- Jurcic, JG, 188P(ab)
- Jürgens, H, 114P(ab)
- Jurisson, SS, 77P(ab)
- Just, WW, 227P(ab)
- Juweid, M, 34, 71P(ab), 112P(ab)
- Joyal, SK, 270P(ab)
- Kaandorp, Y, 19P(ab)
- Kabasakal, L, 217P(ab)
- Kachi, T, 214P(ab)
- Kaczur, T, 212P(ab)
- Kado, H, 181, 302, 1789
- Kadrmas, DJ, 120P(ab), 121P(ab), 144P(ab), 177P(ab)
- Kahaly, G, 533
- Kahl, SB, 233P(ab)
- Kahn, D, 113P(ab), 194P(ab), 1297
- Kaim, A, 1980
- Kainberger, F, 1166
- Kainz, C, 77P(ab)
- Kaiser, HJ, 147
- Kaji, T, 85P(ab), 261P(ab)
- Kajiwara, M, 252P(ab)
- Kakiuchi, T, 198
- Kalaigian, H, 278P(ab)
- Kalden, JR, 1638
- Kalf, V, 51P(ab)
- Kalf, V, 11P(ab), 249P(ab)
- Kalontzi, C, 156P(ab)
- Kamano, T, 45P(ab), 193P(ab)
- Kaminska, A, 27P(ab)
- Kaminski, MS, 21S, 112P(ab), 147P(ab), 186P(ab), 1230
- Kamiya, T, 1862
- Kamoto, Y, 148P(ab), 163P(ab)
- Kamphuis, C, 61P(ab), 178P(ab), 1996
- Kanal, KM, 2027
- Kanamori, S, 252P(ab)
- Kanazawa, N, 152P(ab)
- Kanazawa, S, 529, 2095
- Kanegae, K, 85P(ab), 127P(ab), 261P(ab), 656, 807
- Kaneko, S, 86P(ab), 131P(ab), 230P(ab)
- Kang, DY, 273P(ab)
- Kang, HJ, 85P(ab)
- Kang, WJ, 59P(ab), 60P(ab)
- Kang, X, 3P(ab), 87P(ab), 253P(ab)
- Kanja, J, 185P(ab)
- Kanno, I, 302, 1789
- Kanno, T, 171P(ab), 172P(ab)
- Kansu, E, 1191
- Kanz, L, 147P(ab)
- Kanzaki, H, 129P(ab)
- Kao, C-H, 196P(ab), 256P(ab), 272P(ab), 769, 773, 1354, 1449, 1707, 1798
- Kao, PF, 59P(ab), 197P(ab), 1209
- Kapeller, P, 790
- Kapucu, LÖ, 304, 1267, 1703
- Karabay, O, 587
- Karacalioglu, 199P(ab)
- Karacay, H, 245P(ab)
- Karaloizos, L, 156P(ab)
- Karam, LR, 219P(ab)
- Karamychev, VN, 236P(ab)
- Karayalcin, G, 29P(ab)
- Karkabi, B, 59P(ab)
- Karlsson, P, 118P(ab), 2061
- Karp, JS, 37P(ab), 50P(ab), 120P(ab), 133P(ab), 171P(ab), 178P(ab), 180P(ab), 181P(ab)
- Karpeh, M, 135P(ab)
- Karra, S, 225P(ab)
- Kars, A, 1191
- Karvelis, KC, 260P(ab), 277P(ab)
- Kasai, S, 57P(ab)
- Kaschten, B, 778
- Kaserer, K, 223P(ab), 1575, 1907
- Kasper, EK, 3P(ab)
- Kasperk, R, 81P(ab)
- Kassis, AI, 111P(ab), 183P(ab), 186P(ab), 245P(ab), 1148
- Kässmann, H, 798
- Kastin, A, 16P(ab)
- Kastis, GK, 9P(ab), 172P(ab)
- Kastrati, A, 139P(ab)
- Katada, R, 57P(ab)
- Katagiri, Y, 158P(ab)
- Kataoka, T, 178P(ab)
- Kates, AM, 4P(ab)
- Kathol, RG, 203P(ab)
- Kathren, R, 191P(ab)
- Kato, H, 204P(ab), 251P(ab), 716
- Kato, K, 162P(ab), 226P(ab)
- Kato, T, 161P(ab), 162P(ab), 214P(ab)
- Katoh, C, 807
- Katoma, CLE, 124P(ab)
- Katsifis, A, 50P(ab)
- Katsiyannis, PT, 160P(ab)
- Katsuda, N, 176P(ab), 181P(ab)
- Katsushima, S, 1727
- Katsuura, H, 85P(ab)
- Katti, KV, 225P(ab)
- Katzellenbogen, JA, 34P(ab)
- Kaufmann, R, 94P(ab)
- Kauppi, AC, 115P(ab)
- Kavanagh, PB, 62P(ab), 103P(ab), 104P(ab)
- Kawabe, J, 256P(ab)
- Kawai, K, 49P(ab)
- Kawakami, Y, 889
- Kawamura, T, 889
- Kawashima, H, 226P(ab)
- Kawashima, R, 203
- Kawasumi, Y, 214P(ab)
- Kawatsuma, S, 162P(ab)
- Kay, C, 58P(ab)
- Kay, J, 90P(ab)
- Kazumata, K, 209P(ab), 1521
- Keane, M, 116P(ab)
- Keenan, RJ, 1267
- Kegeles, L, 55P(ab), 82P(ab), 167P(ab), 207P(ab)
- Keil, R, 35P(ab)
- Keilp, J, 207P(ab)
- Kelbæk, H, 89P(ab), 591
- Kellar, KJ, 48P(ab)
- Keller, IB, 52P(ab)
- Kellie, SJ, 1983
- Kelty, NL, 195P(ab), 275P(ab)
- Kemeny, N, 134P(ab), 253P(ab)
- Kemp, BJ, 8P(ab), 106P(ab), 182P(ab), 190
- Kemp, PM, 425
- Kennedy, SC, 216P(ab), 219P(ab)
- Kennel, S, 184P(ab)
- Kenski, DM, 229P(ab)
- Keough, JE, 273P(ab)
- Kerenyi, L, 100P(ab), 196P(ab)
- Kerner, M, 14P(ab), 124P(ab)
- Kertesz, A, 106P(ab)
- Kerwin, RW, 82P(ab), 83P(ab), 204P(ab)
- Keske, U, 954
- Kesler, K, 140
- Ketchum, LE, 15N(11)
- Kettelkamp, R, 203P(ab)
- Kettner, B, 118P(ab), 196P(ab), 224, 259P(ab), 2141
- Khader, N, 59P(ab)
- Khalkhal, I, 139P(ab), 449, 849
- Khawli, LA, 222P(ab), 247P(ab)
- Kiarash, R, 77P(ab)
- Kiesewetter, DO, 85P(ab)
- Kigami, Y, 129P(ab)
- Kijewski, MF, 36P(ab)
- Kijima, T, 149P(ab)
- Kikuchi, K, 86P(ab), 157P(ab)
- Kikut, J, 19P(ab)
- Kilbourn, MR, 15P(ab), 125P(ab), 132P(ab), 202P(ab), 210P(ab)
- Kiliç, AK, 28
- Kilinc, O, 2116
- Kilroy, KJ, 120P(ab), 126P(ab)
- Kilts, C, 35P(ab)
- Kim, BM, 2044
- Kim, B-T, 12P(ab), 54P(ab), 65P(ab), 69P(ab), 154P(ab), 229P(ab), 252P(ab), 303P(ab)
- Kim, CK, 18P(ab), 31P(ab), 126P(ab), 150P(ab), 253P(ab), 1366, 1401
- Kim, DG, 619
- Kim, DH, 150P(ab)
- Kim, DI, 281, 619, 629
- Kim, EE, 210P(ab), 234P(ab)
- Kim, E-H, 234P(ab)
- Kim, HJ, 122P(ab), 248P(ab), 256P(ab)
- Kim, HS, 85P(ab)
- Kim, IS, 76P(ab)
- Kim, J-H, 1444
- Kim, JR, 2161
- Kim, JS, 211P(ab)
- Kim, JY, 65P(ab), 91, 184P(ab)
- Kim, KB, 59P(ab), 60P(ab)
- Kim, KM, 103P(ab)
- Kim, M-K, 76P(ab), 221P(ab), 232P(ab), 236P(ab), 272P(ab)
- Kim, MW, 273P(ab)
- Kim, SE, 12P(ab), 54P(ab), 65P(ab), 69P(ab), 154P(ab), 229P(ab), 252P(ab), 1209
- Kim, SH, 33P(ab), 54P(ab)
- Kim, S-H, 130, 1444
- Kim, SJ, 69P(ab), 195P(ab), 281
- Kim, SK, 103P(ab), 212P(ab), 213P(ab), 235P(ab), 303P(ab)
- Kim, TK, 130P(ab)
- Kim, Y-C, 91
- Kim, YH, 12P(ab)
- Kim, YJ, 14P(ab), 209P(ab), 235P(ab), 255P(ab)
- Kim, YK, 103P(ab), 261P(ab), 267P(ab)
- Kim, YM, 85P(ab), 2161
- Kimura, H, 213P(ab), 1160
- Kimura, T, 250P(ab), 1727
- Kinan, D, 75P(ab)
- King, B, 257P(ab)
- King, MA, 79P(ab), 169P(ab), 180P(ab)
- King, R, 117P(ab), 118P(ab)
- Kinne, RW, 1638
- Kino, S, 57P(ab)
- Kinomura, S, 203
- Kinoshita, M, 933
- Kinoshita, T, 181, 182P(ab)
- Kinter, CM, 21P(ab)
- Kinuya, S, 106P(ab), 436, 2077
- Kinzl, L, 33P(ab), 2145
- Kipper, M, 128P(ab), 132P(ab)
- Kira, T, 107P(ab), 176P(ab)
- Kirath, P, 1191
- Kirch, DL, 172P(ab), 276P(ab), 277P(ab)
- Kirchner, PT, 19P(ab), 123P(ab)
- Kirkman, RL, 63P(ab), 224P(ab)
- Kirsch, C-M, 107P(ab), 262P(ab), 1551
- Kirscher, MH, 114P(ab)
- Kishi, H, 52P(ab), 990
- Kishi, T, 1626
- Kishimoto, T, 220P(ab)
- Kison, PV, 4P(ab), 44P(ab), 51P(ab), 66P(ab), 147P(ab), 258P(ab)
- Kissel, J, 165P(ab)
- Kitabatake, A, 127P(ab)
- Kitagaki, H, 163P(ab), 293, 1875
- Kitahara, H, 1160
- Kitano, H, 938, 1835
- Kitano, T, 334
- Kitayama, H, 256P(ab)
- Kitsiou, AN, 141P(ab)
- Kitsukawa, S, 1123, 2022
- Kiwit, JCW, 1596
- Klauss, V, 153P(ab)
- Kleiman, NS, 253P(ab)
- Klein, D, 350
- Klein, GJ, 93P(ab), 190P(ab)
- Klein, JL, 146P(ab)
- Klein, M, 264P(ab)
- Kleinhans, E, 402
- Klemm, E, 212P(ab)
- Klepko, W, 6P(ab)
- Kletter, K, 29P(ab), 1928
- Kliefoth, AB, 52P(ab)
- Klinkowstein, RE, 234P(ab), 240P(ab)
- Klippenstein, D, 257P(ab)
- Klipper, R, 58P(ab), 125P(ab), 1089
- Klivényl, G, 1769
- Kloiber, R, 169P(ab)
- Kloos, RT, 707
- Klues, HG, 402
- Kluge, R, 32P(ab)
- Klutmann, S, 38P(ab), 1237, 1913
- Kmphuis, C, 178P(ab)
- Knable, MB, 42P(ab), 100P(ab)
- Knapp, FF, 47P(ab), 48P(ab), 49P(ab), 84P(ab), 92P(ab), 105P(ab), 190P(ab), 235P(ab), 241P(ab), 246P(ab), 255, 1672, 1752
- Knapp, WH, 125P(ab), 213P(ab)
- Kneifel, S, 111P(ab)
- Knešárek, K, 180P(ab)
- Knesewitsch, P, 153P(ab)
- Kneussl, M, 6P(ab)

- Knight, JF, 1428  
 Knitzek, K, 173P(ab)  
 Knockaert, D, 267P(ab)  
 Knoerl, SJ, 129P(ab)  
 Knox, S, 71P(ab)  
 Knuschke, P, 270P(ab)  
 Knuuti, JM, 141P(ab), 1320  
 Koay, T, 80P(ab), 254P(ab)  
 Kobashigawa, J, 90P(ab)  
 Kobayashi, H, 76P(ab),  
     127P(ab), 221P(ab), 232P(ab),  
     272P(ab), 829, 1117, 1492  
 Kobayashi, M, 200P(ab)  
 Kobayashi, T, 127P(ab)  
 Kobayashi, S, 656  
 Koç, E, 1703  
 Koch, K-C, 157P(ab), 402  
 Koch, R, 270P(ab)  
 Köchl, H, 6P(ab)  
 Kodaka, R, 961  
 Kodama, H, 49P(ab)  
 Kochler, W, 212P(ab)  
 Koenders, EB, 7P(ab), 268P(ab),  
     2172  
 Koeppel, RA, 15P(ab), 125P(ab),  
     202P(ab), 210P(ab)  
 Koeppel, JA, 203P(ab), 239P(ab)  
 Kofoed, KF, 89P(ab), 90P(ab),  
     272, 591  
 Koga, S, 208P(ab), 213P(ab)  
 Koh, C-S, 201P(ab), 234P(ab),  
     235P(ab), 250P(ab), 257P(ab),  
     261P(ab)  
 Kohgo, Y, 57P(ab)  
 Kohya, T, 127P(ab)  
 Koide, Y, 1002  
 Koizumi, K, 266  
 Koizumi, M, 194P(ab)  
 Kojima, A, 107P(ab), 176P(ab),  
     181P(ab), 217P(ab)  
 Kojima, K, 320, 473  
 Kolben, M, 1398  
 Kole, AC, 810, 1027  
 Koller, J, 798  
 Kolodny, GM, 10P(ab), 11P(ab),  
     104, 1614  
 Komamura, K, 1862  
 Komori, T, 201P(ab)  
 König, B, 198P(ab)  
 Konijnenberg, M, 184P(ab),  
     188P(ab)  
 Konishi, J, 30, 88P(ab),  
     129P(ab), 141P(ab), 148P(ab),  
     157P(ab), 158P(ab), 163P(ab),  
     217P(ab), 224P(ab), 226P(ab),  
     241, 244P(ab), 250P(ab),  
     252P(ab), 390, 938, 1360,  
     1727, 1835, 2017(ie)  
 Konishi, S, 59P(ab), 106P(ab)  
 Konno, M, 127P(ab), 175P(ab)  
 Kontaxakis, G, 8P(ab)  
 Kool, W, 121P(ab), 1736  
 Koole, M, 176P(ab)  
 Kooner, JS, 1696  
 Koops, HS, 810, 1027, 1381  
 Kopiwiada, S, 8P(ab), 160P(ab)  
 Kopp, A, 147P(ab)  
 Koral, KF, 97P(ab), 112P(ab)  
 Körber, C, 259P(ab), 260P(ab)  
 Korf, J, 495, 836  
 Kornblum, HI, 211P(ab)  
 Kornek, G, 1570  
 Kornetka, ZW, 105P(ab)  
 Kornetsky, C, 99P(ab)  
 Korobkin, MT, 707  
 Korvick, D, 1089  
 Kósa, I, 411, 1307  
 Kosaka, N, 52P(ab), 990  
 Koseda, M, 930(ie)  
 Koshiji, T, 88P(ab)  
 Koshiyama, H, 156P(ab)  
 Koss, DL, 276P(ab)  
 Koss, JE, 172P(ab), 277P(ab)  
 Kosslyn, SM, 205P(ab)  
 Kostakoglu, L, 77P(ab), 1021,  
     1191  
 Kostamis, P, 156P(ab)  
 Kottapally, S, 1207  
 Kotz, D, 13N(3), 13N(10),  
     13N(12), 15N(1), 16N(11),  
     17N(2), 17N(4)  
 Kotzerke, J, 33P(ab), 84P(ab),  
     190P(ab), 2145  
 Kouda, K, 1463  
 Kouyoumdjian, J-C, 1214  
 Koyama, K, 256P(ab)  
 Koyama, M, 203  
 Koyanagi, T, 656  
 Kozar, J, 10P(ab)  
 Kozawa, SM, 1757  
 Kozłowski, J, 117P(ab)  
 Kraan, J, 117P(ab)  
 Kraeber-Bodré, F, 246P(ab),  
     1608  
 Krag, DN, 1388  
 Kraitchman, D, 152P(ab)  
 Kramer, M, 46P(ab), 102P(ab)  
 Kransenborg, MHGC, 78P(ab),  
     244P(ab)  
 Krasnow, AZ, 5P(ab), 217P(ab)  
 Kraus, G, 214P(ab)  
 Krause, T, 155  
 Krausz, Y, 264P(ab)  
 Krawczynska, EG, 115P(ab)  
 Kreitman, RJ, 76P(ab)  
 Kremer, LCM, 56P(ab)  
 Krenning, EP, 19P(ab), 39P(ab),  
     62P(ab), 63P(ab), 155P(ab),  
     233P(ab), 252P(ab), 261P(ab),  
     264P(ab), 1662  
 Kresnik, E, 215(ie), 236, 870  
 Krikorian, G, 203P(ab)  
 Kripas, C, 113P(ab)  
 Krishnamurthy, S, 126P(ab)  
 Kroger, LA, 185P(ab), 246P(ab),  
     269P(ab), 842  
 Kröger, S, 38P(ab), 1913  
 Krohn, KA, 53P(ab), 232P(ab),  
     440, 1043, 1327, 1757, 1805  
 Kroll, K, 1327  
 Kroll, S, 14S, 21S  
 Kronauge, JF, 187P(ab)  
 Kropp, J, 47P(ab), 199P(ab),  
     246P(ab), 270P(ab), 271P(ab)  
 Kruck, E, 262P(ab)  
 Krumm, RP, 273P(ab), 1260  
 Krynyckyi, BR, 19P(ab), 126(ab)  
 Krystal, JH, 13P(ab), 82P(ab)  
 Krzos, JR, 38P(ab)  
 Krzywinski, M, 173P(ab)  
 Kuan, H, 169P(ab)  
 Kubo, A, 102P(ab), 220P(ab)  
 Kubo, N, 175P(ab)  
 Kubodera, A, 49P(ab)  
 Kubota, K, 195P(ab), 1219  
 Kudo, S, 537  
 Kudoh, T, 88P(ab), 141P(ab),  
     157P(ab), 390, 938, 1835  
 Kuehn, A, 56P(ab)  
 Kugel, S, 147P(ab)  
 Kuhar, MJ, 12P(ab)  
 Kuhl, DE, 15P(ab), 96P(ab),  
     170P(ab)
- 125P(ab), 202P(ab), 210P(ab),  
     211P(ab), 375(ie)  
 Kuhn, D, 195P(ab)  
 Kühnast, B, 229P(ab)  
 Kühne, A, 271P(ab)  
 Kuijka, JT, 1649(ie)  
 Kuji, I, 200P(ab)  
 Kukis, DL, 185P(ab), 243P(ab),  
     246P(ab), 842, 2105  
 Kulbertus, HE, 260P(ab)  
 Kumada, H, 251P(ab)  
 Kumar, A, 216P(ab)  
 Kumar, M, 97P(ab), 109P(ab),  
     255P(ab)  
 Kumar, S, 117P(ab)  
 Kumar, V, 143P(ab)  
 Kumazaki, T, 149P(ab)  
 Kume, N, 192P(ab), 408, 889  
 Kumita, S, 149P(ab)  
 Kung, HF, 6P(ab), 7P(ab),  
     214P(ab), 215P(ab), 220P(ab),  
     221P(ab), 2069  
 Kung, M-P, 6P(ab), 214P(ab),  
     215P(ab), 220P(ab)  
 Kunieda, E, 102P(ab)  
 Kuniyasu, A, 217P(ab)  
 Kunselman, AR, 16P(ab)  
 Kuo, SW, 194P(ab), 270P(ab),  
     271P(ab)  
 Kupferschläger, J, 175P(ab)  
 Kurata, C, 1667  
 Kurabayashi, S, 1676  
 Kuriyama, T, 1160  
 Kuroda, M, 158P(ab)  
 Kurohara, A, 191P(ab),  
     216P(ab), 242P(ab)  
 Kurtaran, A, 39P(ab), 246P(ab),  
     1570, 1575, 1907, 1928, 2090  
 Kuruoğlu, AÇ, 304  
 Kusakabe, K, 1117  
 Kushner, SA, 6P(ab), 99P(ab)  
 Kusubov, N, 190P(ab)  
 Kusuki, T, 325  
 Kusuoka, H, 44P(ab), 961  
 Kuwahara, H, 43P(ab), 1630  
 Kuwahara, Y, 89P(ab), 137P(ab),  
     213P(ab), 258P(ab), 760, 974  
 Kuwahara, T, 1486  
 Kuwert, T, 23, 26P(ab), 27P(ab)  
 Kvols, LK, 38P(ab)  
 Kwa, SLS, 1074  
 Kwekkeboom, DJ, 19P(ab)  
 Kyotani, S, 1676  
 La Madeleine, C, 165P(ab)  
 Labar, D, 57P(ab), 97P(ab),  
     1655  
 LaBarbara, J, 132P(ab)  
 L'Abbate, A, 396  
 Labriolle-Vaylet, C, 29P(ab)  
 Lacan, GME, 41P(ab)  
 LaCroix, KJ, 170P(ab),  
     177P(ab), 562  
 Lacy, JL, 48P(ab), 75P(ab),  
     76P(ab), 142P(ab), 1958  
 Ladenstein, R, 29P(ab)  
 Ladher, RC, 56  
 Laemmer-Skarke, I, 1398  
 Lage, A, 15  
 Lago, G, 137P(ab)  
 Laguna, R, 1254  
 Lahmer, D, 110P(ab)  
 Lakkis, NM, 253P(ab)  
 Laloux, P, 164P(ab)  
 Lalush, DS, 22P(ab), 37P(ab),  
     170P(ab)
- Lamatrice, RA, 650  
 Lambreg, K, 640  
 Lambert, R, 17P(ab), 459  
 Lamberts, SWJ, 39P(ab)  
 Lamborn, KR, 112P(ab),  
     246P(ab), 842  
 Lamers, RJS, 1605  
 Lamki, L, 244P(ab), 273P(ab),  
     276P(ab)  
 Lamm, RL, 203P(ab)  
 Lamermotsma, AA, 64P(ab),  
     302P(ab), 1696  
 Lamonica, D, 248P(ab),  
     257P(ab)  
 Lampreave, JL, 86P(ab), 624,  
     2087  
 Lan, J-L, 196P(ab), 773, 1354,  
     1707, 2137  
 Lanahan, MV, 63P(ab), 1944  
 Lancellotti, P, 152P(ab)  
 Landolfo, KM, 161P(ab)  
 Landoni, C, 171P(ab)  
 Lane, MA, 207P(ab)  
 Lang, AE, 14P(ab), 209P(ab)  
 Lang, I, 6P(ab)  
 Lang, L, 36P(ab), 135P(ab),  
     230P(ab)  
 Lang, O, 66P(ab), 125P(ab)  
 Lang, S, 1166  
 Langen, K-J, 1596  
 Langleben, D, 203P(ab)  
 Langlotz, CP, 5P(ab)  
 Längström, B, 640, 982, 1273  
 Lanser, M, 214P(ab)  
 Lapela, M, 1393  
 Lapointe, D, 165P(ab)  
 LaRiccia, P, 206P(ab)  
 Larisch, R, 996  
 Larra, F, 1546  
 Larson, SM, 51P(ab), 67P(ab),  
     130P(ab), 134P(ab), 135P(ab),  
     171P(ab), 174P(ab), 188P(ab),  
     223P(ab), 237P(ab), 253P(ab),  
     278P(ab), 484  
 Larsson, SA, 106P(ab)  
 Laruelle, M, 55P(ab), 82P(ab),  
     167P(ab), 207P(ab)  
 Lash, TR, 22N(5)  
 Lass, P, 930(ie)  
 Lassmann, S, 1237  
 Lastoria, S, 634  
 Lattanand, C, 206P(ab)  
 Lauer, I, 108P(ab)  
 Laurette, I, 182P(ab)  
 Laverman, P, 7P(ab), 30P(ab),  
     195P(ab), 242P(ab), 264P(ab),  
     267P(ab), 2172  
 Lawhorn-Crews, JM, 228P(ab)  
 Lawson, MA, 19P(ab), 123P(ab),  
     161P(ab)  
 Lawson, RS, 895  
 Laymon, CE, 108P(ab),  
     109P(ab), 257P(ab)  
 Laymon, CM, 92P(ab)  
 Lazarev, MG, 206P(ab)  
 Laznick, M, 8P(ab)  
 Laznickova, A, 8P(ab)  
 Lazzi, S, 822  
 Le, N, 76P(ab), 221P(ab),  
     236P(ab), 272P(ab)  
 Le, PT, 23P(ab)  
 Le Doussal, J-M, 1937  
 Le Feuvre, C, 156P(ab)  
 Le Guludec, D, 29P(ab),  
     44P(ab), 104P(ab), 140P(ab),  
     142P(ab), 159P(ab), 2194(ie)
- Leach, S, 81P(ab)  
 Lebensart, P, 264P(ab)  
 Lebesque, JV, 1074  
 LeBlanc, JW, 51P(ab), 132P(ab),  
     173P(ab)  
 Leblond, R, 1621  
 Lebtahi, R, 29P(ab), 44P(ab),  
     104P(ab), 140P(ab), 2194(ie)  
 Leccia, F, 1172  
 Lecomte, R, 92P(ab), 165P(ab)  
 Lederman, RJ, 4P(ab)  
 Ledermann, JA, 1743  
 Lee, B-F, 2128  
 Lee, BI, 281  
 Lee, BK, 85P(ab)  
 Lee, DS, 41P(ab), 59P(ab),  
     60P(ab), 103P(ab), 130P(ab),  
     201P(ab), 211P(ab), 212P(ab),  
     213P(ab), 234P(ab), 235P(ab),  
     250P(ab), 255P(ab), 257P(ab),  
     261P(ab), 267P(ab), 303P(ab)  
 Lee, DW, 41P(ab)  
 Lee, HB, 250P(ab)  
 Lee, HH, 4P(ab)  
 Lee, HK, 34P(ab), 273P(ab)  
 Lee, H-K, 130  
 Lee, IK, 31P(ab), 150P(ab)  
 Lee, J, 31P(ab), 150P(ab),  
     253P(ab), 1401  
 Lee, JD, 158P(ab), 281, 619,  
     629, 2044  
 Lee, JS, 41P(ab), 187P(ab),  
     195P(ab), 211P(ab), 257P(ab)  
 Lee, K, 1401  
 Lee, KB, 31P(ab), 150P(ab),  
     253P(ab)  
 Lee, KH, 154P(ab), 252P(ab)  
 Lee, KS, 42P(ab), 100P(ab),  
     252P(ab)  
 Lee, L, 206P(ab)  
 Lee, MC, 41P(ab), 59P(ab),  
     60P(ab), 103P(ab), 130P(ab),  
     201P(ab), 211P(ab), 212P(ab),  
     213P(ab), 234P(ab), 235P(ab),  
     250P(ab), 255P(ab), 257P(ab),  
     261P(ab), 267P(ab), 303P(ab)  
 Lee, P, 200P(ab)  
 Lee, SH, 154P(ab)  
 Lee, S-H, 34P(ab)  
 Lee, SK, 273P(ab)  
 Lee, SL, 2158  
 Lee, SY, 33P(ab), 184P(ab),  
     195P(ab)  
 Lee, TD, 197P(ab)  
 Lee, TY, 205P(ab)  
 Lee, V, 20P(ab)  
 Lee, VW, 221  
 Lee, WR, 154P(ab)  
 Lee, YJ, 234P(ab), 235P(ab),  
     250P(ab), 255P(ab)  
 Leef, J, 1081  
 Leenders, KL, 879  
 Lefcoe, NM, 339  
 Lefebvre, B, 1441  
 Légal, J-D, 825  
 Legg, B, 792  
 Lehikoinen, P, 254P(ab)  
 Lehmann, WD, 47P(ab)  
 Leidholdt, EM, 145P(ab)  
 Leighton, DM, 1280  
 Leimer, M, 39P(ab), 223P(ab),  
     225P(ab), 246P(ab), 1575,  
     1928, 2090  
 Leisure, GP, 250P(ab), 1972  
 Leitha, T, 6P(ab), 202P(ab),  
     1166, 1263

- Lekht, V, 69P(ab)  
 Leleuk, S, 86  
 Lemahieu, I, 176P(ab)  
 Lemmens, JAM, 195P(ab)  
 Leo, R, 58P(ab)  
 Leonard, SM, 179P(ab)  
 Leonardi, L, 243P(ab), 245P(ab)  
 Leong, LK, 62P(ab), 166P(ab)  
 Leppo, JA, 159, 598  
 Lerch, H, 23  
 Leroy, RF, 285  
 Lescoat, G, 900  
 Leskinen, S, 254P(ab), 1393  
 Leslie, WD, 124P(ab), 712  
 Leung, A, 108P(ab)  
 Leutmezer, F, 978  
 Leutnner, M, 4, 254P(ab)  
 Léveillé, J, 17T(ab), 459  
 Lever, JR, 21P(ab)  
 Levin, CS, 9P(ab)  
 Levin, DP, 199P(ab)  
 Levitt, PW, 276P(ab)  
 Levy, A, 42P(ab)  
 Levy, RD, 192P(ab)  
 Lew, R, 231P(ab)  
 Lew, W, 247P(ab)  
 Lewellen, B, 190P(ab), 440  
 Lewellen, TK, 170P(ab), 440,  
     1757  
 Lewin, HC, 3P(ab), 62P(ab),  
     87P(ab), 101P(ab), 102P(ab),  
     103P(ab), 104P(ab), 115P(ab),  
     116P(ab), 154P(ab), 253P(ab)  
 Lewis, BS, 59P(ab)  
 Lewis, JS, 63P(ab), 91P(ab),  
     104P(ab), 1944  
 Ley, AC, 56  
 Leyton, M, 83P(ab)  
 Leyvraz, S, 150P(ab)  
 Li, H, 93P(ab)  
 Li, J, 112P(ab), 169P(ab)  
 Li, N, 222P(ab)  
 Li, ST, 207P(ab)  
 Li, Y, 522  
 Li, Z, 1327  
 Liang, Z, 169P(ab)  
 Liao, K-K, 769  
 Liao, YC, 271P(ab)  
 Liberatore, M, 875  
 Libretti, R, 115P(ab)  
 Libutti, SK, 80P(ab), 98P(ab)  
 Lichte, H, 257P(ab)  
 Lieber, M, 263P(ab)  
 Lieberman, G, 150P(ab)  
 Liedtke, AJ, 1684, 1690  
 Liem, IH, 1605  
 Liepe, K, 199P(ab), 270P(ab)  
 Liersch, T, 70P(ab)  
 Lietzenmayer, R, 19P(ab),  
     67P(ab), 122P(ab), 147P(ab)  
 Lim, BB, 227P(ab)  
 Lim, J, 126P(ab)  
 Lim, JK, 20P(ab)  
 Lim, JS, 2044  
 Lim, SM, 195P(ab), 234P(ab),  
     257P(ab)  
 Lin, BNJ, 193P(ab)  
 Lin, C-H, 1711  
 Lin, CL, 88P(ab)  
 Lin, JD, 59P(ab)  
 Lin, K, 3P(ab), 194P(ab)  
 Lin, KP, 164P(ab)  
 Lin, K-S, 7P(ab)  
 Lin, P-S, 677  
 Lin, Q, 1672  
 Lin, S, 112P(ab)  
 Lin, W-Y, 196P(ab)  
 Lin, W-Y, 930(ie), 1269, 1752,  
     2137  
 Lin, X, 126P(ab)  
 Lin, YD, 187P(ab)  
 Linburg, PC, 699  
 Lind, P, 215(ie), 236, 870  
 Lindberg, S, 357, 2195(ie)  
 Lindholm, P, 254P(ab), 1393  
 Lindner, DJ, 217P(ab)  
 Lindquist, L, 2055  
 Lindsley Balatoni, J, 130P(ab)  
 Lindstedt, RG, 357, 2195(ie)  
 Line, BR, 38P(ab), 218P(ab),  
     222P(ab)  
 Line, CH, 38P(ab)  
 Ling, CD, 1647(ie)  
 Lingford-Hughes, AR, 204P(ab)  
 Link, JM, 440, 1043, 1327,  
     1757, 1805  
 Linke, DB, 212P(ab)  
 Linke, R, 14P(ab), 124P(ab),  
     272P(ab), 849  
 Linnoila, M, 42P(ab), 100P(ab)  
 Liow, J-S, 183P(ab)  
 Lipowska, M, 217P(ab)  
 Lippens, M, 189P(ab)  
 Lips, PTA, 262P(ab)  
 Lisbona, R, 146P(ab)  
 Lisic, EC, 105P(ab)  
 Lister-James, J, 39P(ab),  
     225P(ab)  
 Little, RJA, 96P(ab)  
 Littlefield, JL, 11N(7), 277P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)  
 Luini, A, 24P(ab), 2080  
 Luis, I, 242P(ab)  
 Lukasiewicz, R, 38P(ab)  
 Luker, GD, 77  
 Luketicz, JD, 1267  
 Lumbroso, J, 1590  
 Lundkvist, C, 118P(ab), 208  
 Lundqvist, R, 106P(ab)  
 Lungenschmid, K, 1508  
 Luo, H, 49P(ab), 92P(ab), 1672  
 Luo, J-Q, 23P(ab), 97P(ab),  
     109P(ab), 654  
 Luotolahti, M, 1320  
 Lupoglazoff, JM, 90P(ab)  
 Liu, A, 2097  
 Liu, G-C, 2128  
 Liu, HG, 96P(ab), 148P(ab),  
     149P(ab), 225P(ab)  
 Liu, J, 205P(ab)  
 Liu, L, 180P(ab)  
 Liu, RS, 164P(ab), 187P(ab),  
     205P(ab)  
 Liu, S, 215P(ab), 217P(ab)  
 Liu, Y, 217P(ab), 417  
 Livingston, RB, 146P(ab)  
 Livingstone, AS, 1388  
 Livni, E, 54P(ab), 167P(ab),  
     195P(ab)  
 Lizotte, P, 139P(ab)  
 Ljungberg, M, 97P(ab), 182P(ab)  
 Llacer, J, 9P(ab)  
 Loc'h, C, 71P(ab), 168P(ab),  
     238P(ab)  
 Loder, A, 298  
 Lodge, MA, 178P(ab), 255P(ab)  
 Logan, J, 12P(ab), 13P(ab),  
     42P(ab), 43P(ab), 54P(ab),  
     99P(ab)  
 Loh, A, 484  
 Loiselet, P, 1129  
 Lombardo, I, 55P(ab), 167P(ab)  
 Loncaric, S, 174P(ab), 1335  
 London, ED, 207P(ab)  
 Longari, V, 58P(ab), 117P(ab)  
 Lonner, B, 29P(ab)  
 López, A, 242P(ab)  
 Lopresti, BJ, 165P(ab), 239P(ab)  
 Lorberboym, M, 1366  
 Loreck, D, 265P(ab)  
 Loredo, R, 1089  
 Lorenz, M, 134P(ab)  
 Lorf, T, 70P(ab)  
 Lotfi, K, 55P(ab)  
 Loufti, A, 146P(ab)  
 Loufti, I, 28P(ab)  
 Louw, WKA, 2110  
 Love, C, 29P(ab), 33P(ab),  
     263P(ab), 266P(ab)  
 Lovqvist, A, 1776  
 Low, PS, 191P(ab), 232P(ab),  
     1579  
 Lowe, VJ, 122P(ab), 248P(ab),  
     256P(ab)  
 Löwenberg, B, 39P(ab)  
 Lu, L, 982, 1273  
 Lu, LFL, 7P(ab), 267P(ab)  
 Lubin, E, 86  
 Lubushitzky, R, 104, 1614  
 Lucas, JD, 255P(ab)  
 Lucca, A, 40P(ab)  
 Lucignani, G, 40P(ab)  
 Lüdders, H, 212P(ab)  
 Ludwig, T, 21P(ab)  
 Luger, S, 71P(ab)  
 Lugtenburg, PJ, 39P(ab)  
 Luig, H, 108P(ab)<

- Matsumoto, T. 889  
 Matsumura, K. 208P(ab), 213P(ab), 334  
 Matsunaga, N. 192P(ab), 889  
 Matsunari, I. 59P(ab), 128P(ab), 159P(ab), 411, 1307, 1681  
 Matsuno, S. 1626  
 Matsushita, M. 129P(ab)  
 Matsushita, R. 129P(ab)  
 Matsuzawa, Y. 152P(ab)  
 Mattar, AG. 339  
 Mattes, J. 1762  
 Mattes, MJ. 223P(ab)  
 Matthews, HP. 425  
 Matthews, JC. 1370  
 Mattner, F. 50P(ab)  
 Mattson, R. 26P(ab)  
 Mattsson, S. 357, 2195(lc)  
 Matys, R. 1769  
 Matzen, K. 1762  
 Maounoury, C. 156P(ab), 927(lc)  
 Mäurer, J. 954  
 Maurer, T. 1980  
 Mawlawi, O. 51P(ab)  
 Maxon, HR. III, 659  
 Mayer, SA. 149P(ab)  
 Mayo, MS. 63P(ab)  
 Mayrin, V. 273P(ab), 1260  
 Mazière, B. 71P(ab), 205P(ab), 238P(ab)  
 Mazumdar, M. 253P(ab)  
 Mazza, SM. 116P(ab), 144P(ab)  
 Mazzanti, C. 100P(ab)  
 McBiles, M. 1111  
 McBride, B. 78P(ab)  
 McBride, WJ. 223P(ab)  
 McCallister, SL. 21P(ab)  
 McCarron, JA. 119P(ab)  
 McCarthy, DW. 91P(ab), 137P(ab), 234P(ab), 240P(ab), 1944  
 McCarthy, TJ. 117P(ab)  
 McCartney, WH. 23P(ab), 25P(ab)  
 McCool, D. 129P(ab), 150P(ab)  
 McCormick, JW. 365  
 McCormick, VA. 2012  
 McCready, R. 260P(ab)  
 McCulloch, C. 121P(ab)  
 McCullough, SP. 186P(ab), 191P(ab), 927(lc)  
 McDaniel, DL. 170P(ab)  
 McDevitt, MR. 188P(ab), 223P(ab)  
 McDonald, D. 231P(ab)  
 McDonald, T. 249P(ab)  
 McEwan, AJB. 10P(ab)  
 McFalls, EO. 944  
 McGill, CC. 76P(ab)  
 McGoron, AJ. 216P(ab), 219P(ab)  
 McGough, CG. 241P(ab)  
 McGrath, PD. 115P(ab)  
 McKay, L. 215P(ab)  
 McKinney, CJ. 107P(ab)  
 McLendon, RE. 1376  
 McManus, M. 249P(ab)  
 McMillan, M. 273P(ab)  
 McNulty, PH. 379  
 McPherson, DW. 49P(ab)  
 Meadors, K. 133P(ab)  
 Meares, CF. 185P(ab), 842, 1813, 2105  
 Meeder, JG. 1312  
 Meegalla, SK. 6P(ab), 7P(ab), 214P(ab), 220P(ab), 221P(ab)  
 Meghdadi, S. 1570  
 Mehdiorn, HM. 38P(ab), 1913  
 Mehta, AC. 43P(ab)  
 Mehta, HH. 346  
 Meinken, GE. 222P(ab)  
 Mekhmandarov, S. 86  
 Melacrinis, FF. 1542  
 Melega, WP. 41P(ab)  
 Melhem, ER. 765  
 Melin, JA. 74P(ab), 1655  
 Melles, K. 16P(ab)  
 Meller, B. 108P(ab)  
 Meller, J. 34P(ab), 113P(ab), 130P(ab), 189P(ab), 262P(ab), 1248  
 Mellière, D. 1100  
 Melloul, M. 1069  
 Melo, T. 216P(ab), 219P(ab)  
 Melon, PG. 152P(ab), 260P(ab)  
 Meltzer, CC. 205P(ab), 211P(ab), 1207, 1267  
 Meltzer, PC. 66P(ab), 238P(ab)  
 Memtsoudis, S. 112P(ab)  
 Menda, Y. 1897  
 Mende, T. 202P(ab)  
 Meneghetti, JC. 57P(ab)  
 Mennemeier, M. 149P(ab)  
 Menzel, C. 135P(ab), 1551, 1903  
 Mercier, Gi. 95P(ab), 214P(ab)  
 Merdler, A. 59P(ab)  
 Merhige, ME. 90P(ab)  
 Merlet, P. 90P(ab), 142P(ab), 160P(ab)  
 Merry, M. 10P(ab)  
 Mesa, NR. 1918  
 Mesko, L. 2055  
 Mesotten, L. 142P(ab)  
 Messa, C. 40P(ab)  
 Messinger, NH. 140P(ab)  
 Metten, N. 135P(ab)  
 Metz, C. 1081  
 Metz, KR. 1148  
 Meulemans, A. 159P(ab)  
 Meurisse, H. 164P(ab)  
 Meurisse, M. 260P(ab)  
 Meyer, C. 89P(ab)  
 Meyer, E. 110P(ab), 176, 205P(ab), 206P(ab), 350  
 Meyer, G. 5P(ab), 849  
 Meyer, MA. 184P(ab)  
 Meyer, P. 15P(ab), 70P(ab), 125P(ab), 202P(ab), 210P(ab), 1172, 1638  
 Miale, PA. 21N(10)  
 Michael, LH. 48P(ab)  
 Michel, C. 57P(ab), 97P(ab), 1655  
 Michel, JB. 159P(ab)  
 Michigishi, T. 106P(ab), 436, 2077  
 Mieres, J. 60P(ab)  
 Miers, LA. 185P(ab), 246P(ab), 269P(ab), 842  
 Mignaco, O. 73P(ab)  
 Mignon, M. 2194(lc)  
 Mihara, M. 537  
 Mikolajczyk, K. 277P(ab)  
 Mikosch, P. 215(lc), 236, 870  
 Milan, E. 115P(ab)  
 Milano, CA. 161P(ab)  
 Millard, RW. 216P(ab), 219P(ab)  
 Miller, DD. 918  
 Miller, JH. 893, 1087  
 Millesi, W. 1166  
 Millet, P. 65P(ab)
- Mills, JL. 243P(ab)  
 Mills, SL. 243P(ab)  
 Millward, M. 249P(ab)  
 Min, J-J. 184P(ab), 91  
 Minai, OA. 43P(ab)  
 Minier, J-F. 1546  
 Minn, H. 254P(ab)  
 Minoshima, S. 15P(ab), 27P(ab), 96P(ab), 164P(ab), 202P(ab), 211P(ab), 375(lc)  
 Miraldi, F. 250P(ab), 1972  
 Miranda, L. 3P(ab), 253P(ab)  
 Mirick, GR. 112P(ab), 269P(ab)  
 Mirzadeh, S. 184P(ab), 241P(ab), 1752  
 Mishkin, F. 139P(ab)  
 Mishra, J. 116P(ab)  
 Mithilesh, K. 654  
 Mitomo, O. 1630  
 Mitra, A. 543  
 Mitsumori, A. 529  
 Mitsunami, K. 933  
 Miura, S. 1789  
 Miura, T. 1492  
 Miyajima, A. 153P(ab)  
 Miyake, M. 98P(ab), 195P(ab)  
 Miyake, Y. 127P(ab), 162P(ab)  
 Miyamoto, K. 127P(ab), 226P(ab), 1492  
 Miyaoka, RS. 170P(ab)  
 Miyatake, K. 162P(ab)  
 Miyauchi, T. 1600  
 Miyazaki, Y. 163P(ab)  
 Mizumura, S. 149P(ab)  
 Mizunaga, M. 86P(ab)  
 Mizuno, H. 931(lc)  
 M'Kacher, R. 825  
 Mochizuki, T. 48P(ab), 85P(ab), 127P(ab), 164P(ab), 807  
 Modic, MT. 148P(ab)  
 Modlin, IM. 272P(ab)  
 Modrak, D. 247P(ab)  
 Moe, R. 24P(ab)  
 Moffat, FL. 243, 1388  
 Mohammed, A. 153P(ab), 227P(ab), 242P(ab)  
 Möhler, M. 1197  
 Mokler, FT. 1672  
 Molina, V. 624  
 Moller, P. 81P(ab)  
 Moll-Kotowski, M. 1033  
 Molnar, M. 215(lc), 236  
 Momomura, S. 4P(ab), 141P(ab), 142P(ab), 884  
 Momose, M. 1117  
 Momose, Y. 2161  
 Mondelaers, W. 1563  
 Monetti, N. 86P(ab), 87P(ab), 210P(ab)  
 Mongeau, C-J. 1441  
 Monsieurs, M. 189P(ab)  
 Montane, B. 28P(ab)  
 Montaru, P. 73P(ab)  
 Monville, ME. 97P(ab)  
 Moock, KH. 1647(lc)  
 Moock, M. 1769  
 Moon, DH. 273P(ab), 431  
 Moore, EA. 97P(ab)  
 Moore, SC. 36P(ab), 51P(ab)  
 Moore, WH. 20P(ab), 88P(ab)  
 Moote, D. 258P(ab)  
 Mor, M. 10P(ab), 11P(ab)  
 Morales, A. 15, 57P(ab)  
 Morales, AM. 1918  
 Moran, JK. 250P(ab)  
 Moreno-Cantú, JJ. 350
- Moreesco, RM. 40P(ab)  
 Moretti, J-L. 102P(ab), 928(lc), 1214, 2195(lc)  
 Moretti, R. 115P(ab)  
 Morgan, AE. 54P(ab), 99P(ab)  
 Morgan, GF. 285  
 Morgan, HT. 124  
 Morgan, M. 249P(ab)  
 Morgenroth, C. 23  
 Morguet, A. 34P(ab)  
 Morguet, AJ. 9P(ab)  
 Mori, E. 163P(ab), 293, 376(lc), 1875  
 Morin, C. 10P(ab)  
 Morioka, T. 974  
 Morita, K. 85P(ab), 127P(ab), 158P(ab), 175P(ab), 261P(ab)  
 Morita, R. 129P(ab)  
 Morita, Y. 175P(ab)  
 Moriwaki, H. 961, 1348  
 Moro, D. 70P(ab)  
 Morooka, S. 127P(ab)  
 Morr, I. 259P(ab), 1418  
 Morris, E. 207P(ab)  
 Morris, ED. 207P(ab)  
 Morris, H. 212P(ab)  
 Morris, HA. 108  
 Morris, ID. 895  
 Morris, J. 1910  
 Morris, V. 659  
 Morrison, KS. 173P(ab), 792  
 Mortelmans, L. 134P(ab), 142P(ab), 267P(ab), 269P(ab)  
 Mörtl, M. 259P(ab)  
 Morton, DL. 1185  
 Morton, KA. 11P(ab), 259P(ab), 1297, 1405  
 Morton, TE. 206P(ab)  
 Moscovitch, M. 1511  
 Moses, WW. 171P(ab)  
 Mosesson, RE. 1366  
 Moskovitz, B. 16P(ab)  
 Moskowitz, C'H. 2S  
 Mostarda, A. 115P(ab)  
 Mostbeck, A. 198P(ab)  
 Motomura, N. 176P(ab), 177P(ab), 178P(ab)  
 Motomura, Y. 247P(ab), 248P(ab)  
 Motooka, M. 88P(ab)  
 Moulton, JS. 659  
 Mountz, JD. 225P(ab)  
 Mountz, JM. 96P(ab), 148P(ab), 149P(ab), 216(lc), 224P(ab), 225P(ab)  
 Moustakidis, P. 4P(ab)  
 Moyano, L. 57P(ab)  
 Moyer, BR. 225P(ab)  
 Mozley, D. 214P(ab)  
 Mozley, PD. 6P(ab), 14P(ab), 124P(ab), 206P(ab), 221P(ab), 265P(ab), 268P(ab), 2069  
 Msaki, P. 8P(ab), 106P(ab), 182P(ab)  
 Mu, M. 6P(ab), 7P(ab), 215P(ab)  
 Mudra, H. 153P(ab)  
 Muchllehner, G. 37P(ab), 50P(ab), 133P(ab)  
 Mueller, C. 150P(ab)  
 Mueller, JG. 70P(ab), 929(lc), 1980  
 Muffert, S. 259P(ab)  
 Mühlensiepen, H. 22P(ab), 188P(ab), 230P(ab), 1596
- Mukherjee, J. 41P(ab), 207P(ab), 214P(ab), 231P(ab)  
 Mull, M. 147  
 Mullah, N. 267P(ab)  
 Mullan, BP. 912  
 Mullan, N. 1123  
 Mullen, L. 19P(ab)  
 Muller, SH. 1074  
 Müller, SP. 36P(ab), 110P(ab), 185P(ab), 1536  
 Müller-Berg, M. 19P(ab), 122P(ab), 147P(ab)  
 Müller-Gärtner, H-W. 22P(ab), 188P(ab), 230P(ab), 996, 1596  
 Müller-Schauenburg, W. 19P(ab), 164P(ab), 169P(ab)  
 Mulligan, RS. 82P(ab), 83P(ab)  
 Mulnix, TL. 23P(ab)  
 Munakata, JA. 41P(ab)  
 Munz, DL. 30P(ab), 118P(ab), 196P(ab), 224, 259P(ab), 265P(ab), 1248, 2141  
 Munz, F. 73P(ab), 111P(ab)  
 Münzing, W. 849  
 Muramoto, E. 221P(ab)  
 Murase, K. 166P(ab)  
 Murashima, S. 334  
 Murata, K. 334  
 Murata, T. 204P(ab)  
 Murata, Y. 43, 216P(ab)  
 Muratet, J-P. 1546  
 Murray, IPC. 361, 1095  
 Murray, L. 113P(ab)  
 Murtha, A. 71P(ab)  
 Murthy, K. 146P(ab)  
 Musachio, J. 207P(ab)  
 Musachio, JL. 40P(ab), 48P(ab), 72P(ab), 99P(ab), 119P(ab), 137P(ab), 229P(ab), 1209  
 Muse, I. 137P(ab)  
 Music, RF. 207P(ab)  
 Muswick, GJ. 1972  
 Mut, F. 137P(ab)  
 Muthuswamy, MS. 1243  
 Muto, P. 634  
 Muzi, M. 440, 1805  
 Muzic, RF Jr.. 2048  
 Muzik, O. 56P(ab), 124P(ab), 137P(ab), 200P(ab), 228P(ab)  
 Myers, MT. 95P(ab)  
 Myers, RW. 134P(ab), 135P(ab)
- Nabel, EG. 4P(ab)  
 Nabi, HA. 150P(ab), 248P(ab), 257P(ab)  
 Naddaf, SY. 23P(ab), 97P(ab), 109P(ab), 255P(ab), 654  
 Nagai, R. 152P(ab), 153P(ab)  
 Nagamachi, S. 138P(ab)  
 Nagano, A. 214P(ab)  
 Nagatsuka, S. 95P(ab)  
 Nagaya, N. 1676  
 Nagel, JH. 163P(ab)  
 Nagle, C'E. 17N(2), 1114  
 Naguch, S. 253P(ab)  
 Nagy, D. 229P(ab)  
 Nahmias, C. 1826  
 Nair, N. 262P(ab)  
 Naitoh, J. 150P(ab)  
 Najjar, F. 147P(ab), 254P(ab)  
 Nakada, H. 30  
 Nakada, K. 85P(ab), 127P(ab), 261P(ab), 807  
 Nakagawa, K. 89P(ab), 1123  
 Nakagawa, M. 137P(ab), 213P(ab), 258P(ab)

- Nakagawa, T. 152P(ab), 334  
 Nakahara, H. 138P(ab)  
 Nakajima, K. 126P(ab), 716, 1681  
 Nakajo, H. 149P(tab)  
 Nakamoto, Y. 30, 224P(tab), 244P(tab), 250P(tab), 252P(tab), 1727  
 Nakamura, A. 214P(tab)  
 Nakamura, H. 44P(tab)  
 Nakamura, K. 57P(tab), 220P(tab)  
 Nakamura, S. 53P(tab), 123P(tab), 164P(tab), 251P(tab), 453, 2121  
 Nakamura, T. 98P(tab), 129P(tab), 187P(tab), 209P(tab)  
 Nakanishi, N. 1676, 2084  
 Nakano, A. 158P(ab)  
 Nakao, K. 157P(tab), 1835  
 Nakao, M. 89P(tab)  
 Nakata, I. 127P(tab), 158P(tab), 1492  
 Nakata, Y. 269P(tab)  
 Nakatani, T. 1862  
 Nakayama, H. 217P(tab)  
 Nakayama, M. 217P(tab)  
 Nahiboff, BD. 41P(tab)  
 Nally, JV Jr. 1297  
 Namavarri, M. 10P(tab), 53P(tab), 2003  
 Namba, H. 95P(ab)  
 Nambu, Y. 9  
 Narabayashi, I. 201P(tab), 269P(tab)  
 Narayanan, M. 180P(ab)  
 Narita, T. 26P(tab), 498  
 Narita, Y. 98P(tab), 181, 1789  
 Narula, J. 116P(tab), 159P(tab), 268P(tab)  
 Naruse, H. 157P(tab)  
 Naruse, T. 541  
 Naruto, S. 229P(tab)  
 Nasel, C. 1166  
 Nasu, S. 147P(tab)  
 Natarajan, C. 72P(tab)  
 Nateman, DR. 139P(tab), 140P(tab)  
 Nathan, M. 194P(ab)  
 Nathrath, WBJ. 1398  
 Nativ, O. 16P(tab)  
 Natsui, S. 127P(tab)  
 Naunheim, KS. 248P(ab)  
 Navarro, V. 77P(tab)  
 Nayak, N. 48P(tab), 142P(tab)  
 Need, AG. 108  
 Negash, K. 20P(tab), 229P(tab)  
 Neish, AS. 113  
 Nekolla, SG. 75P(tab), 139P(tab), 145P(tab), 161P(tab), 411  
 Nellemann, P. 37P(tab)  
 Nellis, SH. 1690  
 Nelson, AD. 2048  
 Nelson, CA. 60P(tab), 225P(tab)  
 Nelson, DL. 36P(tab)  
 Nelson, R. 99P(tab)  
 Nemiroff, CB. 40P(tab)  
 Netlich, A. 114P(ab)  
 Nettelbladt, OS. 640  
 Nettleton, JS. 895  
 Netusil, N. 54P(tab)  
 Neuerburg, J. 304P(tab)  
 Neuhoff, A. 44P(tab)  
 Neumann, DR. 263P(tab)  
 Neumann, JJ. 1307  
 Neumann, RD. 236P(tab), 251P(tab), 928P(tab), 1412  
 Neumeyer, J. 209P(tab), 1521  
 Nevere, J. 139P(tab), 257P(tab), 1307  
 Newberg, AB. 206P(tab), 210P(tab)  
 Newling, DWW. 183P(tab)  
 Newport, D. 133P(tab)  
 Ng, C. 132P(tab), 176P(tab)  
 Ng, CK. 136P(tab), 159P(tab), 175P(tab), 209P(tab), 379  
 Nguyen, C. 140P(tab), 159P(tab)  
 Nguyen, K. 10P(tab)  
 Nguyen, N. 48P(tab), 159P(tab)  
 Nguyen, T. 7P(tab)  
 Nichol, CA. 233P(tab)  
 Nicholls, WD. 1983  
 Nichols, D. 16N(9), 24N(6), 26N(1), 27N(4), 33N(5), 34N(2), 38N(11)  
 Nichols, K. 45P(tab), 87P(tab), 101P(tab)  
 Nicholson, RL. 8P(tab), 106P(tab), 182P(tab), 190  
 Nickles, RJ. 23P(tab), 131P(tab), 1684, 1690, 1884, 1958  
 Nicol, PD. 268P(tab)  
 Niclou, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niederle, B. 1575, 1907, 1928, 2090  
 Nieman, L. 786  
 Niemarkt, A. 836  
 Nierop, PR. 1662  
 Niessen, A. 66P(tab)  
 Niessen, WJ. 79P(tab)  
 Nieweg, OE. 810, 1027  
 Nigam, A. 579  
 Nigo, T. 156P(tab)  
 Nida, Y. 200P(ab)  
 Niija, H. 200P(ab)  
 Nijhof, MW. 195P(tab)  
 Nikiforidis, G. 1433  
 Nikkels, PGJ. 1476  
 Niklasson, CA. 357, 2195P(tab)  
 Nisbet, R. 273P(tab)  
 Nishi, J. 107P(tab), 176P(tab)  
 Nishida, H. 320  
 Nishiguchi, K. 192P(ab), 889  
 Nishigori, H. 224P(tab)  
 Nishihara, K. 178P(tab)  
 Nishikawa, J. 884, 1784  
 Nishikawa, T. 9  
 Nishimatsu, H. 129P(tab)  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476  
 Nordahl, TE. 190P(tab)  
 Nordin, BEC. 108  
 Norén, AH. 357, 2195P(tab)  
 Norman, JG. 15N(10)  
 Nosbisch, C. 190P(tab)  
 Nott, LT. 4P(tab), 1468  
 Nozaki, S. 702P(tab)  
 Nuñez, M. 137P(tab)  
 Nüsslin, F. 164P(tab)  
 Nutt, R. 9P(tab), 92P(tab), 133P(tab)  
 Nuutila, P. 141P(tab), 1320  
 Nyts, J. 142P(tab)  
 Nyberg, S. 208  
 Nicol, PD. 268P(tab)  
 Nicolai, E. 17P(tab), 101P(tab)  
 Nicoletti, R. 2153  
 Niedlerle, B. 1575, 1907, 1928, 2090  
 Oakes, TR. 172P(tab), 1714, 1884  
 Oates, E. 28P(tab), 2158  
 Oberdorfer, F. 53P(tab), 465, 1197  
 Obradovich, J. 228P(tab)  
 O'Brien, DP. 86P(tab)  
 Ochi, H. 256P(tab)  
 Ochiai, T. 45P(tab), 193P(tab)  
 Ochrymowycz, LA. 222P(tab)  
 Ochsner, P. 1980  
 O'Connor, MK. 62P(tab), 97P(tab), 166P(tab), 2027  
 O'Connor, SC. 1458  
 Oda, K. 26P(tab)  
 Odawara, Y. 158P(tab)  
 Odch, M. 16P(tab)  
 O'Doherty, MJ. 255P(tab)  
 Odom-Maryon, TL. 2097  
 O'Donnell, RT. 186P(tab), 243P(tab), 269P(tab), 667, 1223, 2105  
 O'Donoghue, JA. 186P(tab), 484  
 Oechslé, K. 67P(tab)  
 Oehr, P. 189P(tab)  
 Oei, H-Y. 1297  
 Nishimoto, N. 220P(tab)  
 Nishimura, K. 141P(tab), 938  
 Nishimura, S. 96P(tab), 211P(tab)  
 Nishimura, T. 44P(tab), 152P(tab), 220P(tab), 408, 961, 1348, 2084  
 Nishimura, Y. 252P(tab), 1360  
 Nishino, M. 162P(tab)  
 Nishio, S. 974  
 Nishiwara, T. 162P(tab)  
 Nishiyama, S. 172P(tab), 198  
 Nishiyama, Y. 1626  
 Nishizawa, S. 43P(tab), 148P(tab), 163P(tab)  
 Nitzsche, EU. 70P(tab), 929P(tab)  
 Noachtar, S. 26P(tab), 27P(tab)  
 Noack, D. 259P(tab)  
 Nobel, M. 1802  
 Nobezawa, S. 171P(tab), 172P(tab)  
 Nobili, F. 96P(tab)  
 Nobrega, JN. 226P(tab)  
 Nobushige, Y. 2121  
 Nock, B. 143P(tab)  
 Noguchi, J. 498  
 Noguchi, T. 1016  
 Nohara, R. 141P(tab), 158P(tab), 390, 938, 1132  
 Noll, D. 65P(tab)  
 Nonneman, S. 97P(tab)  
 Nonogi, H. 140P(tab)  
 Nonomura, A. 1600  
 Nonoshita, M. 473  
 Nooren, CAAM. 1476

- Panin, V.Y. 177P(ab)  
 Pansar, I. 1850  
 Pantelic, M.V. 277P(ab)P(ab)  
 Pantuso, E. 273P(ab)  
 Panyutin, IG. 236P(ab), 928(le). 1412  
 Paolin, A. 516  
 Papathoefanis, F.J. 132P(ab). 193P(ab), 245P(ab)  
 Papazian, V. 50P(ab)  
 Papisov, MI. 223P(ab)  
 Pappas, NR. 13P(ab), 42P(ab), 43P(ab). 54P(ab), 100P(ab)  
 Paracchi, A. 1012  
 Parbhoo, SP. 138P(ab)  
 Parekh, JS. 5P(ab)  
 Paridon, S. 201P(ab)  
 Park, CH. 85P(ab)  
 Park, CI. 619  
 Park, HM. 25P(ab)  
 Park, JM. 252P(ab)  
 Park, JY. 253P(ab)  
 Park, KB. 85P(ab), 195P(ab)  
 Park, K-B. 2161  
 Park, K-O. 91  
 Park, KS. 41P(ab), 211P(ab)  
 Park, Y.H. 33P(ab). 130  
 Parker, A. 108P(ab)  
 Parkes, H. 93P(ab)  
 Parmentier, C. 825  
 Parmett, S. 192P(ab)  
 Parodi, O. 396  
 Parrish, C. 2003  
 Parsey, RV. 167P(ab), 55P(ab)  
 Partin, A. 149P(ab)  
 Pascale, C. 4  
 Pasque, MK. 4P(ab)  
 Pastan, I. 76P(ab). 829  
 Pataraia, E. 978  
 Patel, M. 29P(ab), 265P(ab). 268P(ab), 275P(ab). 346, 1810  
 Pathare, PM. 91P(ab), 228P(ab)  
 Patrick, MR. 47  
 Patselas, G. 7P(ab)  
 Patton, DD. 9P(ab), 16N(10). 26N(12), 172P(ab)  
 Patton, JA. 2035  
 Patz, EF. 227P(ab)  
 Patzelt, E. 1769  
 Pauls, S. 81P(ab)  
 Paulus, P. 147P(ab), 254P(ab)  
 Paus, T. 110P(ab), 205P(ab)  
 Payer, F. 790  
 Paz, A. 1069  
 Peacock, JE Jr. 1454  
 Pearson, DA. 225P(ab)  
 Pechmann, M. 849  
 Peck-Radosavljevic, M. 77P(ab). 223P(ab). 1575  
 Pecorale, A. 208P(ab)  
 Pecorelli, S. 243P(ab)  
 Pedarsani, M. 278P(ab)P(ab)  
 Pedenović, P. 384  
 Peers, S. 267P(ab)  
 Peers, SH. 271P(ab)  
 Peker, C. 159P(ab)  
 Peker, KR. 243  
 Peksoy, I. 199P(ab)  
 Péligrini, M. 61P(ab), 179P(ab)  
 Peltier, P. 1172  
 Pelton, GH. 40P(ab)  
 Pemberton, C. 10N(9)  
 Penninckx, F. 134P(ab)  
 Pentlos, K. 67P(ab)  
 Pentlow, KS. 51P(ab), 174P(ab)  
 Pérez, N. 15
- Pérez, R. 15. 242P(ab)  
 Perkins, TA. 234P(ab), 240P(ab)  
 Perlemuter, L. 1100  
 Perrone, R. 2158  
 Perrone-Filardi, P. 1869  
 Petcov, W. 39P(ab)  
 Petegnief, Y. 159P(ab), 185P(ab)  
 Peter, AS. 140P(ab)  
 Peter, J. 79P(ab), 121P(ab)  
 Peterdy, AE. 712  
 Peterson, LM. 32P(ab), 35P(ab). 1805  
 Peterson, NP. 23P(ab), 25P(ab)  
 Petiet, A. 159P(ab), 185P(ab)  
 Petra, P. 35P(ab)  
 Petretta, M. 101P(ab)  
 Petric, A. 42P(ab)  
 Petrich, T. 125P(ab)  
 Petrides, M. 350  
 Petroff, OAC. 26P(ab)  
 Petronis, J. 149P(ab)  
 Petrov, A. 159P(ab)  
 Petruzzella, FD. 160P(ab)  
 Pfannenberg, AC. 67P(ab)  
 Pfeifer, U. 1551  
 Phelps, ME. 3P(ab), 9P(ab). 10P(ab), 35P(ab), 41P(ab). 53P(ab), 60P(ab), 68P(ab). 69P(ab), 90P(ab), 94P(ab). 133P(ab), 150P(ab), 162P(ab). 165P(ab), 167P(ab), 168P(ab). 211P(ab), 248P(ab), 254P(ab). 272, 278P(ab). 431, 591, 729. 2003  
 Phillips, P. 255P(ab)  
 Phillips, WT. 58P(ab), 125P(ab). 1089  
 Pi, B. 23P(ab)  
 Picardi, V. 1830(le)  
 Pickering, TG. 522  
 Pidlich, J. 1570  
 Pie, JE. 221P(ab), 272P(ab)  
 Piepsz, A. 16P(ab), 216(le). 1646(le), 2016(le)  
 Pierangeli, G. 210P(ab)  
 Piérard, LA. 152P(ab)  
 Pieri, PL. 154P(ab)  
 Piers, DA. 121P(ab). 699, 1381, 1736  
 Pietersz, GA. 47  
 Pietrzyk, U. 256P(ab). 613, 978  
 Piffanelli, A. 133P(ab). 204P(ab), 218P(ab)  
 Pike, VW. 49P(ab). 119P(ab). 231P(ab), 237P(ab). 1965  
 Pilowsky, LS. 82P(ab), 83P(ab). 204P(ab)  
 Pimentel, C. 57P(ab)  
 Pinkert, J. 246P(ab)  
 Pinnell, S. 25P(ab)  
 Pinson, CW. 81P(ab)  
 Piotrowki, A. 212P(ab)  
 Piperno-Neumann, S. 1214  
 Pirker, W. 613  
 Piscani, K. 100P(ab)  
 Piwnica-Worms, D. 13P(ab). 77  
 Place, TR. 260P(ab)  
 Plaizier, MABD. 84P(ab)  
 Plössl, K. 6P(ab), 7P(ab). 214P(ab), 220P(ab), 221P(ab). 2069  
 Po, S. 3P(ab)  
 Pocius, J. 48P(ab)  
 Podoloff, DA. 186P(ab). 191P(ab), 210P(ab), 233P(ab). 234P(ab), 278P(ab)
- Podreka, I. 613, 978  
 Poelstra, R. 214P(ab)  
 Poewe, W. 954  
 Poldermans, D. 155P(ab), 1481  
 Pollak, A. 226P(ab)  
 Pollycove, M. 11N(7)  
 Polollof, D. 113P(ab)  
 Pomper, MG. 137P(ab)  
 Ponto, LLB. 203P(ab)  
 Ponzo, F. 875  
 Pooley, RA. 1690  
 Popilskis, S. 167P(ab)  
 Popli, PA. 177P(ab)  
 Popp, CA. 110P(ab)  
 Porenta, G. 1864  
 Port, RE. 165P(ab)  
 Porter, DV. 185P(ab)  
 Porter, W. 277P(ab)  
 Portnoy, O. 203P(ab)  
 Post, S. 70P(ab)  
 Postiglione, A. 802  
 Potier, JC. 1129, 1841  
 Pötschger, U. 29P(ab)  
 Potter, R. 117P(ab), 118P(ab)  
 Pounds, TR. 122P(ab), 134P(ab). 135P(ab)  
 Pourdehnad, M. 206P(ab). 214P(ab), 274P(ab)  
 Powe, JE. 234, 1452  
 Powers-Risius, P. 228P(ab)  
 Powsner, RA. 221, 765  
 Pozniakoff, T. 82P(ab)  
 Präuer, H. 257P(ab)  
 Prastaro, M. 1869  
 Prato, FS. 8P(ab), 106P(ab). 190  
 Prato, K. 40P(ab)  
 Präuer, H. 80P(ab)  
 Preece, AW. 187P(ab)  
 Prenant, C. 237P(ab)  
 Pretorius, PH. 79P(ab)  
 Prevost, R. 7P(ab)  
 Priario, J. 137P(ab)  
 Price, JC. 165P(ab)  
 Price, LH. 40P(ab)  
 Price, PM. 237P(ab), 239P(ab). 1370  
 Prigent, F. 158P(ab)  
 Primus, FJ. 2097  
 Printz, D. 82P(ab)  
 Prior, JO. 15P(ab), 150P(ab)  
 Prisco, G. 24P(ab), 2080  
 Prohovnik, I. 927(le)  
 Prosperi, D. 875  
 Proye, C. 1172  
 Pruckmayer, M. 6P(ab). 202P(ab), 1166  
 Pruitt, CS. 1388  
 Prvulovich, EM. 1743  
 Puckett, MP. 128P(ab)  
 Pugh, ER. 240P(ab)  
 Pui, MH. 1292  
 Puig, S. 1263  
 Pupi, A. 208P(ab). 384  
 Pupi, F. 384  
 Puri, D. 484  
 Pyatt, B. 222P(ab)  
 Qu, T. 56, 219P(ab), 241P(ab)  
 Quadri, SM. 476  
 Que, TH. 258P(ab)  
 Quinn, TP. 77P(ab), 222P(ab)  
 Rachal, L. 273P(ab)  
 Radcliffe, O. 40P(ab)  
 Radebold, K. 272P(ab)
- Raderer, M. 39P(ab), 77P(ab). 246P(ab), 1570, 1928, 2090  
 Radin, AI. 654  
 Radü, EW. 879  
 Ragan, P. 100P(ab)  
 Ragland, JD. 206P(ab)  
 Rahusen, FD. 302P(ab)  
 Raja, S. 43P(ab), 148P(ab). 212P(ab)  
 Rajagopal, V. 76P(ab)  
 Rajashankarao, B. 1531  
 Rajeevan, N. 13P(ab), 26P(ab). 37P(ab), 40P(ab), 72P(ab). 82P(ab), 123P(ab), 208P(ab). 1719  
 Rajopadhye, M. 215P(ab). 217P(ab)  
 Rakotomanga, A. 275P(ab)  
 Rambaldi, R. 155P(ab)  
 Rammohan, R. 268P(ab)  
 Ramos, M. 15  
 Ramsby, SQ. 37P(ab). 1719  
 Ramsden, CA. 231P(ab)  
 Ranganath, H. 192P(ab)  
 Rao, DV. 84P(ab), 183P(ab). 547  
 Rao, VV. 13P(ab). 77  
 Raoul, J-L. 900  
 Raphael, D. 1511  
 Raphael, S. 258P(ab)  
 Rasey, JS. 35P(ab), 190P(ab). 229P(ab)  
 Raspani, S. 208P(ab)  
 Rasse, M. 1166  
 Rastogi, A. 46P(ab), 102P(ab)  
 Rattan, S. 64P(ab)  
 Raubitschek, AA. 2097  
 Rauch, SL. 168P(ab), 203P(ab)  
 Rauth, AM. 216P(ab), 219P(ab)  
 Raval, B. 276P(ab)  
 Ravert, HT. 21P(ab), 40P(ab). 99P(ab), 100P(ab), 119P(ab). 196P(ab), 207P(ab), 229P(ab). 1209  
 Raylman, RR. 4P(ab), 22P(ab). 92P(ab), 116P(ab)  
 Raymond, R. 226P(ab)  
 Reba, RC. 11N(7), 1081  
 Recker, B. 66P(ab)  
 Reddy, MVR. 226P(ab)  
 Reddy, VK. 116P(ab), 140P(ab)  
 Redlich, PN. 25P(ab)  
 Reed, JH. 93P(ab)  
 Reed, MW. 236P(ab)  
 Regan, D. 21S, 112P(ab)  
 Regiert, T. 1769  
 Regnard, J-F. 1986  
 Rehling, M. 2131  
 Rehm, PK. 200P(ab), 1084  
 Reichart, B. 153P(ab), 161P(ab)  
 Reid, J. 271P(ab)  
 Reid, RH. 339  
 Reidel, G. 159P(ab)  
 Reif, D. 137P(ab)  
 Reijnen, M. 264P(ab)  
 Reijss, AEM. 19P(ab), 155P(ab). 252P(ab), 1662  
 Reilly, RM. 77P(ab). 1036  
 Reiman, E. 161P(ab)  
 Reimer, SE. 123P(ab)  
 Reiners, C. 20P(ab), 86P(ab). 259P(ab), 260P(ab), 263P(ab). 1066  
 Reinhardt, CP. 159, 598  
 Reinhardt, M. 155  
 Reinhold, U. 269P(ab)
- Reintgen, D. 22N(12)  
 Reising, A. 247P(ab)  
 Reisinger, I. 224  
 Reist, CJ. 77P(ab)  
 Reivich, M. 214P(ab)  
 Relic, A. 978  
 Rendl, J. 86P(ab), 263P(ab)  
 Reno, J. 71P(ab), 91P(ab)  
 Renstrom, B. 1684, 1690  
 Rentschler, M. 84P(ab)  
 Requenez, E. 244P(ab)  
 Reschini, E. 117P(ab), 1012  
 Reske, SN. 33P(ab), 81P(ab). 84P(ab), 113P(ab), 181P(ab). 190P(ab), 1030, 2145  
 Resnick, M. 250P(ab)  
 Restrepo, A. 113P(ab)  
 Rettenbacher, L. 798  
 Reubi, J-C. 63P(ab), 2193(le)  
 Reul, J. 212P(ab)  
 Reutens, DC. 176, 205P(ab). 350  
 Reutter, BW. 93P(ab), 228P(ab)  
 Reynaert, C. 164P(ab)  
 Reznik, M. 778  
 Ribeiro, MJ. 168P(ab)  
 Rica, C. 735  
 Ricard, M. 1590  
 Ricautre, GA. 100P(ab)  
 Ricci, R. 204P(ab)  
 Rice, KC. 55P(ab)  
 Richards, S. 149P(ab)  
 Richman, CM. 185P(ab). 246P(ab)  
 Richmond, JCW. 203P(ab). 239P(ab)  
 Richter, E. 108P(ab)  
 Richter, W. 954  
 Riddell, C. 80P(ab), 98P(ab). 179P(ab)  
 Ridelhuber, H. 203P(ab)  
 Rieck, H. 1508  
 Riedelhuber, H. 203P(ab)  
 Riese, DJ. 20P(ab)  
 Rigo, P. 147P(ab), 254P(ab)  
 Rijk, P. 108P(ab)  
 Rinaldi-Carmona, M. 229P(ab)  
 Ringe, B. 70P(ab)  
 Ringelstein, EB. 26P(ab). 27P(ab), 147  
 Rini, JN. 20P(ab)  
 Rink, H. 189P(ab)  
 Rinne, D. 94P(ab)  
 Risso, J. 135P(ab). 1903  
 Rizi, RR. 6P(ab)  
 Rizzo, G. 171P(ab)  
 Rizzo, L. 875  
 Robar, JL. 146P(ab)  
 Robbins, R. 8P(ab), 160P(ab)  
 Roberson, PL. 1243  
 Roberts, AD. 1884  
 Roberts, DA. 6P(ab)  
 Robertson, C. 70P(ab)  
 Robidoux, A. 459  
 Robinson, C. 271P(ab)  
 Rocca, WA. 166P(ab)  
 Rodenhiser, J. 82P(ab), 207P(ab)  
 Roder, F. 75P(ab), 145P(ab)  
 Rodriguez, S. 165P(ab)  
 Rodriguez, A. 32P(ab)  
 Rodriguez, G. 96P(ab)  
 Rodriguez, N. 15  
 Rodriguez, O. 15  
 Rodriguez, RP. 1918  
 Roe, D. 226P(ab)  
 Roelandt, JRRC. 1481, 1662

- Roelants, V. 74P(ab), 75P(ab), 1007  
 Roelcke, U. 879  
 Roemer, W. 1398  
 Roff, E. 1306(lc)  
 Rogers, BE. 63P(ab), 224P(ab), 650  
 Rogers, J. 80P(ab)  
 Rogers, M. 11N(7)  
 Rogers, WL. 51P(ab), 132P(ab), 173P(ab)  
 Rogmann, K. 202P(ab)  
 Rombaut, E. 75P(ab)  
 Romeo, A. 86P(ab)  
 Römer, W. 27P(ab)  
 Romijn, MG. 252P(ab)  
 Romme, PJH. 252P(ab)  
 Rommelfanger, SG. 147P(ab), 186P(ab), 1684  
 Ronga, G. 1542  
 Roob, G. 790  
 Roodenburg, LN. 1476  
 Rooimans, M. 262P(ab)  
 Roolker, W. 196P(ab)  
 Rose, DJ. 220P(ab), 233P(ab)  
 Rose, DS. 211P(ab)  
 Rose, M. 1280  
 Rosen, BR. 54P(ab)  
 Rosen, G. 255P(ab)  
 Rosen, MD. 75P(ab)  
 Rosen, SE. 60P(ab)  
 Ross, CW. 21S  
 Rossetti, C. 30P(ab)  
 Rossigneur, J. 146P(ab)  
 Rossini, D. 115P(ab)  
 Rossleigh, MA. 1280  
 Rossman, PJ. 2027  
 Rossmüller, B. 82P(ab)  
 Rotemberg, G. 1822  
 Roth, GS. 207P(ab)  
 Rothman, RB. 55P(ab)  
 Rouleau, D. 92P(ab)  
 Rousset, OG. 904  
 Rouvier, E. 159P(ab), 246P(ab), 1172, 1937  
 Rowe, CC. 285  
 Rowlinson-Busza, G. 239P(ab)  
 Roy, AM. 111P(ab)  
 Roy, LP. 1428  
 Royal, HD. 1114, 1302  
 Rozanski, A. 45P(ab), 87P(ab), 101P(ab)  
 Ruacan, S. 1021  
 Rubia, FJ. 624  
 Rubin, S. 249P(ab)  
 Rückert, JC. 2141  
 Rudberg, U. 2055  
 Rudnicki, P. 277P(ab)  
 Rueda, B. 90P(ab)  
 Rufini, V. 1202  
 Ruhlmann, J. 151P(ab), 189P(ab)  
 Ruiz, M. 160P(ab)  
 Ruotsalainen, U. 141P(ab)  
 Rusckowski, M. 56, 219P(ab), 241P(ab)  
 Russell, CD. 15P(ab), 1257, 1297  
 Ruth, TJ. 172P(ab), 173P(ab), 792, 1714  
 Ruzicka, T. 996  
 Ryu, JM. 2161  
 Ryu, JS. 34P(ab), 273P(ab)  
 Ryu, YH. 281, 619, 2044  
 Sabri, O. 147, 815  
 Sacher, M. 1366  
 Sadato, N. 53P(ab), 123P(ab), 158P(ab), 164P(ab), 204P(ab), 213P(ab), 245, 251P(ab), 453, 2121  
 Sadelain, M. 130P(ab)  
 Sadzot, B. 778  
 Saffer, JR. 7P(ab), 46P(ab), 120P(ab), 180P(ab), 181P(ab), 221P(ab), 232P(ab)  
 Safi, N. 1214  
 Saga, T. 30, 59P(ab), 224P(ab), 244P(ab)  
 Saha, G. 43P(ab), 148P(ab), 212P(ab)  
 Sahu, SK. 1148  
 Saiki, D. 90P(ab)  
 Sain, JD. 9P(ab), 172P(ab)  
 Saito, H. 453  
 Saito, Y. 157P(ab)  
 Saji, H. 217P(ab), 220P(ab), 226P(ab), 244P(ab)  
 Sakahara, H. 30, 217P(ab), 224P(ab), 244P(ab), 250P(ab), 252P(ab), 1360, 1727, 2017(lc)  
 Sakai, T. 1518  
 Sakai, Y. 127P(ab)  
 Sakamoto, H. 256P(ab)  
 Sakamoto, S. 163P(ab), 293, 1875  
 Sakata, K. 1667  
 Sakuma, H. 334  
 Salako, QA. 185P(ab), 576(lc), 667, 842  
 Salas, C. 1830(lc)  
 Salensky, H. 45P(ab)  
 Saletnich, I. 1202  
 Salminen, E. 249P(ab)  
 Salopek, T. 10P(ab)  
 Saloux, E. 1841  
 Salvadore, B. 4, 254P(ab)  
 Salvatore, M. 17P(ab), 101P(ab), 634, 802, 1869  
 Salvatori, M. 1202  
 Salvia, L. 243P(ab)  
 Salzer-Muhar, U. 202P(ab)  
 Samal, M. 167P(ab), 198P(ab)  
 Samaratunga, RC. 659  
 Sambuceti, G. 396  
 Samei, E. 277P(ab)  
 Samnick, S. 226P(ab)  
 Samuel, AM. 1531  
 Samuel, D. 142P(ab)  
 San, H. 4P(ab)  
 San Pedro, EC. 96P(ab), 148P(ab), 149P(ab)  
 Sanacora, G. 40P(ab)  
 Sanchez, J. 201P(ab)  
 Sandbank, J. 86  
 Sandberg, K. 196P(ab)  
 Sandell, A. 552  
 Sandell, J. 120P(ab), 237P(ab), 2061  
 Sandhu, J. 77P(ab)  
 Sandler, MP. 108P(ab), 1111, 2035  
 Sandmaier, BM. 91P(ab)  
 Sandrock, D. 118P(ab), 196P(ab), 259P(ab), 265P(ab), 2141  
 Sani, S. 129P(ab)  
 Santana-Boado, C. 751  
 Santens, P. 307, 495  
 Santini, C. 875  
 Santoro, GM. 384  
 Saoudi, A. 92P(ab)
- Sarda, L. 29P(ab), 104P(ab), 140P(ab), 159P(ab)  
 Sarkar, SD. 30P(ab), 197P(ab)  
 Sartor, J. 105P(ab), 143P(ab)  
 Sarwar, A. 663  
 Sarwar, M. 53P(ab), 236P(ab)  
 Sasaki, H. 195P(ab)  
 Sasaki, M. 137P(ab), 163P(ab), 213P(ab), 258P(ab), 293, 760, 974, 1875  
 Sasaki, T. 2178  
 Sasaki, Y. 4P(ab), 72P(ab), 141P(ab), 142P(ab), 270P(ab), 884, 1784  
 Sasayama, S. 158P(ab), 390, 1132  
 Sasso, DE. 723  
 Sato, H. 152P(ab)  
 Sato, J. 86P(ab), 126P(ab), 157P(ab)  
 Sato, K. 203  
 Sato, N. 30, 224P(ab), 244P(ab)  
 Sato, S. 200P(ab)  
 Satoh, K. 1626  
 Satoh, N. 172P(ab)  
 Satoh, T. 1676, 2084  
 Satter, M. 207P(ab)  
 Satter, MR. 214P(ab)  
 Satyamurthy, N. 35P(ab), 42P(ab), 53P(ab), 2003  
 Saunders, C. 191P(ab)  
 Saunders, M. 187P(ab)  
 Savi, A. 30P(ab), 171P(ab)  
 Saxena, S. 41P(ab)  
 Sayek, I. 1021  
 Sayfan, J. 244P(ab)  
 Sayre, JW. 3P(ab), 9P(ab)  
 Sébahoun, S. 156P(ab)  
 Scandola, M. 133P(ab)  
 Scanu, P. 1129  
 Schofield, D. 113  
 Schofield, L. 1468  
 Schomburg, A. 135P(ab)  
 Schömig, A. 139P(ab), 1307  
 Schönbächler, R. 118P(ab)  
 Schramm, J. 212P(ab)  
 Schreckenberger, M. 147  
 Schreivogel, I. 262P(ab)  
 Schrikke, U. 75P(ab), 128P(ab), 139P(ab), 145P(ab)  
 Schroder, LE. 659  
 Schröder, O. 66P(ab), 94P(ab), 134P(ab)  
 Schubiger, PA. 118P(ab)  
 Schuellner, MJ. 23P(ab)  
 Schuhmacher, J. 1769  
 Schuierer, G. 26P(ab), 27P(ab)  
 Schulte, K-W. 996  
 Schultze, AE. 1286  
 Schultzer, M. 192P(ab)  
 Schulz, G. 157P(ab), 402  
 Schulzer, M. 792, 1714  
 Schumacher, HR. 114P(ab)  
 Schumpelick, V. 81P(ab)  
 Schuster, D. 276P(ab)  
 Schweiger, M. 26P(ab), 27P(ab), 48P(ab), 56P(ab), 73P(ab), 75P(ab), 80P(ab), 109P(ab), 110P(ab), 111P(ab), 128P(ab), 139P(ab), 145P(ab), 159P(ab), 161P(ab), 238P(ab), 257P(ab), 411, 1307, 1398, 1762  
 Schwartz, RA. 71P(ab)  
 Schwarz, J. 14P(ab), 124P(ab)  
 Schwarz, M. 81P(ab)  
 Schwarz, SW. 104P(ab), 105P(ab), 1944  
 Schwarzbach, M. 53P(ab)  
 Schwender, N. 122P(ab)  
 Schwimmer, J. 60P(ab), 69P(ab), 94P(ab), 248P(ab)  
 Sciagrà, R. 384  
 Sciammarella, MG. 139P(ab)  
 Sciuk, J. 114P(ab)  
 Scopacasa, F. 108  
 Scopinaro, F. 1830(lc)  
 Scorza, R. 117P(ab)  
 Scott, JR. 10P(ab)  
 Seabold, JE. 19P(ab), 123P(ab), 218P(ab), 1111  
 Searles, R. 32P(ab)  
 Sedelnikova, OA. 1412  
 Sedvall, G. 237P(ab), 2061  
 Segall, GM. 122P(ab)  
 Seibyl, JP. 13P(ab), 14P(ab), 21P(ab), 26P(ab), 37P(ab), 40P(ab), 68P(ab), 72P(ab), 82P(ab), 123P(ab), 132P(ab), 175P(ab), 176P(ab), 208P(ab), 209P(ab), 212P(ab), 1500, 1719  
 Seidel, J. 272P(ab)  
 Seike, Y. 961, 1348  
 Seiler, C. 71P(ab)  
 Seio, T. 252P(ab)  
 Seki, H. 9, 247P(ab), 248P(ab), 1016  
 Seltzer, MA. 9P(ab), 150P(ab)  
 Semmler, W. 1819  
 Sen Gupta, S. 30P(ab)  
 Senadhi, VK. 226P(ab)  
 Senda, M. 26P(ab), 131P(ab), 230P(ab), 498, 2178  
 Senden, TJ. 1647(lc)  
 Senekowitsch-Schmidtke, R. 159P(ab), 238P(ab), 1762  
 Seo, DW. 69P(ab)  
 Seo, JK. 201P(ab)  
 Seong, S-C. 130P(ab)  
 Serafini, AN. 113P(ab), 243, 1388, 1910  
 Serdengecti, M. 199P(ab)  
 Seregni, E. 4  
 Serles, W. 978  
 Serseni, D. 608  
 Seto, H. 436, 2077  
 Seymour, K. 1327  
 Sfakianakis, GN. 28P(ab), 108P(ab), 163P(ab), 201P(ab), 243, 1297, 1388, 1910  
 Sgouros, G. 111P(ab), 186P(ab), 188P(ab), 223P(ab), 484, 2196(lc)  
 Shah, BD. 60P(ab), 248P(ab)  
 Shah, DH. 1531  
 Shah, F. 237P(ab)  
 Shah, J. 22P(ab), 230P(ab)  
 Shah, P. 53P(ab)  
 Shahinian, AH. 131P(ab)  
 Shahzad, K. 74P(ab)  
 Shaikh, AA. 273P(ab)  
 Shakudo, M. 256P(ab)  
 Shamsi, HA. 234P(ab)  
 Shanahan, J. 90P(ab)  
 Shankar, LK. 201P(ab), 249P(ab)  
 Shao, L. 37P(ab)  
 Shao, Y. 50P(ab), 278P(ab)  
 Shapiro, B. 275P(ab), 679, 707, 1202, 1460  
 Sharfstein, S. 729, 2003  
 Sharir, T. 62P(ab), 87P(ab), 103P(ab), 104P(ab)  
 Sharkey, RM. 34, 71P(ab), 105P(ab), 112P(ab), 235P(ab), 245P(ab)  
 Sharma, A. 28P(ab), 45P(ab)  
 Sharp, T. 145P(ab)

- Shaw, L.J. 115P(ab), 116P(ab),  
   139P(ab), 140  
 Shefer, RE. 234P(ab), 240P(ab)  
 Sheff, K. 1500  
 Shelton, V. 90P(ab)  
 Shen, C. 124P(ab), 200P(ab)  
 Shen, L-H. 1752  
 Shen, S. 112P(ab), 185P(ab),  
   186P(ab), 246P(ab), 842, 1223  
 Shen, Y. 115P(ab)  
 Shepherd, J. 60P(ab), 69P(ab),  
   94P(ab), 248P(ab)  
 Sherman, ELC. 1944  
 Shi, R. 64P(ab)  
 Shibaizaki, T. 53P(ab)  
 Shibuya, H. 43  
 Shidahara, M. 98P(ab), 187P(ab)  
 Shich, CB. 197P(ab)  
 Shields, AF. 22P(ab), 190P(ab),  
   228P(ab), 1043, 1418, 1757  
 Shiga, T. 85P(ab), 127P(ab),  
   175P(ab), 261P(ab), 807  
 Shigematsu, A. 2161  
 Shigeno, C. 129P(ab)  
 Shigeyama, T. 931(lc)  
 Shih, LB. 105P(ab), 223P(ab),  
   235P(ab)  
 Shikama, N. 89P(ab)  
 Shiloni, E. 264P(ab)  
 Shim, I. 12P(ab), 54P(ab),  
   229P(ab)  
 Shim, YM. 252P(ab)  
 Shimada, K. 1123, 2022  
 Shimamoto, K. 158P(ab), 1492  
 Shimasaki, T. 181P(ab)  
 Shimizu, K. 192P(ab)  
 Shimizu, M. 436, 2077  
 Shimizu, T. 269P(ab)  
 Shimizu, Y. 45P(ab), 193P(ab)  
 Shimomura, T. 1875  
 Shimono, T. 148P(ab), 163P(ab)  
 Simonov, M. 1802  
 Shimoshige, S. 127P(ab),  
   158P(ab)  
 Shimotsu, Y. 140P(ab), 408,  
   1676, 1862, 2084  
 Shin, DW. 629  
 Shin, JW. 34P(ab), 273P(ab)  
 Shin, MJ. 34P(ab)  
 Shin, T. 537  
 Shinhar, S. 1802  
 Shinier, D. 164P(ab)  
 Shinohoh, H. 95P(ab)  
 Shiobara, S. 1681  
 Shiozaki, T. 148P(ab), 163P(ab)  
 Shirakawa, S. 88P(ab)  
 Shirotani, M. 1667  
 Shitabata, P. 449  
 Shiue, C-Y. 231P(ab)  
 Shiue, GG. 231P(ab)  
 Shively, JE. 2097  
 Shnier, D. 5P(ab), 33P(ab),  
   81P(ab), 126P(ab), 146P(ab),  
   273P(ab), 1260  
 Shogase, T. 127P(ab)  
 Shohtsu, A. 147P(ab), 252P(ab)  
 Shoji, Y. 181, 1789  
 Shoner, SC. 232P(ab)  
 Shore, JB. 1260  
 Shrem, Y. 1822  
 Shreve, P. 51P(ab), 108P(ab),  
   109P(ab)  
 Shuke, N. 57P(ab), 86P(ab),  
   126P(ab), 156P(ab), 157P(ab),  
   436, 2077  
 Shulkin, BL. 679  
 Shulman, SD. 509  
 Shumiya, S. 498  
 Sibomana, M. 57P(ab), 97P(ab)  
 Siccardi, AG. 70P(ab)  
 Siddiqui, AR. 56P(ab)  
 Siebner, HR. 109P(ab)  
 Sieckman, GL. 222P(ab),  
   225P(ab)  
 Sieff, C. 187P(ab)  
 Siegel, JA. 28S, 671, 1230, 2167  
 Sif El-Din, AS. 23P(ab)  
 Sigmund, M. 402  
 Signore, A. 1542  
 Sila, CA. 148P(ab)  
 Silaszi, I. 246P(ab)  
 Silberstein, EB. 1831(lc), 2190  
 Silbersweig, D. 202P(ab)  
 Silva, F. 1254  
 Silverman, DHS. 9P(ab),  
   41P(ab), 60P(ab), 68P(ab),  
   69P(ab), 89P(ab), 94P(ab),  
   431  
 Silverman, RW. 133P(ab),  
   278P(ab)  
 Silzofski, WJ. 273P(ab)  
 Simkin, P. 79P(ab)  
 Simms, RW. 221  
 Simon, J. 186P(ab)  
 Simonneau, G. 275P(ab)  
 Simons, M. 189P(ab), 1563  
 Simpson, N. 55P(ab), 119P(ab),  
   167P(ab)  
 Singh, M. 1357  
 Singh, P. 197P(ab)  
 Sinusas, AJ. 61P(ab), 62P(ab),  
   417  
 Sisson, JC. 1111, 1460  
 Sitek, A. 144P(ab), 2183  
 Skinner, M. 221  
 Sklarck, J. 257P(ab)  
 Sköldenberg, B. 2055  
 Skrypnuk, J. 17P(ab)  
 Slama, M. 142P(ab)  
 Slegers, G. 307  
 Sleijfer, DT. 1027  
 Slijpen, ETP. 79P(ab), 178P(ab)  
 Slomka, PJ. 168P(ab), 169P(ab),  
   339  
 Sloof, GW. 255  
 Slosky, JJ. 33N(11)  
 Slotman, BJ. 183P(ab)  
 Smeraldi, E. 40P(ab)  
 Smilowitz, HM. 723  
 Smith, CJ. 215P(ab)  
 Smith, EM. 173P(ab), 174P(ab),  
   2153  
 Smith, GT. 52P(ab), 249P(ab),  
   1286  
 Smith, LT. 277P(ab)  
 Smith, MF. 79P(ab), 227P(ab),  
   856  
 Smith, RG. 231P(ab)  
 Smith, RJ. 37P(ab), 81P(ab),  
   120P(ab), 133P(ab), 164P(ab),  
   206P(ab), 210P(ab)  
 Smith, T. 265P(ab), 268P(ab)  
 Smith, WJM. 14N(9), 22N(1),  
   25N(4), 26N(11), 28N(7),  
   30N(12), 32N(5), 32N(8),  
   33N(2)  
 Smith-Jones, P. 39P(ab),  
   77P(ab), 223P(ab), 246P(ab),  
   1928, 2090  
 Smok, G. 57P(ab)  
 Smylie, MGB. 10P(ab)  
 Smyth, CA. 224P(ab), 225P(ab)
- Snimotsu, Y. 162P(ab)  
 Snow, KW. 243P(ab)  
 Snyder, AZ. 13P(ab)  
 So, Y. 130P(ab), 201P(ab),  
   257P(ab)  
 Soares, EJ. 169P(ab)  
 Soares, JC. 13P(ab), 21P(ab),  
   57P(ab), 82P(ab)  
 Soares, JP. 61P(ab), 62P(ab)  
 Sobesky, J. 148P(ab)  
 Soeda, H. 137P(ab)  
 Sofocleous, C. 192P(ab)  
 Sohn, D. 237P(ab)  
 Sohn, M-H. 11P(ab), 1405  
 Sohn, SK. 150P(ab), 1401  
 Sohn, YJ. 130P(ab)  
 Sokiranski, R. 81P(ab)  
 Söklér, M. 147P(ab)  
 Soler-Soler, J. 751  
 Sollito, R. 108P(ab)  
 Solomon, RA. 149P(ab)  
 Sommer, H. 849  
 Sondak, V. 25P(ab)  
 Song, AW. 110P(ab)  
 Song, H-C. 91, 184P(ab)  
 Sonnenschein, W. 1536  
 Sorantin, E. 2153  
 Soricelli, A. 802, 1869  
 Sors, H. 5P(ab), 275P(ab)  
 Sossi, V. 173P(ab), 1714  
 Soufer, R. 21P(ab), 136P(ab),  
   159P(ab), 175P(ab), 209P(ab),  
   379  
 Spanaki, MV. 68P(ab), 212P(ab)  
 Sparks, RB. 268P(ab)  
 Spaulding, M. 248P(ab)  
 Spector, N. 113P(ab)  
 Speelman, JD. 13P(ab)  
 Spelsberg, A. 81P(ab)  
 Spence, AM. 53P(ab), 440, 1805  
 Spencer, SS. 68P(ab), 212P(ab)  
 Spencer, WH. 253P(ab)  
 Spero, KA. 56P(ab)  
 Spes, C. 153P(ab)  
 Speziale, F. 875  
 Spiecer, KM. 20N(4), 58P(ab)  
 Spiers, PA. 965  
 Spies, SM. 145P(ab), 179P(ab)  
 Spiliotis, J. 1433  
 Spinks, TJ. 1696  
 Squire, OD. 67P(ab)  
 Sridhar, KS. 243  
 Srinivasan, A. 30P(ab), 39P(ab),  
   62P(ab), 63P(ab), 104P(ab),  
   233P(ab), 261P(ab), 264P(ab),  
   729  
 Srivastava, SC. 222P(ab)  
 St. George-Hyslop, PH. 1511  
 Stabin, MG. 15, 83P(ab),  
   184P(ab), 188P(ab), 190P(ab),  
   191P(ab), 927(lc), 1989  
 Stack, BC. 122P(ab), 256P(ab)  
 Stadtmauer, E. 71P(ab)  
 Stadtmauer, EA. 146P(ab)  
 Staib, L. 81P(ab), 202P(ab),  
   209P(ab), 1030  
 Staib-Sebler, E. 134P(ab), 1155  
 Staley, J. 123P(ab), 136P(ab)  
 Starzec, A. 1214  
 Staudenherz, A. 6P(ab), 1263  
 Stauffer, R. 99P(ab)  
 Stayanoff, JC. 228P(ab)  
 Steel, CJ. 237P(ab)  
 Steele, PP. 172P(ab), 276P(ab),  
   277P(ab)
- Steffens, MG. 244P(ab),  
   246P(ab), 247P(ab)  
 Stein, A. 16P(ab)  
 Stein, RC. 71P(ab), 223P(ab),  
   1743  
 Steinberg, B. 60P(ab)  
 Steiner, B. 1263  
 Steiner, G. 223P(ab)  
 Steinert, HC. 80P(ab), 94P(ab),  
   1892  
 Steingart, R. 158P(ab)  
 Steinmetz, AP. 1822  
 Stennert, E. 256P(ab)  
 Stephane, M. 55P(ab), 72P(ab),  
   166P(ab)  
 Stephenson, C. 82P(ab)  
 Sterman, D. 81P(ab)  
 Stern, G. 90P(ab)  
 Stevenaert, A. 778  
 Stevens, H. 495  
 Stevenson, G. 9P(ab)  
 Steventon, RS. 51P(ab),  
   109P(ab)  
 Stewart, D. 209P(ab)  
 Stievenart, JL. 27P(ab), 185P(ab)  
 Stöcklin, G. 159P(ab)  
 Stodicek, SRG. 26P(ab), 27P(ab)  
 Stodila, RZ. 8P(ab), 106P(ab),  
   182P(ab), 190  
 Stoessl, AJ. 792  
 Stoeter, P. 83P(ab)  
 Stone, CD. 365  
 Stone, CK. 1684, 1690, 1958  
 Stoof, JC. 1143, 1879  
 Stoot, J. 8P(ab), 160P(ab)  
 Storey, G. 361, 1095  
 Storm, G. 7P(ab), 30P(ab),  
   195P(ab), 242P(ab), 264P(ab),  
   267P(ab), 2172  
 Stoub, E. 2183  
 Stout, DB. 42P(ab)  
 Stowers, SA. 153P(ab)  
 Strand, S-E. 552  
 Strasser-Fuchs, S. 790  
 Strauss, HW. 8P(ab), 24P(ab),  
   28N(5), 160P(ab), 178P(ab),  
   203P(ab), 918  
 Strauss, J. 28P(ab)  
 Strauss, LG. 8P(ab), 53P(ab),  
   165P(ab), 465, 1197  
 Strauss, M. 125P(ab)  
 Stroehlein, K. 244P(ab),  
   273P(ab)  
 Stroobants, S. 134P(ab),  
   267P(ab)  
 Stubbs, JB. 221P(ab), 268P(ab),  
   1989, 2069  
 Stundzia, A. 503  
 Su, F-M. 71P(ab), 91P(ab)  
 Suckling, J. 204P(ab)  
 Sudo, Y. 72P(ab), 95P(ab)  
 Sueyoshi, K. 201P(ab), 269P(ab)  
 Suga, K. 192P(ab), 543, 889  
 Sugawara, S. 181  
 Sugawara, Y. 66P(ab)  
 Suger, G. 33P(ab), 2145  
 Sugihara, H. 163P(ab), 1977  
 Sugimoto, K. 53P(ab), 158P(ab),  
   164P(ab), 220P(ab), 251P(ab),  
   453, 2121  
 Sugioka, J. 127P(ab)  
 Suh, KJ. 1401  
 Suhara, T. 72P(ab), 95P(ab)  
 Sullo, P. 17P(ab)  
 Sumiya, H. 200P(ab), 1179,  
   1600
- Sun, B-F. 829  
 Sun, KT. 272  
 Sun, Y. 91P(ab)  
 Sundin, AE. 640  
 Sureshkumar, P. 1428  
 Surti, S. 171P(ab)  
 Susskind, H. 374(lc)  
 Sutinen, E. 254P(ab)  
 Suzarte, MR. 1918  
 Suzuki, F. 498  
 Suzuki, H. 53P(ab)  
 Suzuki, K. 72P(ab), 2022  
 Suzuki, N. 220P(ab)  
 Suzuki, T. 152P(ab), 153P(ab)  
 Suzuki, Y. 147P(ab)  
 Suzuki, YS. 2161  
 Swahn, C-G. 118P(ab),  
   120P(ab), 1965, 2061  
 Swaney, C. 108P(ab)  
 Swayne, LC. 34  
 Swindle, LA. 46P(ab), 89P(ab)  
 Swinne, C. 164P(ab)  
 Switzer, J. 126P(ab)  
 Sworin, M. 217P(ab)  
 Sychra, JJ. 276P(ab)  
 Sylvester, JM. 1114  
 Syrbu, SI. 723  
 Syrota, A. 71P(ab), 90P(ab),  
   142P(ab), 205P(ab)  
 Szabatin, M. 277P(ab)  
 Szabó, BG. 1736  
 Szabo, K. 100P(ab), 196P(ab)  
 Szabo, Z. 100P(ab), 167P(ab),  
   194P(ab), 196P(ab), 1209  
 Szakacs, GM. 6P(ab), 114P(ab)  
 Szecsi, J. 26P(ab), 27P(ab)  
 Szeto, ER. 298  
 Szilard, M. 142P(ab)  
 Szilvasi, I. 1928  
 Szymski, GX. 193P(ab)  
 Tabuchi, E. 320  
 Tabuchi, K. 201P(ab)  
 Tabuena, MJ. 1830(lc)  
 Tadamura, E. 88P(ab), 141P(ab),  
   157P(ab), 390, 938, 1835  
 Taddci, GZ. 96P(ab)  
 Tadokoro, H. 2022  
 Tadokoro, M. 161P(ab),  
   162P(ab)  
 Taffet, GE. 48P(ab)  
 Tai, Y-C. 9P(ab)  
 Taillefer, R. 17P(ab), 459, 2019  
 Taillon, LA. 1857  
 Tait, J. 8P(ab), 160P(ab)  
 Takada, M. 129P(ab)  
 Takagi, S. 252P(ab)  
 Takahashi, K. 157P(ab), 582  
 Takahashi, M. 107P(ab),  
   176P(ab), 181P(ab), 217P(ab)  
 Takahashi, N. 53P(ab), 85P(ab),  
   90P(ab), 123P(ab), 158P(ab),  
   159, 164P(ab), 251P(ab), 453,  
   582  
 Takahashi, S. 194P(ab)  
 Takahashi, T. 45P(ab), 193P(ab)  
 Takahashi, W. 252P(ab)  
 Takami, A. 1123, 2022  
 Takamiya, M. 1676, 1862, 2084  
 Takano, K. 192P(ab)  
 Takashima, H. 1626  
 Takashio, T. 86P(ab), 157P(ab)  
 Takayama, T. 177P(ab),  
   178P(ab)  
 Takeda, K. 208P(ab), 213P(ab),  
   334

- Takeda, Y. 200P(ab), 529, 2095  
 Takeishi, Y. 582  
 Takekoshi, N. 59P(ab)  
 Takeuchi, A. 213P(ab)  
 Takeuchi, R. 241, 1360  
 Taki, J. 59P(ab), 716, 1179,  
     1600, 1681  
 Tamai, H. 201P(ab)  
 Tamaka, K. 473  
 Tamaki, N. 85P(ab), 88P(ab),  
     127P(ab), 141P(ab), 157P(ab),  
     175P(ab), 250P(ab), 261P(ab),  
     390, 656, 807, 1727, 1835  
 Tamgac, F. 928(lc)  
 Tamm, E. 244P(ab)  
 Tamura, S. 49P(ab), 138P(ab)  
 Tamura, T. 89P(ab)  
 Tan, P. 209P(ab)  
 Tan, PE. 113  
 Tan, P.-Z. 21P(ab), 136P(ab)  
 Tanabe, M. 1626  
 Tanada, S. 72P(ab), 95P(ab),  
     2022  
 Tanaka, F. 14P(ab), 209P(ab),  
     1511  
 Tanaka, H. 1360  
 Tanaka, K. 127P(ab)  
 Tanaka, Y. 1463  
 Tang, HR. 98P(ab)  
 Taniguchi, K. 153P(ab)  
 Taniguchi, M. 247P(ab),  
     248P(ab), 1016, 1681  
 Taniguchi, Y. 163P(ab)  
 Tanner, JW. 124  
 Tansey, LW. 234P(ab)  
 Tansey, W. 233P(ab)  
 Tapscott, E. 12N(12), 13N(5),  
     14N(5), 15N(3), 16N(5),  
     16N(6), 18N(6), 22N(4)  
 Tashiro, M. 195P(ab)  
 Tateishi, J. 157P(ab)  
 Tateo, M. 142P(ab)  
 Tatsch, K. 14P(ab), 82P(ab),  
     114P(ab), 124P(ab), 153P(ab),  
     262P(ab), 272P(ab), 849, 1138  
 Tatsumi, K. 1160  
 Tatsumi, M. 44P(ab)  
 Tatsumi, T. 269P(ab)  
 Tausig, A. 153P(ab)  
 Taut, H. 199P(ab)  
 Tavernier, R. 155P(ab)  
 Tavitian, B. 229P(ab)  
 Taylor, AT Jr. 86P(ab),  
     217P(ab), 1257, 1297  
 Taylor, I. 1743  
 Taylor, MD. 1884  
 Taylor, RI. 275P(ab)  
 Taylor, SE. 228P(ab), 233P(ab)  
 Teates, CD. 5P(ab)  
 Tedeschi, E. 802  
 Teff, K. 274P(ab)  
 Tega, H. 106P(ab)  
 Teigin, P. 109P(ab)  
 Telang, FW. 42P(ab), 42P(ab)  
 Temo, C. 90P(ab)  
 Tennis, T. 271P(ab)  
 Tentler, M. 143P(ab)  
 Tepe, G. 1819  
 Terrazzino, S. 229P(ab)  
 Terzi, A. 115P(ab)  
 Tesar, RD. 134P(ab), 135P(ab)  
 Testori, A. 245P(ab)  
 Tetigin, P. 109P(ab)  
 Teule, GJJ. 84P(ab), 183P(ab),  
     255, 262P(ab), 302P(ab)  
 Tewson, TJ. 35P(ab)  
 Thakrar, DS. 138P(ab), 150P(ab)  
 Thakur, ML. 64P(ab), 226P(ab),  
     265P(ab), 268P(ab)  
 Thayapran, N. 158P(ab)  
 Thédréz, P. 1608  
 Thelen, MH. 19P(ab), 1033  
 Thetter, O. 257P(ab)  
 Theuws, JCM. 1074  
 Thie, JA. 52P(ab), 249P(ab)  
 Thiel, A. 148P(ab)  
 Thierns, H. 307  
 Thierns, H. 189P(ab)  
 Thierry, AR. 1412  
 Thirumula, S. 263P(ab)  
 Thisted, RA. 285  
 Thomas, SR. 659  
 Thompson, CJ. 146P(ab), 350  
 Thompson, JF. 2195(lc)  
 Thompson, WL. 205P(ab)  
 Thorberg, S-O. 237P(ab)  
 Thornback, JR. 7P(ab),  
     215P(ab), 226P(ab), 267P(ab),  
     271P(ab)  
 Thorstad, W. 1376  
 Thrall, JH. 144P(ab)  
 Thrall, RS. 723  
 Thurtjell, L. 106P(ab)  
 Tiel-van Buul, MMC. 56P(ab)  
 Tieje, N. 1913  
 Tikofsky, RS. 149P(ab), 923  
 Tiling, R. 849  
 Ting, G. 1752  
 Tingey, JM. 91P(ab)  
 Timmeyer, S. 1237  
 Tissingh, G. 1143, 1879  
 Tjuvajev, JG. 130P(ab),  
     236P(ab), 237P(ab)  
 Toba, M. 140P(ab), 162P(ab),  
     1862, 2084  
 Tobin, JR. 206P(ab)  
 Todd-Pokropek, A. 174P(ab)  
 Togami, I. 529  
 Tokuda, Y. 147P(ab)  
 Tol, JL. 196P(ab)  
 Tölle, TR. 26P(ab), 73P(ab)  
 Tolmachev, V. 1273  
 Tolmos, J. 449  
 Tomaru, Y. 53P(ab)  
 Tomas, MB. 29P(ab), 33P(ab),  
     263P(ab), 275P(ab), 346  
 Tomiguchi, S. 107P(ab),  
     176P(ab), 181P(ab), 217P(ab)  
 Tomita, N. 473  
 Tomiyama, Y. 152P(ab)  
 Tomiyoshi, K. 53P(ab),  
     236P(ab), 663, 1424  
 Tomoike, H. 582  
 Tompkins, RG. 195P(ab),  
     266P(ab)  
 Toms, N. 193P(ab)  
 Tonakie, A. 25P(ab)  
 Tonami, H. 9, 1016  
 Tonami, N. 106P(ab), 126P(ab),  
     200P(ab), 436, 716, 1179,  
     1600, 1681, 2077  
 Tondeur, M. 16P(ab), 216(lc),  
     2015(lc)  
 Tondini, C. 1586  
 Toohey, RE. 184P(ab)  
 Torizuka, T. 43P(ab), 147P(ab),  
     250P(ab), 252P(ab), 1727  
 Tornai, MP. 121P(ab)  
 Torosian, M. 10P(ab)  
 Torrente, Y. 218P(ab)  
 Torres, LA. 15  
 Torres, MA. 29P(ab), 30P(ab),  
     34P(ab), 266P(ab)  
 Totonchian, N. 181P(ab)  
 Toussaint, P-J. 206P(ab)  
 Touya, E. 137P(ab)  
 Townsend, DW. 205P(ab),  
     211P(ab), 1207, 1267  
 Townsend, R. 274P(ab)  
 Towson, J. 227P(ab)  
 Toyama, H. 26P(ab), 208P(ab),  
     213P(ab), 498  
 Toyama, K. 266  
 Toyama, T. 152P(ab), 153P(ab)  
 Toyoda, H. 45P(ab), 193P(ab)  
 Toyokuni, T. 35P(ab), 53P(ab)  
 Trachsel, C. 1892  
 Tran, HD. 275P(ab)  
 Tran, LLP. 267P(ab)  
 Tran, N. 32P(ab)  
 Traub, T. 29P(ab), 77P(ab)  
 Travaini, L. 171P(ab)  
 Travis, MJ. 83P(ab)  
 Treisman, GJ. 40P(ab)  
 Trejtnar, F. 8P(ab)  
 Treumann, T. 80P(ab), 257P(ab)  
 Trevena, I. 19N(4)  
 Treves, ST. 113, 311, 1056,  
     1458  
 Träger, H. 113P(ab)  
 Triantafillou, B. 149P(ab)  
 Trisjono, F. 124  
 Tronco, G. 30P(ab), 197P(ab),  
     266P(ab)  
 Troncone, L. 1202  
 Trotta, F. 204P(ab)  
 Trouillet, JL. 29P(ab)  
 Truckenbrodt, R. 1762  
 Trudeau, JD. 110P(ab)  
 Truong, DC. 278P(ab)  
 Tsai, JS. 205P(ab)  
 Tsai, MF. 59P(ab)  
 Tsai, SC. 196P(ab)  
 Tsai, Z-T. 1752  
 Tsao, J. 503  
 Tschelissnigg, K. 2153  
 Tsuboyama, T. 129P(ab)  
 Tsuchida, C. 213P(ab)  
 Tsuchida, T. 53P(ab), 123P(ab),  
     158P(ab), 164P(ab), 213P(ab),  
     245, 251P(ab), 453, 2121  
 Tsuchihashi, K. 1492  
 Tsuchiya, H. 1179, 1600  
 Tsuda, G. 453  
 Tsui, BMW. 23P(ab), 25P(ab),  
     37P(ab), 120P(ab), 121P(ab),  
     166, 170P(ab), 177P(ab),  
     179P(ab), 562  
 Tsuji, S. 200P(ab)  
 Tsukada, H. 198  
 Tsukamoto, E. 85P(ab),  
     127P(ab), 175P(ab), 261P(ab),  
     656, 807  
 Tsunoda, M. 200P(ab)  
 Tsunoda, T. 1630  
 Tu, CH. 205P(ab)  
 Tulchinsky, M. 16P(ab),  
     273P(ab)  
 Turek, JJ. 1579  
 Turk, MJ. 232P(ab)  
 Turkington, TG. 92P(ab),  
     108P(ab), 109P(ab), 257P(ab)  
 Turpin, S. 17P(ab), 459, 1621  
 Turra, S. 516  
 Twardock, AR. 265P(ab)  
 Tzen, KY. 59P(ab), 197P(ab)  
 Ucan, ES. 2116  
 Uccelli, L. 133P(ab), 218P(ab)  
 Uchida, M. 473  
 Uchida, Y. 1160  
 Udelson, JE. 75P(ab)  
 Ueberfuhr, P. 161P(ab)  
 Ueda, S. 325  
 Ueda, Y. 9, 247P(ab), 248P(ab),  
     1016, 1179  
 Uehara, T. 152P(ab), 961  
 Ueki, K. 541  
 Uematsu, H. 251P(ab), 453,  
     2121  
 Uematsu, M. 1676  
 Uemura, K. 182P(ab), 302, 1789  
 Ueno, M. 148P(ab), 163P(ab)  
 Uesugi, Y. 269P(ab)  
 Üğur, Ö. 199P(ab)  
 Ullrich, SP. 94P(ab)  
 Umehara, I. 43  
 Ünal, S. 1897  
 Ünlü, M. I. 116, 304, 1703  
 Unterweger, O. 236, 870  
 Urbach, H. 212P(ab)  
 Urbina, RA. 42P(ab)  
 Uren, RF. 27P(ab), 191P(ab),  
     311, 1428, 1983, 2195(lc)  
 Uribe, J. 93P(ab)  
 Ushiojima, Y. 1977  
 Usui, K. 57P(ab), 86P(ab),  
     126P(ab)  
 Utsunomiya, K. 269P(ab)  
 Utunomiya, K. 201P(ab)  
 Uyttendaele, D. 1563  
 Vaalburg, W. 117P(ab),  
     130P(ab), 810, 1027, 1476,  
     1736  
 Vacheron, A. 156P(ab)  
 Vaerenberg, MM. 1845  
 Vafaei, M. 110P(ab)  
 Vagneur, K. 9P(ab)  
 Vaidyanathan, G. 47P(ab),  
     104P(ab)  
 Valcke, J. 5P(ab)  
 Valderama, E. 29P(ab)  
 Valdivia, S. 192P(ab)  
 Valent, P. 1575  
 Valente, CM. 119P(ab), 236P(ab)  
 Valette, H. 21P(ab), 72P(ab)  
 Valind, SO. 640  
 Valk, PE. 108P(ab), 122P(ab),  
     134P(ab), 135P(ab)  
 Valkema, R. 39P(ab), 60P(ab),  
     155P(ab), 252P(ab), 1662  
 Vallabhajosula, S. 20P(ab),  
     77P(ab), 171P(ab)  
 Van Aken, 198P(ab)  
 van Beek, JHGM. 1312  
 van Campen, LCMC. 18P(ab)  
 Van Cott, A. 211P(ab)  
 Van Cutsem, E. 134P(ab)  
 van de Putte, LBA. 265P(ab)  
 van de Ven, MTP. 265P(ab),  
     266P(ab)  
 Van de Walle, J. 199P(ab)  
 Van de Wiele, C. 155P(ab),  
     198P(ab), 199P(ab), 495  
 Van den Abbeele, AD. 1148  
 Van den Eeckhout, A. 198P(ab),  
     199P(ab)  
 Van den Heuvel, PA. 1845  
 van der Graaf, WTA. 130P(ab)  
 van der Laken, CJ. 265P(ab)  
 van der Mark, TW. 117P(ab)
- van der Meer, JWM. 30P(ab),  
     47P(ab), 119, 195P(ab),  
     242P(ab), 264P(ab), 265P(ab),  
     266P(ab), 2172  
 van der Wall, EE. 1312  
 Van der Wall, H. 44P(ab), 361,  
     1095, 1646(lc)  
 van der Zee, AGJ. 1381  
 van Dieren, EB. 84P(ab)  
 van Dijk, CN. 196P(ab)  
 van Domburg, RT. 1662  
 van Dyck, CH. 21P(ab),  
     136P(ab), 1500  
 van Eijck, CHJ. 252P(ab)  
 Van Espen, MB. 16P(ab)  
 van Gameren, A. 39P(ab),  
     63P(ab), 233P(ab), 261P(ab)  
 van Goor, H. 264P(ab)  
 Van Haelst, JP. 176P(ab),  
     198P(ab)  
 Van Heertum, RL. 55P(ab),  
     82P(ab), 149P(ab), 167P(ab),  
     207P(ab), 923  
 van Herk, M. 1074  
 Van Hoe, L. 134P(ab)  
 van Horn, JR. 810  
 van Imhoff, GW. 1736  
 Van Imschoot, S. 189P(ab)  
 van Kaick, G. 8P(ab), 259P(ab),  
     465, 1197  
 Van Laere, K. 1563  
 van Lier, JE. 165P(ab)  
 van Lingen, A. 18P(ab), 60P(ab),  
     84P(ab), 255, 302P(ab), 1481  
 Van Mourik, JC. 262P(ab)  
 Van Poppel, H. 269P(ab)  
 van Rensburg, AJ. 2110  
 van Rijk, PP. 61P(ab), 170P(ab),  
     178P(ab), 1996  
 van Royen, EA. 13P(ab),  
     56P(ab), 1143, 1703, 1879  
 van Waarde, A. 117P(ab)  
 VanBrocklin, HF. 20P(ab),  
     190P(ab), 228P(ab), 229P(ab),  
     240P(ab)  
 Vander Borght, T. 74P(ab),  
     75P(ab), 164P(ab)  
 Vanhove, C. 78P(ab), 88P(ab)  
 Vanoli, E. 30P(ab)  
 Vanoli, M. 117P(ab)  
 Vanoverschelde, J-LJ. 74P(ab),  
     1655  
 Vansant, JP. 115P(ab)  
 Varela, A. 1830(lc)  
 Vargas, HM. 72P(ab)  
 Vargas, JA. 1830(lc)  
 Vargas, MP. 449  
 Varma, V. 113P(ab)  
 Varpula, M. 254P(ab)  
 Varrella, P. 634  
 Varrone, A. 14P(ab), 17P(ab),  
     101P(ab), 802, 1869  
 Vassilakos, PJ. 1433  
 Vattimo, A. 215(lc), 822  
 Vaufrey, F. 21P(ab)  
 Vaughn, M. 32P(ab)  
 vd Poest, E. 262P(ab)  
 vd Valk, P. 262P(ab)  
 Veenma-van der Duin, L. 836  
 Vella, A. 215(lc), 822  
 Vento, J. 723  
 Ventroni, G. 1542  
 Venz, S. 954  
 Véra, P. 27P(ab), 104P(ab)  
 Verani, MS. 253P(ab)  
 Verbruggen, A. 218P(ab)

- Verelst, J. 16P(ab)  
 Vergara, E. 634  
 Vergote, J. 1214  
 Verhagen, RAW. 196P(ab)  
 Verhoeff, NP. 13P(ab), 26P(ab), 72P(ab), 82P(ab), 123P(ab), 208P(ab)  
 Verkh, L. 113P(ab)  
 Verma, AK. 277P(ab)  
 Vermey, A. 1476  
 Vernon, C. 95P(ab)  
 Veronesi, U. 24P(ab), 70P(ab), 2080  
 Verreault, J. 1441  
 Versijpt, J. 198P(ab)  
 Versteegh, RT. 183P(ab), 262P(ab)  
 Verweire, W. 198P(ab)  
 Vesselle, H. 229P(ab)  
 Vezza, PR. 1617  
 Vezzuto, P. 1869  
 Viale, G. 24P(ab), 2080  
 Vidal, R. 73P(ab)  
 Vilain, D. 140P(ab)  
 Vilani, J. 257P(ab)  
 Vilardell, M. 950  
 Villemagne, VL. 55P(ab), 72P(ab), 137P(ab), 207P(ab), 229P(ab)  
 Vilner, BJ. 227P(ab)  
 Vines, D. 14P(ab), 209P(ab)  
 Vining, M. 215P(ab)  
 Violot, D. 825  
 Virgolini, I. 29P(ab), 39P(ab), 77P(ab), 223P(ab), 225P(ab), 246P(ab), 1570, 1575, 1907, 1928, 2090  
 Visser, CA. 18P(ab), 60P(ab), 1481  
 Visser, FC. 18P(ab), 60P(ab), 255, 1481, 2035  
 Visser, KR. 1312  
 Visser, TJ. 39P(ab), 62P(ab), 63P(ab), 117P(ab), 233P(ab), 261P(ab), 264P(ab)  
 Vitali, P. 96P(ab)  
 Vivino, FB. 273P(ab), 1260  
 Vlachojannis, JG. 1433  
 Voelker, KW. 1972  
 Voellmy, DR. 1892  
 Voipio-Pulkki, L-M. 141P(ab)  
 Volkert, WA. 215P(ab), 222P(ab), 225P(ab)  
 Volkow, ND. 12P(ab), 13P(ab), 42P(ab), 43P(ab), 54P(ab), 99P(ab), 100P(ab), 222P(ab), 238P(ab)  
 Voll, B. 80P(ab)  
 Volm, M. 53P(ab)  
 Volterrani, D. 215(lc), 822  
 Voltini, F. 58P(ab), 61P(ab)  
 vom Dahl, J. 157P(ab), 402  
 von Ammon, K. 879  
 von der Ohe, MR. 1062  
 von Rijswijk, MH. 699  
 von Schulthess, GK. 80P(ab), 94P(ab), 1892  
 Vontobel, P. 879  
 Vora, JK. 159P(ab)  
 Vorbeck, F. 39P(ab), 1570, 1928, 2090  
 Vosberg, H. 996  
 Votaw, DB. 35P(ab)  
 Votaw, JR. 35P(ab), 107P(ab), 110P(ab), 509  
 Voûte, PA. 56P(ab)
- Voytko, ML. 206P(ab)  
 Vriens, P. 8P(ab), 160P(ab)  
 Vriesendorp, HM. 476  
 Vu, D. 278P(ab)  
 Vuillez, JP. 70P(ab), 246P(ab), 1172  
 Vuong, BK. 36P(ab)
- Wackers, FJT. 61P(ab), 62P(ab), 153P(ab), 417, 918  
 Wagner, J. 25P(ab)  
 Wagner, S. 227P(ab), 242P(ab)  
 Wahl, LM. 1826  
 Wahl, RL. 1S(ed), 4P(ab), 145, 21S, 22P(ab), 25P(ab), 43P(ab), 44P(ab), 51P(ab), 66P(ab), 109P(ab), 112P(ab), 147P(ab), 186P(ab), 258P(ab), 1230, 1302  
 Waitman, J. 154P(ab)  
 Wakabayashi, S. 498  
 Wakamatsu, R. 541  
 Waki, A. 53P(ab), 90P(ab), 123P(ab), 158P(ab), 164P(ab), 204P(ab), 245, 251P(ab), 453, 2121  
 Wakisaka, S. 138P(ab)  
 Wald, M. 28P(ab)  
 Waldmann, TA. 221P(ab), 232P(ab)  
 Walicka, MA. 111P(ab), 186P(ab)  
 Walker, AP. 25P(ab)  
 Walker, RWH. 124P(ab)  
 Walker, Z. 124P(ab)  
 Wallace, S. 233P(ab), 234P(ab)  
 Wallace, W. 116P(ab)  
 Wallach, F. 1366  
 Wallhaus, TR. 1958  
 Wallis, JW. 79P(ab)  
 Walrand, S. 74P(ab)  
 Walsh, RA. 216P(ab)  
 Wan, G. 247P(ab), 248P(ab)  
 Wang, CH. 88P(ab)  
 Wang, FP. 103P(ab)  
 Wang, G-J. 12P(ab), 42P(ab), 43P(ab), 54P(ab), 100P(ab), 169P(ab)  
 Wang, H. 257P(ab)  
 Wang, J. 93P(ab)  
 Wang, JK. 164P(ab)  
 Wang, K. 142P(ab)  
 Wang, NN. 77P(ab)  
 Wang, S. 47P(ab), 1579  
 Wang, SJ. 196P(ab)  
 Wang, S-J. 1269, 1752, 2137  
 Wang, ST. 129P(ab)  
 Wang, T. 207P(ab)  
 Wang, TST. 2017(lc)  
 Wang, W. 121P(ab)  
 Wang, Y. 792  
 Wanner, M. 134P(ab)  
 Ward, HB. 944  
 Warsh, JJ. 119P(ab)  
 Warshaw, AL. 58P(ab)  
 Wartski, M. 275P(ab), 1986  
 Washburn, LC. 659  
 Washington, L. 6P(ab)  
 Wassmann, H. 23  
 Watabe, H. 55P(ab), 135P(ab), 136P(ab), 187P(ab)
- Watanabe, K. 49P(ab)  
 Watanabe, N. 270P(ab), 436, 2077  
 Watanabe, S. 89P(ab)  
 Watanabe, W. 45P(ab), 193P(ab)  
 Watanabe, Y. 961  
 Watanuki, S. 98P(ab), 195P(ab)  
 Waterhouse, RN. 227P(ab), 229P(ab)  
 Watson, DD. 115P(ab), 160P(ab)  
 Watzlowik, P. 80P(ab), 161P(ab)  
 Wauters, J-P. 15P(ab)  
 Waxman, AD. 68P(ab), 117P(ab), 118P(ab), 138P(ab), 923  
 Wear, JA. 171P(ab)  
 Webb, E. 77  
 Webber, RL. 24P(ab)  
 Weber, B. 111P(ab)  
 Weber, DA. 174P(ab)  
 Weber, E. 189P(ab)  
 Weber, EJ. 139P(ab)  
 Weber, W. 26P(ab), 80P(ab), 108P(ab), 257P(ab)  
 Weder, W. 80P(ab)  
 Wehe, DK. 173P(ab)  
 Weiden, P. 71P(ab)  
 Weijts, L. 161P(ab)  
 Weiland, FL. 218P(ab)  
 Weilhammer, P. 173P(ab)  
 Weinberger, DR. 42P(ab), 100P(ab)  
 Weinberger, J. 48P(ab)  
 Weindl, A. 111P(ab)  
 Weiner, RE. 723  
 Weinmann, P. 102P(ab), 928(lc)  
 Weinstein, H. 598  
 Weintraub, WS. 115P(ab)  
 Weir, G. 108P(ab)  
 Weissenel, P. 153P(ab)  
 Weismueller, S. 272  
 Weiss, M. 262P(ab)  
 Weiss, R. 82P(ab), 207P(ab)  
 Weiss, S. 1254  
 Welch, A. 182P(ab)  
 Welch, MJ. 34P(ab), 36P(ab), 53P(ab), 91P(ab), 234P(ab), 240P(ab)  
 Weller, R. 181P(ab)  
 Wells, G. 79P(ab)  
 Welsh, J. 149P(ab)  
 Wen, C. 2158  
 Wen, PY. 1148  
 Wen, PYC. 245P(ab)  
 Wen, TW. 88P(ab)  
 Wendt, J. 20P(ab)  
 Wendt, RE. 186P(ab), 191P(ab), 210P(ab), 278P(ab)  
 Wendt, RE III. 927(lc)  
 Wenisch, HJC. 1155  
 Weon, YC. 34P(ab)  
 Werner, E. 1066  
 Werner, T. 237P(ab)  
 Wernette, K. 15P(ab), 202P(ab)  
 Wessell, DE. 23P(ab), 25P(ab), 179P(ab)  
 Wessels, B. 113P(ab)  
 Wessels, BW. 1746  
 Wester, HJ. 73P(ab)  
 Westphal, OGA. 357, 2195(lc)  
 Wexler, B. 82P(ab)  
 Weyhrich, JT. 190P(ab)  
 Whalley, D. 17P(ab)
- Whang, GJ. 619  
 Whang, J. 1958  
 Whatley, M. 80P(ab), 98P(ab)  
 White, CA. 69P(ab), 185P(ab)  
 White, G. 27P(ab)  
 White, MP. 76P(ab), 2019  
 White, T. 202P(ab)  
 Whittle, S. 187P(ab)  
 Widner, PJ. 218P(ab)  
 Wieneke, H. 156P(ab)  
 Wienhard, K. 133P(ab)  
 Wieser, HG. 111P(ab)  
 Wiest, PW. 38P(ab)  
 Wijns, W. 2035  
 Wilbur, DS. 91P(ab), 228P(ab)  
 Wilder, RB. 1223  
 Wilderman, SJ. 51P(ab), 132P(ab), 173P(ab)  
 Wilkinson, R. 266P(ab)  
 Willeke, F. 53P(ab)  
 Willemens, A. 161P(ab)  
 Willemens, ATM. 130P(ab), 258P(ab), 1312  
 Williams, BS. 650  
 Williams, C. 52P(ab)  
 Williams, JE. 13N(6)  
 Williams, K. 139P(ab)  
 Williams, KA. 1857  
 Williams, NE. 217P(ab)  
 Williams, R. 194P(ab)  
 Williams, LE. 2097  
 Willis, GS. 11P(ab)  
 Willkomm, P. 151P(ab)  
 Willms, K. 66P(ab)  
 Willoch, F. 73P(ab), 109P(ab)  
 Wilson, AA. 71P(ab), 119P(ab), 236P(ab)  
 Wilson, DA. 276P(ab)  
 Wilson, DC. 190P(ab)  
 Wilson, DM. 225P(ab)  
 Wilson, DW. 9P(ab), 93P(ab), 172P(ab)  
 Winkler, P. 26P(ab)  
 Winogrodzka, A. 1143, 1879  
 Winthrop, MD. 842  
 Wirth, B. 86P(ab)  
 Wirth, M. 199P(ab)  
 Wiseman, GA. 69P(ab), 185P(ab)  
 Wishart, JM. 108  
 Witjes, JA. 246P(ab), 247P(ab)  
 Witjes, MJH. 1476  
 Wittry, MD. 918  
 Welsh, J. 149P(ab)  
 Wen, C. 2158  
 Wen, PY. 1148  
 Wen, PYC. 245P(ab)  
 Wen, TW. 88P(ab)  
 Wendt, J. 20P(ab)  
 Wendt, RE. 186P(ab), 191P(ab), 210P(ab), 278P(ab)  
 Wendt, RE III. 927(lc)  
 Wenisch, HJC. 1155  
 Weon, YC. 34P(ab)  
 Werner, E. 1066  
 Werner, T. 237P(ab)  
 Wernette, K. 15P(ab), 202P(ab)  
 Wessell, DE. 23P(ab), 25P(ab), 179P(ab)  
 Wessels, B. 113P(ab)  
 Wessels, BW. 1746  
 Wester, HJ. 73P(ab)  
 Westphal, OGA. 357, 2195(lc)  
 Wexler, B. 82P(ab)  
 Weyhrich, JT. 190P(ab)  
 Whalley, D. 17P(ab)
- Woodruff, P. 204P(ab)  
 Woods, RM. 110P(ab)  
 Woods, SW. 13P(ab), 202P(ab)  
 Wörmann, B. 70P(ab)  
 Worsley, DF. 192P(ab)  
 Wright, EP. 263P(ab)  
 Wu, AH. 32P(ab)  
 Wu, AM. 2097  
 Wu, C. 89P(ab), 232P(ab), 829  
 Wu, F. 1273  
 Wu, HM. 145P(ab), 165P(ab), 167P(ab)  
 Wu, JC. 417  
 Wu, L. 35P(ab), 53P(ab), 268P(ab), 2003  
 Wu, LC. 164P(ab)  
 Wu, Q. 224P(ab), 225P(ab)  
 Wu, SM. 265P(ab)  
 Wu, SY. 270P(ab)  
 Wu, TH. 187P(ab)  
 Wulfrank, D. 189P(ab)  
 Wunderlich, G. 246P(ab), 270P(ab), 271P(ab)  
 Wüstner, M. 34P(ab)  
 Wutz, W. 22P(ab), 188P(ab)  
 Wymenga, AB. 119  
 Xiao, Y. 48P(ab)  
 Xu, LC. 217P(ab)  
 Xu, X. 217P(ab)
- Yachiku, S. 86P(ab)  
 Yaguchi, I. 127P(ab)  
 Yahanda, A. 25P(ab)  
 Yamada, I. 43  
 Yamada, K. 1219  
 Yamada, N. 884  
 Yamada, S. 1219  
 Yamada, Y. 1160  
 Yamadera, A. 187P(ab)  
 Yamaguchi, M. 95P(ab), 1630  
 Yamaguchi, T. 1160  
 Yamaji, S. 163P(ab), 293, 376(lc), 1875  
 Yamakado, K. 334  
 Yamakado, T. 334  
 Yamamoto, I. 9. 129P(ab), 247P(ab), 248P(ab), 1016  
 Yamamoto, K. 53P(ab), 158P(ab), 164P(ab), 251P(ab), 269P(ab), 453  
 Yamamoto, T. 126P(ab)  
 Yamamoto, W. 57P(ab), 86P(ab), 157P(ab), 716  
 Yamamoto, Y. 166P(ab), 1626  
 Yamanouchi, M. 89P(ab)  
 Yamashina, I. 30  
 Yamashita, H. 157P(ab)  
 Yamashita, S. 152P(ab)  
 Yamashita, T. 172P(ab), 194P(ab)  
 Yamashita, Y. 1518  
 Yamauchi, D. 2097  
 Yanagisawa, A. 931(lc)  
 Yang, D. 233P(ab)  
 Yang, DJ. 234P(ab)  
 Yang, F. 169P(ab)  
 Yang, H. 15P(ab)  
 Yang, HC. 16P(ab)  
 Yang, Q. 1570  
 Yang, S-O. 34P(ab)  
 Yang, Z. 35P(ab)  
 Yang, ZY. 41P(ab), 231P(ab)  
 Yano, R. 204P(ab), 251P(ab)  
 Yano, S. 541  
 Yao, R. 179P(ab)

- Yao, SS, 45P(ab), 87P(ab),  
     101P(ab)  
 Yao, WJ, 129P(ab), 164P(ab)  
 Yao, W-J, 1711  
 Yao, Z, 30, 224P(ab), 244P(ab),  
     2017(lc)  
 Yasuda, S, 147P(ab), 252P(ab)  
 Yasue, S, 1681  
 Yasumura, Y, 162P(ab)  
 Yaw, M, 6P(ab)  
 Ye, J, 180P(ab)  
 Yeatman, LA, 272  
 Yeh, CY, 88P(ab)  
 Yen, T-C, 1798  
 Yeo, E, 1087  
 Yeung, D, 132P(ab)  
 Yeung, H, 134P(ab)  
 Yeung, HWD, 67P(ab),  
     135P(ab), 188P(ab)  
 Yeung, R, 24P(ab)  
 Yilmaz, M, 587  
 Ying, X, 247P(ab)  
 Yokogami, K, 138P(ab)  
 Yokoi, F, 55P(ab), 72P(ab),  
     137P(ab), 166P(ab)  
 Yokota, M, 161P(ab)  
 Yokoyama, A, 53P(ab),  
     204P(ab), 245, 251P(ab)  
 Yokoyama, I, 4P(ab), 141P(ab),  
     142P(ab), 884  
 Yokoyama, K, 106P(ab),  
     126P(ab), 436, 2077  
 Yokoyama, S, 93P(ab)  
 Yokoyama, T, 107P(ab)  
 Yonekura, K, 4P(ab), 142P(ab),  
     884
- Yonekura, Y, 53P(ab), 90P(ab),  
     123P(ab), 148P(ab), 158P(ab),  
     163P(ab), 164P(ab), 204P(ab),  
     213P(ab), 245, 251P(ab), 453,  
     1360, 1518, 2121  
 Yonemitsu, N, 537  
 Yoon, PH, 629  
 Yoon, JLC, 1280  
 Yoo, P, 232P(ab)  
 Yoo, TM, 829  
 Yoon, CY, 1711  
 Yu, C-Y, 1711  
 Yu, D-C, 1335  
 Yu, H, 170P(ab)  
 Yu, HJ, 235P(ab)  
 Yu, H-S, 2128  
 Yu, YM, 195P(ab)  
 Yuan, A, 186P(ab)  
 Yuasa, K, 9, 1016  
 Yuasa, M, 240P(ab)  
 Yoshida, H, 1667  
 Yoshida, K, 89P(ab), 1123,  
     2022  
 Yoshida, S, 204P(ab), 216P(ab),  
     242P(ab), 933  
 Yoshida, T, 137P(ab), 213P(ab),  
     258P(ab), 760, 974  
 Yoshihikai, T, 537  
 Yoshikawa, D, 156P(ab)  
 Yoshikawa, E, 171P(ab),  
     172P(ab)  
 Yoshikawa, K, 1784  
 Yoshimi, E, 90P(ab)  
 Yoshimoto, M, 204P(ab)  
 Yoshioka, S, 203  
 Yoshizaki, K, 220P(ab)  
 Yosizumi, T, 152P(ab)  
 Yospur, LS, 449  
 You, DL, 59P(ab)  
 You, J, 169P(ab)  
 Young, C, 108P(ab)  
 Young, S, 211P(ab)
- Young, VR, 195P(ab)  
 Yoursy, T, 26P(ab)  
 Yu, CL, 164P(ab)  
 Yu, CY, 129P(ab)  
 Yu, H, 170P(ab)  
 Yu, HJ, 235P(ab)  
 Yu, H-S, 2128  
 Yu, YM, 195P(ab)  
 Yuan, A, 186P(ab)  
 Yuasa, K, 9, 1016  
 Yuasa, M, 240P(ab)  
 Yüceket, S, 130P(ab), 189P(ab)  
 Yuch, T-C, 1292  
 Yun, JJ, 417  
 Yune, MJ, 281  
 Yutani, K, 44P(ab)  
 Zaers, J, 165P(ab)  
 Zajicek, K, 42P(ab)  
 Zakko, S, 234P(ab)  
 Zalipsky, S, 267P(ab)  
 Zalutsky, MR, 47P(ab), 77P(ab),  
     104P(ab), 105P(ab)  
 Zamerkin, AJ, 689  
 Zamora, PO, 227P(ab)  
 Zanardi, R, 40P(ab)  
 Zanco, P, 261  
 Zander, C, 156P(ab)  
 Zangari, M, 76P(ab)  
 Zanzonico, P, 20P(ab), 113P(ab),  
     522, 2196(lc)  
 Zare, F, 233P(ab), 234P(ab)  
 Zaret, BL, 417, 931(lc)  
 Zasadny, KR, 14S, 21S, 43P(ab),  
     Ziegler, SI, 56P(ab), 161P(ab),  
     257P(ab), 411  
 Ziessman, HA, 1114, 1617  
 Ziffer, JA, 139P(ab), 140P(ab)  
 Zilleruelo, G, 28P(ab)  
 Zilles, K, 1596  
 Zimmer, L, 49P(ab)  
 Zimmerman, BE, 219P(ab),  
     575(lc)  
 Zimmerman, R, 56P(ab)  
 Zimmerman, RE, 51P(ab)  
 Zimmermann, R, 153P(ab)  
 Zimny, M, 81P(ab), 249P(ab),  
     815  
 Zinn, KR, 224P(ab), 225P(ab)  
 Zito, F, 61P(ab)  
 Zloty, M, 114P(ab)  
 Zoboli, S, 86P(ab), 210P(ab)  
 Zoccarato, O, 154P(ab)  
 Zoghbi, SS, 13P(ab), 14P(ab),  
     26P(ab), 37P(ab), 72P(ab),  
     82P(ab), 123P(ab), 208P(ab),  
     1500, 1719  
 Zoli, P, 516  
 Zöphel, K, 271P(ab)  
 Zorlutuna, Y, 28  
 Zubal, IG, 37P(ab), 68P(ab),  
     132P(ab), 176P(ab), 212P(ab),  
     1719  
 Zubierta, JK, 40P(ab), 220P(ab),  
     233P(ab)  
 Zuckier, LS, 1558  
 Zurrida, S, 70P(ab)  
 Zusman, RR, 46P(ab), 89P(ab)  
 Zwas, ST, 1822

**A****Abscess**

intra-abdominal, experimental, imaging with  $^{99m}\text{Tc}$

PEG liposomes and HYNIC-IgG, 264P(ab)

subperiosteal, metaphyseal osteomyelitis and, epiphyseal photopenia with, 1084

**Absolute organ activity**, estimated by background correction, 2167**Absorbed fractions**, re-evaluation, photons and electrons in small spheres, 188P(ab)**Absorptiometry**, dual-energy X-ray, age-related differences in bone mineral density, 129P(ab)**Acetazolamide**

myocardial ischemia induced by, in severe coronary artery disease, 408

PET evaluation, occlusive cerebrovascular disease, 760

SPECT, predictor of vasospasm after subarachnoid hemorrhage, 149P(ab)

$^{99m}\text{Tc}$  ECD SPECT challenged by, transient global amnesia, 1360

**Acetylcholinesterase**

evaluation of inhibitors, radiochemical synthesis and, 229P(ab)

PET measurement of activity, Alzheimer's and Parkinson's disease, 95P(ab)

**N-Acetylcysteine**,  $^{99m}\text{Tc}$  labeled, experimental tumor model, 221P(ab)**Acquired immunodeficiency syndrome (AIDS)**

dementia, cerebral perfusion scanning in treatment, 298

nephropathy,  $^{99m}\text{Tc}$  MAG3 scintigraphy study, 28P(ab)

primary lymphoma and nonmalignant lesions,  $^{201}\text{Tl}$  retention, 1366

**Acquisition orbits**, effect on  $^{99m}\text{Tc}$  cardiac SPECT, 61P(ab)**Acupuncture**

brain activation by, PET study, 205P(ab)

effects on regional cerebral blood flow,  $^{99m}\text{Tc}$  HMPAO SPECT measurement, 206P(ab)

**Adenoma**, pleomorphic, salivary glands,  $^{67}\text{Ga}$  uptake, 537**Adenosine**

dual isotope SPECT, quantification of transient ischemic dilation ratio, CAD, 103P(ab)

hemodynamic response to, myocardial blood flow relations, postmenopausal women, 32P(ab)

intravenous, reproducibility of  $^{99m}\text{Tc}$  sestamibi myocardial SPECT with, 31P(ab)

treadmill exercise  $^{99m}\text{Tc}$  sestamibi SPECT, radionuclide angiography and, CAD patients, 102P(ab)

**Adenosine receptor**

$\text{A}_{2\alpha}$ , CNS ligand,  $^{11}\text{C}$  KF17837 evaluation, 498

biodistribution and radiation dose, mice and baboon, 188P(ab)

mapping with  $^{18}\text{F}$  CPFPX PET, primate brain, 230P(ab)

myocardial stunning and, 944

**Adenosine receptor antagonist**, preclinical evaluation of, 22P(ab)**Adenosine triphosphate**, intravenous infusion,  $^{99m}\text{Tc}$  tetrofosmin tomography during, 582**Adenoviruses**, tissue binding sites for,  $^{131}\text{I}$  fiber protein, 222P(ab)**ADHD**, see Attention deficit hyperactivity disorder**Adrenal cortex**, tumors,  $^{11}\text{C}$  etomidate and MET PET imaging, 982**Adrenal gland**

cholesterol-P- $^{18}\text{F}$  fluorobenzoate, PET imaging,

baboon, 36P(ab)

mass, incidentaloma, diagnosis, 707

metastases, from renal cell carcinoma,  $^{131}\text{I}$  iodocholesterol accumulation in, 656

**Adrenal medulla**,  $^{131}\text{I}$  MIBG scintigraphy, adults, 1007**Adrenergic receptors**

alpha, iodinated analog of propranolol as myocardial tracer, 50P(ab)

alpha-2, primate cerebral,  $^{11}\text{C}$  P11432 PET, 72P(ab)

**Adriamycin**, DTPA, tumor imaging potential of, 234P(ab)**Adverse reactions**, positron emitting radiopharmaceuticals, 2190**Aerosol**, bronchiolar mucociliary clearance, in asthma, 193P(ab)**Aerosol deposition measurements**

inertial changes in particle size, nebulizer systems, 118P(ab)

lung, from planar imaging, use of simulation in, 98P(ab)

standard nebulizer, use of holding compartment and, 117P(ab)

**Aerosol therapy**, lung morphology, supercomputer description, for imaging analysis, 745**Aging**

cerebral perfusion and, SPECT, 965

dopamine D2 receptor binding and, PET study, monkey, 207P(ab)

dopamine receptor binding with  $^{123}\text{I}$  IBF and, SPECT, 1511

dopamine transporter imaging,  $^{18}\text{F}$  FPCIT PET, 1521 gender and effects on sacroiliac joint scintigraphy, 1269 influence on normal coronary vasomotion, 162P(ab)

$^{123}\text{I}$  MIBG assessment of physiological fluctuation, left ventricle sympathetic nervous system, 1667 normal, presynaptic monoaminergic vesicles in,  $^{11}\text{C}$  DTBZ PET in, 15P(ab)

**Alcohol**, addiction

brainstem serotonin transporter availability in, 100P(ab)

gender differences in regional cerebral metabolism, 100P(ab)

**Alcoholism**, reduced GABA benzodiazepine receptor in, gender differences, SPECT study, 204P(ab)**Aldosteronism**, primary, adrenocortical SPECT using  $^{131}\text{I}$  NP-59, 1460**Alpha particle therapy**, new line of cancer treatment, 17N(2)**Altanserin**, H-2 and F-18 dual labeled, PET ligand for serotonin-2A receptor, 21P(ab)**Alveolar permeability**, inhaled surfactant effects, pulmonary deposition of  $^{99m}\text{Tc}$  DTPA, 543**Alzheimer's disease**

acetylcholinesterase activity, PET measurement of, 95P(ab)

beta-amyloid protein of,  $^{99m}\text{Tc}$  mama-chrysamine G probe, 218P(ab)

cerebellar metabolic reduction in, 374(1e)

cerebral glucose metabolism in, standardized uptake value for assessment, 163P(ab)

determination of regional cerebral blood flow, significance imaging, 425

FDG uptake, whole brain, 210P(ab)

$^{18}\text{F}$  FDG PET prediction

cognitive decline, 96P(ab)

memory impaired patients without dementia, 96P(ab)

$^{123}\text{I}$  IMZ SPECT in, 927(1e)

mild-to-moderate, paradoxical hippocampus perfusion in, PET, 293

$^{99m}\text{Tc}$  HMPAO brain SPECT, correlative study with quantitative electroencephalography, 96P(ab)

**Ambulatory Patient Classification (APC)**

proposed, 25N(4)

new developments in, 33N(11)

**American Board of Nuclear Medicine (ABNM)**

change in officers, 30N(4)

**Amino acids**

blood-to-brain transport, studied with 6-fluoro-L-DOPA, 43P(ab)

in brain neoplasms, diagnosis with  $^{123}\text{I}$  IMT SPECT, 23

radiolabeled, uptake in glioma model, rat, 1596 transport, lymphoma cells, 238P(ab)

**Amnesia**, transient global,  $^{99m}\text{Tc}$  ECD SPECT in, 1360**Amphetamines**

dopamine release induced by, inhibition by GBR 12909, 55P(ab)

substituted,  $^{11}\text{C}$  McN5652 binding, brain, 100P(ab)

**Amyloidosis**

kinetic studies,  $^{123}\text{I}$  serum amyloid P component, 699 scintigraphic hypoplasmen in, 221

**Anatomic standardization**, localization of serotonin receptors using,  $^{11}\text{C}$  WAY-100635 use, 136P(ab)**Anger**, Hal O., first scintillation camera, 15N(3)**Angina**, preinfarction,  $^{201}\text{Tl}$  and  $^{123}\text{I}$  BMIPP perfusion-metabolism mismatch in, 1492**Angiography**

pulmonary, stripe sign, 721

radionuclide database, predicting myocardial perfusion abnormalities, 75P(ab)

first-pass

gated perfusion SPECT comparison, 76P(ab) murine, technique for, 48P(ab)

portable multiwire gamma camera, 75P(ab)

$^{123}\text{I}$  radiotracers, multicrystal gamma camera and, 938 multiple myeloma and high-output failure, 1

**Angioplasty**

balloon, atherosclerosis, 1819

coronary

myocardial fatty acid metabolism after, 933

reversible perfusion defects after,  $^{201}\text{Tl}$  SPECT, 59P(ab)

percutaneous transluminal coronary, normal SPECT after, 115P(ab)

**Angiotensin receptors**

$^{11}\text{C}$  L-159,884 investigation, PET, 1209

subtype I, dietary sodium manipulation effects, 196P(ab)

**Anion exchange trapping**,  $^{18}\text{F}$  fluoride, off-the-shelf anion exchange devices, 239P(ab)**Ankle joint**, chronic pain, value of bone scintigraphy in, 196P(ab)**Annexin**,  $^{99m}\text{Tc}$ , investigation of experimental heart transplant rejection, 8P(ab)**Anorexia nervosa**,  $^{99m}\text{Tc}$  HMPAO brain SPECT use in, 304**Antibodies**,  $^{131}\text{I}$  G250, pharmacokinetic model, renal cell carcinoma, 484**Anti-carcinoembryonic antigen**

biodistribution and dosimetry study, medullary thyroid cancer, 1608

single-chain antibody,  $^{99m}\text{Tc}$  MET labeled, cancer imaging, 47

**Anti-carcinoembryonic antigen antibody**,  $^{111}\text{In}$  bivalent hapten and, medullary thyroid cancer, 1172**Antipsychotic drugs**

broad-spectrum, 5-HT2A receptor occupancy and, schizophrenia, 83P(ab)

olanzapine

dopamine receptor binding in cortex and striatum, 82P(ab)

striatal dopamine D2 receptor binding by, SPECT study, 82P(ab)

**Antisense imaging**, hybrid oligonucleotide for, 219P(ab)**Anti-SSEA-1 antibody**, dosimetry of, human granulocytes, 268P(ab)**Anti-thyroglobulin antibodies**, new radioimmunoassay measurement of, comparison with immunoradiometric assay, 271P(ab)

**Antitumor agent.** DACA,  $^{113}\text{C}$  SN 23719 analog of, nude mice bearing human tumor xenografts, 239P(ab)

**Aortic aneurysms.** accumulation of  $^{111}\text{In}$  oxine-labeled leukocytes in, 157P(ab)

**Aphasia.** progressive, rCBF SPECT and MRI, 96P(ab)

**Aplastic anemia.** anti NCA-95 antibody, bone marrow immunoscintigraphy, children, 267P(ab)

**Apoptosis.** heterotopic heart transplant, cyclosporine effects, 160P(ab)

**L-Arginine.** coronary vasomotion and, chronic smokers, 3P(ab)

**Aromatic amino acid decarboxylase.** cerebral,  $^{123}\text{I}$  strategy for measurement, 49P(ab)

**Arterial blood sampling.** one-point,  $^{123}\text{I}$  IMP quantification of cerebral blood flow, 166P(ab)

**Angiography**

- cerebral vasospasm, after subarachnoid hemorrhage, SPECT, 76S
- visceral, acute lower gastrointestinal bleeding, 108I

**Arteriovenous shunting.** in multiple myeloma and high-output failure, 1

**Arthritis**

- antigen-induced, cartilage alterations in, rat, 163R
- rheumatoid
- lung disease associated with, FDG uptake in thyroid cancer, 234
- radiolabeled interleukin-1 receptor antagonist imaging of inflamed joints, 265P(ab)
- two-phase scintigraphy vs modern imaging, 265P(ab)

**Artifacts.** nonuniform attenuation correction, all nuclear imaging, 276P(ab)

**Asthma.** bronchiolar mucociliary clearance in, 193P(ab)

**Atevirdine.** treatment of AIDS dementia, cerebral perfusion scanning evaluation of, 298

**Atherectomy.** rotational, transient regional ischemia during, 402

**Atherosclerosis**

- detection, positron-sensitive probe and  $^{18}\text{F}$  FDG, 4P(ab)
- molecular imaging,  $^{99m}\text{Tc}$  labeled endothelin derivative, 181R

**Atropine.** effects on gastric emptying, obese patients, 274P(ab)

**Attention deficit hyperactivity disorder**

- cerebral blood flow in, on and off Ritalin, SPECT study, 203P(ab)
- $^{99m}\text{Tc}$  ECD uptake in, Ritalin effects, 203P(ab)

**Attenuation correction**

- artificial neural networks for compensation, 73S
- cardiac SPECT
- misalignment between transmission and emission scans, 41I
- right-angle dual camera, 61P(ab)

Chang, in brain SPECT quantification, 190

compensation, scatter correction effects,  $^{99m}\text{Tc}$  myocardial SPECT, 74P(ab)

down-scatter, simultaneous emission transmission imaging, 178P(ab)

effects on lesion detection, PET, lung cancer, 109P(ab)

end-diastolic vs ungated, myocardial perfusion SPECT, in CAD, 74P(ab)

extreme conditions, ordered-subset reconstruction algorithms in, cardiac SPECT, 37P(ab)

fanbeam cardiac SPECT, effect of truncated projections, 166

fanbeams with scanning point sources, quantitative SPECT, 199R

fast sequential asymmetric fanbeam transmission CT for, cardiac SPECT imaging, 133S, 134R(ed)

Fourier rebinning, 3D transmission scans, PET, 178P(ab)

gamma prior, noise reduction in cardiac SPECT, 181P(ab)

gated  $^{99m}\text{Tc}$  sestamibi SPECT, evaluation of myocardial viability, 74P(ab)

improvement in myocardial defect contrast and uniformity, anthropomorphic phantom, 180P(ab)

iterative reconstruction, PET, 179P(ab), 181P(ab)

measured, positron emitters, gamma camera coincidence imaging, 38P(ab)

measured with  $^{153}\text{Gd}$ ,  $^{99m}\text{Tc}$  brain SPECT, 181P(ab)

ML-EM reconstruction, CAD diagnosis accuracy and, 73P(ab)

multiple line source array for, SPECT transmission scans, 218S

myocardial activity distributions, emission reconstruction algorithm and, 74P(ab)

myocardial SPECT, fan-beam  $^{99m}\text{Tc}$  sestamibi, 177P(ab)

nonuniform

- all nuclear imaging, 276P(ab)
- brain SPECT imaging, 171R
- data consistency conditions in, 177P(ab)
- $^{67}\text{Ga}$  SPECT, compensation for, 36P(ab)
- in quantitative  $^{123}\text{I}$  brain SPECT, 37P(ab)
- $^{99m}\text{Tc}$  brain SPECT, 36P(ab)

optimization of, whole-body FDG PET scans, 258P(ab)

quantitative assessment of regional cerebral blood flow and, SPECT, 181

quantitative estimate of myocardial activity and, phantom experiments, 4P(ab)

scanning line source, transmission measurement by, 175P(ab)

scatter and, importance for quantitative brain SPECT, 8P(ab)

scatter correction and resolution compensation, anthropomorphic phantom, 179P(ab)

segmentation of  $^{18}\text{F}$  FDG emission scans, with fuzzy logic, 164P(ab)

segmentation of short-transmission scans, in PET, 169P(ab)

signal-to-noise analysis, whole-body FDG PET, 98P(ab)

single photon transmission scanning on, BGO PET, 23P(ab)

singles-transmission

- dual-head coincidence imaging, 37P(ab)
- scatter and emission contamination of, 37P(ab)

Sorenson, in brain SPECT quantification, 190

SPECT perfusion imaging, combined and separate interpretations, 73P(ab)

three-headed SPECT camera, transmission imaging for, 110S

$^{201}\text{Tl}$  SPECT images, 180° and 360° acquisition for, 562

transmission CT, uncollimated line array source in, 176P(ab)

true effects of, evaluation, 178P(ab)

weight effects, transmission SPECT scanning in myocardial perfusion imaging, 46P(ab)

**Attenuation/signal intensity.** regional differences, CT/MRI, liver scintigraphy, 52R

**Autoradiography**

- comparison of iodotyrosines and methionine uptake, glioma model, rat, 159R
- radiosynthesis and, serotonin receptors, 237P(ab)
- RP316 binding distribution, studies of dopamine D4 receptors, rat brain, 226P(ab)

**Avalanche photodiode detectors.** PET and SPECT, measurement of Depth-of-interaction, 92P(ab)

**Avascular necrosis.** limping child, assessment with skeletal scintigraphy, 105R

**Avidin**

- rapid internalization, after binding to tumor cells, 224P(ab)
- tumor accumulation of, glycosylation and isoelectric point effects, 224P(ab)

**Avidin-biotin**

- antibody guided three-step therapy, high-grade glioma, 70P(ab)
- diagnosis and therapy with, pretargeted, 181S
- immunoscintigraphy, before second look in ovarian cancer, 243P(ab)

**Axillary nodes.** metastasis,  $^{18}\text{F}$  FDG PET in presurgical staging, 4

**B**

**Background correction.** absolute organ activity estimated by, 216T

**Behçet's disease.**  $^{99m}\text{Tc}$  HMPAO brain SPECT in, 95O

**Bell's palsy.** peripheral facial nerve paralysis, prognosis using submandibular gland scintigraphy, 71R

**Benzamide.** radioiodinated binding location, B16 melanoma, 227P(ab)

comparative biodistributions, B16 melanoma, mice, 227P(ab)

**Benzodiazepine receptor**

- binding
- anxiety disorders, SPECT measurement of, 202P(ab)
- to  $^{123}\text{I}$  iomazenil, Machado-Joseph disease, 151R
- PET and SPECT quantitation of, 209P(ab)

**CBF and, changes during cerebral hypoperfusion,** 208P(ab)

$^{11}\text{C}$  FMZ visualization, detection of irreversible ischemic neuronal damage, 148P(ab)

equilibrium measurement,  $^{123}\text{I}$  IOM, reproducibility of, 208P(ab)

$^{123}\text{I}$  iomazenil SPECT, schizophrenia, 82P(ab)

probes for study of,  $^{123}\text{I}$  synthesis and evaluation, SPECT, 50P(ab)

vigabatrin effects,  $^{123}\text{I}$  iomazenil SPECT, 26P(ab)

**Benzodiazepine receptor antagonist.** neuroprotective agent effects, focal cerebral ischemia, rat, 213P(ab)

**Benzodiazepines.** abuse, changes in receptors and development of tolerance, 13P(ab)

**Benzylfluoride.**  $^{19}\text{F}$ -labeled derivatives, stable, development of, 230P(ab)

**Beta particles.** radiation absorbed doses, walls of hollow organs, 198R

**Bifunctional antibody-hapten.** tumor pretargeting, for radioimmunodetection and radioimmunotherapy, 65

**Bifunctional chelate**

- choice, clearance of radiometal BFC-biomolecule conjugates, 91P(ab)
- two-step tumor targeting, RCC tumors, 78P(ab)

**Bile leak.** after laparoscopic cholecystectomy,  $^{99m}\text{Tc}$  HIDA versus cholangiopancreatography for, 180Z

**Biliary obstruction.** hepatobiliary scan, segmental parenchymal excretion delay on  $^{99m}\text{Tc}$  DISIDA, 273P(ab)

**Binding potential.**  $^{11}\text{C}$  CGF, estimation by iterative fitting, 167P(ab)

**Biodistribution**

- BMIPP
- isomers, intra-individual comparison, 167Z
- oral glucose loading effects, 185O
- $^{18}\text{F}$  methyl tyrosine, potential tumor-detecting agent, 66S
- radioimmunotherapy,  $^{99m}\text{Tc}$  anti-EGF-receptor antibody, tumor of epithelial origin, 15

**Biological risks.** health hazards of radiation exposure, brain imaging research, children, 68R

**Biomarkers.** tumor cell proliferation, breast tumor, 320P(ab)

**Biopsy.** image-guided,  $^{201}\text{Tl}$  SPECT utility in, thoracic tumor, 193P(ab)

**Biotin**

analogs, infection imaging, 267P(ab)  
antibody-based pretargeting, 228P(ab)  
conjugates, properties, application with different radionuclides, 143P(ab)  
radiolabeled, pretargeted radioimmunotherapy with, 105P(ab)  
<sup>99m</sup>Tc-labeled, early image detection, rabbit colitis model, 125P(ab)  
<sup>99m</sup>Tc PEG liposomes, avidin-induced clearance, infection, 267P(ab)

**Biotin-chelate conjugates**, for pretargeted diagnosis and therapy, avidin-biotin system, 1813

**Biotinylated antibody**, intraperitoneal tumors pretargeted with, radiolabeled streptavidin penetration, 30

**Bismuth-213**, antibodies labeled with, prostate cancer therapy, 223P(ab)

**BSpecific antibodies**

bivalent haptens, delivery of therapeutic dose of radioiodine, 1937  
colon cancer xenografts pretargeted with, <sup>68</sup>Ga chelate imaging of, 1769, 1776(e)

**Bladder cancer**, monoclonal or polyclonal radioimmunoassay for, 269P(ab)

**Blood flow**, *see also* Cerebral blood flow

cerebral  
brain perfusion SPECT, procedure guidelines, 923  
imaging, <sup>99m</sup>Tc HMPAO and <sup>99m</sup>Tc ECD comparison, 613

major depressive disorder, <sup>99m</sup>Tc HMPAO SPECT, 608

noninvasive quantitation, <sup>15</sup>O water and dual PET system, 1789

<sup>15</sup>O water PET, signal-enhancing switched protocols, cognitive task study, 350

paradoxical hippocampus, Alzheimer's disease, 293  
PET evaluation, occlusive cerebrovascular disease, 760

PET studies, Pico-Count flow-through detector, 509  
regional, significance imaging, 425  
regional scintigraphy, tick-borne encephalitis and meningoencephalitis, 2055

<sup>99m</sup>Tc ECD SPECT, transient global amnesia, 1360  
<sup>99m</sup>Tc HMPAO SPECT, Behcet's disease, 950

**myocardial**

dynamic <sup>15</sup>O water scan, without blood-pool scan, 1696  
estimates of absolute perfusion, <sup>13</sup>N ammonia and <sup>15</sup>O water, 1655

high-resolution cardiac PET, 2022  
L-arginine effects, in chronic smokers, 3P(ab)  
measurement, cardiac output and, <sup>13</sup>N ammonia PET, 89P(ab)

<sup>13</sup>N ammonia flow quantitation, myocardial septum, 591

<sup>13</sup>N ammonia PET, 1123  
nifedipine effects, with ischemic heart disease, 89P(ab)

noninvasive probe, cold pressor testing and mental stress, 89P(ab)

noninvasive quantitation, <sup>15</sup>O water and dual PET system, 1789

normal, age and gender effects, 162P(ab)  
oxygen consumption and, simultaneous measurement with <sup>11</sup>C acetate, 272

perfusion-contraction mismatch, hibernating myocardium, 396

polar map, linear least square with spillover correction, PET, 161P(ab)

real time estimation of parametric images, neural networks for, 168P(ab)

with stable angina, single-vessel coronary artery disease and, 89P(ab)

**Blood-pool imaging**

gated

exercise with, survival in stem cell transplantation, 76P(ab)

pulmonary artery pressure, in pulmonary hypertension, 156P(ab)

index, radionuclide scrotal versus gonadal venography, varicocele diagnosis, 1069

low-dose dobutamine, myocardial viability assessment, 59P(ab)

<sup>15</sup>O carbon monoxide, myocardial factor images, 1696  
short gated SPECT, comparison of global and regional parameters with MRI, 75P(ab)

**Blood time-activity curves**, quantitation of, <sup>18</sup>F FDG PET, mouse, 729

**Blood vessels**, walls, radiation dose to, model calculations, 184P(ab)

**Body weight**, radiocalcium absorption, single-isotope test, 108

**Bombesin**, <sup>111</sup>In DTPA investigation, 62P(ab)

**Bombesin receptors**, <sup>99m</sup>Tc analogs that bind with, prostate cancer cells, 7P(ab)

**Bone**

dual-head pinhole scintigraphy, 1444

lesions, <sup>99m</sup>Tc MIBI as a tracer in, response to chemotherapy, 928(e)

malignant tumors, scintigraphic findings in limb salvage, 1087

neoplasms, glucose metabolism in, PET evaluation of, 810

normal and morbid ankles, pinhole SPECT, 130

turnover, with delayed puberty and hypogonadism, SPECT in young males, 104

weight-bearing, indirect mechanical load modulation of bone mineral density, 129P(ab)

**Bone graft**, cranial, technique for survival, CT and SPECT, 99P(ab)

**Bone loss**, prediction of, in hyperparathyroidism, quantitative bone SPECT, 1614

**Bone marrow**

biological dosimetry, for incorporated <sup>90</sup>Y, 547

dosimetry model, mouse, 1243

ectopic hematopoietic, appendicular skeleton, after trauma, 1980

scintigraphy, with <sup>99m</sup>Tc anti-NCA-95, malignant osteoporosis, 1033

<sup>201</sup>Tl uptake, before and after multiple myeloma, 473

toxicity, radiation absorbed dose from <sup>186</sup>Re monoclonal antibody, 1746

**Bone metastases**

distribution, breast cancer, 114P(ab)

<sup>18</sup>F PET, planar bone imaging vs, prostate, thyroid, and lung cancer patients, 113P(ab)

micronucleus assay, radiotoxicity after <sup>90</sup>Sr therapy, 2077

palliative therapy, <sup>131</sup>I BDP3, 242P(ab)

**Bone mineral density**

elderly women, pattern of <sup>99m</sup>Tc HMDP skeletal uptake and, 129P(ab)

in insulin-dependent diabetes patients, 194P(ab)  
regional, age-related differences, dual-energy X-ray absorptiometry, 129P(ab)

weight-bearing bone, indirect mechanical load modulation of, 129P(ab)

whole-body, chronic renal replacement therapy effects, 129P(ab)

**Bone pain**

metastatic lesions

dose heterogeneity and prediction of myelotoxicity for, 84P(ab)

palliation of, radionuclides for, 84P(ab)

palliation

beta emitters for, marrow-sparing effects, 84P(ab)

<sup>188</sup>Re APD future use for, 236P(ab)

trabecular bone, electron transport, 3D model for, 183P(ab)

**Bone scan**

abnormality, acute childhood leukemia, 1983

chronic recurrent multifocal osteomyelitis, 1778

flare phenomenon

metabolic marker identification, in bone metastasis from breast cancer, 194P(ab)

quantitation, in prostate cancer, 194P(ab)

high-resolution SPECT, 3D imaging of small animals, 9P(ab)

image quality of, hydration effects, 196P(ab)  
metastatic disease, cancer patients with

musculoskeletal pain, 113P(ab)

pediatric, special issues, unique clinical studies, 13N(3)

single or double hot spots in, differential diagnosis, 1263

SPECT and, follow-up of allogenic vascularized bone transplant, 114P(ab)

<sup>99m</sup>Tc MDP

comparison to bone SPECT, 130P(ab)

therapy for osteomalacia, 2095

<sup>99m</sup>Tc MIBI and bone SPECT image fusion in, head and neck tumors, 1166

triphasic, orthopedic disease, 516

two-phase scintigraphy, vs modern imaging, rheumatoid arthritis, 265P(ab)

value, in newly diagnosed prostate cancer, 194P(ab)

whole body and pinhole, Reiter's syndrome, 33P(ab)

**Bone tumors**

malignant, <sup>99m</sup>Tc MIBI assessment of P-glycoprotein, 1179

metastatic, type I collagen C telopeptide in, 269P(ab)

prediction of tumor response, <sup>201</sup>Tl scintigraphy use in, 1600

primary

<sup>18</sup>F FDG and <sup>99m</sup>Tc MDP bone scintigraphy

comparison, 114P(ab)

<sup>99m</sup>Tc MDP scintigraphy and long-term follow-up of, 1563

**Boron neutron capture therapy**, <sup>18</sup>F FBPA, glioma patients, 325

**Bowel activity**, nonspecific, imaging inflammation with <sup>99m</sup>Tc AGF-Fab, 30P(ab)

**Boxing**, determination of regional cerebral blood flow, significance imaging, 425

**Brachytherapy**, intravascular, liposome-encapsulated <sup>99m</sup>Tc, 219P(ab)

**Brain**

central 5-hydroxytryptamine receptors, carbonyl-carbon-11 WAY-100635 binding to, 1965

<sup>11</sup>C nicotine binding, PET quantification, 2048

2D and 3D PET, quantitative comparison, 1714

3D coincidence imaging, scan duration and acceptance angle effects, 175P(ab)

functional imaging, 929(e)

age-adjusted normal image database for, 211P(ab)

GABA-receptors in, <sup>11</sup>C MPGA dosimetry and biodistribution, 307

glucose metabolism, in Cushing's disease, 786

mapping, intersubject registration, assessment by comparison of anatomic landmarks, 168P(ab)

neoplasms

FDG lumped constant in malignant glioma, 440

<sup>123</sup>I IMT examination of amino acids in, 23

preoperative evaluation with <sup>18</sup>F FDG or <sup>11</sup>C MET, 778

perfusion SPECT, procedure guidelines for, 923

<sup>99m</sup>Tc HMPAO, systemic lupus erythematosus with CNS involvement, 930(e)

<sup>99m</sup>Tc tetrofosmin SPECT, comparison with <sup>201</sup>Tl, 802

**Brain death**, scintigraphic evaluation, pediatric patients, 55P(ab)

**Brain injury**

hypoxic, <sup>99m</sup>Tc ECD SPECT, cerebral palsy, 619

symptoms, correlation with SPECT perfusion findings, 97P(ab)

- traumatic**  
 cerebral perfusion of asymptomatic carotid artery occlusion, 629  
 FDG and  $^{99m}$ Tc HMPAO discordance in uptake of, 1357
- Brain mitochondria**, diethyl maleate-treated, glutathione and  $^{99m}$ Tc meso-HMPAO, 2178
- Brain natriuretic peptide**, severity of ischemia and denervation, ischemic heart disease patients, 153P(ab)
- Brain tumors**  
 energy requirement in neuron and tumor, comparative analysis, 204P(ab)  
 $^{125}$ I Udr radiotherapy, rats, 1148  
 $^{131}$ I distribution in, pinhole SPECT, 856  
 PET data utility, image-guided neurosurgery and X-knife radiosurgery, 214P(ab)  
 preliminary clinical study,  $^{18}$ F FMT PET, 53P(ab)  
 primary, FDG uptake after intracavitary  $^{131}$ I monoclonal antibody, 1376  
 proliferation, quantitation with  $^{11}$ C thymidine PET, 53P(ab)  
 recurrent, registered camera-based and dedicated PET images, 257P(ab)  
 standardized uptake value, FDG PET scan, 164P(ab)  
 suspected intracranial metastatic, FDG PET in staging workup of, 254P(ab)  
 $^{99m}$ Tc tetrofosmin SPECT, 313P(ab)  
 transuranium and uranium cohort, United States, 191P(ab)
- Breast**  
 benign and malignant lesions,  $^{99m}$ Tc MIBI uptake in, 449  
 cyst, simulating thyroid cancer metastases,  $^{131}$ I imaging, 1910  
 dedicated PET scanner for, two curve-plate detectors, 171P(ab)  
 imaging, planar and SPECT comparison,  $^{99m}$ Tc sestamibi, 849  
 routine imaging  
   addition of medial view to, solid-state gamma camera, 139P(ab)  
   solid-state gamma camera, 319P(ab)
- Breast cancer**  
 bone metastasis from  
   bone metabolic marker in diagnosis of bone scan flare, 194P(ab)  
   whole-body FDG PET for evaluation, 147P(ab)  
 dedicated breast and axillary node imaging, PET, 170P(ab)  
 detectability, evaluation with modified anthropomorphic phantom, 1951  
 detection, PET and SPECT comparison, 1424  
 early, sentinel lymph node identification in, 1388  
 early detection,  $^{18}$ F FDG PEM metabolic imaging system, 146P(ab)  
 factor analysis in, reproducibility of input functions, PET, 165P(ab)  
 factors influencing tumor imaging, 1036  
 granular cell tumor, FDG PET evaluation, 1398  
 high-dose chemotherapy, outcome prediction by baseline FDG-PET study, 146P(ab)  
 $^{131}$ I IPAB sigma receptor ligand, detection of tumor proliferation, 227P(ab)  
 imaging, native peptide ligand and mAb against EGFR, 77P(ab)  
 locally advanced, blood flow and metabolism in, 146P(ab)  
 male,  $^{99m}$ Tc MDP scintimammography in, 28  
 multifocal, scintimammography in, 313P(ab)  
 palpable and nonpalpable lesions,  $^{99m}$ Tc MIBI scintimammography in, 86  
 $\mu$ -glycoprotein expression effects,  $^{99m}$ Tc MIBI uptake in, 1021  
 planar scintimammography, iterative SPECT effects on outcome, 318P(ab)
- p53 mutant human xenografts, efficacy of  $^{99}$ Y radioimmunoconjugate in, 842  
 preliminary clinical evaluation, dual-view pinhole collimator, 25P(ab)
- primary**  
 axillary lymphatic spread and, new scintigraphic combination for, 244P(ab)  
 carcinoembryonic antigen imaging, 150P(ab)  
 metastatic axillary lymph node imaging with  $^{99m}$ Tc MIBI, 459  
 $^{99m}$ Tc tetrofosmin SPECT detection of, 314P(ab)  
 radioguided surgery, 22N(12)  
 recurrence,  $^{99m}$ Tc MIBI scintimammography in, 319P(ab)  
 recurrent or metastatic, whole-body  $^{18}$ F FDG PET detection of, 431  
 response to neoadjuvant chemotherapy,  $^{99m}$ Tc sestamibi scintimammography, 316P(ab)  
 sentinel axillary node, lymphoscintigraphy and radioguided biopsy, 2080  
 sentinel node  
   combined imaging and gamma probe in, 24P(ab)  
   lymphatic mapping for, 24P(ab)  
   lymphoscintigraphy, improved visualization with injection technique, 25P(ab)  
   lymphoscintigraphy and radioguided biopsy, 24P(ab)  
 sigma-2 receptor density, ploidy, recruitment, and tamoxifen treatment, 320P(ab)  
 skeletal metastasis in, distribution of, 114P(ab)  
 staging,  $^{18}$ F FDG PET use in, 4  
 suspected, combined use of mammography and scintimammography, 138P(ab)  
 synergistic therapy for, RIT and Taxol, 246P(ab)  
 $^{99m}$ Tc MIBI scintimammography,  $^{123}$ I MIVE2 complementary role in, 319P(ab)  
 $^{99m}$ Tc sestamibi scintimammography, planar and SPECT imaging comparison, 849  
 technetium SSTR binding peptide, miraluma comparison, 315P(ab)  
 whole-body FDG PET  
   assessment of axillary metastasis, 254P(ab)  
   prognostic value of, 254P(ab)  
 xenographs, imaging with  $^{99m}$ Tc alpha-fetoprotein, 222P(ab)
- Breast lesions**, palpable and nonpalpable,  $^{99m}$ Tc MIBI scintimammography in, 86
- Bromine-76 BrdU**, PET, as a proliferation marker, 1273
- Brugada syndrome**, regional cardiac adrenergic denervation,  $^{123}$ I MIBG SPECT, 1129
- Bubeck method**,  $^{99m}$ Tc MAG3 clearance studies, 1066
- Bull's eye display**,  $^{123}$ I IMP SPECT, evaluation of cerebral cortex, 107P(ab)
- C**
- Calcitonin**, suprasensitive measurement, follow-up of medullary thyroid cancer patients, 268P(ab)
- Calcitriol**, serum, single-isotope radiocalcium absorption test, 108
- Calcium**, absorption, single-isotope radiocalcium absorption test, 108
- Calcium antagonists**, for renovascular hypertension, false-positive captopril renography and, 1621
- Camera system**  
 dual-headed, coincidence and collimated emission tomography on, 132P(ab)  
 high-resolution PET detector, depth of interaction, 50P(ab)  
 positron, effects of inter-plane septal shields in, 171P(ab)
- Cancer**, see also specific type or site  
 diagnosis and treatment, radiolabeled IGF-I development for, 77P(ab)  
 imaging,  $^{99m}$ Tc MET scFv, 47
- Cancer cells**
- alpha particle therapy, 17N(2)  
 antibody pretargeted radiotherapy, 20N(2)  
 glucose transporter proteins and hexokinase activity, FDG uptake and, 251P(ab)  
 proliferation, glucose transporter-1 expression and,  $^{18}$ F FDG uptake comparison, 250P(ab)
- Cancer of unknown primary origin**,  $^{111}$ In octreotide value in, 316P(ab)
- Cannabinoid receptors**, brain  
 $^{18}$ F SR144385 PET studies, 229P(ab)  
 SPECT imaging, 12P(ab)
- Capsaicin**, pain induced by, opioid receptor binding and, PET measurement, 207P(ab)
- Captopril**, renography  
 false-positive, calcium antagonists and, 1621  
 orthiodohippurate and diethylenetriaminepentaacetic acid, 522
- Carbidopa**, pretreatment,  $^{18}$ F DOPA dosimetry with, 1884
- Carbon-10 dioxide**, steady state PET imaging, regional cerebral blood flow, 131P(ab)
- Carbon-11**  
 cocaine derivative, PET tracer for imaging dopamine transporters, 118P(ab)  
 drugs labeled with, P-glycoprotein reversal of, tumor bearing rats, 130P(ab)  
 high specific radioactivity, 237P(ab)  
 kappa opiate antagonist, synthesis and evaluation, 119P(ab)
- Carbon-11 ACBC**, PET, detection of recurrent brain tumors, 52P(ab)
- Carbon-11 acetate**  
 glucose utilization and oxidative metabolism, left bundle branch block, 261, 263  
 measurement, myocardial oxygen consumption and blood flow, 272
- Carbon-11 alpha-MTrp**, PET  
 serotonin synthesis rate, in psychiatric disorders, 83P(ab)  
 serotonin synthesis rate differences, 136P(ab)  
 serotonin synthesis rate or capacity, 137P(ab)
- Carbon-11 Altropine**, high and low injections, dopamine transporter density and affinity, 66P(ab)
- Carbon-11 caffeine**, synthesis, PET studies and, 238P(ab)
- Carbon-11 carbon dioxide**, substitute of phosgene for carbonylation, primary amines, 131P(ab)
- Carbon-11 CFT**, binding potential, estimation by iterative fitting, 167P(ab)
- Carbon-11 choline**  
 automated synthesis of, tumor imaging with PET, 240P(ab)  
 PET, imaging of prostate cancer, 990
- Carbon-11 cyanide**, production, irradiation of ammonia at liquid nitrogen temperatures, 241P(ab)
- Carbon-11 DTBZ**, PET  
 presynaptic monoaminergic vesicles, postural tremor, 210P(ab)  
 study of Tourette syndrome, 202P(ab)
- Carbon-11 FMAU**, prostate tumor cell differentiation, fast- and slow-growing, rat, 131P(ab)
- Carbon-11 FMZ**  
 early detection, irreversible ischemic neuronal damage, 148P(ab)  
 $^{18}$ F FDG, PET comparison, in epilepsy, 26P(ab)  
 PET, 3D image processing, epileptic foci, 26P(ab)
- Carbon-11 glucose**  
 FDG uptake and, malignant gliomas, 318P(ab)  
 radiation dosimetry, distribution and, human imaging studies, 1805
- Carbon-11 HED**, PET,  $^{123}$ I MIBG comparison, acute MI patients, 128P(ab)
- Carbon-11 hydroxyephedrine**, serial assessment of sympathetic reinnervation, after heart transplant, 161P(ab)

- Carbon-11 KF17837.** central nervous system adenosine  $A_{2A}$  receptor ligand, 498
- Carbon-11 L-159,884.** PET, angiotensin II/AT<sub>1</sub> receptors, 1209
- Carbon-11 McNS652.** quantitation of metabolites to, 239P(ab)
- Carbon-11 MDL 100907** integrated synthetic route to precursors of, 119P(ab) PET, serotonergic receptor, 209 serotonin receptor analog, kinetic analysis, 136P(ab)
- Carbon-11 Methionine** enzymatic synthesis of, 131P(ab) <sup>18</sup>F FDG and, evaluation of lymphadenopathy in sarcoidosis, 1160 <sup>18</sup>F FDG combined with, PET, tumors of lung and mediastinum, 640 in focal cortical dysplasia, comparison with PET and SPECT, 974 PET <sup>18</sup>F FDG comparison, lung cancer, 80P(ab) measurement of muscle protein synthesis, 195P(ab) preoperative evaluation with, gliomas, 778 uptake, squamous cell head and neck cancer, 1393
- Carbon-11 methanesulphonyl chloride.** no-carrier added, 119P(ab)
- Carbon-11 methyltriflate.** inhibitor, interleukin-1 converting enzyme, 132P(ab)
- Carbon-11 mHED.** quantitation, presynaptic cardiac sympathetic function, 1327
- Carbon-11 MPGA.** biodistribution and dosimetry, GAGA-receptors, brain, 307
- Carbon-11 nicotine.** specific binding, PET quantification, brain, 2048
- Carbon-11 N-methyl-4-piperidylbenzilate.** cholinergic activity, hypoperfusion and, bilateral carotid artery ligation, 198
- Carbon-11 NNC 112.** PET, neocortical D1 dopamine receptors, 2061
- Carbon-11 raclopride** binding, methylphenidate-induced changes in, 12P(ab) endogenous dopamine competition with, brain, 54P(ab) measurement of dopamine release, brain, 55P(ab) striatal binding potential, measure of Huntington's disease progression, 209P(ab)
- Carbon-11 Rolipram.** phosphodiesterase-IV inhibitor radioligand, PET imaging, 119P(ab)
- Carbon-11 SCH 23390.** distribution of, in normal subjects, 792
- Carbon-11 SKF 82957.** dopamine D1 agonist tracer, PET, 236P(ab)
- Carbon-11 SN 23719.** biodistribution and metabolism, nude mice bearing human tumor xenografts, 239P(ab)
- Carbon-11 soyeanates.** synthesis, novel generic route to, 237P(ab)
- Carbon-11 SR 46349B.** radioligand for serotonin receptors, brain, 237P(ab)
- Carbon-11 thymidine** FDG and, measurement of therapy response, 1757 PET compartmental analysis and mathematical analysis, 1043 quantitation of brain tumor proliferation, 53P(ab)
- Carbon-11 triamcinolone acetonide.** nasal, biodistribution and kinetics in PET, 1972
- Carbon-11 tyrosine** <sup>18</sup>F FDG and, detection of oral dysplasia, 1476 imaging, metastatic testicular nonseminoma germ cell tumors, 1027
- Carbon-11 WAY-100635** binding to central serotonin receptors, brain, 1965 localization of serotonin receptors using, anatomic standardization technique, 136P(ab)
- Carbon-11 WIN 35,428.** binding to dopamine transporters, 2D and 3D PET comparison, 65P(ab)
- Carbon-14 FDG.** PET, tumor cell spheroids as model for evaluation of irradiation changes, 1762
- Carbon-14 urea.** exempt distribution, 28N(3)
- Carbon-14 urea breath test,** 1306(le) low specificity of, *Helicobacter pylori* infection, 57P(ab) procedure guideline, 2012 serum B-12 values determined with, *H. pylori* patients, 271P(ab)
- Carbon monoxide.** poisoning, HMPAO brain SPECT in, 769
- Carcinoembryonic antigen** chimeric antibody against, presurgical colon cancer patients, 2097 imaging, primary breast cancer, 150P(ab) immunoscintigraphy, recurrent colorectal carcinoma, 151P(ab) <sup>188</sup>Rh labeled anti-, in gastrointestinal cancer, 34
- Carcinoid metastases.** liver, <sup>131</sup>I MIBG therapy, 1743
- Carcinoid tumor.** metastatic, orbit, <sup>131</sup>I MIBG uptake in, 647
- Cardiac catheterization.** early referral to, impact of gated SPECT on rate of, 87P(ab)
- Cardiac simulation study.** <sup>201</sup>Tl SPECT studies, 180 and 360° acquisition for attenuation compensation, 562
- Cardiomyopathy** Adriamycin myocardial effects of MIBG, 47P(ab) hypertrophic metabolic diversity in, 390 resting microvascular ischemia in, 161P(ab) idiopathic dilated myocardial glucose utilization and heart failure severity in, 162P(ab) new fatty acid analog imaging in, 127P(ab) ischemic ischemic cardiomyopathy, PET, 4P(ab) renography before heart transplant in, 2153 obstructive hypertrophic, septal reduction therapy, myocardial perfusion SPECT use in, 31P(ab)
- Cardioprotection.** <sup>123</sup>I BMIPP and <sup>201</sup>Tl mismatch, preinfarction angina, 1492
- Cardiototoxicity.** <sup>111</sup>In antimyosin detection of, after anthracycline therapy, children, 56P(ab)
- Carotid artery.** ligation, cholinergic activity and hypoperfusion in, 198
- Carotid artery disease.** occlusive encephalo-duro arterial synangiosis, diamox SPECT, 213P(ab) oxygen metabolism in, proton MRS and PET, 213P(ab)
- Carotid endarterectomy.** PET evaluation of cerebral hemodynamics, occlusive cerebrovascular disease, 760
- Cartilage.** alterations, <sup>123</sup>I ALP imaging, antigen-induced arthritis, rat, 1638
- Cassen.** Benedict, nuclear medicine pioneer, 16N(5)
- CD36 deficiency.** platelet monocyte, absent myocardial <sup>123</sup>I BMIPP uptake, 1681
- Cell cycle.** measurement, <sup>18</sup>F FLT vs thymidine, 229P(ab)
- Central nervous system** adenosine  $A_{2A}$  receptor ligand, <sup>11</sup>C KF17837 evaluation, 498 lesions, HIV patient, <sup>201</sup>Tl SPECT imaging, 317P(ab)
- Cerebellar metabolic reduction.** in Alzheimer's disease, 374(le)
- Cerebellum** crossed diaschisis, from intracranial hematoma, basal ganglia or thalamus, 2044 movement coordination, PET activation studies of, 110P(ab)
- Cerebral blood flow.** see also Blood flow cerebral metabolic rate of oxygen and, rate of visual stimulation effects, 110P(ab)
- cerebral water clearance estimates, <sup>15</sup>O water PET, 206P(ab) comparative study, PET and IMP-SPECT with arterial blood sampling, 163P(ab) fully-automated determination, elimination of errors in quantitative brain SPECT, 106P(ab) global, anxiety disorders, <sup>15</sup>O water PET study, 203P(ab) hypoperfusion, cholinergic activity and, 198 noninvasive quantification <sup>123</sup>I IMP SPECT, dynamic planar imaging, 163P(ab) PET, 106P(ab) postoperative recovery, prediction with <sup>123</sup>I IMZ SPECT, 148P(ab) quantitative analysis of SPECT, 3D surface projection, 164P(ab) rCMRGc coupling and, <sup>18</sup>F FDG imaging of normal brain, aging effects, 97P(ab) regional ADHD, on and off Ritalin, SPECT study, 203P(ab) brain activation during word learning, PET, 206P(ab) <sup>10</sup>CO<sub>2</sub> PET imaging of, 131P(ab) exchange surface estimate of brain capillaries, rat, 208P(ab) glucose metabolism and, in Sjögren's syndrome, 1354 during high caloric food challenge, anorexia nervosa patients, 203P(ab) scatter and attenuation correction effects, SPECT, 181 <sup>99m</sup>Tc HMPAO brain SPECT, 203 regional pattern, progressive aphasia, rCBF SPECT and MRI, 96P(ab) regional stability of, 216(le) stroke, outcome after 6 hours, <sup>99m</sup>Tc ECD SPECT prediction, 213P(ab) during transient global amnesia, HMPAO findings, 155
- Cerebral cortex** central processing of vestibular information, PET activation studies, 110P(ab) dorsolateral prefrontal, <sup>99m</sup>Tc HMPAO SPECT in major depressive disorder, 608 fast and slow finger movements, primary motor areas and, PET study, 205P(ab) <sup>123</sup>I IMP SPECT, bull's eye display, 107P(ab)
- Cerebral ischemia** benzodiazepine receptors and CBF changes, rat brain, 208P(ab) focal, neuroprotective agent effects, rat, 213P(ab) <sup>123</sup>I IMZ SPECT in, 1348 transient global amnesia, <sup>99m</sup>Tc ECD SPECT, 1360 visualization with <sup>57</sup>Co and <sup>99m</sup>Tc HMPAO labeled leukocytes, 495
- Cerebral metabolic rate of glucose.** noninvasive measurement, standardized input function, 164P(ab)
- Cerebral metabolic rate of oxygen** assessment of glucose metabolism, Alzheimer's disease, 163P(ab) cerebral blood flow and, rate of visual stimulation effects, 110P(ab)
- Cerebral palsy.** <sup>99m</sup>Tc ECD SPECT in, comparison with MRI, 619
- Cerebral perfusion imaging** asymptomatic carotid artery occlusion, after gun shot, 629 impairment, with toluene abuse, 632
- Cerebral perfusion reserve.** SPECT, findings in mitochondrial encephalomyopathy, 961
- Cerebrovascular disease** acetazolamide-induced myocardial ischemia, brain SPECT in, 408 chronic occlusive, pre- and postoperative PET studies, 213P(ab)

- occlusive, PET evaluation of cerebral hemodynamics, 760
- Cerebrovascular reserve**, imaging, single-day, 148P(ab)
- Cervical cancer**, FDG PET use in, 66P(ab)
- Cervical neoplasm**, prostate adenocarcinoma and, FDG PET early detection, 250P(ab)
- Charcot joint**, marrow versus infection, scintigraphy in, 346
- Chemoluminescence immunoassay**, radioimmunoassay comparison, measuring thyroid hormone levels, 271P(ab)
- Chemoresistance**, prediction, <sup>99m</sup>Tc MIBI and tetrofosmin comparison, 216P(ab)
- Chemotherapy**
  - gallium scan, role in extranodal lymphoma, 95
  - gallium scintigraphy, in non-Hodgkin's lymphoma, 1586
  - lymphoma patients, restaging gallium scan after, 317P(ab)
  - multiple myeloma, <sup>201</sup>Tl uptake before and after, 473
  - non-Hodgkin's lymphoma, 2S
  - prediction of response, <sup>201</sup>Tl and <sup>99m</sup>Tc sestamibi comparative SPECT, lung cancer, 1626
  - radionuclide therapy and, synergy between, 900
  - small cell lung cancer, <sup>99m</sup>Tc MIBI uptake in, 91
  - tumor response
    - prediction by <sup>201</sup>Tl scintigraphy, 1600
    - <sup>99m</sup>Tc MIBI as a tracer in bone lesions, 928(lc)
- Chernobyl**, differentiated childhood thyroid cancer from, characteristics, 20P(ab)
- Chest pain**
  - acute, myocardial perfusion imaging in emergency room, 153P(ab)
  - emergency department, stress imaging subsequent to rest imaging, 140P(ab)
  - nuclear cardiology protocols, emergency department chest pain center, 139P(ab)
- Chimeric antibody**, <sup>111</sup>In T84.66, presurgical colon cancer patients, 2097
- Chinese Society of Nuclear Medicine**, fifth national meeting, 30N(1)
- Chitosan**, colloidal <sup>188</sup>Re entrapped, radionuclide therapy, 235P(ab)
- Cholangiopancreatography**, endoscopic retrograde, versus <sup>99m</sup>Tc HIDA, for bile leaks, 1802
- Cholecystectomy**
  - laparoscopic, bile leaks after, <sup>99m</sup>Tc HIDA versus cholangiopancreatography for, 1802
  - value of gallbladder ejection fraction, for chronic biliary dysfunction, 273P(ab)
- Cholecystitis**, acute, morphine for, predictive value of gallbladder nonvisualization after, 126P(ab)
- Cholecystokinin analog**, internalization and biodistribution, 63P(ab)
- Cholescintigraphy**, quantitative, sphincter of oddi dysfunction test, 58P(ab)
- Cholinergic activity**, hypoperfusion and, carotid artery ligation, 198
- Cholinergic neurons**, <sup>18</sup>F FBT binding, monkey brain, 206P(ab)
- Choroid plexus**, epithelium, blood-CSF permeability barrier of <sup>99m</sup>Tc sestamibi, 13P(ab)
- Chromium-51 EDTA**, clearance, single-plasma sample, adults, 2131
- Chyloperitoneum**, lymphoscintigraphy in, 1292
- Chylothorax**, lymphoscintigraphy in, 1292
- Chyluria**, lymphoscintigraphy in, 1292
- Cisapride**, effects on salivary function, reflux esophagitis patients, 1449
- Clearance studies**, <sup>99m</sup>Tc MAG3, Bubeck method, 1066
- Clot imaging**, deep venous thrombosis, activated platelet imaging with MP-2026, 30P(ab)
- Cobalt**, divalent, as a label for lymphocyte distribution, PET and SPECT, 836
- Cobalt-57**, <sup>99m</sup>Tc HMPAO labeled leukocytes and, visualization of ischemic infarct, 495
- Cocaine**
  - addiction
    - gabaergic strategy for treatment, 99P(ab)
    - methylphenidate effects on brain metabolic changes, 100P(ab)
  - chronic L-depenrenyl treatment, effects on dopamine system, 54P(ab)
  - chronic use, mu opioid receptor binding changes after abstinence, 99P(ab)
  - pharmacology, distribution in human brain, <sup>11</sup>C cocaine images, PET, 42P(ab)
- Cocaine analogs**
  - <sup>76</sup>Br PE2Br, dopamine uptake sites, 238P(ab)
  - dopamine transporter imaging, Parkinson's disease, 1879
  - SPECT, early-stage, drug-naive Parkinson's disease, 1143
- Cognitive activation studies**, 3D PET, EXACT HR+ and <sup>15</sup>O water, 205P(ab)
- Coincidence imaging**
  - ADAC MCD dual head camera, performance of, 173P(ab)
  - 3D, scan duration and acceptance angle effects, brain, 175P(ab)
  - dual-head
    - collimated emission tomography, 132P(ab)
    - FDG PET comparison
      - lesion detection, 109P(ab)
      - mediastinal staging of lung cancer, 257P(ab)
    - <sup>18</sup>F FDG in primary lung nodules, 109P(ab)
    - phantom study with <sup>18</sup>F FDG, 23P(ab)
    - singles-transmission attenuation correction for, 37P(ab)
  - dual-head camera, FDG PET, primary lung nodules, 31P(ab)
  - dual-head gamma camera, recurrent colorectal carcinoma, 654
  - FDG, solitary pulmonary nodule, cost effectiveness, 248P(ab)
  - FDG PET with a gamma camera
    - assessment of pulmonary lesions, 108P(ab)
    - oncology, 108P(ab)
  - FDG uptake, prediction of survival and, pancreatic cancer, 252P(ab)
  - FDG uptake and <sup>99m</sup>Tc HMPAO brain perfusion, traumatic brain injury, 1357
  - gamma camera
    - measured attenuation correction, 38P(ab)
    - transmission scanning on, 92P(ab)
  - hot spot imaging of positron emitters, clinical lesion detection, 176P(ab)
  - lesion detection thresholds, positron imaging cameras, 51P(ab)
  - planar, PET and, staging malignant melanoma, 1892
- Colitis**, experimental, <sup>99m</sup>Tc liposomes in, 2172
- Collagen C telopeptide**, type I, bone tumor on radiation therapy, 269P(ab)
- Collimators**
  - fanbeam
    - <sup>99m</sup>Tc HMPAO
      - acute carbon monoxide poisoning, 769
      - Sjögren's syndrome, 773
    - with scanning point sources, for SPECT, 1996
    - three-headed SPECT camera, nonuniform attenuation correction, 1105
  - fan-beam, truncation artifacts in, 178P(ab)
  - high-energy, septal penetration and scatter in, 121P(ab)
  - high-resolution synthetic, 93P(ab)
  - holes and photomultipliers, dual samplings, SPECT, 169P(ab)
  - penetration and scatter, method for measurement, 51P(ab)
  - pinhole
    - <sup>131</sup>I distribution in brain tumors, 856
    - scintimammography, preliminary evaluation of breast cancer, 25P(ab)
- <sup>99m</sup>Tc sestamibi scintimammography with, 23P(ab) rotating slant hole, 3D image reconstruction algorithm for, SPECT, 179P(ab)
- Colon**, prolonged transit, differentiation, <sup>111</sup>In-labeled polystyrene pellets, 1062
- Colon cancer**
  - presurgical patients, chimeric monoclonal antibody against carcinoembryonic antigen, 2097
  - pretargeted xenografts, <sup>68</sup>Ga chelate imaging, 1769, 1776(e)
  - therapeutic dose of radioiodine, using bispecific antibody-targeted haptens, 1937
  - tumor response, induced hypertension and kinin degradation inhibition effects, 106P(ab)
- Colonic adenoma**, high FDG uptake, PET, 252P(ab)
- Colonic emptying**, proximal, differentiation with <sup>111</sup>In polystyrene pellets, 1062
- Colorectal cancer**
  - FDG PET, immunoscintigraphy comparison, 151P(ab)
  - hepatic metastasis, <sup>18</sup>F FDG PET optimization for, 253P(ab)
    - <sup>111</sup>In B7.3, radiation absorbed dose estimates for, 671
    - <sup>123</sup>I VIP receptor scintigraphy, 39P(ab)
    - liver metastases from
      - <sup>18</sup>F FU prediction of therapy response, 1197
      - <sup>15</sup>O and <sup>18</sup>F PET in, 465
  - potentially resectable, FDG PET, 253P(ab)
    - recurrent
      - additional value of FDG PET in, 134P(ab)
      - coincidence imaging with <sup>18</sup>F FDG, 654
      - extrahepatic metastasis detection with FDG PET and CT, 134P(ab)
    - FDG PET, patients with serum CEA elevation, 135P(ab)
      - PET and CT comparison, 134P(ab)
      - site-by-site correlation, FDG PET reading and histopathology findings, 134P(ab)
      - small volume disease, radioimmunotherapy in, 70P(ab)
      - streptavidin-anti-CEA antigen and <sup>90</sup>Y DOTA-peptide-biotin pretargeting, 245P(ab)
    - tumor markers in, value as decision criteria, FDG PET scans, 135P(ab)
    - xenografts, radioimmunotherapy and chemotherapy, 247P(ab)
- Commission on Health Care Policy and Practice (CHCPP)**
  - ambulatory payment classifications, 25N(4)
  - coverage instructions for lung PET, 28N(7)
  - fraud and abuse, 21N(10)
  - hospital outpatient prospective payment system, 26N(11)
  - Medicare for PET, 22N(1)
  - Medicare physician fee schedule proposed for 1999, 32N(8)
  - news, 30N(12)
  - physician evaluation program, 32N(5)
  - reimbursement roadshow, 33N(2)
  - utilization analysis database goes online, 14N(9)
- Compartmental analysis**, hepatic extraction efficacy of <sup>99m</sup>Tc mebrofenin, toxic-induced liver disease, 1286
- Compartmental modeling**, interactive, 1649(lc)
- Compton scattering correction**, artificial neural networks for compensation, 735
- Compton camera**
  - prototype, low energy imaging with, 173P(ab)
  - scatter apertures, parallel-hole collimators and, 132P(ab)
  - scattering detector for, 51P(ab)
- Computed tomography**
  - automatic 3-D matching, lung damage after radiotherapy, 1074
  - contrast-enhanced, grading of gliomas, 318P(ab)
  - dynamic, diagnostic abilities, <sup>201</sup>Tl SPECT and, pulmonary masses, 45P(ab)

electron beam, patients referred for myocardial perfusion scintigraphy, 32P(ab)  
emission transmission, attenuation maps in 3D multimodality registration, 169P(ab)  
emission tuned aperture, for scintimammography, 24P(ab)  
helical, pulmonary embolism, impact on use of V/Q scan, 5P(ab)  
spiral, vs V/Q scanning, diagnosis of pulmonary embolism, 5P(ab)  
transmission, fast sequential asymmetric fanbeam, for attenuation correction, 133S, 134S(cd)

**Computer and Instrumentation Council**, SNM, 10N(9)  
**Computers**  
fully automated program, diagnosing pulmonary embolism, 192P(ab)  
image processing assisted by, simultaneously acquired dual isotope SPECT images, 276P(ab)  
JAVA software  
internet-based platform independent system for nuclear medicine, 278P(ab)  
post-processing of brain PET data, 277P(ab)  
quantitative gated SPECT, myocardial perfusion imaging, 275P(ab)

**Computer simulation**  
bone marrow dosimetry model, mouse, 1243  
human lung morphology, for imaging analysis, 74S  
intraoperative probes, radionuclide-guided cancer surgeries, 92P(ab)  
spiral CT vs V/Q scanning, pulmonary embolism, 5P(ab)  
synthetic collimator, traditional parallel-hole collimators and, 93P(ab)

**Computer systems**, year 2000 problems, 30N(12)  
**Congestive heart failure**, sympathetic denervation in, <sup>18</sup>F PFBG detection of, 159P(ab)  
**Constipation**, prolonged colonic transit, differentiation, <sup>113</sup>In-labeled polystyrene pellets, 1062  
**Contrast agents**  
effects during immunoradiometric assay, for tumor-associated antigens, 270P(ab)  
gadolinium or iodinated, effects on <sup>67</sup>Ga uptake, mice, 11P(ab)  
**Copper isotopes**, radioactive, targeted tumor therapy, 677  
**Copper-62 ATSM**, tumor agent, bioreductive drug activation, 90P(ab)  
**Copper-62 PTSM**  
human biodistribution and dosimetry, PET, 1958  
PET, clinical trials, 142P(ab)  
**Copper-64**  
anti-colon carcinoma monoclonal antibody labeled with, radioimmunotherapy studies, 105P(ab)  
radiotherapy and dosimetry, somatostatin receptor-positive tumor bearing rat model, 104P(ab)  
remote system for processing of, 240P(ab)  
routine production, compact cyclotron, 234P(ab)  
**Copper-64 ATSM**, hypoxia targeting agents labeled with, EMT6 hypoxic tumor model, 91P(ab)  
**Copper-64 BOPP**, synthesis and PET evaluation, 233P(ab)  
**Copper-64 TETA-octreotide**  
localization, ovarian cancer xenografts, 63P(ab)  
radiotherapy, toxicity, and dosimetry, tumor-bearing rats, 1944  
**Copper-64 TETA-TYR/u3/U-octreotate**, binding studies, rodent biodistribution and primate PET imaging, 63P(ab)  
**Coregistration**  
FDG PET and MRI, head and neck, 2121  
multitracer and multimodal, semiautomated, gated cardiac studies, 145P(ab)  
**Coronary artery**, transmyocardial laser revascularization effects, myocardial perfusion imaging, 32P(ab)  
**Coronary artery bypass surgery**, effects on brain perfusion, 587

**Coronary artery disease (CAD)**  
acetazolamide-induced myocardial ischemia in, brain SPECT, 408  
angioplasty for, myocardial fatty acid metabolism after, 933  
chronic, viable myocardium in, rest-redistribution <sup>201</sup>Tl tomography, 1869  
3D coronary artery trees, 3D left ventricles from perfusion SPECT, 146P(ab)  
detection, symptom limited exercise stress testing, 154P(ab)  
<sup>123</sup>I IPPA myocardial SPECT, 2019  
ischemia, left ventricular dysfunction patients, myocardial SPECT, 101P(ab)  
post-exercise regional wall motion abnormalities as marker, gated SPECT, 87P(ab)  
preexisting left bundle branch block, myocardial perfusion imaging in, 579  
resting pulse pressure and outcomes, myocardial perfusion imaging, 116P(ab)  
revascularization after, SPECT and echocardiography, 18P(ab)  
single-vessel, stable angina due to, blood flow in, 89P(ab)  
stent model of left ventricular dysfunction, PET validation of, 142P(ab)  
stress-induced perfusion defects, myocardial uptake of PHIPPA 3–10 in, 153P(ab)  
stress myocardial perfusion scintigraphy, 1662  
subsequent MI, location, results of prior SPECT, 140P(ab)  
<sup>99m</sup>Tc MIBI SPECT, diagnostic accuracy in men and women, 751, 756  
<sup>99m</sup>Tc Q12 and <sup>201</sup>Tl uptake, myocardial viability, 159  
<sup>99m</sup>Tc sestamibi and tetrofosmin comparison, SPECT, 17P(ab)  
<sup>99m</sup>Tc tetrofosmin tomography, during adenosine triphosphate infusion, 582  
<sup>201</sup>Tl regional myocardial activity, left ventricular dysfunction and, 101P(ab)  
transient regional ischemia, during rotational atherectomy, 402  
wall motion analysis, radionuclide angiography database in, 75P(ab)

**Coronary artery stenosis**  
after MI, <sup>99m</sup>Tc sestamibi SPECT for detection, 152P(ab)  
<sup>201</sup>Tl dipyridamole, electron beam CT and, 156P(ab)

**Coronary flow reserve**  
after correction of transposition of great arteries, children, 56P(ab)  
hemodynamic response to adenosine and, postmenopausal women, 32P(ab)  
impaired, elevated plasma cholesterol levels, women, 90P(ab)

**Coronary restenosis**, <sup>188</sup>Re liquid filled balloons in inhibition of, swine model, 48P(ab)

**Coronary stent**, implantation, myocardial perfusion imaging after, 1307

**Coronary syndromes**, acute, evaluation with <sup>123</sup>I BMIPP, 1117

**Cost-effectiveness**  
adrenal incidentaloma diagnosis, 707  
decision analysis model, evaluation of surgery for intractable seizures, 69P(ab)  
FDG coincidence imaging, solitary pulmonary nodule, 248P(ab)  
FDG PET, non-small cell lung cancer staging, 80P(ab)  
management of recurrent melanoma, whole-body FDG PET vs conventional imaging, 94P(ab)  
in nuclear medicine, 17N(1)

<sup>82</sup>Rb myocardial perfusion imaging, coronary disease, 90P(ab)  
staging of malignant melanoma, whole-body FDG PET vs conventional imaging, 94P(ab)

**Creatinine**, serum, lupus nephritis, <sup>67</sup>Ga prediction of response to therapy, 2137  
**Crohn's disease**, <sup>99m</sup>Tc RP128, imaging inflammatory lesions, 271P(ab)  
**Crosstalk**, multi-isotope SPECT imaging, a priori information of spectral data, 176P(ab)  
**CUP syndrome**, FDG PET, 256P(ab)  
**Cushing's disease**, glucose metabolism in, brain, 786  
**Cyclosporin A**, multidrug resistance P-glycoprotein, <sup>99m</sup>Tc metal complexes for, 77  
**Cytotoxin**, hypoxic, targeted tumor therapy, 677

## D

**Data acquisition**, spatial sampling, high resolution animal tomograph, 133P(ab)  
**Database**, age-adjusted normal image, interpretation of functional brain images, 211P(ab)  
**Deafness**, decreased cerebral metabolic rate in, FDG PET, 211P(ab)  
**Decompression illness**, determination of regional cerebral blood flow, significance imaging, 425  
**Demand ischemia**, <sup>99m</sup>Tc nitroimidazole uptake, swine, 1468  
**Dementia**  
AIDS, cerebral perfusion scanning in treatment, 298  
depressive pseudodementia, abnormal rCBF distribution, brain perfusion SPECT, 41P(ab)  
Lewy bodies, dopamine transporter loss in, 124P(ab)  
**Dendrimer-1B4M DTPA**, <sup>111</sup>In and <sup>188</sup>Y labeled, biodistribution, 232P(ab)  
**Deoxyglucose**, accumulation, glucose transporter protein-independent tumor cells, 245  
**Department of Energy (DOE)**  
FFT for tritium, 21N(1)  
isotope availability, 22N(5)  
**L-deprenyl**, chronic treatment, cocaine-induced increase in nucleus accumbens dopamine, 54P(ab)  
**Depression**  
hypofrontality and negative symptoms, <sup>99m</sup>Tc HMPAO SPECT, 608  
major  
cerebral serotonergic receptors in, fluvoxamine effects, 40P(ab)  
reduced midbrain serotonin transporter binding, <sup>111</sup>I beta-CIT SPECT, 40P(ab)  
serotonergic and dopaminergic activity, <sup>18</sup>F FES PET, 40P(ab)  
regional cerebral activity, antidepressant activity with somatization effects, 41P(ab)  
unipolar, correlation of mu opioid receptor upregulation and mood scores, females, 40P(ab)  
**Depth of interaction**  
high-resolution brain imaging, LSO-based PET for, 133P(ab)  
measurement, avalanche photodiodes in, 92P(ab)  
PET detector module, 170P(ab)  
**Desmoplasia**, <sup>99m</sup>Tc MIBI uptake and, benign and malignant breast lesions, 449  
**Dexamethasone**, treatment, plasma glucose levels and, <sup>18</sup>F FDG uptake in gliomas, 879  
**Diabetes**  
cardiovascular events in, regional abnormality in <sup>123</sup>I MIBG myocardial SPECT, 157P(ab)  
foot problems in, 275P(ab)  
insulin-dependent, bone mineral density in patients with, 194P(ab)  
non-insulin-dependent  
coronary microangiopathy, glycemic control, and insulin in, 4P(ab)  
heart and skeletal muscle glucose use in, 141P(ab)  
type 2, insulin resistance and glucose metabolism, 884  
**Diabetes mellitus**  
noninsulin-dependent, myocardial oxidative metabolism in, 1835

- with sympathetic nervous dysfunction,  $^{123}\text{I}$  MIBG lung uptake in, 334
- type II, prolonged lung retention of  $^{123}\text{I}$  MIBG, 116
- Dialysis**, renal, effects on whole-body bone density, 129P(ab)
- Diaschisis**
- crossed cerebellar, from intracranial hematoma, basal ganglia or thalamus, 2044
  - ipsilateral thalamic hypoperfusion and, in temporal lobe epilepsy, 281
  - in subcortical stroke recovery, rest and Diamox rCBF brain SPECT, 148P(ab)
- Diethyl maleate**, brain mitochondria treated with, glutathione and  $^{99m}\text{Tc}$  meso-HMPAO use in, 2178
- Dimethylnitrosamine**, hepatocyte growth factor or, increased  $^{99m}\text{Tc}$  GAS uptake per hepatocyte, 1463
- Dipyridamole**
- myocardial perfusion imaging with, preexisting left bundle branch block, 579
  - stress or exercise,  $^{99m}\text{Tc}$  sestamibi lung uptake, 339
- DNA**
- strand breaks, DNA cleavage by decay of oligonucleotides, 236P(ab)
  - synthesis,  $^{76}\text{Br}$  BrdU PET, as a proliferation marker, 1273
- Dobutamine**
- flow heterogeneity and, single coronary stenosis, 417
  - low-dose, contractile response and, chronically dysfunctional myocardial segments, 1841
  - rest and low-dose  $^{13}\text{N}$  ammonia gated SPECT, cardiac function, 141P(ab)
  - stress myocardial perfusion scintigraphy, 1662
  - stress SPECT, myocardial perfusion, 115P(ab)
- Dopamine**
- cocaine-induced abnormalities, methylphenidate effects, 100P(ab)
  - $^{11}\text{C}$  raclopride binding and, 12P(ab)
  - D1 radiotracer competition, PET studies, 55P(ab)
  - $^{123}\text{I}$  IBZM and melanin, melanoma metastases, 996 release
    - amphetamine-induced, inhibition by GBR 12909, 55P(ab)
    - measurement with  $^{11}\text{C}$  raclopride, 55P(ab)
    - nicotine-induced, H-3 raclopride binding studies, 54P(ab)
  - resting synaptic release, in schizophrenia, SPECT imaging of, 82P(ab)
  - striatal release, amphetamine-induced, SPECT measurements of, 207P(ab)
- Dopamine D1 agonist**, PET tracer,  $^{11}\text{C}$  SKF 82957, 236P(ab)
- Dopamine receptors**, binding, temporal cortex and striatum, sertindole and olanzapine treatment, 82P(ab)
- Dopamine D1 receptors**
- neocortical,  $^{11}\text{C}$  NNC 112 PET examination of, 2061
  - PET imaging, D-1 agonist R- $^{11}\text{CSKF}$  82957, 71P(ab)
- Dopamine D2 receptors**
- aging effects, PET, monkey, 207P(ab)
  - binding of  $^{123}\text{I}$  epidepride, labeled lipophilic metabolites, 72P(ab)
  - binding with  $^{123}\text{I}$  IBF, SPECT, age-related changes, 1511
  - extrastriatal
    - 3D PET analysis, 72P(ab)
    - $^{123}\text{I}$  epidepride measurement, 123P(ab)
    - PET quantitation using multi-injection approach, 71P(ab)
  - H-3 raclopride binding, 12P(ab)
  - Huntington disease, reduced striatal uptake on  $^{123}\text{I}$  EPID and, 124P(ab)
  - $^{123}\text{I}$  IBZM imaging, hypoxic-ischemic brain injury, infants, 1703
- imaging, pituitary adenomas and prolactinomas, 19P(ab)
- loss of binding sites, Parkinson's disease, 954
- occupancy, risperidone-treated schizophrenic patients, SPECT, 1138
- regulation of central cholinergic activity, PET, 12P(ab)
- striatal, binding by olanzapine,  $^{123}\text{I}$  IBZM SPECT study, 82P(ab)
- Dopamine D4 receptors**
- RP316 binding distribution in, rat brain, 226P(ab)
  - SPECT studies, radioiodinated benzamide derivative for, 226P(ab)
- Dopaminergic system**, pre- and postsynaptic, combined analysis, Parkinsonian syndromes, 124P(ab)
- Dopamine transporters**
- assessment, PET, pharmacological MRI, microdialysis, and behavior studies, 54P(ab)
  - $^{11}\text{C}$  altropine, selective DAT ligand for, 238P(ab)
  - $^{11}\text{C}$  PE21 binding to, PET studies, monkey brain, 118P(ab)
  - deficit, in Parkinson's disease
    - $^{123}\text{I}$  FP-CIT SPECT for, 13P(ab)
    - SPECT, 14P(ab)
  - density and affinity, determination with  $^{11}\text{C}$ -Altropine injection, 66P(ab)
  - evaluation of dopaminergic transmissions, movement disorders, 14P(ab)
  - $^{18}\text{F}$  FPCIT PET, 1521
  - $^{18}\text{F}$  FPCIT PET imaging, 209P(ab)
  - $^{123}\text{I}$  altropine, phase I clinical trial, 239P(ab)
  - $^{123}\text{I}$  altropine imaging, Parkinson's disease, 214P(ab)
  - imaging, early-stage, drug-naïve Parkinson's disease, 1143
  - imaging agent,  $^{99m}\text{Tc}$  TRODAT-1 as, Parkinson's disease, 220P(ab)
  - imaging with  $^{123}\text{I}$  FP-CIT SPECT, Parkinson's disease, 1879
  - kinetics,  $^{11}\text{C}$  WIN 35,428, PET, 42P(ab)
  - loss, dementia with Lewy bodies and Parkinson's disease, 124P(ab)
  - mapping,  $^{18}\text{F}$  PET, 35P(ab)
  - mazindol effects, normal brain, 166P(ab)
  - measurement,  $^{123}\text{I}$   $\beta$ -CIT and FPCIT SPECT, Parkinson's patients, 1500
  - occupancy
    - intravenous methylphenidate, 42P(ab)
    - oral methylphenidate, 43P(ab)
  - PE21 cocaine derivative for imaging, dual-probe microdialysis, 49P(ab)
  - PET tracer for imaging,  $^{11}\text{C}$ -labeled cocaine derivative, 118P(ab)
  - pre- and postsynaptic sites, simultaneous assessment, 7P(ab)
  - serotonin and, impact in  $^{123}\text{I}$  beta-CIT SPECT, 42P(ab)
  - $^{99m}\text{Tc}$  TRODAT-1
    - biodistribution and dosimetry of, 221P(ab), 2069
    - binding to, dopaminergic drug effects, 214P(ab)
    - Parkinson's disease, 6P(ab)
    - uptake sites,  $^{76}\text{Br}$  PE2Br, cocaine analog, 238P(ab)
- Dose calibrator**, values, correct use of, 575(ie)
- Dosimetry**
- absorbed distribution,  $^{166}\text{Ho}$  endovascular irradiation, 85P(ab)
  - adenosine receptor antagonist  $^{18}\text{F}$  CPFPX, mice and baboon, 188P(ab)
  - auger-emitting diagnostic radionuclides, in human spermatozoa, 895
  - biodistribution and,  $^{99m}\text{Tc}$  TRODAT-1, imaging of dopamine transporters, 221P(ab)
  - biodistribution and radiation estimates,  $^{18}\text{F}$  FP-TZTP, 85P(ab)
  - biologic
    - after repeated  $^{131}\text{I}$  treatments, thyroid cancer patients, 825
  - bone marrow, for  $^{90}\text{Y}$ , 547
- bladder, carbidopa pretreatment,  $^{18}\text{F}$  DOPA PET, 1884
- bladder wall,  $^{18}\text{F}$ -related radiopharmaceuticals, PET studies, 187P(ab)
- bone marrow model, mouse, 1243
- $^{11}\text{C}$  MPGA, GAGA-receptors, brain, 307
- $^{62}\text{Cu}$  PTSM, PET, 1958
- $^{64}\text{Cu}$  TETA-octreotide, tumor-bearing rats, 1944
- decreased radiation dose, new L6 immunoconjugate for, 185P(ab)
- 3D model of electron transport, trabecular bone, 183P(ab)
- estimates, whole-body biodistribution of  $^{18}\text{F}$  FLT, monkey, 190P(ab)
- heterogeneity and prediction of myelotoxicity, bone metastases treatment, 84P(ab)
- $^{123}\text{I}$  altropine, phase I clinical trial, 239P(ab)
- $^{131}\text{I}$  anti-B1 antibody therapy, non-Hodgkin's lymphoma, 1S
- $^{131}\text{I}$ , outpatient therapy, PC-based external dose calculation, 277P(ab)
- $^{111}\text{In}$  labeled DOTATOC, neuroendocrine tumors, 221P(ab)
- internal
- MCNP 4B to calculate distributions in voxelized phantom, 83P(ab)
  - photons and electrons in small spheres, 188P(ab)
  - TLD method, whole-body PET, 187P(ab)
  - walls of blood vessels, model calculations, 184P(ab)
- iodine, uptake, thyroid cancer, 188P(ab)
- liquid beta emitter in balloon catheter,  $^{188}\text{Re}$ , TLD system, 84P(ab)
- low-energy vs high-energy beta emitters, palliation of bone pain, 84P(ab)
- marrow absorbed estimates, treatment with  $^{131}\text{I}$  Lym-1, 113P(ab)
- MIRDOSE 3.1, erroneous results, 927(ie)
- non-target organ doses, bone marrow ablation with  $^{166}\text{Ho}$  EDTMP, 186P(ab)
- patient-specific whole-body, non-Hodgkin's lymphoma, 14S
- radiation
- Bi-213 monoclonal antibody bound to membranes, tumor cells, 184P(ab)
  - cell kinetics model of thrombocytopenia, 1223
  - $^{11}\text{C}$  glucose, human imaging studies, 1805
  - $^{131}\text{I}$  LYM-1 pharmacokinetics and, non-Hodgkin's lymphoma, 112P(ab)
  - individual skeletal lesions treated with  $^{153}\text{Sm}$  EDTMP, 2110
  - $^{131}\text{I}$  therapy, position, size, and shape of thyroid nodule effects, 185P(ab)
  - non-Hodgkin's lymphoma,  $^{131}\text{I}$  anti-CD20 antibody for, 186P(ab)
- radiation absorbed doses and biological effects, differentiated thyroid cancer, 189P(ab)
- radioimmunotherapy,  $^{99m}\text{Tc}$  anti-EGF-receptor antibody, tumor of epithelial origin, 15
- radioiodine, using bispecific antibody-targeted haptens, 1937
- radioisotope therapy, multiple camera types for, quantification, 185P(ab)
- radionuclide, palliation of bone pain in metastatic lesions, 84P(ab)
- red marrow
- patient-specific estimates, correlation with myelotoxicity and, 112P(ab)
  - prediction of hematological toxicity in radioimmunotherapy, 186P(ab)
  - splenic volume, patient-specific, for radioimmunotherapy, 186P(ab)
- statistical considerations and,  $^{18}\text{F}$  FMT, 190P(ab)
- $^{99m}\text{Tc}$ -labeled IGM murine antibody, granulocytes, 268P(ab)
- $^{99m}\text{Tc}$  TRODAT-1, dopamine transporter imaging, 2069

- tumor,  $^{131}\text{I}$  SPECT, B-cell lymphoma, 112P(ab)  
worldwide by internet, Memorial Sloan-Kettering protocol for thyroid treatment, 278P(ab)
- DOTATOC**, somatostatin analog, metal coordination chemical aspects and tumor targeting, 63P(ab)
- Drug abuse**  
cocaine, distribution in human brain,  $^{11}\text{C}$  cocaine images, PET, 42P(ab)  
methylphenidate  
intravenous, dopamine transporter occupancy by, 42P(ab)  
oral, dopamine transporter occupancy by, 43P(ab)
- Drug labeling**, changes, 1831(lc)
- Dynamic studies**  
input function in, blind estimation approach, 64P(ab)  
kinetic parameter estimation, SPECT, 65P(ab)  
parametric images in, PET, 65P(ab)
- E**
- Echocardiography**  
dobutamine  
hibernating myocardium, 396  
recovery after revascularization, CAD, 18P(ab)  
transesophageal,  $^{201}\text{Tl}$  imaging and, myocardial viability, 60P(ab)
- Education**, nuclear medicine, computer-assisted instruction, 277P(ab)
- Education and Research Foundation**, SNM, 14N(5). 29N(4)
- EGFR**. *see* Epidermal growth factor receptor
- Ejection fraction**  
gallbladder  
cholecystectomy for chronic biliary dysfunction, 273P(ab)  
three methods for calculation, 126P(ab)  
gated SPECT, prognostic value, dual isotope exercise or adenosine stress SPECT, 101P(ab)  
 $^{123}\text{I}$  myocardial radiotracer, multicrystal gamma camera and, 938  
influence of gating errors, SPECT myocardial perfusion quantitation, 45P(ab)
- left ventricular  
computation from  $^{201}\text{Tl}$  SPECT, 103P(ab)  
gated SPECT correlation, defect size effects, 61P(ab)  
multiwire camera and tantalum-178, first-pass imaging, 76P(ab)  
portable multiwire gamma camera for assessment, 75P(ab)  
radionuclide angiography vs myocardial perfusion SPECT, 75P(ab)  
 $^{99m}\text{Tc}$  sestamibi myocardial perfusion SPECT, 45P(ab)  
predictive value of gated blood-pool imaging, stem cell transplantation, 76P(ab)
- Electroencephalography**, quantitative, correlation with  $^{99m}\text{Tc}$  HMPAO brain SPECT, Alzheimer's disease, 96P(ab)
- Electrophilic fluorination**, remote synthesis device for, 240P(ab)
- Emission scan**  
misalignment, effects on attenuation-corrected cardiac SPECT, 411  
registration errors, sequential scanning, 365
- Encephalitis**  
herpes simplex,  $^{99m}\text{Tc}$  ECD SPECT in, 790  
tick-borne, regional cerebral blood flow scintigraphy in, 2055
- Encephalomyopathy**, mitochondrial, SPECT findings in, 961
- Encephalopathy**, hypoglycemic,  $^{99m}\text{Tc}$  HMPAO SPECT, neonate, 1711
- Endocarditis**, experimental, scintigraphic detection with  $^{99m}\text{Tc}$  GP IIa/IIb receptor, 47P(ab)
- Endovascular irradiation**,  $^{166}\text{Ho}$ , balloon angi catheter, 85P(ab)
- Enzyme inhibitors**, tyrosine kinase, epidermal growth factor receptor synthesis, 20P(ab)
- Epidemiology**, thyroid cancer incidence, iodine-deficiency area Unterfranken, 259P(ab)
- Epidermal growth factor receptor**  
factors influencing tumor imaging, 1036  
native peptide ligand and mAb against, breast cancer, 77P(ab)  
 $^{99m}\text{Tc}$  anti-EGF-receptor antibody, tumor of epithelial origin, 15, 1918  
tyrosine kinase inhibitors, synthesis, 20P(ab)
- Epilepsy**  
 $^{11}\text{C}$  flumazenil, 3D image processing, 26P(ab)  
 $^{11}\text{C}$  FMZ,  $^{18}\text{FDG}$  PET comparison, 26P(ab)  
childhood, ictal SPECT and FDG PET accuracy in, 212P(ab)  
continuous partial seizures, FDG PET localization of epileptic foci, 211P(ab)  
epileptogenic zone in,  $^{99m}\text{Tc}$  ECD as predictor of, 68P(ab)  
extratemporal cortical resection in, FDG PET for clinical outcome of, 68P(ab)  
 $^{18}\text{F}$  FDG PET, 27P(ab)  
focal  
cerebral perfusion and metabolism in, 26P(ab)  
glucose consumption,  $^{18}\text{F}$  FDG PET, 27P(ab)  
ictal-interictal SPECT difference images, 27P(ab)  
focal cortical dysplasia,  $^{11}\text{C}$  MET use in, 974  
intractable seizures, FDG 511 keV SPECT in, 212P(ab)  
isolation of hypometabolism, patient-specific normal database evaluation, 107P(ab)  
partial, FDG PET vs ictal SPECT, 68P(ab)  
perfusion decreases, HMPAO SPECT, 212P(ab)  
pre-surgical evaluation, FDG PET, 69P(ab)  
SPECT brain imaging, meta-analysis of, 285  
surgical outcome in,  $^{99m}\text{Tc}$  HMPAO SPECT in prediction of, 68P(ab)
- temporal lobe  
extratemporal hypometabolism, FDG PET, 69P(ab)  
 $^{18}\text{F}$  FDG uptake in, 176  
interictal SPECT, ipsilateral thalamic hypoperfusion on, 281  
preictal SPECT in, 978
- Epiphyseal photopenia**, metaphyseal osteomyelitis and subperiosteal abscess, 1084
- Erythrocytes**, normalization of FDG studies, alternative method, 552
- Esophageal cancer**  
 $^{18}\text{F}$  FDG PET use in, 1002  
preoperative staging, FDG PET, 252P(ab)
- Estrogen receptors**,  $^{18}\text{F}$  fluoroestradiol binding, SHBG, 35P(ab)
- Ethanol**, percutaneous injection, treatment of autonomous thyroid adenoma, 1012
- EXACT HR+**,  $^{15}\text{O}$  water and, 3D PET cognitive activation studies, 205P(ab)
- Exercise stress testing**  
symptom limited, detection of severe CAD, 154P(ab)  
 $^{99m}\text{Tc}$  MIBI SPECT and, diagnostic accuracy in men and women, 751, 756
- Extracorporeal irradiation**,  $^{99m}\text{Tc}$  MDP scintigraphy, primary malignant bone tumors, 1563
- Extracranial tumors**,  $^{123}\text{I}$  IMT imaging, 1737
- F**
- Facial nerve**, paralysis, prognosis using submandibular gland scintigraphy, 716
- Factor analysis**, regularization, cardiac  $^{15}\text{O}$  water studies, 160P(ab)
- Familial amyloid polyneuropathy**, myocardial changes in, 142P(ab)
- Familial diseases**, nonmedullary thyroid cancer, 260P(ab)
- FasLigand**, adenoviral-mediated gene transfer of,  $^{99m}\text{T}$  anti-Fas ligand, 225P(ab)
- Fast Flux Test Facility (FFTF)**, DOE consideration of, 21N(1)
- Fat necrosis**, intramedullary, multiple bones, with pancreatitis, 1401
- Fatty acids**  
analog imaging, ischemic heart disease and idiopathic dilated cardiomyopathy, 127P(ab)
- BMIPP**  
isomers, intra-individual comparison, 1672  
metabolism, 47P(ab)
- free, uptake, myocardium and skeletal muscle, after  $^{18}\text{F}$  FTHA, 1320
- metabolism  
myocardial  
after coronary angioplasty, 933  
angiotensin-converting enzyme inhibitor therapy effects, after MI, 127P(ab)  
implications in acute MI, 127P(ab)
- radioiodinated, SPECT, metabolic alterations in skeletal muscle ischemia, 162P(ab)
- uptake  
evaluation with  $^{123}\text{I}$  BMIPP, in acute coronary syndromes, 1117  
right ventricular function and, 1676
- Fatty acid tracers**  
BMIPP comparison, during myocardial ischemia and hypoxia, 1684  
myocardial uptake, comparison to beta-oxidation rates by tritiated palmitate, 1690
- FDG. Fluorodeoxyglucose**; *see* Fluorine-18-FDG.
- Fetus**, thyroid, radioiodine treatment of hyperthyroidism in pregnancy, 357, 2194(I)
- Fever of unknown origin**, clinical value of immunoscintigraphy in, 1248
- FIAU**, tissue uptake, D-54 glioma xenograft mouse model, 104P(ab)
- Fibrous dysplasia**, visualization, during somatostatin receptor scintigraphy, 238
- Fibula**, donor, scintigraphic findings in limb salvage, 1087
- Filter**, automatic task-dependent selection, PET images, 79P(ab)
- Flare response**, seen in therapy for osteomalacia, 2095
- Fletcher**, James W., lines from the president, 23N(6)
- Fluorine-18**  
benzylfluoride derivatives, stable, development of, 230P(ab)  
5-HT1A silent antagonists, changes in serotonin levels, 36P(ab)  
imaging, central nicotinic acetylcholine receptors, 21P(ab)  
incorporation, xenon difluoride, 231P(ab)  
indole derivatives, acetylcholinesterase inhibitors, 229P(ab)
- PET**  
mapping dopamine transporter sites, 35P(ab)  
planar bone imaging vs. prostate, thyroid, and lung cancer patients, 113P(ab)
- Fluorine-18 AFDG**, accumulation, glucose transporter protein-independent tumor cells, 245
- Fluorine-18 altanserin**  
PET, cerebellar data as input for, 165P(ab)  
quantification of serotonin receptors with, PET, 136P(ab)
- Fluorine-18 cholesteryl fluorobenzoate**, adrenal imaging agent, PET, baboon, 36P(ab)
- Fluorine-18 CPFPX**  
 $\text{A}_1$  adenosine receptor antagonist, preclinical evaluation, 22P(ab)
- PET, mapping of adenosine receptors in primate brain, 230P(ab)

- Fluorine-18 desmethoxyfallypride.** specific binding, monkey, 207P(ab)
- Fluorine-18 DOPA** dosimetry, with carbidopa pretreatment, 1884 extrastrial uptake, normal brain, 214P(ab) metastatic melanomas, 318P(ab)
- Fluorine-18 DPN.** PET, central opioid receptor imaging, 73P(ab)
- Fluorine-18 fallypride.** specific binding, monkey, 207P(ab)
- Fluorine-18 FBnCNE.** PET, sigma receptor ligand, 229P(ab)
- Fluorine-18 FBPA.** PET, glioma patients, 325
- Fluorine-18 FDG** accumulation importance of glucose transport in, 321P(ab) importance of glucose transport on, 251P(ab) CD36 deficiency, enhanced myocardial glucose uptake with, 152P(ab) <sup>11</sup>C FMZ, PET comparison, in epilepsy, 26P(ab) <sup>11</sup>C glucose uptake and, FDG uptake and, 318P(ab) <sup>11</sup>C Met and, evaluation of lymphadenopathy in sarcoidosis, 1160 <sup>11</sup>C methionine combined with, PET, tumors of lung and mediastinum, 640 <sup>11</sup>C thymidine and, measurement of therapy response, 1757 <sup>11</sup>C tyrosine and, detection of oral dysplasia, 1476 coincidence imaging with, recurrent colorectal carcinoma, 654 commercial regional distribution, changing regulatory environment, 144P(ab) comparison with rest-redistribution <sup>201</sup>Tl SPECT, viable myocardium, 1481 dexamethasone and plasma glucose levels, in malignant gliomas, 879 dual-head coincidence imaging, detection of laryngeal cancer postradiotherapy, 1385 gamma camera imaging, myocardial viability after MI, 152P(ab) idiopathic dilated cardiomyopathy, myocardial glucose utilization and heart failure severity, 162P(ab) 511KEV SPECT and PET, oncologic applications, 257P(ab) metastasis in thyroid cancer, <sup>131</sup>I scan negative patients, 257P(ab) with modified scintillation camera, myocardial viability, 2035 myocardial metabolic rate of glucose calculated by, viability determination, 141P(ab) nonattenuation-corrected whole-body PET, lesion-to-background ratio, 1219 normalization of, alternative method, 552 PET additional value in recurrent colorectal cancer, 134P(ab) adenosine receptors and myocardial stunning, 944 in bronchioloalveolar lung cancer, 1016 in cervical cancer, 66P(ab) chronic osteomyelitis, 2145 chronic vertebral osteomyelitis, 33P(ab) <sup>11</sup>C methionine comparison, lung cancer, 80P(ab) cognitive decline in Alzheimer's disease, 96P(ab) colorectal cancer, value of tumor markers as decision criteria, 135P(ab) comparison with <sup>99m</sup>Tc ECD SPECT and <sup>11</sup>C MET PET, epilepsy, 974 coregistration, head and neck, 2121 cryptogenic complex-partial seizures, 27P(ab) CT comparison, recurrent colorectal cancer, 134P(ab) detection and therapy of metastatic germ cell tumors, 815 esophageal cancer, 1002 evaluation of parapharyngeal meningioma from intracranial space, 302 findings in cerebral microangiopathy, 147 glucose metabolism in bone tumors, 810 granular cell tumor, breast, 1398 impairment by elevated glucose, 1030 <sup>111</sup>In somatostatin receptor scintigraphy and, neuroendocrine neoplasms, 319P(ab) Ki67 and, use in thyroid cancer, 19P(ab) lung cancer evaluation, 9 metastasis from uterine cervical cancer, 2084 muscle activity in runners, 195P(ab) observer-independent analysis of epilepsy, 27P(ab) pediatric neurological disorders, 56P(ab) prediction of Alzheimer's disease in memory impaired patients without dementia, 96P(ab) presurgical staging of breast cancer, 4 quantitating blood time-activity curves, mouse, 729 recurrent colorectal cancer, patients with serum CEA elevation, 135P(ab) Sjögren's syndrome, 1354 staging malignant melanoma, 1892 synaptic activation induced by repetitive transcranial magnetic stimulation, 109P(ab) <sup>99m</sup>Tc HL91 correlation, tumor hypoxia identification, 99 therapeutic limb perfusion, Merkel's cell carcinoma, 2087 versus <sup>201</sup>Tl, thyroid tumors, 453 tumor response in sarcoma, 95P(ab) uptake, pancreatic tumors, 1727 uptake after intracavitary <sup>131</sup>I, brain tumors, 1376 phantom study, coincidence imaging with dual-head camera, 23P(ab) positron-sensitive probe and, detection of atherosclerosis, 4P(ab) preoperative evaluation with, gliomas, 778 preoperative lymph node staging, squamous cell cancer, head and neck, 122P(ab) preoperative staging, esophageal cancer, 252P(ab) radiotherapy, hypermetabolic gliomas, 184P(ab) rCBF and rCMRGlc coupling, normal brain, aging effects, 97P(ab) repeated, value in advanced bone and soft tissue sarcoma, 255P(ab) rest and exercise stress, myocardial PET, diminished LVEF patients, 161P(ab) resting microvascular ischemia, hypertrophic cardiomyopathy patients, 161P(ab) soft tissue masses, 6-hour study, 255P(ab) spatial distribution in rat brain, small animal PET scanner, 133P(ab) SPECT <sup>123</sup>I BMIPP comparison, chronic ischemic heart disease, 255 iterative reconstruction, 124 recovery after revascularization, CAD, 18P(ab) viability vs improvement, heart failure symptoms, 18P(ab) synthesis as potential imaging agent, PET, 231P(ab) tumor imaging, procedure guidelines, 1302 uptake benign pulmonary nodules, 248P(ab) comparison with glucose transporter-1 expression and proliferation of cancer cells, 250P(ab) diabetes effects, untreated lung cancer, 43P(ab) discordance with <sup>99m</sup>Tc HMPAO, traumatic brain injury, 1357 gastrointestinal, symptoms and, 253P(ab) glucose concentration and radiation dose relations, 189P(ab) glucose transporter proteins and hexokinase activity, cancer cells, 251P(ab) hypoxic effect on brain slices, PAT technique, 204P(ab) myocardial, in hyperinsulinemia, 379 non-small cell lung cancer, 247P(ab) over 2-deoxyglucose, cancer cells, 251P(ab) pneumonia, 1267 quantification of, net influx constant, 123P(ab) reflection of glucose transport activity in tumors, 251P(ab) rheumatoid arthritis-associated lung disease, thyroid cancer and, 234 temporal lobe epilepsy, 176 tumor size effects, murine sarcoma model, 255P(ab) urinary excretion, during PET, 250P(ab) utilization, PET, left bundle branch block, 261, 263 whole-body PET, recurrent or metastatic breast cancer, 431
- Fluorine-18 FDG PEM.** metabolic imaging system, early detection of breast cancer, 146P(ab)
- Fluorine-18 FDOPA.** PET, blood-to-brain transport of large neutral amino acids, 43P(ab)
- Fluorine-18 FESP.** PET assessment of depression, luvoxamine effects, 40P(ab) dopaminergic and serotonergic activity in depression, 40P(ab)
- Fluorine-18 FET.** uptake, SW707 tumor tissue, 313P(ab)
- Fluorine-18 FE<sub>n</sub>NTI.** PET, studies of delta opioid receptors, 21P(ab)
- Fluorine-18 FHMP.** radiotracer for monoamine oxidase, PET, 231P(ab)
- Fluorine-18 FHPG** probe, PET imaging of gene expression, tumor-bearing mice, 230P(ab) simplified one-spot synthesis, gene therapy, 231P(ab)
- Fluorine-18 FLT** imaging of cell proliferation, 228P(ab) radiosynthesis of, 22P(ab) vs thymidine, comparative uptake and cell cycle measurements, 229P(ab) whole-body distribution, dosimetry estimates of, monkey, 190P(ab)
- Fluorine-18 fluoride.** trapping/releasing, off-the-shelf anion exchange devices, 239P(ab)
- Fluorine-18 fluoroarylation.** organometallic intermediates, synthesis, 21P(ab)
- Fluorine-18 fluoroestradiol.** high binding for sex hormone binding globulin, 34P(ab), 35P(ab)
- Fluorine-18 fluoro-L-dopa.** enzymatic synthesis, 230P(ab)
- Fluorine-18 fluoro-L-proline.** synthesis of, 144P(ab)
- Fluorine-18 fluoroproline.** PET, pulmonary fibrosis, 116P(ab)
- Fluorine-18 5-fluorouracil** PET, arterial input function of an anticancer drug, 165P(ab) tissue and tumor, sources of error in, 1370
- Fluorine-18 FMT** dosimetry, statistical considerations and, 190P(ab) preliminary clinical study, brain tumor patients, 53P(ab)
- Fluorine-18 FPCIT.** PET, dopamine transporter imaging, 1521
- Fluorine-18 FTHA** BMIPP comparison, during myocardial ischemia and hypoxia, 1684 fatty acid analog, comparison to beta-oxidation rates by tritiated palmitate, 1690 free fatty acid uptake after, myocardium and skeletal muscle, 1320
- Fluorine-18 FU** and <sup>15</sup>O water, PET, liver metastases from colorectal cancer, 465 pharmacokinetics in tumors, PET measurements, 232P(ab) prediction of therapy response, liver metastases from colorectal cancer, 1197
- Fluorine-18 methyl tyrosine.** biodistribution studies, potential tumor-detecting agent, 663
- Fluorine-18 NFEPP.** PET, regulation of central cholinergic activity, 12P(ab)

- Fluorine-18 PFBG**, detection of sympathetic denervation, congestive heart failure model, 159P(ab)
- Fluorine-18 SR144385**, PET studies, brain cannabinoid receptors, 229P(ab)
- Fluorine-18 xenon difluoride**, incorporation of <sup>18</sup>F into, 231P(ab)
- Fluorodeoxyglucose (FDG)**, aging effects on glucose consumption, epileptic children, 57P(ab)
- PET, tumor metabolic rates in sarcoma, 250
- release from cells, glucose-6-phosphatase catalytic unit and, 67P(ab)
- uptake, ischemia-induced increase, heart model, 48P(ab)
- Fluorodopa**, PET study, Dopa decarboxylase activity in schizophrenia, 83P(ab)
- 5-Fluoro-1-(2'-deoxy-2'-fluoro- $\beta$ -D-ribofuranosyl)uracil**, trapping, Morris hepatoma cells, 1419
- Fluoxetine**, monoamine oxidase inhibition by, 41P(ab)
- Fluvoxamine**, effects on cerebral serotonergic receptors, PET assessment of depression, 40P(ab)
- Focal cortical dysplasia**, <sup>11</sup>C MET use in, 974
- Folate receptors**, density, tumor xenografts with, uptake of <sup>111</sup>In DTPA-folate in, 232P(ab)
- imaging, <sup>111</sup>In DTPA-methotrexate, 234P(ab)
- <sup>111</sup>In, radiation dosimetry and tracer excretion kinetics, 191P(ab)
- internalization of <sup>111</sup>In DTPA-folate, KB tumor xenografts, 91P(ab)
- targeted radiopharmaceutical, tumor targeting, 1579
- Food and Drug Administration (FDA)**, Modernization Act of 1997, 15N(1)
- Fourier transformation**, left ventricular ejection fraction accuracy, dual region of interest, 1857
- Frontotemporal dementia**, cerebral glucose metabolism in, 1875
- Furosemide**, <sup>99m</sup>Tc MAG3 study, quantitative gravity-assisted drainage in, 28P(ab)
- Fusion**, 3D correlation approach for registration, multimodality body images, 163P(ab)
- G**
- GABA**, *see* Gamma Aminobutyric Acid
- GABAergic strategy**, treatment of cocaine addiction, 99P(ab)
- Gadolinium**, effects on uptake of radioiodine, thyroid gland, 259P(ab)
- Gallbladder**, ejection fraction, three methods for calculation, 126P(ab)
- nonvisualization, predictive value, after morphine for acute cholecystitis, 126P(ab)
- Gallium**, imaging
- osteomyelitis, 29P(ab)
  - renal biopsy measurement comparison, lupus nephritis, 196P(ab)
  - scan, role in primary extranodal lymphoma, 95
  - scintigraphy, relapsing polychondritis, 1977
- Gallium-67**, high-dose scans, FDG PET vs, staging of melanoma, 11P(ab)
- scintigraphy
- heart transplantation, children, 57P(ab)
  - Hodgkin's disease after chemotherapy, 10P(ab)
  - non-Hodgkin's lymphoma, 1586
  - non-Hodgkin's lymphoma after chemotherapy, 11P(ab)
  - prediction of response, lupus nephritis, 2137
  - SPECT, nonuniform attenuation in, compensation for, 36P(ab)
- <sup>99m</sup>Tc DMSA and, assessment of bone and joint infection, 2128
- uptake**
- gadolinium and iodinated contrast agent effects on, mice, 11P(ab)
  - intense muscle, sarcoidosis patient, 1605
  - pleomorphic adenoma of salivary glands, 537
  - transfected cells and tumors, 11P(ab)
  - transferrin receptor expression and, 1405
- Gallium-67 citrate**
- bone uptake, granulocyte colony-stimulating factor-producing lung cancer, 241
  - renal parenchymal malacoplakia, 1454
- Gallium-67 NS3**, evaluation, rats, 233P(ab)
- Gallium-68**, chelate imaging, pretargeted colon carcinoma xenografts, 1769, 1776(e)
- Gamma-aminobutyric acid (GABA) receptors**, brain, <sup>11</sup>C MPGA dosimetry and biodistribution, 307
- Gamma camera**
- conventional scintillation, compared with solid-state, quality of images from each, 132P(ab)
  - dual-head, PET, comparison with dedicated multiring current general scanner, 171P(ab)
  - energy resolution, window width and, image comparison, 23P(ab)
  - energy resolution of, method for improvement, 555
  - maximum-likelihood estimation, 64x64 CdZnTe array, 173P(ab)
  - method of evaluation, glomerular filtration rate, children and adults, 1784
  - orthogonal nonrotational detections, cardiac imaging, 172P(ab)
  - performance characteristics, Monte Carlo simulation, 97P(ab)
  - solid-state, routine breast imaging, 319P(ab)
  - system performance, end-to-end verification, 277P(ab)
  - whole-body image quantification, radioisotope therapy dosimetry, 185P(ab)
- Gamma probes**
- intraoperative, sentinel lymph node identification in, breast cancer, 1388
  - intraoperative detection, neuroendocrine tumors, 1155
- Ganciclovir**, imaging, thymidine kinase receptor gene expression, 2003
- Gastric cancer**, FDG PET accuracy in, 135P(ab)
- Gastric emptying**
- children, scintigraphy, 865
  - neurologic trauma, male, 1798
  - parasympathetic control, obese patients, 274P(ab)
  - spinal cord injured patients, 272P(ab)
  - T4 replacement for <sup>111</sup>I cancer workup, thyroid cancer patients, 59P(ab)
- Gastrinoma**
- metastatic, <sup>99m</sup>Y-DOTA-lanreotide treatment, 2090
  - Zollinger-Ellison syndrome, octreoscan results in, 272P(ab)
- Gastrin-releasing peptide receptor**, adenoviral-mediated gene transfer of, bombesin analog, 224P(ab)
- Gastroenteropancreatic tumors**
- intraoperative gamma probe detection, 1155
  - role of FDG PET in, compared to somatostatin receptor scintigraphy, 125P(ab)
- Gastrointestinal bleeding**, lower, visceral arteriography in, 1081
- Gastrointestinal cancer**, <sup>188</sup>Rh-labeled anti-carcinoembryonic antigen MAb in, 34
- Gastrointestinal tract**
- active bleeding, <sup>99m</sup>Tc RBC combined bleeding scan and colonoscopy, 273P(ab)
  - hollow organs, radiation absorbed doses to walls of, 1989
  - involvement, progressive systemic sclerosis, 272P(ab)
  - symptoms, uptake of FDG and, PET, 253P(ab)
- Geiger-Müller detector**, continuous monitoring of <sup>131</sup>I therapy, 1558
- Gender**, aging and, effects on sacroiliac joint scintigraphy, 1269
- Gender differences**
- age and, influence on normal coronary vasomotion, 162P(ab)
  - cerebral perfusion, SPECT, 965
  - <sup>123</sup>I MIBG assessment, left ventricle sympathetic nervous system, 1667
  - reduced GABA benzodiazepine receptor in alcoholism, SPECT study, 204P(ab)
  - referral patterns, sestamibi scans, 155P(ab)
  - regional cerebral metabolism, alcohol, 100P(ab)
  - <sup>99m</sup>Tc MIBI SPECT, coronary artery disease, diagnostic accuracy, 751, 756
- Gene expression**, herpes simplex virus type 1 thymidine kinase reporter, radiolabeled penciclovir for, 53P(ab)
- Gene therapy**
- <sup>18</sup>F FHPG probe, PET, tumor-bearing mice, 230P(ab)
  - hepatoma cells, expressing the HSV-tk gene, 1419
  - HSV-1-tk and lacZ, viral vector in 9L gliosarcoma cells, 236P(ab)
  - human thyroid peroxidase gene, anaplastic thyroid cancer cells, 259P(ab)
  - LDL receptors to the liver, monitored by <sup>111</sup>In LDL, 125P(ab)
  - malignant glioma, FDG evaluation of response, 255P(ab)
  - noninvasive imaging of HSV1-tk marker gene, PET radiotracer for, 130P(ab)
  - nonviral, polyethyleneimine as a nonviral transfection agent, 233P(ab)
  - simplified one-pot synthesis, <sup>18</sup>F FHPG, 231P(ab)
- Geometric point response correction**, iterative reconstruction of <sup>18</sup>F SPECT, 124
- Germ cell tumors**
- FDG PET for staging and restaging, therapy control and, 66P(ab)
  - metastatic, FDG PET for detection and therapy of, 815
  - metastatic testicular nonseminoma, <sup>11</sup>C tyrosine imaging, 1027
- Glialoma**
- cerebral, comparison of iodotyrosines and methionine uptake in, rat, 1596
  - <sup>18</sup>F FBPA PET in, 325
  - P-glycoprotein status in, <sup>99m</sup>Tc sestamibi usefulness in, 138P(ab)
  - high grade, <sup>99m</sup>Tc HMPAO and ECD uptake and retention, 315P(ab)
  - hypermetabolic, radiotherapy with <sup>18</sup>F FDG, 184P(ab)
  - malignant
  - <sup>11</sup>C glucose uptake and FDG, 318P(ab)
  - FDG evaluation of response to gene therapy, 255P(ab)
  - <sup>18</sup>F FDG uptake, dexamethasone treatment and glucose levels, 879
  - glucose metabolism measured with PET, 440
  - noninvasive grading, 318P(ab)
  - preoperative evaluation, <sup>18</sup>F FDG and <sup>11</sup>C MET, 778
  - pre-targeting antibody guided three-step therapy with avidin-biotin, 70P(ab)
  - recurrent
  - detection with <sup>11</sup>C ACBC PET, 52P(ab)
  - diagnosis with <sup>123</sup>I IMT SPECT, 23
- Glomerular filtration rate**
- camera-based method of evaluation, children and adults, 1784
  - <sup>51</sup>Cr EDTA clearance, single-plasma sample, adults, 2131
  - estimation, single blood sampling with Bubeck's method, 85P(ab)
  - estimation of, children, 1646(e)
  - renal depth estimates, accuracy of, 1822
- Glucose**
- blood level, effects on PET FDG uptake in stomach, 126P(ab)

- BMIPP** metabolism and, canine myocardium, 1132  
cerebral, metabolism, Tourette syndrome, PET studies, 202P(ab)  
concentration, radiation dose and, <sup>18</sup>F FDG uptake relations to, 189P(ab)  
metabolism  
bone, PET evaluation of, 810  
cerebral  
in Cushing's disease, 786  
in frontotemporal dementia, 1875  
cerebral blood flow and, in Sjögren's syndrome, 1354  
<sup>18</sup>F AFDG accumulation in tumor cells, 245  
FDG tumor uptake, quantification of, net influx constant, 123P(ab)  
impairment of <sup>123</sup>I BMIPP uptake, hypertrophic cardiomyopathy, 390  
insulin resistance in diabetes, 884  
quantification of, myocardial, <sup>11</sup>C glucose PET, 145P(ab)  
oral loading, biodistribution of BMIPP and, 1850  
plasma  
dexamethasone treatment and, malignant glioma, 879  
elevated, impairment of <sup>18</sup>F FDG PET, 1030  
transport, FDG accumulation and, neoplasms, 321P(ab)  
utilization, heart and skeletal muscle, non-insulin-dependent diabetes, 141P(ab)
- Glucose-6-phosphatase**, catalytic unit, FDG release from cells and, 67P(ab)
- GLUT-1**  
expression, FDG uptake, pancreatic tumors, 250P(ab)  
FDG uptake and cellularity, uptake, pancreatic tumors, 1727
- Glutathione**  
loss of accumulation of <sup>99m</sup>Tc MIBI and, MDR protein expression, tumor cells, 1214  
<sup>99m</sup>Tc meso-HMPAO, diethyl maleate-treated mouse brain mitochondria, 2178
- Glycogen**, storage, quantification of, myocardial, <sup>11</sup>C glucose PET, 145P(ab)
- P-Glycoprotein**  
effects, <sup>99m</sup>Tc sestamibi parathyroid scintigraphy, 1617  
expression  
hematologic malignancy, <sup>99m</sup>Tc MIBI, 1191  
<sup>99m</sup>Tc MIBI uptake, breast cancer, 1021  
tumor washout rates and <sup>99m</sup>Tc MIBI accumulation, 228  
glioma and metastatic brain tumor, <sup>99m</sup>Tc sestamibi usefulness in, 138P(ab)  
lung cancer, <sup>99m</sup>Tc tetrofosmin scintigraphy, 1830(l)e  
MDR1, transport of <sup>99m</sup>Tc sestamibi, plasma membrane cholesterol, 317P(ab)  
multidrug resistance, novel technetium (III)-Q complexes for, 77  
pharmacokinetics, reversal of <sup>11</sup>C-labeled drugs, tumor bearing rats, 130P(ab)  
<sup>99m</sup>Tc MIBI assessment, malignant bone and soft-tissue tumors, 1179
- Glycosylation**, isoelectric point and, effects on tumor accumulation of avidin, 224P(ab)
- Goiter**, toxic multinodular, efficacy of radioiodine therapy for, 260P(ab)
- Goldsmith**, Stanley J.  
profile, 12N(12)  
state of the journal, 11N(12)
- Gorton**, Slade (Sen.), U. S. Congress aid to nuclear medicine, 16N(11)
- GPIIb/IIIa receptor**, DMP 444 diagnostic results, deep venous thrombosis, 218P(ab)
- Granular cell tumor**, breast, FDG PET evaluation of, 1398
- Granulocyte colony-stimulating factor (G-CSF)**  
lung carcinoma, bony thallium and gallium uptake, 241
- radiolabeled, pharmacokinetics and biodistribution, primates, 187P(ab)
- Graves' disease**  
after <sup>131</sup>I treatment of thyroid nodules, 262P(ab)  
<sup>111</sup>I pentetreotide in, 533  
radioiodine treatment outcomes, thyroid gland, 712
- Growth factor receptor**, <sup>51</sup>Cr EDTA estimation of, 85P(ab)
- Growth hormone**, treatment effects on kidney function, Turner syndrome, 198P(ab)
- GRPr**, see Gastrin-releasing peptide receptor
- Gunshot wound**, asymptomatic carotid artery occlusion after, cerebral perfusion imaging, 629
- H**
- Head and neck cancer**  
FDG PET, prognosis, 256P(ab)  
recurrent  
FDG PET imaging, 122P(ab)  
whole-body FDG PET imaging, 122P(ab)  
response to radiotherapy, <sup>201</sup>Tl SPECT in prediction of, 138P(ab)  
squamous cell, <sup>11</sup>C methionine uptake in, 1391  
synchronous lung lesions with, FDG PET, 248P(ab)
- Head and neck tumors**, primary and recurrent, <sup>99m</sup>Tc MIBI and bone SPECT image fusion in, 1166
- Head injury**, neurologic trauma, male, gastric emptying in, 1798
- Health care**, changing environment, impact on continuous quality improvement activities, 276P(ab)
- Health Care Financing Administration (HCFA)**  
Ambulatory Patient Classifications (APC), 33N(11)  
coverage instructions for lung PET, 28N(7)  
hospital outpatient prospective payment system, 26N(11)  
Medicare physician fee schedule proposed for 1999, 32N(8)
- Health maintenance organizations (HMOs)**, cost-effectiveness in nuclear medicine, 17N(1)
- Heart**, see also Cardiac; Congestive heart failure:  
Transplantation, heart  
artificial, tomographically determining cardiac output and ejection fraction for, 172P(ab)  
intervention, high-risk perfusion scans, 154P(ab)  
ischemia, <sup>99m</sup>Tc Q 64, kinetics, dog, 216P(ab)  
minimizing cardiac motion blurring and improving image signal-to-background, 121P(ab)  
myocardial perfusion imaging, practice guidelines for, 918  
myocytes, <sup>99m</sup>Tc Q compounds, uptake in laminin, 216P(ab)  
neoplasm, metastasis from uterine cervical cancer, FDG PET, 2084  
neuronal function, impairment in acute myocarditis, <sup>123</sup>I MIBG scintigraphy study, 1841  
perfused, myocardial kinetics of <sup>99m</sup>Tc Q64, 219P(ab)  
regional adrenergic denervation, Brugada syndrome, <sup>123</sup>I MIBG SPECT, 1129  
sympathetic nervous system of, <sup>123</sup>I MIBG assessment, 1667
- Heart disease**  
congenital, coronary flow reserve after correction, children, 56P(ab)  
ischemic  
new fatty acid analog imaging in, 127P(ab)  
nifedipine effects on myocardial blood flow, 89P(ab)
- Heart failure**, in multiple myeloma and high-output failure, arteriovenous shunting in, 1
- Heart ventricle**, left, myocardial perfusion imaging, mathematical model for heterogeneity, 1312
- Helicobacter pylori**  
<sup>14</sup>C urea breath test, procedure guideline, 2012 infection, low specificity of <sup>14</sup>C urea breath test, 57P(ab)  
serum B-12 values, determined with <sup>14</sup>C urea breath test, 271P(ab)
- Hematoma**, subcortical, basal ganglia or thalamus, crossed cerebellar diaschisis from, 2044
- Hemispherectomy**, PET motor activation studies in, 211P(ab)
- Hemodialysis**, renal osteodystrophy, pentavalent <sup>99m</sup>Tc DMSA scintigraphy in, 541
- Heparin**, sites of administration, skeletal uptake of <sup>99m</sup>Tc MDP, 893
- Hepatobiliary scan**, biliary atresia, low birth weight premature infants, 200P(ab)
- Hepatobiliary system**, scintigraphy, infants, 311
- Hepatocyte growth factor**, dimethylnitrosamine or, increased <sup>99m</sup>Tc GAS uptake per hepatocyte, 1463
- Hepatoma**, <sup>188</sup>Re microspheres, intratumoral injection, 1752
- Hepatoma cells**, expressing HSV-tk, FFUDR trapping of, 1419
- Herpes simplex encephalitis**  
<sup>99m</sup>Tc ECD SPECT in, 790  
<sup>99m</sup>Tc HMPAO and ECD discordance, SPECT, 1508
- Herpes simplex virus**  
thymidine kinase gene (HSV-tk), Morris hepatoma cells expressing, FFUDR trapping of, 1419
- Herpes simplex virus I**, adenoviral-directed, imaging with ganciclovir, 2003
- Hippocampus**, paradoxical perfusion, Alzheimer's disease, 293
- Ho-166 chitosan**, new radiation synovectomy agent, 195P(ab)
- Hodgkin's disease**  
FDG PET for post-treatment evaluation, 254P(ab)  
<sup>67</sup>Ga citrate <sup>111</sup>In pentetreotide comparison, children, 29P(ab)  
limited, somatostatin receptor scintigraphy in, 39P(ab)  
outcome after one cycle of chemotherapy, <sup>67</sup>Ga scintigraphy, 10P(ab)  
tissue viability of recurrent masses, FDG PET evaluation, 147P(ab)
- Ho-166 DOTMP**, bone marrow ablation with, non-target organ doses in, 186P(ab)
- Holman**, B. Leonard, in memoriam, 18N(5)
- Holmium-166 DW-166HC**, biodistribution and kinetics, 2161
- Hot spot imaging**, positron emitters, clinical lesion detectability for, 176P(ab)
- Hot spots**, in whole bone scanning, 1263
- Huntington's disease**  
decreased monoaminergic terminals, <sup>11</sup>C DTBZ PET, 125P(ab)  
progression, striatal binding potential of <sup>11</sup>C raclopride, 209P(ab)
- Hürthle cell tumor**  
in hot thyroid nodules, <sup>99m</sup>Tc MIBI dual-phase scintigraphy, 822  
thyroid, somatostatin receptor expression, 243
- Hydrazino nicotinyl**, derivative, labeling liposomes with <sup>99m</sup>Tc, 7P(ab)
- Hydronephrosis**, infants, radionuclide renography or renal duplex Doppler ultrasound diagnosis, 199P(ab)
- Hydroxamamide**, chelating agent, <sup>99m</sup>Tc labeling proteins and peptides, 217P(ab)
- 5-Hydroxytryptamine**, see Serotonin
- HYNIC**, derivatized peptides  
hydrazone-protected, <sup>99m</sup>Tc labeling of, 217P(ab)  
<sup>99m</sup>Tc rhenium, 220P(ab)
- Hypercholesterolemia**, impaired coronary reserve and, women, 90P(ab)
- Hyperinsulinemia**, <sup>18</sup>F FDG uptake in, myocardial, 379

- Hyperparathyroidism**  
preoperative localization of lesions,  $^{99m}\text{Tc}$  MIBI uptake and oxyphil cell content, 1441  
primary  
bone loss in, prediction with quantitative bone SPECT, 1614  
dual- versus single-tracer scan for, 1100  
procedure guidelines, parathyroid scintigraphy, 1111  
secondary,  $^{123}\text{I}/^{99m}\text{Tc}$  sestamibi subtraction SPECT in, 263P(ab)
- Hypertension**  
essential  
exercise renography in supine position, 87P(ab)  
with left ventricular hypertrophy, impaired cardiac sympathetic innervation in, 1486  
pulmonary  
gated SPECT blood pool imaging and pulmonary artery pressure in, 156P(ab)  
right ventricular hypertrophy, 1676  
renovascular  
calcium antagonists for, false-positive captopril renography in, 1621  
captopril renal scintigraphy, 86P(ab)  
type 2 diabetes, insulin resistance and glucose metabolism, 884
- Hyperthyroidism**  
myocardial fatty acid metabolism in,  $^{123}\text{I}$  BMIPP evaluation of, 127P(ab)  
pregnancy, radioiodine treatment, 357, 2194(l)  
radioactive iodine, timing for treatment, 20P(ab)
- Hypofrontality**, negative symptoms and,  $^{99m}\text{Tc}$  HMPAO SPECT in major depressive disorder, 608
- Hypogonadism**, delayed puberty and, quantitative bone SPECT in young males with, 104
- Hypometabolism**, isolation of, patient-specific normal database evaluation, epilepsy, 107P(ab)
- Hypoperfusion**, ipsilateral thalamic, interictal SPECT in temporal lobe epilepsy, 281
- Hyposplenism**, scintigraphic, in amyloidosis, 221
- Hypothyroidism**  
gastric emptying and, thyroid cancer patients, 59P(ab)  
neonatal,  $^{99m}\text{Tc}$  pertechnetate scintigraphy in, 201P(ab)  
**Hypoxemia**, reverse ventilation-perfusion mismatch, in lung cancer, 1986
- Hypoxia**  
 $^{67}\text{Cu}$  ATSM as a tissue tracer, lung cancer, 53P(ab)  
EMT6 tumor model,  $^{67}\text{Cu}$  ATSM-radiolabeled targeting agents, 91P(ab)  
fraction, tumor volume determination, Markov random field segmentation, 164P(ab)  
quantification,  $^{18}\text{F}$  FETA as tracer for, 35P(ab)  
quantitative FMISO PET analysis, soft tissue sarcomas, 190P(ab)  
tumors  
 $^{99m}\text{Tc}$  BnAO imaging, 216P(ab)  
 $^{99m}\text{Tc}$  HL91 as marker of, 220P(ab)  
 $^{99m}\text{Tc}$  nitroimidazole imaging, 219P(ab)
- I**
- IGF-I**, see Insulin-like growth factor I
- Image orientation**, stereotaxic, brain SPECT, 503
- Image quality**  
comparison, solid-state and conventional gamma camera, 132P(ab)  
hydration effects, bone scans, 196P(ab)  
measurement, PET scanner performance evaluation, 133P(ab)  
myocardial defect detection, comparison of human and channelized hotelling observers in, 170P(ab)
- Image reorientation**, impact on quantitative myocardial SPECT perfusion imaging, 1864
- Immunoconjugates**,  $^{99m}\text{Tc}$  DOTA-labeled, optimized conditions for chelation, 2105
- Immunoglobulin M**, human monoclonal, intraperitoneal radiolabeled, targeting of ovarian cancer, mice, 476
- Immunoglobulin G**,  $^{99m}\text{Tc}$  labeled to, nicotinyl hydrazine derivative, 119
- Immoscintigraphy**  
bone marrow  
anti-NCA-90 antibody MN-3, 113P(ab)  
comparison with plain bone X-ray, bone scans, and other findings, 150P(ab)  
detection of bone metastases from breast cancer, 150P(ab)  
cancer,  $^{99m}\text{Tc}$ -labeled scFv, 47  
clinical value, fever of unknown origin patients, 1248  
ectopic hematopoietic bone marrow, appendicular skeleton, after trauma, 1980  
FDG PET comparison, colorectal cancer, 151P(ab)  
metabolizable linker, with angiotensin II treatment, 244P(ab)  
one- and two-step systems, comparative targeting of experimental infarction, 159P(ab)  
pan-adenoacarcinoma antibody, suspected ovarian cancer, 150P(ab)  
solid tumors, chimeric TNT-3 monoclonal antibody mutant, 222P(ab)  
 $^{99m}\text{Tc}$  MDP and  $^{99m}\text{Tc}$  HIG and  $^{99m}\text{Tc}$  white blood cell comparison, orthopedic disease, 516  
tumor localization, colon carcinoma xenografts, 1769, 1776(e)
- Incidentaloma**, adrenal, diagnostic evaluation, 707
- Indium-111**  
antibody labeled with, detection of bleomycin-induced lung injury, rat, 723  
biotin-chelates, for pretargeting, 1813  
evaluation of radiometal complexes, transport-deficient rats, 91P(ab)  
human monoclonal IgM labeled with, targeting of ovarian cancer, mice, 476  
somatostatin analogs labeled with  
comparison, 39P(ab)  
tumor scintigraphy and radionuclide therapy, 261P(ab)
- Indium-111 antimyosin-antibody**  
myocarditis, mimicking acute MI, 140P(ab)  
scintigraphy, heart damage after anthracycline therapy, children, 56P(ab)
- Indium-111 B72.3**, radiation absorbed dose estimates for, ovarian and colorectal cancer, 671
- Indium-111 capromab pentetide**, detection of abdominal metastases, prostate cancer, 650, 653
- Indium-111 DOTA-CCK**, internalization and biodistribution, 63P(ab)
- Indium-111 DOTA-lanreotide**, biodistribution, safety and radiation dose, tumors, 1928
- Indium-111 DTPA**, clearance, cerebrospinal fluid, ommayogram, 210P(ab)
- Indium-111 DTPA-adriamycin**, tumor imaging potential of, 234P(ab)
- Indium-111 DTPA-D-Phe-1-octreotide**  
scanning, preoperative staging of medullary thyroid cancer, 1907  
scintigraphy, malignant thymic masses, 634
- Indium-111 DTPA-folate**  
kinetics of internalization, KB tumor xenografts, 91P(ab)  
tracer excretion kinetics, radiation dosimetry and, 191P(ab)  
for tumor targeting, 1579  
uptake, tumor xenografts with folate receptor density, 232P(ab)
- Indium-111 DTPA-G-CSF**, pharmacokinetics and biodistribution, primates, 187P(ab)
- Indium-111 DTPA-methotrexate**, imaging tumor folate receptors with, 234P(ab)
- Indium-111 DTPA<sup>0</sup>,Pro<sub>1</sub>Tyr<sub>4</sub> bombesin**, investigation of bombesin receptors, 62P(ab)
- Indium-111 LDL**, gene transfer monitored by, LDL receptors, 125P(ab)
- Indium-111 leukocytes**  
accumulation, aortic aneurysms, 157P(ab)  
 $^{99m}\text{Tc}$  sulfur colloid scintigraphy versus, Charcot joint, 346
- Indium-111 NS3**, evaluation, rats, 233P(ab)
- Indium-111 octreotide**  
imaging, detection of cardiac allograft rejection, 3P(ab)  
somatostatin receptor scintigraphy, postsurgical examinations in meningioma, 1913  
unknown primary carcinoma, 316P(ab)
- Indium-111 oxine**, leukocyte labeling with, 266P(ab)
- Indium-111 pentetreotide**  
 $^{67}\text{Ga}$  citrate comparison, Hodgkin's disease in children, 29P(ab)  
Graves' disease, 533  
somatostatic receptor scintigraphy, visualization of fibrous dysplasia, 238  
somatostatin receptor expression, Hürthle cell thyroid cancer, 243
- Indium-111 polystyrene pellets**, differentiation of prolonged colonic transit, 1062
- Indium-111 ProstaScint**  
pelvic anatomy, CT and MRI correlation, 275P(ab)  
posterior 180 degree SPECT, lesion detection capability, prostate cancer, 195P(ab)  
in rising PSA values, after radical prostatectomy, 149P(ab)
- Indium-111 somatostatin receptor**, scintigraphy, FDG PET and, neuroendocrine neoplasms, 319P(ab)
- Indium-111 T84.66**, against carcinoembryonic antigen, presurgical colon cancer patients, 2097
- Indium-111 WBC**,  $^{99m}\text{Tc}$  liposome comparison with, experimental colitis, rabbit model, 58P(ab)
- Infants**. *see also* Pediatric patients  
hepatobiliary scintigraphy, 311  
hypoxic-ischemic brain injury,  $^{123}\text{I}$  IBZM D2 receptor imaging, 1703
- Infection**  
bone,  $^{99m}\text{Tc}$  HMPAO and additional SPECT in, 34P(ab)  
bone and joint,  $^{99m}\text{Tc}$  DMSA and  $^{67}\text{Ga}$  assessment of, 2128  
bone and soft tissue,  $^{99m}\text{Tc}$  Fab fragment for diagnostic imaging, 34P(ab)  
imaging  
radiolabeled liposomes, experimental osteomyelitis, 1089  
 $^{99m}\text{Tc}$  tetrofosmin scintigraphy in pulmonary tuberculosis, 2116  
inflammation and  
accumulation of  $^{99m}\text{Tc}$  chemotactic peptides and FDG by, 266P(ab)  
detection with  $^{99m}\text{Tc}$  PEG-liposomes, 30P(ab)  
radiolabeled interleukin-8 for scintigraphic imaging of, 266P(ab)  
 $^{99m}\text{Tc}$ -labeled proteins and peptides for imaging of, 268P(ab)  
models for evaluation of infection-specific imaging agents, 267P(ab)  
prosthetic, FDG PET imaging for assessment of, 33P(ab)  
prosthetic vascular graft,  $^{99m}\text{Tc}$  HMPAO labeled leukocyte scan for, 875  
 $^{99m}\text{Tc}$  HYNIC-IgG for imaging of, 119  
 $^{99m}\text{Tc}$  labeled leukotriene B4 antagonists as imaging agents for, 215P(ab)
- Inflammation**, musculoskeletal,  $^{99m}\text{Tc}$  MDP,  $^{99m}\text{Tc}$  WBC, and  $^{99m}\text{Tc}$ / $^{99m}\text{Tc}$  HIG comparison, 516
- Inflammatory bowel disease**  
experimental, liposome imaging of, 58P(ab)  
 $^{99m}\text{Tc}$  liposomes, compared with  $^{99m}\text{Tc}$  HMPAO and  $^{99m}\text{Tc}$  HYNIC-IgG, 2172

- In memoriam**  
 B. Leonard Holman, 18N(5)  
 Niels Alexander Lassen, 24N(4)
- Input function**  
 arterial, PET studies using double-laminar catheter, 171P(ab)  
 in dynamic studies, blind estimation approach, 64P(ab)  
 noninvasive derivation of, dynamic PET, 145P(ab)  
 noninvasive measurement, time-of-flight positron measuring system, 172P(ab)  
 standardized, measurement of cerebral metabolic rate of glucose, 164P(ab)
- Instrumentation**  
 automated synthesis of <sup>11</sup>C choline, tumor imaging with PET, 240P(ab)  
 convertible field-of-view PET camera, construction and imaging characteristics, 93P(ab)  
 curve-plate detectors, whole-body PET scanner, 50P(ab)  
 interactive guide for microPET, 278P(ab)
- Insulin**, hyperinsulinemia, <sup>18</sup>F FDG myocardial uptake in, 379
- Insulin-like growth factor I**, radiolabeled, diagnosis and treatment of cancer, 77P(ab)
- Insulin resistance**  
 glucose metabolism and, type 2 diabetes, 884  
 imaging, FDG PET, 142P(ab)
- Intercellular adhesion molecule-1**, <sup>111</sup>In-labeled antibody against, bleomycin-induced lung injury, rat, 723
- Interleukin-1**, receptor antagonist, imaging of inflamed joints, rheumatoid arthritis, 265P(ab)
- Interleukin-1 converting enzyme**, inhibitor of, <sup>11</sup>C methyltriflate, 132P(ab)
- Interleukin-6**, receptor imaging, <sup>99m</sup>Tc-labeled anti-interleukin-6 receptor antibody for, 220P(ab)
- Interleukin-8**, radiolabeled, scintigraphic imaging of infection and sterile inflammation, 266P(ab)
- Internet**, PACS, JAVA-based remote viewing and processing of images, 168P(ab)
- Intrapерitoneal tumor**  
 pretargeting with biotinylated antibody, radiolabeled streptavidin penetration, 30  
 rapid internalization of avidin after binding, 224P(ab)
- Intrapulmonary functional shunting**, reverse ventilation-perfusion mismatch, in lung cancer, 1986
- Iodine**  
 contamination, semiquantitative rapid urinary iodide test, 263P(ab)  
 timing for treatment, hyperthyroidism, 20P(ab)
- Iodine-123**  
 beta-adrenergic receptor tracer, iodinated analog of propranolol, 50P(ab)  
 BMIPP, acute coronary syndrome patients, 1117  
 imaging studies, nicotinic acetylcholine receptors, 48P(ab)  
 myocardial radiotracer, multicrystal gamma camera and, 938  
 radiopharmaceuticals, automated system for production of, 240P(ab)  
 serum amyloid P component labeled with, systemic AA and AL amyloidosis patients, 699  
 SPECT, regional cerebral blood flow, scatter and attenuation correction effects, 181  
 subtraction, dual- versus single-tracer scan for, parathyroid, 1100
- Iodine-123 ALP**, imaging of cartilage alterations, arthritis, rat, 1638
- Iodine-123 BMIPP**  
 absent uptake, platelet/monocyte CD36 deficiency, 1681  
 biodistribution of, effects of oral glucose loading, 1850  
 CD36 deficiency, enhanced myocardial glucose uptake with, 152P(ab)
- free fatty acid uptake, dobutamine effects, stunned myocardium, 158P(ab)  
 impaired regional fatty acid uptake, right ventricular hypertrophy, 1676  
 metabolism, metabolic substrate effects, canine myocardium, 1132  
 myocardial scintigraphy, myocardial fatty acid metabolism in hyperthyroidism, 127P(ab)  
 reduced uptake, myocardium at risk after MI, 155P(ab)  
<sup>201</sup>Tl mismatch, preinfarction angina, 1492  
 uptake  
 chronically dysfunctional myocardial segments, 1841  
 chronic ischemic heart disease, <sup>18</sup>F FDG SPECT comparison, 255  
 impairment of, hypertrophic cardiomyopathy, 390
- Iodine-123 β-CIT**  
<sup>123</sup>I FPCIT SPECT and, measurement of dopamine transporters, Parkinson's, 1500  
 uptake, brain, influence of technical factors, 166P(ab)
- Iodine-123 EPID**  
 concentration, absolute quantitation, SPECT, baboon, 168P(ab)  
 IBZM comparison, dopamine receptor imaging, pituitary, 19P(ab)  
 measurement, striatal and extrastriatal dopamine D2 receptors, 123P(ab)  
 reduced striatal uptake, clinical deficits in Huntington disease, 124P(ab)  
 SPECT, binding, dopamine D2 receptors, 72P(ab)
- Iodine-123 ERC9**, diagnosis, melanoma, 10P(ab)
- Iodine-123 FP-CIT, SPECT**  
 dopaminergic deficit in Parkinson's disease, 13P(ab)  
 early-stage, drug-naïve Parkinson's disease, 1143  
<sup>123</sup>I β-CIT SPECT, measurement of dopamine transporters, Parkinson's, 1500  
 imaging of dopamine transporters in Parkinson's disease, 1879
- Iodine-123 FTM**, measurement, cerebral aromatic amino acid decarboxylase, 49P(ab)
- Iodine-123 IBF**, SPECT, binding with dopamine D2 receptors, age-related changes, 1511
- Iodine-123 IBSP**, selective serotonin receptor imaging agent, 226P(ab)
- Iodine-123 IBZM**  
 dopamine receptor imaging, hypoxic-ischemic brain injury, 1703  
 melanin and, melanoma metastases, 996  
 SPECT  
 loss of dopamine-D2 receptor binding sites in Parkinson's disease, 954  
 Parkinson's disease and multisystemic atrophy, 210P(ab)  
 risperidone-treated schizophrenic patients, 1138  
 striatal dopamine D2 receptor binding by olanzapine, 82P(ab)
- Iodine-123 IMP**  
 noninvasive microsphere method, regional cerebral blood flow comparative study, 163P(ab)  
 quantification of cerebral blood flow, one-point arterial blood sampling, 166P(ab)  
 SPECT, major cerebral artery occlusive disease, 1348
- Iodine-123 IMT**  
 noninvasive grading, gliomas, 318P(ab)  
 SPECT  
 diagnosis of recurrent glioma, 23  
 extracranial tumors, 1737
- Iodine-123 IMZ**, SPECT  
 Alzheimer's disease, 927(le)  
 major cerebral artery occlusive disease, 1348  
 postoperative cerebral blood flow recovery prediction, 148P(ab)
- Iodine-123 IOM**  
 benzodiazepine receptor binding, Machado-Joseph disease, 1518
- equilibrium measurement, benzodiazepine receptors, 208P(ab)  
 imaging, chronic benzodiazepine use in healthy humans, 13P(ab)
- Iodine-123 IPPA**  
 myocardial SPECT, coronary artery disease, 2019  
 oral administration, localization of lymphatic leakage site, 2141
- Iodine-123 MIBG**  
 assessment of physiological fluctuation, left ventricle sympathetic nervous system, 1667  
 ischemic heart disease, brain natriuretic peptide reflects severity of ischemia, 153P(ab)  
 lung uptake, diabetes with sympathetic nervous dysfunction, 334  
 myocardial SPECT, regional abnormality, cardiovascular events in diabetes, 157P(ab)  
 myocardial washout, after acute MI and reperfusion therapy, 128P(ab)  
 prolonged lung retention, diabetic patients, 116  
 scintigraphy study, impairment of cardiac neuronal function, acute myocarditis, 1841  
 serial SPECT images, after cardiac transplant, 1862  
 SPECT  
<sup>11</sup>C HED PET comparison, acute MI patients, 128P(ab)  
 lung adrenergic neuron function, irradiation lung, 192P(ab)  
 regional cardiac adrenergic denervation, Brugada syndrome, 1129  
 sympathetic neuronal damage measured by, acute MI, 128P(ab)
- Iodine-123 9MPA**, fatty acid analog imaging, idiopathic dilated cardiomyopathy and ischemic heart disease, 127P(ab)
- Iodine-123 VIP**, receptor imaging  
 location if VIPoma by, 1575  
 pancreatic cancer, 1570
- Iodine-124**, tracer amounts, presence of therapeutic amounts of <sup>131</sup>I,
- Iodine-125**, SPECT, dopamine D4 receptor studies, 226P(ab)
- Iodine-125 CNcb1**, synthesis and radioiodination, improved water solubility, 228P(ab)
- Iodine-125 F(ab')2**, renal uptake, lowering of ITS pI by acylation with glycolate, 221P(ab)
- Iodine-125 GB**, cytotoxicity of, mammalian cells, 111P(ab)
- Iodine-125 MIBG**  
 kinetics, beta-receptor blockade effects, 47P(ab)  
 myocardial effects, adriamycin cardiomyopathy, 47P(ab) PET, 51P(ab)
- Iodine-125 ODN**, radiotoxicity of, mammalian cells, 1412
- Iodine-125 rotenone**, as myocardial flow tracer, <sup>99m</sup>Tc sestamibi comparison, 228P(ab)
- Iodine-125 SB-207710**, radioligand for 5-HT<sub>4</sub> receptors, rat brain, 49P(ab)
- Iodine-125 UdR**  
 methotrexate and, treatment of neoplastic meningitis, rats, 245P(ab)  
 methotrexate enhancement, rhabdomyosarcoma cells, 183P(ab)  
 radiotherapy, brain tumors, rats, 1148
- Iodine-131**  
 ablation therapy, remnant tissue, postoperative thyroid cancer patients, 261P(ab)  
 detection of metastases, differentiated thyroid cancer, 1897  
 distribution, brain tumors, pinhole SPECT, 856  
 false-positive uptake, breast cyst simulating thyroid cancer metastases, 1910  
 fiber protein, tissue binding sites for adenoviruses, 222P(ab)  
 low-dose, thyroglobulin and, differentiated thyroid cancer, 870

- negative scintigraphy,  $^{201}\text{TI}$  uptake with, papillary thyroid cancer, 236
- quantitative imaging, improvement using Compton scattering, 181P(ab)
- radioiodine treatment outcomes, thyroid gland, Graves' disease, 712
- radionuclide therapy, synergy with chemotherapy, 900
- repeated treatments, thyroid cancer, biologic dosimetry after, 825
- residualizing labels, peptide-based, for radioimmunotherapy, 223P(ab)
- scanning doses, treatment outcome after surgery for differentiated thyroid cancer, 1546
- small dose scintigraphy, detecting metastatic tumors from thyroid cancer, 261P(ab)
- SPECT, experimental verification of Monte Carlo simulation, 97P(ab)
- therapeutic amounts, tracer amounts of  $^{124}\text{I}$  in presence of, PET, 51P(ab)
- therapy**
- hyperthyroidism or thyroid cancer
    - postthyroidectomy, 259P(ab)
    - quantitative safety guidelines to others after, radiation risks, 189P(ab)
  - thyroid cancer, radiotoxicity after, 436
  - thyroid disease, real-life radiation burden to in-living relatives of patients, 189P(ab)
  - thyroid nodules, Graves' disease after, 262P(ab)
  - thyrotoxicosis, from differentiated thyroid cancer, 1202
- therapy, continuous monitoring, Geiger-Müller detector for, 1558
- thyroid cancer, posttherapy localization of large renal cyst, 2158
- thyroid hormones labeled with, detection of recurrent or metastatic thyroid cancer, 262P(ab)
- uptake value, position, size, and shape of thyroid nodule effects, 185P(ab)
- whole body scan, thyroglobulin and, role in differentiated thyroid cancer metastases, 1542
- Iodine-131 anti-B1**
- antibody therapy
    - B-cell lymphoma, 218
    - non-Hodgkin's lymphoma, 1S, 21S
    - outpatient, release of patients after, 28S
    - nonmyeloablative, outpatient radioimmunotherapy, 1230
- Iodine-131 BDP3**, palliative therapy, bone metastases, 242P(ab)
- Iodine-131 BMIPP**
- coronary angioplasty, myocardial fatty acid metabolism after, 933
  - fatty acid, metabolism, 47P(ab)
- Iodine-131 G250**, pharmacokinetic model, renal cell carcinoma, 484
- Iodine-131 iodocholesterol**, accumulation, adrenal metastases from renal cell carcinoma, 656
- Iodine-131 LYM-1**, pharmacokinetics and radiation dosimetry, non-Hodgkin's lymphoma and leukemia, 112P(ab)
- Iodine-131 MIBG**
- preparation via solid phase organic chemistry, 143P(ab)
  - scintigraphy, adults, 1007
  - therapy, carcinoid liver metastases, 1743
  - uptake, metastatic carcinoid tumor of the orbit, 647
- Iodone-131 monoclonal antibody**, intracavitary, FDG uptake after, primary brain tumors, 1376
- Iodine-131 NP-59**, adrenocortical SPECT using, 1460
- Iodine-131 Oncolym**, ascorbic acid pH 7.5 formulated, evaluation, 243P(ab)
- Iodine-131 sodium iodide**, uptake, liquid vs capsule, thyroid, 20P(ab)
- Iodotyrosines**, uptake, glioma model, rat, 1596
- Irradiation**, metabolic changes after, tumor cell spheroids as model for evaluation, 1762
- Ischemic sensitivity**, organs, thrombolytic threshold and, 265P(ab)
- Isotopes**, *see also* Radioisotopes
- available, DOE's role in, 22N(5)
  - production, 17N(4)
  - University of Missouri Research Reactor (MURR), 13N(6)
- J**
- JAVA software**, *see* Computers
- Joint replacement**, screening test, bone scintigraphy use in, 34P(ab)
- Journal of Nuclear Medicine**
- maintaining high quality, 12N(12)
  - Martin P. Sandler, new editor, 9N(9), 29N(4)
  - state of the journal, 11N(12)
- K**
- Kawasaki disease**, cardiac sequelae with,  $^{99m}\text{Tc}$  sestamibi myocardial perfusion imaging, children, 201P(ab)
- Kidney**
- allograft dysfunction, serial imaging in, 197P(ab)
  - angiotensin II/AT<sub>1</sub> receptors,  $^{11}\text{C}$ -L-159,884 PET investigation, 1209
  - automatic separation of renal parenchyma and pelvis, fuzzy ROI, 198P(ab)
  - congenital solitary, renal function in children with, DMSA quantification study, 199P(ab)
  - cortical scarring,  $^{99m}\text{Tc}$  DMSA scintigraphy, 1280
  - cortical scintigraphy,  $^{99m}\text{Tc}$  MAG3 identification of pyelonephritis, children, 1254
  - dysfunction, renography before heart transplant, cardiomyopathy patients, 2153
  - failure, parenchymal malacoplakia,  $^{67}\text{Ga}$  citrate scanning, 1454
  - function
    - $^{51}\text{Cr}$  EDTA clearance, single-plasma sample, adults, 2131
    - 24h DMSA comparison with  $^{51}\text{Cr}$  EDTA, 198P(ab)
    - morphine effects, scintigraphy, 197P(ab)
    - urinary excretion of  $^{99m}\text{Tc}$  MAG3, 1257
  - hypoplastic dysplastic, with vaginal ectopic ureter,  $^{99m}\text{Tc}$  DMSA scintigraphy in, 113
  - $^{123}\text{I}$  F(ab')2 uptake, lowering of ITS pl by acylation with glycolate, 221P(ab)
  - imaging agents, cysteine-derived  $^{99m}\text{Tc}$  chelates, 217P(ab)
  - osteodystrophy, pentavalent  $^{99m}\text{Tc}$  DMSA scintigraphy in, 541
  - radical nephrectomy, assessment of function after,  $^{99m}\text{Tc}$  DMSA SPECT, 16P(ab)
  - radiopharmaceuticals in, radioimager in, rat, 185P(ab)
  - small, vesicoureteral reflux in, children, 197P(ab)
  - $^{99m}\text{Tc}$  DMSA SPECT, evaluation of parenchymal changes with urinary tract infection, infants, 197P(ab)
  - $^{99m}\text{Tc}$  DMSA uptake, SPECT, 28P(ab)
  - $^{99m}\text{Tc}$  MAG3 clearance
    - proteinuria and transplant patients, 86P(ab)
    - renography, normal parameters, 86P(ab)
    - without blood sampling, 86P(ab)
  - transplant, *see* Transplantation
  - volume determination,  $^{99m}\text{Tc}$  DMSA SPECT vs TCT, 16P(ab)
- Knee**, internal derangement, arthroscopy proven, analysis of SPECT in, 130P(ab)
- KR-30035**, verapamil analogue, reversal of multidrug resistance, 320P(ab)
- L**
- Lactic acidosis**, SPECT, findings in mitochondrial encephalomyopathy, 961
- Laryngeal cancer**
- early stage, FDG PET imaging, 122P(ab)
  - $^{18}\text{F}$  FDG detection of, after radiotherapy, 1385
- Lassen**, Niels Alexander, in memoriam, 24N(4)
- Left bundle branch block**
- FDG utilization, oxidative metabolism and, 261, 263
  - myocardial perfusion imaging in, 579
- Left ventricular ejection fraction**, dual region of interest to improve accuracy, 1857
- Left ventricular function**
- assessment of volume, gated SPECT, myocardial phantom for, 175P(ab)
  - center of gravity as index of, myocardial perfusion gated SPECT, 157P(ab)
  - continuous ambulatory radionuclide monitoring of, 931(lc)
  - ischemic dysfunction,  $^{13}\text{N}$  ammonia and  $^{15}\text{O}$  water estimates of perfusion, 1655
  - measurements during exercise, prognosis by, 140
  - occult dysfunction, CAD patients without prior infarction,  $^{99m}\text{Tc}$  sestamibi SPECT, 87P(ab)
  - postrevascularization improvements in, PET blood flow/metabolism mismatches, 162P(ab)
  - regional myocardial  $^{201}\text{TI}$  activity, combined assessment, CAD patients, 101P(ab)
  - sympathetic nervous system, physiological fluctuation,  $^{123}\text{I}$  MIBG assessment, 1667
  - $^{201}\text{TI}$  myocardial gated SPECT, 927(lc)
- Left ventricular hypertrophy**, essential hypertensive patients, impaired cardiac sympathetic innervation in, 1486
- Leukemia**
- acute lymphoblastic, abnormality in bone scans, pediatric, 1983
  - normal organ dosimetry, alpha-particle emitter bismuth-213, 188P(ab)
- Leukocytes**
- labeling with  $^{111}\text{In}$  oxine, 266P(ab)
  - radiolabeling of,  $^{99m}\text{Tc}$  exometazime use in, 912
  - $^{99m}\text{Tc}$  exometazime labeled, volume and plasma effects on, 243P(ab)
- Ligand receptor model**, parameter and index image approaches, PET, 205P(ab)
- Limb perfusion**, therapeutic, PET evaluation in Merkel's cell carcinoma, 2087
- Lines from the president**
- Fletcher, James W., 23N(6)
  - SNM, 28N(5)
- Liposomal delivery system**,  $^{125}\text{I}$  ODN radiotoxicity, mammalian cells, 1412
- Liposomes**
- monoclonal antibody-coupling, improved radioimmundetection with, 224P(ab)
  - PEG, multiple injections, effect on pharmacokinetics, 242P(ab)
  - radiolabeled, imaging of experimental osteomyelitis, 1089
  - $^{99m}\text{Tc}$  comparison with  $^{111}\text{I}$  WBC, experimental colitis, rabbit model, 58P(ab)
  - experimental colitis, 2172
  - hydrazinol nicotinyl derivative in, 7P(ab)
  - $^{99m}\text{Tc}$  Biotin-PEG, avidin-induced clearance, infection, 267P(ab)
  - $^{99m}\text{Tc}$  PEG, imaging experimental intra-abdominal abscesses with, 264P(ab)
- Liver**
- asialoglycoprotein receptor imaging, 3-compartment model analysis,  $^{99m}\text{Tc}$  GSA for, 57P(ab)
  - carcinoid metastases,  $^{111}\text{I}$  MIBG therapy, 1743
  - function,  $^{99m}\text{Tc}$  GSA and PMT comparison, dynamic SPECT, 126P(ab)
  - glucose-6-phosphatase catalytic unit, FDG release from cells and, 67P(ab)
  - imaging
    - procedure guidelines, 1114

- scintigraphic hyposplenism in amyloidosis, 221
- metastases**
- colorectal cancer
    - FDG PET scanning for, 253P(ab)
    - <sup>18</sup>F FDG prediction of therapy response, 1197
    - from colorectal cancer, <sup>18</sup>F FDG and <sup>15</sup>O water PET, 465
  - quantitative histopathology, hepatic extraction efficacy of <sup>99m</sup>Tc mebrofenin, 1286
  - scintigraphy, CT/MRI attenuation signal intensity differences, 529
  - <sup>99m</sup>Tc MAG3-biocytin and <sup>99m</sup>Tc DISIDA, uptake inhibition study, 272P(ab)
  - tumor detection, hepatic SPECT, 169P(ab)
- Liver cancer.** <sup>188</sup>Re sulfur colloid, suspended in lipiodol, 235P(ab)
- Liver disease,** toxic-induced, hepatic extraction efficacy of <sup>99m</sup>Tc mebrofenin, 1286
- Loevinger-Berman Award,** 24N(10)
- Lumped constant.** FDG, glucose metabolism in malignant glioma, 440
- Lung**
- abnormal uptake of thallium, post-exercise stunning and, 46P(ab)
  - adenocarcinoma, radioimmunotherapy of <sup>188</sup>Re EGF-R antibody, 242P(ab)
  - bronchiolar mucociliary clearance of aerosol, in asthma, 193P(ab)
  - damage after radiotherapy, automatic 3-D matching SPECT, 1074
  - fibrosis, PET imaging with cis-4-<sup>18</sup>F FP, 116P(ab)
  - functioning primary metastases, differentiated thyroid cancer, thyrotoxicosis from, 1202
  - <sup>123</sup>I MIBG uptake, diabetics with sympathetic nervous dysfunction, 334
  - injury, bleomycin-induced, <sup>111</sup>In-labeled antibody in detection of, rat, 723
  - irradiated, abnormalities in adrenergic neuron function, <sup>123</sup>I MIBG SPECT for, 192P(ab)
  - lesions
    - synchronous FDG PET, patients with head and neck cancer, 248P(ab)
    - <sup>99m</sup>Tc tetrofosmin SPECT, 1830(lc)
  - metastases in, thyroid cancer, children and adolescents, 1531
  - morphology, supercomputer description, for imaging analysis, 745
  - muscarinic receptors in, visualization by PET, 117P(ab)
  - nodules
    - benign, FDG uptake, 248P(ab)
    - <sup>18</sup>F FDG dual-head coincidence imaging in, 109P(ab)
    - PET imaging, phantom study, 108P(ab)
    - primary, dual-head coincidence imaging of <sup>18</sup>F FDG, 31P(ab)0
  - perfusion recovery, incomplete with anticoagulant therapy along, 275P(ab)
  - PET, coverage instructions, CHC/P, 28N(7)
  - radiation damage, effects on <sup>99m</sup>Tc DTPA clearance, 374(lc)
  - retention of <sup>123</sup>I MIBG, diabetic patients, 116
  - scanning
    - diagnosis of recurrence of pulmonary embolism, 5P(ab)
    - with Doppler ultrasound of lower extremities, pulmonary embolism, 6P(ab)
  - V/Q SPECT, diagnosis of chronic thromboembolic pulmonary hypertension, 6P(ab)
  - V/Q vs helical CT, pulmonary embolism, 5P(ab)
  - segmental reference chart, reporting of scintigrams with, 1095
  - solitary nodules, technetium SSTR binding peptide and FDG PET comparison, 315P(ab)
  - <sup>99m</sup>Tc sestamibi uptake, dipyridamole-based stress or exercise, 339
  - ventilation, pulmonary SPECT in obstructive lung disease patients, 889
  - virtual scintigraphy, variability of perceived defect size, 361
- Lung cancer**
- bronchioloalveolar, <sup>18</sup>F FDG PET in, 1016
  - chemo-radiotherapy, <sup>99m</sup>Tc tetrofosmin/<sup>201</sup>Tl dual-SPECT prediction of effects, 191P(ab)
  - chemosensitivity, P-glycoprotein expression by <sup>99m</sup>Tc sestamibi, 137P(ab)
  - <sup>67</sup>Cu ATSM as a hypoxic tissue tracer, 53P(ab)
  - dedicated and camera-based PET imaging comparison, FDG, 108P(ab)
  - diagnostic testing discrepancies, FDG PET, 248P(ab) evaluation, <sup>18</sup>F FDG PET and <sup>201</sup>Tl SPECT comparison, 9
  - granulocyte colony-stimulating factor produced by, bony thallium and gallium uptake, 241
  - <sup>123</sup>I HEPIE as imaging agent, SPECT preclinical studies, 227P(ab)
  - imaging, <sup>11</sup>C methionine and <sup>18</sup>F FDG PET comparison, 80P(ab)
  - mediastinal staging, FDG PET comparison with dual head coincidence camera, 257P(ab)
  - non-small cell
    - FDG uptake effects, 247P(ab)
    - <sup>18</sup>F FDG combined with <sup>11</sup>C methionine, PET, 640
    - P-glycoprotein and, <sup>99m</sup>Tc tetrofosmin scintigraphy, 1830(lc)
    - P-glycoprotein expression in, tumor washout rates and <sup>99m</sup>Tc MIBI mediastinal lymph node staging with <sup>99m</sup>Tc sestamibi, 316P(ab)
    - whole-body FDG PET in staging of, 80P(ab)
  - PET, attenuation correction effects on lesion detection, 109P(ab)
  - PET scanning, clinical impact of, 249P(ab)
    - accumulation, 228
  - preoperative TND staging, FDG PET and CT scanning, utility of, 80P(ab)
  - reverse ventilation-perfusion mismatch, intrapulmonary functional shunting, 1986
  - small-cell
    - chemotherapy response, <sup>99m</sup>Tc sestamibi or <sup>201</sup>Tl comparative SPECT, 1626
    - radioimmunotherapy, anti-CEA/anti-DTPA antibody and <sup>131</sup>I DTPA hapten, 70P(ab)
    - somatostatin receptor scintigraphy in, 224, 2195(l)
    - <sup>99m</sup>Tc MIBI uptake in, 91
    - <sup>99m</sup>Tc tetrofosmin SPECT, comparison with FDG PET, 44P(ab)
  - untreated, diabetes effects on <sup>18</sup>F FDG uptake, 43P(ab)
- Lung disease**
- diffuse, regional threshold detection, 44P(ab)
  - obstructive, <sup>133</sup>Xe SPECT in, 889
- Lung perfusion, scintigraphy, quantitative analysis of,** 1630
- Lung tumors**
- differentiation of malignant from benign, dynamic CT and <sup>201</sup>Tl SPECT, 45P(ab)
  - solitary
    - criteria for determination of malignant from benign, FDG PET, 44P(ab)
    - <sup>99m</sup>Tc sestamibi differentiation of malignant from benign, 43P(ab)
- Lupus nephritis**
- <sup>67</sup>Ga, prediction of response to therapy, 2137
  - renal biopsy measurement, gallium image comparison, 196P(ab)
- LVEF, *see* Ejection fraction, left ventricular**
- Lymphadenectomy,** sentinel, cutaneous melanoma, 1185
- Lymphadenopathy,** in sarcoidosis, <sup>18</sup>F FDG and and <sup>11</sup>C Met PET evaluation, 1160
- Lymphangiectasia,** intestinal, children, 201P(ab)
- Lymphangiography,** lymphoscintigraphy and, in lymphangiectasia, 1634
- Lymphatic leakage,** localization of, oral administration of <sup>123</sup>I IPPA and, 2141
- Lymphatic mapping**
- for breast cancer, 24P(ab)
  - radioguided surgery, melanoma and breast cancer, 22N(12)
- Lymph nodes**
- abdominal, metastases from prostate cancer, capromab pentide detection, 650, 653
  - axillary, metastatic, imaging with <sup>99m</sup>Tc MIBI in breast cancer, 459
  - breast cancer lesions, evaluation with modified anthropomorphic phantom, 1951
  - sentinel, *see* Sentinel nodes
- Lymphocytes,** distribution, divalent cobalt as a label, PET and SPECT, 836
- Lymphoma**
- B-cell
    - <sup>131</sup>I anti-B1 antibody for, 21S
    - <sup>131</sup>I humanized LL2 anti-CD22 MAb against, 71P(ab)
    - subcutaneous tumor xenograft model in non-irradiation nude mice, 235P(ab)
    - <sup>99m</sup>Tc LL2 evaluation, histology and flow cytometry results, 244P(ab)
    - tumor dosimetry from <sup>131</sup>I SPECT of, 112P(ab)
    - central nervous system, in AIDS, <sup>201</sup>Tl retention in diagnosis, 1366
    - chemotherapy in, restaging gallium scan after, 317P(ab)
    - CNS, <sup>99m</sup>Tc sestamibi and <sup>201</sup>Tl comparison extranodal, role of gallium scan in, 95
    - FDG PET
      - performed after chemotherapy, 67P(ab)
      - performed before high-dose chemotherapy, 67P(ab)
      - malignant, residual disease after therapy, FDG PET for detection of, 253P(ab)
    - non-Hodgkin's
      - bone marrow radiation doses and, radioimmunotherapy with IDEC-Y2B8, 69P(ab)
      - centralized radiolabeling of antibodies, 11S
      - conventional treatments, 2S
      - FDG PET for post-treatment evaluation, 254P(ab)
      - gallium scintigraphy in, 1586
      - <sup>131</sup>I anti-B1 antibody therapy, 1S
      - <sup>131</sup>I LYM-1 mouse, prolonged survival in patient treated with, 269P(ab)
      - outcome after one cycle of chemotherapy, <sup>67</sup>Ga scintigraphy, 11P(ab)
      - patient-specific whole-body dosimetry, 14S
      - radioimmunotherapy, <sup>90</sup>Y-labeled CDR-grafted monoclonal antibody for, 105P(ab)
      - response to <sup>131</sup>I anti-B1 RIT, FDG PET, 147P(ab)
      - response to chemotherapy, FDG PET, 147P(ab)
      - staging, <sup>11</sup>C MET and <sup>18</sup>F FDG comparison, whole-body PET, 254P(ab)
  - Lymphoma cells,** amino acid transport in, 238P(ab)
  - Lymphoscintigraphy**
    - advancing medical care in radioguided surgery, 13N(12), 22N(12)
    - breast, sentinel node visualization, 25P(ab)
    - in chyluria, chyloperitoneum, and chylothorax, 1292
    - cutaneous, melanoma, drainage to popliteal and epitrochlear lymph nodes and, 2195(l)
    - dermolymphoscintigraphy, cutaneous melanoma, 25P(ab)
    - different patterns with intestinal lymphangiectasia, children, 201P(ab)
    - identification of drainage patterns, sentinel node identification in melanoma, 25P(ab)
    - kinetics of three agents, cutaneous melanoma, 1185
    - lymphangiography and, in lymphangiectasia, 1634
    - radioguided biopsy and, sentinel axillary node, breast cancer, 2080
    - <sup>99m</sup>Tc labeled nanocolloid, squamous cell cancer, vulva, 1381

<sup>99m</sup>Tc sulfur colloid versus <sup>99m</sup>Tc liposomes, rabbit model. 314P(ab)

## M

- Machado-Joseph disease.** benzodiazepine receptor binding. <sup>123</sup>I iomazenil. 1518
- MAG3.** See Mercaptoacetyltriglycine.
- Magnetic resonance imaging (MRI).** assessment of dopaminergic neurotransmitters. 54P(ab) cerebral palsy, comparison with <sup>99m</sup>Tc ECD SPECT. 619 cerebral perfusion impairment, with toluene abuse. 632 comparison with <sup>99m</sup>Tc MIBI and <sup>99m</sup>Tc tetrofosmin, parathyroid glands. 320 coregistration, head and neck. 2121 functional, lung, vs radionuclide V/Q scans. 6P(ab) global and regional parameters, short gated blood-pool SPECT comparison. 75P(ab) grading of gliomas. 318P(ab) granular cell tumor, breast. 1398 HMPAO SPECT and, brain, Neuro-Behcet's syndrome. 1707 <sup>15</sup>O water PET combined with, activations and deactivations. 110P(ab) PET images, simultaneous dynamic acquisition. 93P(ab) spatial normalization of influx images. <sup>18</sup>F DOPA extrastriatal uptake. 214P(ab) <sup>201</sup>Tl uptake, before and after multiple myeloma therapy. 473
- Magnetic resonance spectroscopy.** proton, SPECT and, mild neuropsychiatric manifestations. 204P(ab)
- Malacoplakia.** renal parenchymal. <sup>67</sup>Ga citrate scanning. 1454
- Mammography.** quality standards. 30N(4)
- Manpower.** benchmarking physician workforce. Manpower Committee (SNM). 11N(7)
- Maple Medical Isotope Reactor Project.** Nordion. 19N(4)
- McCune-Albright syndrome.** somatostatin receptor scintigraphy, visualization of fibrous dysplasia during. 238
- MDRI gene.** MIBI washout, association with p-glycoprotein in lung cancer. 228
- Measurement Assurance Program (MAP).** radiopharmaceuticals. 18N(6)
- Meckel's diverticulum.** heterotopic gastric mucosa. <sup>99m</sup>Tc pertechnetate SPECT. 1458 pitfalls of nuclear imaging. 276P(ab)
- Mediastinal metastases.** lung tumors and. <sup>18</sup>F FDG combined with <sup>11</sup>C methionine. PET. 640
- Mediastinitis.** after sternotomy. <sup>99m</sup>Tc HMPAO-labeled leukocytes, surgery follow-up. 29P(ab)
- Medicare.** HCFA coverage instructions for lung PET. 28N(7) physician fee schedule proposed for 1999. 32N(8) protect yourself from fraud and abuse. 21N(10)
- Melanin.** <sup>123</sup>I IBZM, melanoma metastases. 996
- Melanoma**
- B16 binding location of radioiodinated benzamide. 227P(ab) comparative biodistributions of radioiodinated benzamide in mice. 227P(ab) cutaneous dermolphoscopy in. 25P(ab) sentinel node localization in. 245P(ab) three lymphoscintigraphic agents in. 1185 cutaneous lymphoscintigraphy in, drainage to popliteal and epitrochlear lymph nodes and. 2195(l) diagnosis. <sup>123</sup>I ERC9 use in. 10P(ab) high-risk patients, whole-body FDG PET superiority in primary staging and follow-up. 94P(ab)

- locally advanced, FDG PET and isolated limb perfusion therapy in. 95P(ab) malignant alpha-melanocyte stimulating hormone analogs <sup>99m</sup>Tc/<sup>188</sup>Re labeling. 222P(ab) staging, whole-body FDG PET vs conventional imaging. 94P(ab) staging with planar coincidence scintigraphy and PET. 1892 <sup>99m</sup>Tc sestamibi imaging accuracy in. 137P(ab) metastatic detection with <sup>201</sup>Tl scintigraphy. 799 <sup>123</sup>I IBZM and melanin in. 996 whole-body FDG PET accuracy in staging of. 94P(ab) metastatic. <sup>18</sup>F DOPA in. 318P(ab) radioguided surgery. 22N(12) recurrent, staging, whole-body FDG PET vs conventional imaging. 94P(ab) screening, S100 tumor marker in comparison to FDG. 269P(ab) sentinel lymph nodes in. <sup>99m</sup>Tc albumin identification of. 10P(ab) staging, high-dose <sup>67</sup>Ga scans vs FDG PET. 11P(ab) <sup>99m</sup>Tc- and <sup>188</sup>Re-labeled cyclic melanotropin peptide analogs, murine model. 77P(ab)
- Memory.** hippocampal function in. <sup>15</sup>O water PET studies. 111P(ab) learning and, brain activation during, regional CBF. PET study. 206P(ab)
- Meningioma.** parapharyngeal, from intracranial space. FDG PET evaluation. 302 postsurgical examinations, somatostatin receptor scintigraphy in. 1913 postsurgical follow-up, somatostatin receptor scintigraphy. 38P(ab)
- Meningitis.** neoplastic, treatment with <sup>125</sup>I Udr and methotrexate, rats. 245P(ab)
- Meningoencephalitis.** viral, regional cerebral blood flow scintigraphy in. 2055
- Mercaptoacetyltriglycine chelator (MAG3).** labeling peptides with. 56
- Merkel's cell carcinoma.** therapeutic limb perfusion in. PET. 2087
- Mesothelioma.** malignant pleural, prognostic value of FDG PET. 81P(ab)
- Meta-analysis.** SPECT brain imaging, in epilepsy. 285
- Metabolic substrate.** effects on <sup>123</sup>I BMIPP metabolism, canine myocardium. 1132
- Metahydroxyephedrine.** PET imaging, presynaptic cardiac sympathetic function. 1327
- Metaiodobenzylguanidine (MIBG).** diagnostic use of, children. 679
- Methanesulphonyl.** <sup>11</sup>C labeled with, no-carrier added. 119P(ab)
- Methionine (MET).** new enzymatic synthesis method. 131P(ab) uptake, glioma model, rat. 1596
- Methotrexate.** <sup>125</sup>I Udr enhanced by, rhabdomyosarcoma cells. 183P(ab)
- 15-(p-iodophenyl)-3(R,S)-Methylpentadecanoic acid FTHA comparison.** during myocardial ischemia and hypoxia. 1684 intra-individual comparison. 1672 myocardial uptake, platelet/monocyte CD36 deficiency. 1681
- Methylphenidate.** brain metabolic changes induced by, cocaine abusers. 100P(ab) dopamine concentrations and. <sup>11</sup>C raclopride. 54P(ab)
- Microangiography.** coronary, glycemic control and insulin resistance, in diabetes. 4P(ab)
- Microangiopathy.** cerebral, findings in. 147

**Microdialysis.** dual-probe, PE21 cocaine derivative for imaging dopamine transporters. 49P(ab)

**Micronucleus assay.** bone metastases, <sup>89</sup>Sr therapy for, radiotoxicity after. 2077

**Microspheres.** <sup>188</sup>Re-labeled

intrarterial tumor treatment. 246P(ab) intratumoral injection in hepatoma. 1752

**Midbrain.** neurochemical systems, misidentification of anatomical structures, PET. 208P(ab)

**MIRD dose estimate report.** radiation absorbed estimates for <sup>111</sup>In B72.3, ovarian and colorectal cancer. 671

**MIRDose 3.1.** dosimetry, erroneous results. 927(l)e

**Molybdenum-99.** low specific activity, cation anion exchange column system. 241P(ab)

**Monoamine oxidase.**

<sup>18</sup>F FHMP as PET radiotracer for. 231P(ab) inhibition, fluoxetine. 41P(ab)

**Monoamine oxidase B.** nicotine effects, brain, baboon. 13P(ab)

**Monoclonal antibodies.**

alpha particle therapy. 17N(2) antibody pretargeted radiotherapy. 20N(2)

Bi-213, radiation dosimetry for, tumor cells. 184P(ab) chimeric, human IgG constant region, radioimmunotherapy. 77P(ab)

chimeric TNT-3 mutant, rapid clearance, immunoscintigraphy of solid tumors. 222P(ab) CHX-DTPA-conjugated, Yttrium-labeled isomers of, biodistribution. 829

conventional treatments, non-Hodgkin's lymphoma. 2S coupling liposomes, improved radioimmunodetection with. 224P(ab) dendrimer-1B4M-DTPA alone or conjugated with, biodistribution. 232P(ab)

G-250

immunosciptigraphy and biodistribution of, renal cell carcinoma, mice. 244P(ab)

metastasized renal cell carcinoma. 247P(ab) two radiolabeled injections of, renal cell carcinoma. 246P(ab)

<sup>131</sup>I Lym-1, two methods of marrow-absorbed dose estimates. 113P(ab)

<sup>131</sup>I LYM-1 mouse, prolonged survival in patient treated with. 269P(ab)

<sup>188</sup>Rh-labeled anti-carcinoembryonic antigen, gastrointestinal cancer. 34

<sup>99m</sup>Tc-labeled murine, transient changes in white blood cell counts after. 265P(ab)

<sup>99m</sup>Tc LL2, B-cell lymphoma. 244P(ab)

**Monte Carlo simulation.**

<sup>131</sup>I SPECT, experimental verification. 97P(ab) lung scintigraphy, segmental reference chart. 1095

method for measurement, collimators. 51P(ab) scatter and attenuation, artificial neural networks for compensation. 735

software package, gamma camera performance characteristics. 97P(ab)

SPECT, quadric-based object model for. 121P(ab) virtual lung scintigraphy, variability of perceived defect size. 361

**Morphine.**

acute cholecystitis, predictive value of gallbladder nonvisualization after. 126P(ab)

effects on kidney function, scintigraphy. 197P(ab)

**Motion correction.** four techniques, SPECT imaging of the heart. 2027

**Movement disorders.** evaluation of dopaminergic transmissions, <sup>123</sup>I IBF and beta-CIT SPECT in. 14P(ab)

**Multidrug resistance.**

bone cancer, multitracer examinations of. 52P(ab)

functional imaging of, novel technetium (III)-Q complexes for. 77

p-glycoprotein expression, hematologic malignancy, <sup>99m</sup>Tc MIBI. 1191

- p-glycoprotein expression effects,  $^{99m}$ Tc MIBI uptake, breast cancer, 1021
- protein associated with, blood-CSF permeability barrier of  $^{99m}$ Tc sestamibi, 13P(ab)
- protein expression, loss of accumulation of  $^{99m}$ Tc MIBI, tumor cells, 1214
- reversal by KR-30035, 320P(ab)
- tumor washout rates,  $^{99m}$ Tc MIBI accumulation and, lung cancer, 228
- Multi-injection approach.** extrastriatal D2 receptors, PET, 71P(ab)
- Multiple myeloma.**  $^{201}$ Tl bone marrow uptake before and after, 473
- Multiple sclerosis.** anti-lymphocyte monoclonal antibody treatment, thyroid dysfunction after, 263P(ab)
- Muscarinic acetylcholine receptors.** isomers of IPIP, resolution, radiolabeling, and evaluation, 49P(ab)
- Muscarinic ligands.**  $^{18}$ F FP-TZTP, biodistribution and radiation estimates for, 85P(ab)
- Muscarinic receptors** myocardial, familial amyloid polyneuropathy, 142P(ab) visualization, lung, PET, 117P(ab)
- Muscle** activity, in runners, FDG PET imaging of, 195P(ab)  $^{67}$ Ga uptake, sarcoidosis patient, 1605 microcirculation, symptomatic Persian Gulf war veterans, Xenon clearance method, 114P(ab) skeletal, ischemia, metabolic alterations seen on FDG PET and fatty acid SPECT, 162P(ab)
- Myasthenia gravis.** malignant thymic masses,  $^{111}$ In-DTPA-D-Phe<sup>1</sup>-octreotide, 634
- Myeloma, multiple** bone marrow immunoscintigraphy or plain bone X-ray, bone scan, and other findings, 150P(ab) high-output failure and, arteriovenous shunting in, 1 whole-body  $^{99m}$ Tc sestamibi scanning in, 138P(ab)
- Myoblast.**  $^{99m}$ Tc complex labeling, biodistribution studies, 218P(ab)
- Myocardial cells.**  $^{99m}$ Tc tetrofosmin,  $^{99m}$ Tc MIBI and  $^{201}$ Tl uptake, rat, 266
- Myocardial factor images.** dynamic  $^{15}$ O water scan, 1696
- Myocardial hypoxia.**  $^{18}$ F FTHA and BMIPP comparison, 1684
- Myocardial infarction** acute angiotensin-converting enzyme inhibitor therapy, effects on fatty acid metabolism, 127P(ab) ECG-gated  $^{99m}$ Tc sestamibi SPECT in follow-up study, 140P(ab)  $^{123}$ I MIBG washout after, 128P(ab) implications of impaired fatty acid uptake, 127P(ab) radioimmunoassay for myosin heavy chain fragment, 268P(ab) reperfusion therapy, time-independent myocardial salvage in, 139P(ab) sympathetic neuronal damage measured by  $^{123}$ I MIBG SPECT, 128P(ab) experimental comparative targeting, immunoscintigraphy, 159P(ab) small-animal PET scanner for, 9P(ab) inotropic stimulation, perfusion-contraction mismatch during, 396 large, LV dysfunction and, comparison of  $^{201}$ Tl and  $^{99m}$ Tc mibi gated SPECT, 104P(ab) myocardial perfusion imaging for, practice guidelines, 918 prediction of left ventricular recovery, MIBI FDG SPECT and echocardiography, 18P(ab) preinfarction angina,  $^{123}$ I BMIPP and  $^{201}$ Tl mismatch, 1492 residual stenosis after,  $^{99m}$ Tc sestamibi SPECT for detection, 152P(ab) subsequent, location, results of prior SPECT, 140P(ab)
- Myocardial ischemia** acetazolamide-induced, in coronary artery disease, brain SPECT, 408 detection with  $^{99m}$ Tc nitroimidazole, rabbits, 598  $^{18}$ F FTHA and BMIPP comparison, 1684 glycogen phosphorylase isoenzyme BB as serum marker, exercise SPECT, 158P(ab) identification of, emergency department, 139P(ab) increase in FDG uptake, glucose transporter effects, rat heart model, 48P(ab) nifedipine effects, global and regional contraction, 46P(ab) stress testing, myocardial perfusion imaging, 32P(ab)  $^{99m}$ Tc Q 64, kinetics, dog model, 216P(ab)
- Myocardial perfusion**, evaluation with  $^{123}$ I BMIPP, in acute coronary syndromes, 1117
- Myocardial perfusion imaging**, see also SPECT activity distributions, attenuation corrected, emission reconstruction algorithm, 74P(ab) acute chest pain, emergency department, 153P(ab) adenosine dual isotope SPECT, transient ischemic dilation ratio, 103P(ab) after coronary stent implantation, 1307 after heart transplant, prognosis, 116P(ab) attenuation correction, combined and separate interpretations, 73P(ab) CAD,  $^{99m}$ Tc labeled agents, 17P(ab) cardiac risk, women, 115P(ab) comparative study of PET and SPECT, 23P(ab) coronary artery stenosis, electron beam CT and dipyridamole  $^{201}$ Tl SPECT, 156P(ab) 3D coronary artery trees, 3D left ventricles from perfusion SPECT, CAD, 146P(ab) defect detection, comparison of human and channelized hotelling observers in, 170P(ab)dobutamine-atropine stress, safety, 1662 dobutamine stress, prognostic value, 115P(ab) emission/transmission,  $^{201}$ Tl and  $^{153}$ Gd scanning line source, 73P(ab) exercise, serum marker of ischemia, 158P(ab) exercise and/or dipyridamole hyperemia, left bundle branch block, 579 fast-gated, wall motion and thickening, 88P(ab) FDG, impaired coronary reserve and hypercholesterolemia, women, 90P(ab) gated early referral to catheterization after, 87P(ab) left ventricular function, center of gravity as index of, 157P(ab) radionuclide angiography vs, 75P(ab) time-limited usefulness, 88P(ab) gated  $^{99m}$ Tc sestamibi, gradation of interpreter confidence, value of, 101P(ab) gated SPECT, attenuation correction in, CAD, 74P(ab) gated SPECT and LV ejection fraction defect size effects, 61P(ab) reproducibility, background and dose effects, 62P(ab) heterogeneity with angiographically normal coronary arteries, 156P(ab) high risk perfusion scans, intervention, 154P(ab) hypoplastic left heart syndrome, children, 200P(ab)  $^{123}$ I IPPA, coronary artery disease, 2019  $^{125}$ I rotenone, as a deposited flow tracer,  $^{99m}$ Tc sestamibi comparison, 228P(ab) left ventricular dysfunction, ischemia in, 101P(ab) left ventricular septal hypoperfusion, obstructive hypertrophic cardiomyopathy, 31P(ab) multiwire camera and tantalum-178, left ventricular function and perfusion, 76P(ab)  $^{13}$ N ammonia, mathematical model for heterogeneity, 1312 noise reduction, iterative OSEM reconstruction, 160P(ab) nuclear cardiology protocols, emergency department chest pain center, 139P(ab)
- $^{15}$ O water studies, coronary reserve, 160P(ab) PET or SPECT, comparative study, 120P(ab) procedural guidelines for, 918 quality control, 45P(ab) quantitative beating bulls-eye plot for, 276P(ab) comparison of techniques, 102P(ab) computer tutorial, 275P(ab) gating errors and, 45P(ab) infarct size and severity assessment, 62P(ab) reorientation algorithm effects on, 1864 validation and diagnostic yield, 103P(ab) women, effects on accuracy of Wiener filtering, 46P(ab)
- $^{82}$ Rb, cost of coronary disease and, 90P(ab) resting pulse pressure and outcomes, CAD patient, 116P(ab) results, location of subsequent MI and, 140P(ab) serial changes, medical therapy or revascularization, 31P(ab) severe fixed thallium defect, myocardial infarction patients, 154P(ab) SPECT quantitation, automatic approach to, 62P(ab) stress  $^{99m}$ Tc sestamibi for flow heterogeneity, 417 very abnormal, natural history of, 3P(ab) stress imaging or rest imaging, acute chest pain in the emergency department, 140P(ab) stress testing with, glycogen phosphorylase-BB levels in, 32P(ab)  $^{99m}$ Tc MIBG, agent for sympathetic neurons, 215P(ab)  $^{99m}$ Tc MIBI, diagnostic accuracy in men and women, 751, 756  $^{99m}$ Tc MIBI and  $^{201}$ Tl uptake, myocardial cells, rat, 266  $^{99m}$ Tc NOET, initial and redistribution, 160P(ab)  $^{99m}$ Tc, scatter correction effect on attenuation compensation, 74P(ab)  $^{99m}$ Tc sestamibi after coronary artery bypass graft, ventricular function, 88P(ab) occult left ventricular dysfunction, 87P(ab) post-exercise regional wall motion abnormalities, 87P(ab) resting left ventricular ejection fraction, 45P(ab) scatter correction effects, 180P(ab)  $^{99m}$ Tc tetrofosmin, during adenosine triphosphate infusion, 582 tetrofosmin, sestamibi, and Q-12 retention comparison, swine model, 159P(ab) transient regional ischemia, during rotational atherectomy, 402 transmission SPECT, weight effects on attenuation correction, 46P(ab) transmyocardial laser revascularization effects, CAD, 32P(ab) zero coronary calcium score prevalence in, 32P(ab)
- Myocardial tracers.**  $^{99m}$ Tc nitroimidazole, detection of myocardial ischemia, rabbits, 598
- Myocarditis** impairment of neuronal function in,  $^{123}$ I MIBG scintigraphy study, 1841 mimicking acute MI,  $^{111}$ In antimyosin-antibody and rest thallium imaging, 140P(ab)
- Myocardium** activity, attenuation correction effects on estimate of, 4P(ab) beta-receptor blockade effects, MIBG kinetics, 47P(ab) chronically dysfunctional segments, abnormal  $^{123}$ I BMIPP uptake, 1841 chronic ischemic,  $^{18}$ F FDG SPECT comparison with  $^{123}$ I BMIPP, 255 contraction, regional fatty acid uptake, right ventricular hypertrophy, 1676 dysfunctional,  $^{13}$ N ammonia and  $^{15}$ O water estimates of perfusion, 1655

fatty acid metabolism  
after coronary angioplasty, 933  
comparison to beta-oxidation rates by tritiated palmitate, 1690  
free fatty acid uptake, after  $^{18}\text{F}$  FTHA, 1320  
hibernating  
dobutamine echocardiography in, 396  
 $^{201}\text{Tl}$  SPECT for detection of viability, 384  
metabolic substrate effects,  $^{123}\text{I}$  BMIPP metabolism, 1132  
necrosis/apoptosis,  $^{99m}\text{Tc}$  glucarate as marker of, 159P(ab)  
oxidative metabolism, abnormality, in noninsulin-dependent diabetes, 1835  
oxygen consumption and blood flow, measurement with  $^{11}\text{C}$  acetate, 272  
phantom study, motion correction techniques, SPECT, 2027  
stress-strain relations, efficiency and, ischemic cardiomyopathy patients, 4P(ab)  
stunned, dobutamine effects on free fatty acid uptake,  $^{123}\text{I}$  BMIPP study, 158P(ab)  
stunning  
adenosine receptors and,  $^{18}\text{F}$  FDG PET, 944  
evaluation protocol, gated SPECT imaging, 102P(ab)  
subendocardial infarction and, gated  $^{99m}\text{Tc}$  sestamibi scintigraphy, 152P(ab)  
 $^{201}\text{Tl}$  subcellular localization and kinetics, rat, 242P(ab)  
viability  
after MI, utility of  $^{18}\text{F}$  FDG imaging in, 152P(ab)  
in CAD, attenuation correction effects on gated  $^{99m}\text{Tc}$  sestamibi SPECT, 74P(ab)  
with chronic coronary artery disease, rest-redistribution  $^{201}\text{Tl}$  tomography, 1869  
contractile response and, chronically dysfunctional segments, 1841  
decision analysis model, patients evaluated for heart transplant, 60P(ab)  
FDG SPECT assessment of, 2035  
 $^{18}\text{F}$  FDG and  $^{201}\text{Tl}$  SPECT comparison, 1481  
 $^{18}\text{F}$  FDG uptake and water-perfusible tissue fraction, 141P(ab)  
 $^{123}\text{I}$  IPPA SPECT, coronary artery disease, 2019  
lisinidomin and,  $^{201}\text{Tl}$  SPECT study, 156P(ab)  
low-dose dobutamine gated blood pool imaging, 59P(ab)  
postrevascularization improvements, PET blood flow/metabolism mismatches, 162P(ab)  
relative rate of glucose in, 141P(ab)  
rest-redistribution  $^{201}\text{Tl}$  imaging and transesophageal echocardiography, 60P(ab)  
SPECT predictors for, before coronary bypass surgery, 60P(ab)  
stent model of left ventricular dysfunction, PET validation of, 142P(ab)  
 $^{99m}\text{Tc}$  Q12 and  $^{201}\text{Tl}$  uptake, acute coronary reperfusion, 159  
 $^{99m}\text{Tc}$  tetrofosmin/ $^{18}\text{F}$  FDG SPECT, 155P(ab)  
 $^{201}\text{Tl}$  SPECT for detection of, in hibernation, 384

## N

**Nasopharyngeal cancer**  
recurrent, FDG PET detection of, 256P(ab)  
 $^{99m}\text{Tc}$  sestamibi accumulation in cell lines, 314P(ab)

**National Institute of Standards and Technology (NIST), Measurement Assurance Program (MAP), radiopharmaceuticals**, 18N(6)

**Neoplasms**, FDG accumulation, importance of glucose transport on, 251P(ab)

**Nephropathy**, AIDS,  $^{99m}\text{Tc}$  MAG3 scinti-renography study, 28P(ab)

**Neural networks**  
artificial, scatter and attenuation in radionuclide imaging, 735  
feedforward artificial, real time estimation of parametric images of myocardial perfusion, 168P(ab)

**Neuro-Behçet's syndrome**,  $^{99m}\text{Tc}$  HMPAO SPECT and MRI, brain, 1707

**Neuroblastoma**, MIBG vs conventional techniques, long-term follow-up, 29P(ab)

**Neuroectodermal tumors**, primitive, spinal cord, PET FDG imaging, 1207

**Neuroendocrine neoplasms**, FDG PET,  $^{111}\text{In}$  somatostatin receptor scintigraphy and, 319P(ab)

**Neuroendocrine tumors**  
 $^{111}\text{In}$  pentetreotide fusion imaging, Y-90 somatostatin analog, 38P(ab)  
intraoperative gamma probe detection, 1155  
 $^{99m}\text{Tc}$  and  $^{111}\text{In}$  imaging comparison, 38P(ab)

**Neuroleptic therapy**, Tourette's syndrome,  $^{99m}\text{Tc}$  HMPAO perfusion patterns, 624

**Neurologic trauma**, male, gastric emptying in, 1798

**Neurology**, energy requirement in neuron and tumor, comparative analysis, 204P(ab)

**Neuronal transporter**, presynaptic cardiac sympathetic function,  $^{11}\text{C}$  MHED PET, 1327

**Neuroprotective agent**, FK506, focal cerebral ischemia, rat, 213P(ab)

**Neuropsychological testing**, findings in cerebral microangiopathy and, 147

**Neuroreceptors**, midbrain, misidentification of anatomical structures, PET, 208P(ab)

**Neurosurgery**, image-guided, brain tumor, PET data utility in, 214P(ab)

**Neurotoxicity**, methamphetamine- and MPTP-induced, GDNF effects, Parkinson's disease, 41P(ab)

**Nicotine**, dopamine release induced by, H-3 raclopride binding studies, 54P(ab)

**Nicotinic acetylcholine receptors**  
central  
 $^{18}\text{F}$  imaging of, 21P(ab)  
PET, baboons, 72P(ab)  
SPECT, tobacco dependence and neurodegenerative disease, 48P(ab)

**Nicotinyl hydrazine**, derivative,  $^{99m}\text{Tc}$  labeled to IgG, 119

**Nifedipine**, effects on myocardial contraction, ischemic heart disease, 46P(ab)

**Nitric oxide**, inhaled therapy,  $^{13}\text{N}$  NO inhalation system for, 117P(ab)

**Nitric oxide synthase**, neuronal inhibitors, radiolabeled, PET studies, 137P(ab)

**Nitrogen-13 ammonia**  
estimate of absolute myocardial perfusion, left ventricular ischemic dysfunction, 1655  
flow quantitation, myocardial septum, 591  
glucose utilization and oxidative metabolism, left bundle branch block, 261, 263  
myocardial perfusion imaging, mathematical model for heterogeneity, 1312  
PET, myocardial blood flow measurements, 1123

**Nitrogen-13 cisplatin**, PET monitoring of uptake, ovarian cancer, 316P(ab)

**Nitrogen-13 NO**, inhalation system, effectiveness of inhaled nitric oxide therapy, 117P(ab)

**Nitroglycerin**, gated  $^{99m}\text{Tc}$  sestamibi SPECT after, detection of viable myocardium, 59P(ab)

**Nitroheterocycles**,  $^{99m}\text{Tc}$  nitroimidazole uptake, swine model of demand ischemia, 1468

**Nitroimidazole**, fluorinated derivatives of, tracer for quantifying hypoxia, 35P(ab)

**Noise**  
PET transmission, new method for suppression, 180P(ab)

reduction, random coincidence events in 3D PET, 178P(ab)

**Noonan syndrome**, lymphangiectasia, lymphoscintigraphy and lymphangiography in, 1634

**Nordion**, Maple Medical Isotope Reactor Project, 19N(4)

**Norepinephrine**  
impaired cardiac sympathetic innervation, in essential hypertension, 1486  
MIBG, agent for sympathetic neurons, myocardial and neuroendocrine tumor imaging, 215P(ab)

**Normalization**, FDG studies, alternative method, 552

**Nuclear cardiology**, quality control, Italian study, 154P(ab)

**Nuclear medicine**  
advances  
innovative strategies in thyroid cancers, 11N(9)  
smart medicine and surgery, 1998 annual meeting, 13N(8)  
solid-state detectors, 15N(11)  
advances in, 17N(2)  
companies  
costs of procedures, 2194(l)  
diagnostic radiopharmaceuticals, 20N(3), 2194(l)  
forecasts, 27N(2)  
new isotope production company, 17N(4)  
radiopharmaceuticals market, 14N(7)  
cost-effectiveness in, 17N(1)  
history, 16N(10)  
Cassen, Benedict, 16N(5)  
discovery of technetium, 29N(12)  
first scintillation camera, 15N(3)  
Ross, Joseph F., 22N(4)  
Seaborg, Glenn T., 16N(6)  
market research  
costs of procedures, 2194(l)  
diagnostic radiopharmaceuticals, 20N(3), 2194(l)  
forecasts, 27N(2)  
radiopharmaceuticals market, 14N(7)  
resident's cybermentor, web-based resource, 277P(ab)  
role in radioguided surgery, 13N(10), 15N(10)  
role of health economics in, 2196(l)  
U. S Congress aid to, 16N(11)  
year 2000 problems, 30N(12)

**Nuclear Regulatory Commission (NRC)**  
nonmyeloablative  $^{131}\text{I}$  anti-B1 radioimmunotherapy, outpatient, 1230  
patient release guidelines,  $^{111}\text{I}$  therapy, 259P(ab)  
radioactivity in sewage, 28N(3)  
regulations, release of patients administered radioactive materials, 28S

## O

**Obesity**, gastric emptying in, parasympathetic control of, 274P(ab)

**Octreoscan**, Zollinger-Ellison syndrome patients, 272P(ab)

**Octreotide**, somatostatin receptor scintigraphy fibrous dysplasia, 238  
in small-cell lung cancer, 224, 2195(l)

**Office of Government Relations (SNM)**  
committee meeting highlights, 27N(4)  
mid-year report, 24N(6)  
NRC activity, 16N(9)  
pharmacy compounding, 26N(1)  
radiopharmaceutical approval regulations, 33N(5)  
update, 38N(11)

**Oligodeoxyribonucleotides**, mammalian cells, radiotoxicity of  $^{125}\text{I}$  ODN in, 1412

**Oligonucleotides**  
auger-emitting isotopes attached to, DNA cleavage by decay of, 236P(ab)  
imaging with PET, 229P(ab)

- Ommayogram.** cerebrospinal fluid clearance of  $^{111}\text{In}$  DTPA, leptomeningeal carcinomatosis, 210P(ab)
- Opioid receptors**
- central,  $^{18}\text{F}$  DPN PET imaging, 73P(ab)
  - delta,  $^{18}\text{F}$  FETNTI PET studies, 21P(ab)
  - kappa, synthesis and evaluation, 119P(ab)
  - mu
    - binding, capsaicin-induced pain and, PET, 207P(ab)
    - brain, chronic cocaine users after abstinence, 99P(ab)
    - upregulation and mood scores, depressed females, 40P(ab)
- Oral dysplasia.** detection,  $^{11}\text{C}$  tyrosine and  $^{18}\text{F}$  FDG, 1476
- Orbit,** metastases, carcinoid tumor,  $^{131}\text{I}$  MIBG uptake in, 647
- Organometallic agents.**  $^{18}\text{F}$  fluoroarylation-labeled agents, synthesis, 21P(ab)
- Orthopedic disease.**  $^{99m}\text{Tc}$  MDP and  $^{99m}\text{Tc}$  HIG and  $^{99m}\text{Tc}$  WBC comparison, 516
- Osseous metastases**
- $^{188}\text{Re}$  HEDP treatment of, 659
  - symptomatic, systemic radionuclide therapy, 245P(ab)
- Osteodystrophy,** renal, pentavalent  $^{99m}\text{Tc}$  DMSA scintigraphy in, 541
- Osteoid osteoma,** limping child, assessment with skeletal scintigraphy, 1056
- Osteomalacia.** therapy for, flare response seen in, 2095
- Osteomyelitis**
- bone, gallium, and MRI in, 29P(ab)
  - chronic recurrent multifocal, bone scintigraphy in, 1778
  - chronic vertebral, diagnosis with  $^{18}\text{F}$  FDG PET vs  $^{99m}\text{Tc}$  scintigraphy, 33P(ab)
  - diabetic patients, 275P(ab)
  - experimental chronic, scintigraphic evaluation, 195P(ab)
  - imaging experimental, radiolabeled liposomes, 1089
  - limping child, assessment with skeletal scintigraphy, 1056
  - metaphyseal, subperiosteal abscess and, epiphyseal photopenia associated with, 1084
  - monoclonal antibody fragment imaging of, 33P(ab)
  - $^{99m}\text{Tc}$  sulfur colloid, versus  $^{111}\text{In}$  leukocyte scintigraphy, Charcot joint, 346
  - vertebral,  $^{18}\text{F}$  FDG PET and  $^{99m}\text{Tc}$  AGAbs scintigraphy in, 2145
- Osteoporosis**
- bone mineral density, insulin-dependent diabetic patients, 194P(ab)
  - radiocalcium absorption, single-isotope test, 108
- Osteosarcoma,** untreated, FDG PET evaluation of, 95P(ab)
- Outcomes assessment**
- risk stratification, cardiac risk in women, SPECT imaging, 115P(ab)
  - stress SPECT, referral to cardiac catheterization after, 116P(ab)
  - $^{201}\text{Tl}$  scintigraphy in,  $^{131}\text{I}$  therapy in thyroid cancer, 807
  - very abnormal stress myocardial perfusion SPECT, natural history of, 3P(ab)
- Outpatient prospective payment system.** HCPCS, 26N(11)
- Ovarian cancer**
- FDG PET before second look surgery, surgery alternative, 249P(ab)
  - immunoscintigraphy before second look, surgery alternative, 243P(ab)
- $^{111}\text{In}$  B72.3, radiation absorbed dose estimates for, 671
- $^{13}\text{N}$  cisplatin uptake, PET monitoring of, 316P(ab)
- recurrences, whole-body FDG, PET, CT scan and immunoscintigraphy, 66P(ab)
- suspected, immunoscintigraphy with pan-adenocarcinoma antibody, 150P(ab)
- targeting, human monoclonal IgM labeled with  $^{111}\text{In}$  and  $^{90}\text{Y}$ , 476
- Oxidative metabolism**
- impairment of  $^{123}\text{I}$  BMIPP uptake, hypertrophic cardiomyopathy, 390
  - myocardial, abnormality, in noninsulin-dependent diabetes, 1835
- Oxygen.** metabolism, proton MRS and PET, occlusive carotid artery disease, 213P(ab)
- Oxygen-15.** PET, cerebral blood flow studies, Picocount flow-through detector, 509
- Oxygen consumption,** myocardial, measurement with  $^{11}\text{C}$  acetate, 272
- Oxygen utilization,** perfusion and, elimination in tumors, PET, 107P(ab)
- Oxygen-15 water**
- activations and deactivations, combined PET and MRI study, 110P(ab)
  - estimate of absolute myocardial perfusion, left ventricular ischemic dysfunction, 1655
  - $^{18}\text{F}$  FU and, PET, liver metastases from colorectal cancer, 465
- PET**
- global cerebral blood flow changes in anxiety disorders, 203P(ab)
  - paradoxical hippocampus perfusion, in Alzheimer's disease, 293
  - signal-enhancing switched protocols, cognitive task study, 350
  - tumor response to therapy, 314P(ab)
- Oxyphil cells,** content,  $^{99m}\text{Tc}$  MIBI uptake and, preoperative localization of lesions, hyperparathyroidism, 1441
- P**
- Pancreatic cancer**
- ductal, FDG PET in diagnosis and management of, 81P(ab)
  - FDG uptake
    - expression of GLUT-1 glucose transporter, 250P(ab)
    - prediction of survival and, 252P(ab)
  - high-end spiral CT and MRI, FDG PET comparison, 81P(ab)
  - $^{123}\text{I}$  VIP receptor imaging in, 1570
  - prognosis, FDG PET and, 81P(ab)
  - unresectable, intraoperative radiation therapy, evaluation with FDG PET, 252P(ab)
- Pancreatic tumors**
- elevated glucose levels, impairment of  $^{18}\text{F}$  FDG PET, 1030
  - FDG PET, GLUT-1 and cellularity in, 1727
- Pancreatitis**
- experimental,  $^{99m}\text{Tc}$  chemotactic peptide and FDG accumulation, 58P(ab)
  - intramedullary fat necrosis, multiple bones, 1401
- Parametric imaging**
- ligand-receptor model, wavelet transform, 65P(ab)
  - spatially-coordinated model fitting method, dynamic PET, 65P(ab)
- Parathyroid adenoma**
- dual- versus single-tracer scan for, 1100
  - MIBI scintigraphy, concomitant thyroid nodular disease and, 264P(ab)
- Parathyroidectomy,** radioguided surgery, 13N(10), 15N(10)
- Parathyroid gland**
- abnormal tissue, delayed images with  $^{99m}\text{Tc}$  sestamibi, 264P(ab)
- dual- versus single-tracer scan for, 1100
- lesions, preoperative localization in, hyperparathyroidism, 1441
- scintigraphy
- factors affecting sensitivity of, 263P(ab)
  - perchlorate in, 1306(lc)
  - procedure guidelines in, 1111
  - thallium and technetium scanning comparison, 1433
  - secondary hyperparathyroidism,  $^{123}\text{I}$ ,  $^{99m}\text{Tc}$  sestamibi subtraction SPECT in, 263P(ab)
  - $^{99m}\text{Tc}$  MIBI, comparison with  $^{99m}\text{Tc}$  tetrofosmin, ultrasound and MRI, 320
  - $^{99m}\text{Tc}$  sestamibi scintigraphy, P-glycoprotein effects, 1617
  - $^{99m}\text{Tc}$  sestamibi detectability in, 19P(ab)
- Parkinsonian plus syndromes,** loss of dopamine-D2 receptor binding sites in, 954
- Parkinsonian syndromes,** pre- and postsynaptic dopaminergic system, combined analysis, 124P(ab)
- Parkinson's disease**
- acetylcholinesterase activity, PET measurement of, 95P(ab)
  - dopaminergic deficit in,  $^{123}\text{I}$  FP-CIT SPECT for, 13P(ab)
  - dopamine transporter imaging
    - $^{18}\text{F}$  FPCIT PET, 1521
    - $^{123}\text{I}$   $\beta$ -CIT and FPCIT SPECT measurement, 1500
    - $^{123}\text{I}$  FP-CIT SPECT, 1879
    - ligand dopascan, SPECT, 14P(ab)
  - dopa-untreated, SPECT imaging of dopamine system, 14P(ab)
  - early-stage, drug-naïve, dopamine transporter imaging, 1143
  - evaluation of dopaminergic transmission,  $^{123}\text{I}$  IPT SPECT, 14P(ab)
  - GDNF effects, methamphetamine- and MPTP-induced neurotoxicity, 41P(ab)
  - $^{123}\text{I}$  altropine imaging, dopamine transporters, 214P(ab)
  - loss of dopamine-D2 receptor binding sites in, 954
  - multisystemic atrophy and,  $^{123}\text{I}$  IBZM brain SPECT, 210P(ab)
  - striatum in, functional morphometry,  $^{123}\text{I}$  CIT SPECT, 209P(ab)
  - $^{99m}\text{Tc}$  TRODAT-1 as imaging agent, dopamine transporter, 220P(ab)
  - $^{99m}\text{Tc}$  TRODAT-1 imaging of dopamine transporters, 6P(ab)
  - vesicular monoamine transporter type-2 in,  $^{11}\text{C}$  DTBZ binding to, 15P(ab)
- Parotid gland,** neoplasms,  $^{99m}\text{Tc}$  pertechnetate scintigraphy with lemon juice, 43
- Partial volume effect**
- lesion size, contrast ratio and, quantitative imaging for, 173P(ab)
  - PET, correction for, 904
  - PET and SPECT, autoradiographic brain phantom for, 121P(ab)
- Patient management pathways,** cost-effectiveness in nuclear medicine, 17N(1)
- Patient preparation,** children, nuclear medicine, 490
- Patlak analysis,** maximum-likelihood reconstruction and, FDG PET, 107P(ab)
- Patlak model,** myocardial blood flow measurements,  $^{13}\text{N}$  ammonia PET, 1123
- Pediatric patients**
- age-related brain distribution of  $^{99m}\text{Tc}$  ECD, SPECT, 200P(ab)
  - bone marrow immunoscintigraphy, anti NCA-95 antibody, aplastic anemia, 267P(ab)
  - brain death, scintigraphic evaluation, 55P(ab)
  - brain imaging research, health hazards of radiation exposure, 689

- cardiotoxicity.  $^{111}\text{In}$  antimyosine detection of, 56P(ab)  
changes in serotonin synthesis capacity.  
  developmental, PET studies, 124P(ab)  
chronic recurrent multifocal osteomyelitis, 1778  
congenital heart disease, palliative surgery, lung  
  perfusion scintigraphy after, 202P(ab)  
congenital solitary kidney, DMSA quantification study,  
  199P(ab)  
coronary flow reserve, after correction of transposition  
  of great arteries, 56P(ab)  
diagnostic use of MIBG, 679  
diuretic renography, 2015(lc)  
DMSA interpretative variability, after urinary tract  
  infection, 1428  
epilepsy  
  aging effects on glucose consumption, 57P(ab)  
  ictal SPECT and FDG PET accuracy in, 212P(ab)  
estimating glomerular filtration rate, 1646(lc)  
gastric emptying, scintigraphy, 865  
glomerular filtration rate, camera-based method of  
  evaluation, 1784  
heart transplantation,  $^{67}\text{Ga}$  scintigraphy, 57P(ab)  
hypoglycemic encephalopathy,  $^{99m}\text{Tc}$  HMPAO  
  SPECT, neonate, 1711  
hypoplastic left heart syndrome, myocardial perfusion  
  imaging in, 200P(ab)  
hydronephrosis, radionuclide renography or renal  
  duplex Doppler ultrasound diagnosis, 199P(ab)  
 $^{123}\text{I}$  IBZM receptor imaging, hypoxic-ischemic brain  
  injury, infants, 1703  
infants, evaluation of parenchymal changes with  
  urinary tract infection, SPECT, 197P(ab)  
intestinal lymphangiectasia, lymphoscintigraphic  
  findings, 201P(ab)  
Kawasaki disease, cardiac sequelae with,  $^{99m}\text{Tc}$   
  sestamibi myocardial perfusion imaging,  
  201P(ab)  
limping child, assessment with skeletal scintigraphy,  
  1056  
low birth weight premature infants, biliary atresia.  
  hepatobiliary scans, 200P(ab)  
neurological disorders, normal MRI, critical role of  
  FDG PET imaging in, 56P(ab)  
nuclear medicine  
  preparation of children, 490  
  special issues, unique clinical studies, 13N(3)  
pulmonary metastases, thyroid cancer, 1531  
pyelonephritis,  $^{99m}\text{Tc}$  MAG3 identification of, 1254  
radionuclide shunt, quantification, 56P(ab)  
renal blood flow, noninvasive measurement, 200P(ab)  
 $^{99m}\text{Tc}$  MAG3 renography, 201P(ab)  
 $^{99m}\text{Tc}$  pertechnetate scintigraphy in, neonatal  
  hypothyroidism, 201P(ab)  
vesicoureteral reflux, small kidney, radionuclide  
  cystography in, 197P(ab)
- Peptic ulcer disease.**  $^{14}\text{C}$  urea breath test, procedure  
  guideline, 2012
- Peptides**  
chemotactic  
  multivalent radiopharmaceuticals targeted with,  
    223P(ab)  
   $^{99m}\text{Tc}$ -labeled, comparison of uptake with FDG,  
    focal infection, 266P(ab)  
labeling with  $^{99m}\text{Tc}$  NHS MAG#, 56  
site-specific receptor-avid,  $^{99m}\text{Tc}$ , cancer targeting in  
  humans, 225P(ab)  
 $^{99m}\text{Tc}$ -labeled, route and rate of clearance, 8P(ab)  
vasoactive intestinal, receptor scintigraphy, colorectal  
  cancer, 39P(ab)
- Perchlorate**, in parathyroid scintigraphy, 1306(lc)
- Permeability-Surface product**, blood-brain transport, rat  
  brain capillaries, 208P(ab)
- Phantom**, voxelized, calculation of radiation dosimetry  
  with, 83P(ab)
- Pharmacokinetics**  
analysis of  $^{18}\text{FDG}$  PET, heterogeneous tissues,  
  166P(ab)  
effect of multiple injections, stabilized liposomes,  
  242P(ab)  
 $^{18}\text{F}$  FU, tissue and tumor, sources of error, 1370  
radioimmunotherapy,  $^{99m}\text{Tc}$  anti-EGF-receptor  
  antibody, tumor of epithelial origin, 15
- Pharmacy compounding**, Office of Government  
  Relations (SNM), 26N(1)
- Phelps, Michael**, U. S. Congress aid to nuclear medicine,  
  16N(11)
- Pheochromocytoma**  
diagnostic use of MIBG, children, 679  
 $^{131}\text{I}$  MIBG scintigraphy, adults, 1007  
localization,  $^{11}\text{C}$  hydroxyephedrine PET, 260P(ab)
- PHIPA 3-10**, myocardial uptake, stress-induced  
  perfusion defects in CAD, 153P(ab)
- Photodynamic therapy**, early tumor response to, FDG  
  PET assessment of, animal, 165P(ab)
- Photon energy**, recovery, effective energy resolution of  
  gamma cameras, 555
- Physician evaluation program**, CHCPP, 32N(5)
- Picture Archiving and Communication System**  
(PACS), JAVA-based remote viewing and  
  processing of images, 168P(ab)
- Pinhole scan**, dual, bone, 1444
- Piperidinyl ester**, radioiodinated, muscarinic  
  acetylcholine receptors, 49P(ab)
- Pituitary gland**, adenomas and prolactinomas, dopamine  
  receptor imaging comparison, 19P(ab)
- Placenta**, radiopharmaceutical binding and transfer, 1810
- Placental transfer**, radionuclides, human and animal  
  comparison, 187P(ab)
- Pneumonia**, FDG uptake in, PET, 1267
- Polychondritis**, relapsing, increased subglottic gallium  
  uptake in, 1977
- Polycythemia**, estimation of red blood cell volume,  
  30P(ab)
- Polyethyleneimine**, nonviral gene transfection agent,  
  imaging and biodistribution, 233P(ab)
- Positron autoradiography technique (PAT)**, FDG  
  uptake, hypoxic effect on brain slices, 204P(ab)
- Positron emission tomography (PET)**  
activation studies  
  central processing of vestibular information,  
    110P(ab)  
  cerebellum role in movement planning, 110P(ab)  
  sensory processing in Parkinson's and Huntington's,  
    111P(ab)  
  acupuncture, brain activation by, 205P(ab)  
  altered myocardial stress-strain relations, ischemic  
    cardiomyopathy, 4P(ab)  
  arterial blood radioactivity in, double-laminar catheter,  
    171P(ab)  
  assessment of dopaminergic neurotransmitters, 54P(ab)  
  BGO, single photon transmission scanning on, 23P(ab)  
  blood flow and metabolism, in locally advanced breast  
    cancer, 146P(ab)  
  brain, JAVA tools for post-processing of data,  
    277P(ab)  
  brain glucose metabolism, in Cushing's disease, 786  
  brain MAO, nicotine effects on, baboon, 13P(ab)  
  brain tumors, image-guided neurosurgery and X-knife  
    radiosurgery, 214P(ab)  
 $^{76}\text{Br}$  BrdU, as a proliferation marker, 1273  
 $^{11}\text{C}$  altropine, selective DAT ligand for, 238P(ab)  
camera, inter-plane septal shields in, 171P(ab)  
cardiac, rest and low-dose dobutamine,  $^{13}\text{N}$  ammonia  
  gated, 141P(ab)  
cardiac gated, list mode data acquisition for, 93P(ab)  
 $^{11}\text{C}$  caffeine, synthesis and preliminary studies,  
  238P(ab)  
 $^{11}\text{C}$  carbonyl-way 100635, serotonin receptor binding  
  potential with, 167P(ab)
- $^{11}\text{C}$  choline, imaging of prostate cancer, 990  
 $^{11}\text{C}$  choline and  $^{18}\text{F}$  FDG, prostate cancer, 52P(ab)  
 $^{11}\text{C}$  cocaine images, distribution in human brain,  
  42P(ab)
- $^{11}\text{C}$  DTBZ  
  binding to VMAT2 in Parkinson's disease, 15P(ab)  
Huntington disease, 125P(ab)  
presynaptic monoaminergic vesicles in normal  
  aging, 15P(ab)
- cerebral blood flow differences, food challenge,  
  anorexia nervosa patients, 203P(ab)
- cerebral blood flow studies, Pico-Count flow-through  
  detector, 509
- cerebral perfusion and metabolism, complex-partial  
  seizures, 26P(ab)
- $^{11}\text{C}$  etomidate and MET, adrenal cortex and tumors,  
  982
- cholinergic activity and hypoperfusion, carotid artery  
  ligation, 198
- $^{11}\text{C}$  hydroxyephedrine, localization of  
  pheochromocytoma, 260P(ab)
- $^{11}\text{C}$  L-159,884, angiotensin II AT<sub>1</sub> receptors, 1209
- $^{11}\text{C}$  MDL 100,907, serotonergic receptor, 209
- $^{11}\text{C}$  MET, focal cortical dysplasia, 974
- $^{11}\text{C}$  Met and and  $^{18}\text{F}$  FDG, evaluation of  
  lymphadenopathy in sarcoidosis, 1160
- $^{11}\text{C}$  MET and FDG pharmacokinetics, prostate cancer,  
  67P(ab)
- $^{11}\text{C}$  mHED, presynaptic cardiac sympathetic function,  
  1327
- $^{11}\text{C}$  MPGA, biodistribution and dosimetry, GAGA-  
  receptors, brain, 307
- $^{11}\text{C}$  NNC 112, neocortical dopamine D1 receptors,  
  2061
- coincidence imaging and  
  ADAC MCD dual head camera, performance of,  
    173P(ab)  
  lesion detection, 109P(ab)  
  staging malignant melanoma, 1892
- convertible field-of-view camera, construction and  
  imaging characteristics, 93P(ab)
- $^{11}\text{C}$  P11432, cerebral adrenergic receptors, primate,  
  72P(ab)
- $^{11}\text{C}$  raclopride, binding, methylphenidate-induced  
  changes in, 12P(ab)
- cranial bone graft, technique for survival, 99P(ab)
- $^{11}\text{C}$  SCH 23390, in normal subjects, 792
- $^{11}\text{C}$  thymidine, compartmental analysis and  
  mathematical analysis, 1043
- $^{11}\text{C}$  thymidine and FDG, measurement of therapy  
  response, 1757
- $^{11}\text{C}$  tyrosine, metastatic testicular nonseminoma germ  
  cell tumors, 1027
- $^{11}\text{C}$  WIN 35,428, dopamine transporter kinetics,  
  42P(ab)
- $^{64}\text{Cu}$  BOPP, synthesis and evaluation, 233P(ab)
- $^{62}\text{Cu}$  PTSM, clinical trials, 142P(ab)
- $^{62}\text{Cu}$  PTSM, human biodistribution and dosimetry,  
  1958
- 3D  
  Compton scattering on, quantitative thorax  
    measurement, 98P(ab)
- 2D comparison,  $^{11}\text{C}$  WIN 35,428 binding to  
  dopamine transporters, 65P(ab)  
  extrastratial D2 receptors, 72P(ab)  
  Fourier rebinning for, 178P(ab)  
  random coincidence events in, 178P(ab)
- D-1 agonist, imaging of dopamine D1 receptors,  
  71P(ab)
- 2D and 3D  
  human brain studies, 1714  
  practical tumor activity quantification strategies,  
    258P(ab)
- detector module, depth of interaction, 170P(ab)  
dopamine transporter  
   $^{11}\text{C}$  PE21 binding to, monkey brain, 118P(ab)

- mazindol effects, normal brain, 166P(ab)
- dual-head
- coincidence imaging, <sup>18</sup>F FDG, laryngeal cancer, 1385
  - dual-head gamma camera PET comparison, 171P(ab)
- dual system, <sup>15</sup>O water and, quantitation of cerebral blood flow, 1789
- dynamic
- arterial input function of an anticancer drug, 165P(ab)
  - binding sites of <sup>11</sup>C McN5652, 167P(ab)
  - imaging of oligonucleotides with, 229P(ab)
  - noninvasive derivation of input function, 145P(ab)
  - parametric image reconstruction in, 176P(ab)
  - parametric images in, 65P(ab)
  - tumor volume determination, Markov random field segmentation, 164P(ab)
- experimental myocardial infarction, small animals, 9P(ab)
- <sup>18</sup>F altanserin, quantification of serotonin receptors, 136P(ab)
- FDG
- accuracy in gastric cancer, 135P(ab)
  - after chemotherapy, germ cell cancer, 67P(ab)
  - alternative to second-look surgery, ovarian cancer, 249P(ab)
  - breast cancer, assessment of axillary metastases, 254P(ab)
  - breast cancer lesions, evaluation with modified anthropomorphic phantom, 1951
  - carcinoma of unknown primary, 256P(ab)
  - cerebral glucose metabolism in frontotemporal dementia, 1875
  - cerebral metabolic rate in deaf patients, 211P(ab)
  - cerebral metabolic rate of glucose, 164P(ab)
  - before chemotherapy, germ cell cancer, 67P(ab)
  - comparison of CT and tumor markers, testicular cancer, 249P(ab)
  - coregistration, head and neck, 2121
  - criteria for determination of malignant from benign lung tumors, 44P(ab)
  - detection of extrahepatic metastases, recurrent colorectal cancer, 134P(ab)
  - diagnosis of systemic vasculitis, 267P(ab)
  - diagnostic testing discrepancies, lung cancer, 248P(ab)
  - distribution in a changing regulatory environment, 144P(ab)
  - early stage laryngeal cancer, 122P(ab)
  - early tumor response to photodynamic therapy, animal, 165P(ab)
  - epileptic foci in continuous partial seizures, 211P(ab)
  - evaluation of parapharyngeal meningioma from intracranial space, 302
  - evaluation of radiation therapy in unresectable pancreatic cancer, 252P(ab)
  - extratemporal hypometabolism on, temporal lobe epilepsy, 69P(ab)
  - FDA-indeterminate thyroid nodules, 123P(ab)
  - gamma camera imaging of pulmonary lesions, 108P(ab)
  - gastroenteropancreatic neuroendocrine tumors, 125P(ab)
  - GLUT-1 and cellularity, pancreatic tumors, 1727
  - granular cell tumor, breast, 1398
  - head and neck cancer, 256P(ab)
    - recurrence, 122P(ab)
    - high-risk thyroid cancer patients, 19P(ab)
    - high uptake, colonic adenoma, 252P(ab)
    - Hodgkin's disease and non-Hodgkin's lymphoma, post-treatment study, 254P(ab)
    - immunoscintigraphy comparison, colorectal cancer, 151P(ab)
    - <sup>131</sup>I-negative papillary thyroid carcinoma, 258P(ab)  - insulin resistance imaging, 142P(ab)
  - isolated limb perfusion therapy and, melanoma, 95P(ab)
  - lung cancer
    - clinical impact of, 249P(ab)
    - mediastinal staging of, 257P(ab)  - malignant glioma, response to gene therapy for, 255P(ab)
  - malignant lymphoma, residual disease after therapy, 253P(ab)
  - metabolic alterations in skeletal muscle ischemia, 162P(ab)
  - metastasis from uterine cervical cancer, 2084
  - methionine combination, thymic tumor, 258P(ab)
  - neuroectodermal tumor, spinal cord, 1207
  - noise reduction by iterative reconstruction, 80P(ab)
  - nonattenuation-corrected whole-body, lesion-to-background ratio, 1219
  - non-Hodgkin's lymphoma
    - assessment of response to chemotherapy, 147P(ab)
    - response to nonmyeloablative <sup>131</sup>I RIT, 147P(ab)  - non-small cell lung cancer staging, cost-effectiveness, 80P(ab)
  - optimization of urinary excretion during, 250P(ab)
  - outcome prediction in breast cancer, after chemotherapy, 146P(ab)
  - pancreatic cancer
    - high-end spiral CT and MRI comparison, 81P(ab)
    - prognosis, 81P(ab)  - pancreatic ductal adenocarcinoma, 81P(ab)
  - pharmacokinetic analysis in heterogeneous tissues, 166P(ab)
  - potentially resectable colorectal cancer, 253P(ab)
  - preoperative TND staging of lung cancer, 80P(ab)
  - pre-surgical evaluation in epilepsy, 69P(ab)
  - prognostic value, malignant pleural mesothelioma, 81P(ab)
  - prostate adenocarcinoma, detection of metastatic disease, 250P(ab)
  - recurrent colorectal cancer, scanning for liver metastases, 253P(ab)
  - recurrent nasopharyngeal carcinomas, 256P(ab)
  - redifferentiation therapy, thyroid cancer, 1903
  - residual or recurrent ovarian cancer, 249P(ab)
  - rest and exercise stress comparison, diminished LVEF patients, 161P(ab)
  - segmentation of, with fuzzy logic, 164P(ab)
  - site-by-site correlation of findings, colorectal cancer, 134P(ab)
  - staging and restaging germ cell tumors, 66P(ab)
  - stomach uptake, blood glucose level relations, 126P(ab)
  - suspected infection in orthopedic prostheses, 33P(ab)
  - suspected intracranial metastatic tumors, 254P(ab)
  - synchronous lung lesions, patients with head and neck cancer, 248P(ab)
  - synthesis as potential imaging agent, 231P(ab)
  - <sup>99m</sup>Tc MDP bone scintigraphy comparison, primary bone tumor, 114P(ab)
  - technetium SSTR binding peptide comparison
    - breast cancer, 315P(ab)
    - solitary pulmonary nodule, 315P(ab)
    - thyroid cancer, 123P(ab)  - tissue viability of recurrent lymphoma masses, 147P(ab)
  - versus <sup>201</sup>Tl, thyroid tumors, 453
  - tumor marker S100 in comparison to, melanoma patients, 269P(ab)
  - tumor metabolic rates in sarcoma, 250
  - untreated osteosarcoma, 95P(ab)
  - uptake
    - after intracavitary <sup>131</sup>I, brain tumors, 1376
    - pneumonia, 1267
    - tonsils, 256P(ab)
- and water-perfusible tissue fraction, myocardial viability, 141P(ab)
- vs ictal SPECT, in partial epilepsy, 68P(ab)
- whole-body
- accuracy in staging of metastatic melanoma, 94P(ab)
  - bony metastases in breast cancer, 147P(ab)
  - conventional imaging, cost-effectiveness, melanoma, 94P(ab)
  - recurrent head and neck cancer, 122P(ab)
  - superiority in high-risk melanoma patients, 94P(ab)
  - whole-brain uptake, Alzheimer's disease, 210P(ab)
- FDG and <sup>11</sup>C tyrosine, detection of oral dysplasia, 1476
- FDG lumped constant, malignant glioma, 440
- FDG utilization and oxidative metabolism, left bundle branch block, 261, 263
- <sup>18</sup>F DOPA, with carbidopa pretreatment, 1884
- <sup>18</sup>F FBPA, glioma patients, 325
- <sup>18</sup>F FBT, binding in monkey brain, 206P(ab)
- <sup>18</sup>F FCWAY, evaluation, 135P(ab)
- <sup>18</sup>F FDG
- adenosine receptors and myocardial stunning, 944
  - in bronchioloalveolar lung cancer, 1016
  - esophageal cancers, 1002
  - glucose metabolism in bone tumors, 810
  - impairment by elevated glucose, 1030
  - presurgical staging of breast cancer, 4
  - quantitation of blood time-activity curves, mouse, 729
  - Sjögren's syndrome, 1354
  - <sup>201</sup>Tl SPECT comparison, lung cancer evaluation, 9
  - uptake measurements, malignant gliomas, 879
- <sup>18</sup>F FDG, detection and therapy of metastatic germ cell tumors, 815
- <sup>18</sup>F FDG and <sup>11</sup>C methionine, tumors of lung and mediastinum, 640
- <sup>18</sup>F FDG and <sup>99m</sup>Tc HL91 correlation, tumor hypoxia, 99
- <sup>18</sup>F FDG uptake
- rheumatoid arthritis-associated lung disease, 234
  - temporal lobe epilepsy, 176
- <sup>18</sup>F fluoro-3[<sup>18</sup>F]-2-azetidinylmethoxy] pyridine, nicotinic receptors, 72P(ab)
- <sup>18</sup>F FMT, preliminary clinical study of brain tumor, 53P(ab)
- <sup>18</sup>F FPCIT, dopamine transporter imaging, 1521
- <sup>18</sup>F FPCIT, imaging of dopamine transporters, 209P(ab)
- <sup>18</sup>F FTHA, free fatty acid uptake after, myocardium and skeletal muscle, 1320
- <sup>18</sup>F FU, pharmacokinetics in tumors, 232P(ab)
- <sup>18</sup>F FU, sources of error, 1370
- <sup>18</sup>F methyl tyrosine, biodistribution of, 663
- <sup>18</sup>F-related radiopharmaceuticals, bladder wall dose estimates, 187P(ab)
- <sup>68</sup>Ga, colon carcinoma xenografts, 1769, 1776(e)
- herpes simplex virus type I thymidine receptor gene, ganciclovir imaging, 2003
- high-resolution
- myocardial blood flow, 2022
  - noise suppression in, 180P(ab)
- high-resolution detector, depth of interaction, 50P(ab)
- <sup>123</sup>I BMIPP uptake, hypertrophic cardiomyopathy, 390
- input functions, factor analysis for generation of, 167P(ab)
- insulin resistance, type 2 diabetes, 884
- intravascular ultrasound and, transplant coronary vasculopathy, 90P(ab)
- iterative image reconstruction for, Pentium systems and web-based interface, 8P(ab)
- lesion detectability, effect of contrast, size, and SNR, ROC analysis, 9P(ab)
- lesion detection thresholds, positron imaging cameras, 51P(ab)

- letter from Donna Shalala, Secretary of HHS, 22N(1)
- localized MRI spectra, simultaneous dynamic acquisition, 93P(ab)
- low scatter, positron plane-source which approaches the limit of, 172P(ab)
- LSO-based, depth of interaction capability, high-resolution brain imaging, 133P(ab)
- lung**
- coverage instructions, CHCPP, 28N(7)
  - visualisation of muscarinic receptors, 117P(ab)
- LSO-based, depth of interaction capability, high-resolution brain imaging, 133P(ab)
- lung**
- coverage instructions, CHCPP, 28N(7)
  - visualisation of muscarinic receptors, 117P(ab)
- lung cancer, Medicare reimbursement, CHCPP, 22N(1), 33N(2)
- lymphocyte distribution, divalent cobalt as a label for study of, 836
- measured attenuation correction, improved image quality, 38P(ab)
- microPET, interactive guide for, 278P(ab)
- Monte Carlo simulation, dedicated breast and axillary node imaging, 170P(ab)
- motor activation studies, hemispherectomized patients, 211P(ab)
- multitracer examinations, bone cancer, 52P(ab)
- myocardial perfusion reserve, stable angina, 89P(ab)
- <sup>13</sup>N ammonia
- myocardial blood flow measurements, 1123
  - myocardial septum, 591
- <sup>13</sup>N ammonia, measurement of myocardial blood flow and cardiac output, 89P(ab)
- nasal <sup>11</sup>C triamcinolone acetonide, biodistribution and kinetics, 1972
- neuronal nitric oxide synthase inhibitors, radiolabeled, 137P(ab)
- noninvasive quantification, renal blood flow in pediatric patients, 200P(ab)
- <sup>15</sup>O, fast and slow finger movements, primary motor areas, 205P(ab)
- <sup>15</sup>O and <sup>18</sup>F, liver metastases from colorectal cancer, 465
- <sup>15</sup>O water
- cerebral water clearance estimates, 206P(ab)
  - global cerebral blood flow changes in anxiety disorders, 203P(ab)
  - hippocampal function in memory, 111P(ab)
  - iterative filtered backprojection reconstruction, 183P(ab)
  - myocardial factor images with, 1696
  - tumor response to therapy, 314P(ab)
- oxygen metabolism, occlusive carotid artery disease, 213P(ab)
- paradoxical hippocampus perfusion, Alzheimer's disease, 293
- parametric imaging, index image approaches and, 205P(ab)
- partial volume effects in, correction for, 904
- perfusion-contraction mismatch, hibernating myocardium, 396
- phantom study, lung nodules, 108P(ab)
- phosphodiesterase-IV inhibitor radioligand, <sup>11</sup>C rolipram, 119P(ab)
- pre- and postoperative studies, cerebral artery bypass surgery, 213P(ab)
- predictive value, extratemporal cortical resection in epilepsy, 68P(ab)
- quantification
- <sup>11</sup>C nicotine binding, brain, 2048
  - myocardial glycogen storage and glucose metabolism, 145P(ab)
- radiolabeled penciclovir for, HSV1-TK gene expression, 53P(ab)
- radiopharmaceuticals, adverse reactions to, 2190
- radiotracers
- imaging of tumor proliferation, 237P(ab)
  - therapeutic gene transfer and expression, 130P(ab)
- reference tissue models, for irreversible radioligands, 64P(ab)
- regional cerebral activity, in depression, antidepressant activity, 41P(ab)
- reporter gene expression, 35P(ab)
- reproducibility of input functions, factor analysis in breast cancer, 165P(ab)
- satellite model, gamma camera coincidence system, 108P(ab)
- scanner performance, image quality measurement for, 133P(ab)
- serotonin transporter radioligands, precursor synthesis, radiolabeling and, 120P(ab)
- short-transmission scans, segmentation of, 169P(ab)
- signal-enhancing switched protocols, cognitive task study, 350
- singles-transmission, scatter and emission contamination of, 37P(ab)
- small animal scanner
- improvement of spatial sampling, 133P(ab)
  - millimeter spatial resolution, 133P(ab)
- spatial relations representations, neural systems, 205P(ab)
- SPECT and, quantitation of benzodiazepine receptor binding, 209P(ab)
- SPECT combination, LSO-NaI(Tl) phoswich detector, 9P(ab)
- SPECT comparison, breast cancer detection, 1424
- statistical power analysis for, 1826
- studies, binding competition between endogenous dopamine and D1 radiotracer, 55P(ab)
- <sup>99m</sup>Tc ECD, transient global amnesia, 1360
- <sup>99m</sup>Tc furiosomim, differentiated thyroid cancer, 1536
- therapeutic limb perfusion, Merkel's cell carcinoma, 2087
- tracer kinetic modeling, measuring reporter gene expression, 10P(ab)
- tumor tracers, metabolic changes after irradiation, 1762
- two curve-plate detectors, breast imaging, 171P(ab)
- whole-body
- attenuation correction, optimization of, 258P(ab)
  - curve-plate detectors in, 50P(ab)
  - FDG, breast cancer, 254P(ab)
  - <sup>18</sup>F FDG, breast cancer detection, 431
  - internal dosimetry by TLD method, 187P(ab)
  - lymphoma staging, <sup>11</sup>C MET and <sup>18</sup>F FDG comparison, 254P(ab)
- without arterial blood sampling, perfusion and oxygen utilization rate, 107P(ab)
- <sup>90</sup>Y and, distribution of <sup>90</sup>Y-labeled pharmaceuticals, 174P(ab)
- YSO LSO phoswich detector, 52P(ab)
- Postural tremor**, isolated, presynaptic monoaminergic vesicles, <sup>11</sup>C DTBZ PET, 210P(ab)
- Practice guidelines**
- brain perfusion SPECT, 923
  - <sup>18</sup>F FDG tumor imaging, 1302
  - hepatic and splenic imaging, 1114
  - myocardial perfusion imaging, 918
  - parathyroid scintigraphy, 1111
  - renovascular hypertension, 1297
- Pregnancy**
- hyperthyroidism in, radioiodine treatment, 357, 2194(1)
  - placental transfer of radionuclides, human and animal comparison, 187P(ab)
- Pretargeting**
- alpha particle therapy, 17N(2)
  - antibody pretargeted radiotherapy, 20N(2)
  - biotin-chelates for, avidin biotin system, 1813
  - bispecific antibody-targeted haptens, radioiodine using, 1937
- BS-MAb, colon carcinoma xenografts, 1769, 1776(c) for radioimmunodetection and radioimmunotherapy, 65
- Probes**, intraoperative
- radionuclide-guided cancer surgeries, 92P(ab)
  - stacked solid-state, 22P(ab)
- Procedure manual**, web-based multi-media, 278P(ab)
- Progressive systemic sclerosis**, gastrointestinal involvement in, diagnosis, 272P(ab)
- ProStascint**, <sup>111</sup>In
- effects after radical prostatectomy, 149P(ab)
  - metastases detection with, localized prostate cancer, 150P(ab)
- pelvic anatomy**, CT and MRI correlation, 275P(ab)
- Prostate adenocarcinoma**, cervical neoplasms with, FDG PET early detection, 250P(ab)
- Prostate cancer**
- abdominal metastases, <sup>111</sup>In capromab pendetide detection of, 650, 653
  - bone scan flare phenomenon in, quantitation, 194P(ab)
  - <sup>11</sup>C choline and <sup>18</sup>F FDG PET, 52P(ab)
  - <sup>11</sup>C choline PET imaging of, 990
  - dual isotope SPECT images, simultaneously acquired, computer program for, 276P(ab)
  - lesion detection, ProstaScint, 195P(ab)
  - metastases detection, <sup>111</sup>In ProStascint and, 150P(ab)
  - metastatic, <sup>11</sup>C MET and FDG pharmacokinetics in, 67P(ab)
  - monoclonal antibody J591, specific to extracellular domain of PSMA, 77P(ab)
  - newly diagnosed, value of bone scan in, 194P(ab)
  - PC-3 cells, bombesin receptor, <sup>99m</sup>Tc analogues that bind with, 7P(ab)
  - radical prostatectomy, rising PSA values after, <sup>111</sup>In ProStascint effects, 149P(ab)
  - <sup>186</sup>Re HEDP, cisplatin combination, supra-additive treatment effects, 183P(ab)
  - targeting, <sup>105</sup>Rh bombesin analogs, 222P(ab)
  - xenografts, imaging with <sup>99m</sup>Tc alpha-fetoprotein, 222P(ab)
- Prostatectomy**, rising prostate-specific antigen after, weighted Gleason score, 317P(ab)
- Prostate disease**, diagnosis, total vs free PSA estimation, 270P(ab)
- Prostate gland**, tumor cells, fast- and slow-growing, <sup>11</sup>C FMAU differentiation, rat, 131P(ab)
- Prostate-specific antigen**
- rising, after prostatectomy, weighted Gleason score, 317P(ab)
  - total vs free estimation, diagnosis of prostate disease, 270P(ab)
- Prostate-specific membrane antigen**, extracellular domain, monoclonal antibody J591 specific, prostate cancer, 77P(ab)
- Prostheses**, infection, FDG PET imaging for assessment of, 33P(ab)
- Protein labeling**, alpha-emitting radionuclide BI-213, 91P(ab)
- Protein synthesis**, muscle, measurement with <sup>11</sup>C MET PET, 195P(ab)
- PSA**, see Prostate-specific antigen
- PSMA**, see Prostate-specific membrane antigen
- Puberty**, delayed, quantitative bone SPECT in young males with, 104
- Public relations**, SNM efforts, 1998 annual meeting, 10N(9)
- Pulmonary embolism**
- acute, anticoagulant therapy, incomplete recovery with, 275P(ab)
  - diagnosis
    - fully automated computer program for, 192P(ab)
    - SPECT V Q lung scan, 191P(ab)  - Doppler ultrasound of lower extremities, V Q lung scan and, 6P(ab)
  - helical CT scanning of, 5P(ab)
  - lung scan
    - low probability subgroup, 192P(ab)
    - screening requests for V Q scans, 193P(ab)  - SPECT, stripe sign, 721
  - spiral CT scanning, vs lung V Q scanning, 5P(ab)
  - spurious recurrence, assessment of pulmonary lung scan for, 5P(ab)
  - suspected

- ventilation scintigraphy in ICU patients, 5P(ab)  
 V Q scan and helical CT for, 193P(ab)
- Pulmonary endothelium.** prolonged retention of  $^{123}\text{I}$  MIBG, diabetic patient, 116
- Pulmonary nodules.**  $^{99m}\text{Tc}$  tetrofosmin SPECT, 2016(lc)
- Pyelonephritis.**  $^{99m}\text{Tc}$  MAG3 identification of, children, 1254
- Q**
- QT dispersion.**  $^{201}\text{TI}$  SPECT and, life-threatening ventricular arrhythmias, 155P(ab)
- Quality control**  
 continuous quality improvement activities, health care changes and, 276P(ab)  
 gamma camera system performance, end-to-end verification, 277P(ab)  
 gating errors, myocardial perfusion SPECT data, 45P(ab)  
 nuclear cardiology, Italian study, 154P(ab)  
 performance phantom, SPECT coincidence PET imaging, 174P(ab)  
 radiochemical purity of  $^{99m}\text{Tc}$  sestamibi, three paper chromatography methods for, 241P(ab)  
 tomographic nonuniformity, 174P(ab)
- Quantification**  
 accuracy, cardiac SPECT, 179P(ab)  
 calibration procedure and, photon energy recovery for scatter correction, 175P(ab)  
 3D, gated blood pool SPECT, multiple reference models, 145P(ab)  
 lung aerosol deposition measurements, planar imaging, 98P(ab)  
 non-invasive, regional cerebral blood flow, PET, 106P(ab)  
 nonuniform distribution, lung perfusion scintigraphy, 1630  
 planar imaging, absolute organ activity, 2167  
 practical tumor activity, 2D and 3D PET, 258P(ab)  
 radiation dose, individual skeletal lesions treated with  $^{153}\text{Sm}$  EDTMP, 2110  
 radionuclide shunt, children, 56P(ab)  
 receptor binding, for irreversible radioligands, reference tissue method, 64P(ab)
- Quantitation**  
 blood time-activity curves,  $^{18}\text{F}$  FDG PET, mouse, 729  
 cerebral blood flow,  $^{15}\text{O}$  water and PET dual system, 1789  
 2D and 3D PET, human brain studies, 1714  
 estimate of myocardial activity, attenuation correction effects, 4P(ab)  
 estimate of relative renal function, static DMSA scintigraphy, 17P(ab)  
 image performance, measurement of lesion size, contrast ratio and partial volume effect, 173P(ab)  
 nonuniform attenuation correction,  $^{99m}\text{Tc}$  brain SPECT, 36P(ab)  
 projections of X-ray CT-derived templates, planar nuclear scans, 98P(ab)  
 scatter correction effects, planar scintimammography, 1590  
 SPECT, nonuniform attenuation correction in brain imaging, 1719  
 SPECT myocardial perfusion imaging, 62P(ab)  
 influence of gating errors, 45P(ab)
- R**
- Radial artery tonometry.** gated myocardial SPECT and, noninvasive measurement of contractility, 103P(ab)
- Radiation**  
 absorbed dose  
 $^{111}\text{In}$  DOTA, 1928  
 $^{186}\text{Re}$  monoclonal antibody, bone marrow toxicity and, 1746
- walls of hollow organs, 1989  
 adaptive response, lymphocytes, in bone scintigraphy, 184P(ab)  
 dose, tissue level, radioimager in, rat kidney, 185P(ab)  
 low-level exposure, health hazards, brain imaging research, children, 689  
 lung damage caused by, effects on  $^{99m}\text{Tc}$  DTPA clearance, 374(lc)  
 radioactive internal contamination, brain tumors and, transuranium and uranium cohort, 191P(ab)  
 risk  
 quantitative safety guidelines to others after  $^{131}\text{I}$  therapy, 189P(ab)  
 real-life burden, in-living relatives after  $^{131}\text{I}$  therapy, 189P(ab)
- Radiation safety.** release of patients administered radioactive materials, NRC regulations, 28S
- Radiation therapy**  
 antibody pretargeted, 20N(2)  
 gallium scan, role in extranodal lymphoma, 95  
 gene, 928(lc)  
 internal, biodistribution and kinetics of  $^{166}\text{Ho}$  chitosan complex, 2161  
 $^{125}\text{I}$  Udr, brain tumors, rats, 1148  
 MAURITIUS somatostatin analog, tumor diagnosis and therapy, 223P(ab)  
 non-Hodgkin's lymphoma, 2S  
 release of patients administered radioactive materials, NRC regulations, 28S  
 somatostatin receptor-mediated, MAURITIUS in, 246P(ab)  
 thyroid cancer, impact factors on prognosis, 259P(ab)
- Radioactivity.** arterial blood, Pico-Count flow-through detector, 509
- Radiocalcium.** absorption, single-isotope test, 108
- Radiodetection.** intraoperative, neuroendocrine tumors, 1155
- Radioguided surgery**  
 advancing medical care, 13N(10), 13N(12), 15N(10)  
 melanoma and breast cancer, 22N(12)
- Radioimaging.**  $^{123}\text{I}$  VIP receptor, pancreatic cancer, 1570
- Radioimmunoassay**  
 anti-thyroglobulin autoantibodies, comparison with immunoradiometric assay, 271P(ab)  
 chemiluminescence immunoassay comparison, measuring thyroid hormone levels, 271P(ab)  
 effects of contrast agents, tumor-associated antigens, 270P(ab)  
 excretion of 3,3'-diiodothyronine sulfate, thyroxine-treated patients, 270P(ab)  
 osteoporosis, markers of bone metabolism in, 270P(ab)  
 prostate disease, total vs free PSA estimation, 270P(ab)
- Radioimmunodetection**  
 pretargeted, medullary thyroid cancer, 1172  
 tumor pretargeting for, 65
- Radioimmunoscopy.**  $^{111}\text{In}$  capromab pentetide, abdominal metastases from prostate cancer, 650, 653
- Radioimmunotherapy**  
 antibodies for, centralized radiolabeling, 11S  
 antibody fragments in, radiation dose and dose rate role in, 112P(ab)  
 anti-CEA anti-DTPA antibody and  $^{131}\text{I}$  DTPA hapten, small cell lung cancer, 70P(ab)  
 anti-CEA antigen and  $^{99m}\text{Tc}$  DOTA-peptide-biotin pretargeting, colorectal cancer, 245P(ab)  
 anti-colon carcinoma monoclonal antibody,  $^{64}\text{Cu}$  and  $^{111}\text{I}$  comparison, 105P(ab)  
 ascorbic acid pH 7.5,  $^{131}\text{I}$  Oncolym, 243P(ab)  
 chemotherapy and, preclinical multimodal therapy, colonic cancer xenografts, 247P(ab)  
 colorectal cancer patients, small volume disease, 70P(ab)
- walls of hollow organs, 1989  
 adaptive response, lymphocytes, in bone scintigraphy, 184P(ab)  
 dose, tissue level, radioimager in, rat kidney, 185P(ab)  
 low-level exposure, health hazards, brain imaging research, children, 689  
 lung damage caused by, effects on  $^{99m}\text{Tc}$  DTPA clearance, 374(lc)  
 radioactive internal contamination, brain tumors and, transuranium and uranium cohort, 191P(ab)  
 risk  
 quantitative safety guidelines to others after  $^{131}\text{I}$  therapy, 189P(ab)  
 real-life burden, in-living relatives after  $^{131}\text{I}$  therapy, 189P(ab)
- Radiation safety.** release of patients administered radioactive materials, NRC regulations, 28S
- Radiation therapy**  
 antibody pretargeted, 20N(2)  
 gallium scan, role in extranodal lymphoma, 95  
 gene, 928(lc)  
 internal, biodistribution and kinetics of  $^{166}\text{Ho}$  chitosan complex, 2161  
 $^{125}\text{I}$  Udr, brain tumors, rats, 1148  
 MAURITIUS somatostatin analog, tumor diagnosis and therapy, 223P(ab)  
 non-Hodgkin's lymphoma, 2S  
 release of patients administered radioactive materials, NRC regulations, 28S  
 somatostatin receptor-mediated, MAURITIUS in, 246P(ab)  
 thyroid cancer, impact factors on prognosis, 259P(ab)
- Radioactivity.** arterial blood, Pico-Count flow-through detector, 509
- Radiocalcium.** absorption, single-isotope test, 108
- Radiodetection.** intraoperative, neuroendocrine tumors, 1155
- Radioguided surgery**  
 advancing medical care, 13N(10), 13N(12), 15N(10)  
 melanoma and breast cancer, 22N(12)
- Radioimaging.**  $^{123}\text{I}$  VIP receptor, pancreatic cancer, 1570
- Radioimmunoassay**  
 anti-thyroglobulin autoantibodies, comparison with immunoradiometric assay, 271P(ab)  
 chemiluminescence immunoassay comparison, measuring thyroid hormone levels, 271P(ab)  
 effects of contrast agents, tumor-associated antigens, 270P(ab)  
 excretion of 3,3'-diiodothyronine sulfate, thyroxine-treated patients, 270P(ab)  
 osteoporosis, markers of bone metabolism in, 270P(ab)  
 prostate disease, total vs free PSA estimation, 270P(ab)
- Radioimmunodetection**  
 pretargeted, medullary thyroid cancer, 1172  
 tumor pretargeting for, 65
- Radioimmunoscopy.**  $^{111}\text{In}$  capromab pentetide, abdominal metastases from prostate cancer, 650, 653
- Radioimmunotherapy**  
 antibodies for, centralized radiolabeling, 11S  
 antibody fragments in, radiation dose and dose rate role in, 112P(ab)  
 anti-CEA anti-DTPA antibody and  $^{131}\text{I}$  DTPA hapten, small cell lung cancer, 70P(ab)  
 anti-CEA antigen and  $^{99m}\text{Tc}$  DOTA-peptide-biotin pretargeting, colorectal cancer, 245P(ab)  
 anti-colon carcinoma monoclonal antibody,  $^{64}\text{Cu}$  and  $^{111}\text{I}$  comparison, 105P(ab)  
 ascorbic acid pH 7.5,  $^{131}\text{I}$  Oncolym, 243P(ab)  
 chemotherapy and, preclinical multimodal therapy, colonic cancer xenografts, 247P(ab)  
 colorectal cancer patients, small volume disease, 70P(ab)
- editorial.** 42(ed)  
**hematological toxicity in, red marrow dosimetry prediction of.** 186P(ab)
- $^{131}\text{I}$  anti-B1 antibody for, B-cell lymphoma, 21S with IDEC-Y2B8, non-Hodgkin's lymphoma tumor and bone marrow radiation doses from, 69P(ab)
- $^{131}\text{I}$  distribution in brain tumors, pinhole SPECT, 856
- $^{131}\text{I}$  G250 antibody, renal cell carcinoma, 484
- $^{131}\text{I}$  humanized LL2 anti-CD22 MAb, against B-cell malignancies, 71P(ab)
- induced hypertension and kinin degradation inhibition, tumor xenografted mice, 106P(ab)
- intraperitoneal, targeting of ovarian cancer, mice, 476
- marrow toxicity, correlation with marrow absorbed dose,  $^{186}\text{Re}$ , 1746
- myosin heavy chain fragment, early detection of acute MI, 268P(ab)
- new L6 immunoconjugate, decreased hepatic radiation dose, 185P(ab)
- non-Hodgkin's lymphoma, 2S  
 dosimetry of  $^{131}\text{I}$  anti-CD20 for, 186P(ab)  
 $^{99m}\text{Tc}$ -labeled CDR-grafted monoclonal antibody for, 105P(ab)
- nonmyeloablative  $^{131}\text{I}$  anti-B1, outpatient therapy, 1230
- patient-specific whole-body dosimetry, non-Hodgkin's lymphoma, 14S
- pregenerated, PB-212/B1-212 generator, tumored mice, 91P(ab)
- pretargeted  
 antibody streptavidin and  $^{99m}\text{Tc}$  DOTA-Biotin, 71P(ab)  
 anti-tenascin 86C6-streptavidin conjugates and biotin, 105P(ab)
- biotin conjugate properties, 143P(ab)  
 $^{64}\text{Cu}$  TETA-octreotide, tumor-bearing rats, 1944  
 using bispecific antibody-targeted haptens, 1937
- radiolysis of  $^{99m}\text{Tc}$  immunoconjugates, 243P(ab)
- red marrow dose, patient-specific estimates, correlation with myelotoxicity and, 112P(ab)
- $^{188}\text{Re}$  EGF-R antibody, human lung adenocarcinoma xenografted to mice, 242P(ab)
- residualizing radioiodine labels for, peptide-based, 223P(ab)
- $^{188}\text{Rh}$ -labeled anti-carcinoembryonic antigen monoclonal antibody, gastrointestinal cancer, 34
- RIT and Taxol, synergistic therapy for breast cancer, 246P(ab)
- single-cell targeting,  $^{213}\text{Bi}$ -labeled antibodies, 111P(ab)
- solid tumors, with  $^{131}\text{I}$  labeled chimeric TNT monoclonal antibodies, 247P(ab)
- splenic volume, patient-specific dosimetry, therapeutic response and, 186P(ab)
- $^{99m}\text{Tc}$  anti-EGF-receptor antibody, tumor of epithelial origin, 15, 1918
- thrombocytopenia, cell kinetics model after, 1223
- tumor pretargeting for, 65
- two-step targeting, medullary thyroid cancer, 246P(ab)
- $^{99m}\text{Tc}$ , efficacy in p53 mutant human breast cancer xenografts, 842
- $^{99m}\text{Tc}$  DOTA, optimized conditions for chelation, 2105
- Radioiodine**  
 pulmonary metastases, thyroid cancer, children and adolescents, 1531
- purification and reduction, for radiopharmaceutical syntheses, 143P(ab)
- secretion, tears, 1452
- therapy  
 high-activity, thyroid cancer, 260P(ab)  
 outpatient, PC-based external dose calculation, 277P(ab)
- semiquantitative rapid urinary iodide test, 263P(ab)
- toxic multinodular goiter, 260P(ab)
- uptake, thyroid gland, gadolinium effects, 259P(ab)

- Radioiodine therapy**  
 high-dose, side effects, thyroid cancer, 1551  
 thyroid cancer, radiotoxicity after, 436  
 treatment  
   amifostine in, salivary glands, 1237  
   hyperthyroidism, in pregnancy, 357, 2194(l)  
   thyroid gland, Graves' disease, 712
- Radioisotopes**  
 irradiation of ammonia, liquid nitrogen temperatures, 241P(ab)  
 preparation of children in nuclear medicine, 490
- Radiolabeling**, centralized, antibodies for  
 radioimmunotherapy, 11S
- Radiolysis**, effects on <sup>90</sup>Y-labeled Lym-1 antibody preparations, 667
- Radionuclide imaging**  
 kidney, renal depth estimates of glomerular filtration rates, 1822  
 left ventricular function, during exercise, 140  
 male breast cancer, use of <sup>99m</sup>Tc MDP  
   scintimammography in, 28  
 myocardial perfusion, coronary stent implantation, 1307  
 pitfalls of nuclear imaging, Meckel's diverticulum, 276P(ab)
- Radionuclide monitoring**, continuous ambulatory, left ventricular function, 931(l)e
- Radionuclide pharyngo-esophageal transit (RPET)**, effectiveness of Zenker's diverticulum-esophagostomy, 58P(ab)
- Radionuclides**  
 alpha-particle emitting  
   bismuth-labeled, prostate cancer, 223P(ab)  
   normal organ dosimetry, leukemia patients, 188P(ab)  
   PB-212/BI-212 generator, tumorized mice, 91P(ab)  
   single-cell targeting with <sup>213</sup>Bi-labeled antibodies, 111P(ab)  
   studies of labeling proteins, 91P(ab)  
 improved separations in production, for PET, 232P(ab)  
 localized activity, projections of X-ray CT-derived templates, planar nuclear scans, 98P(ab)
- Radionuclide therapy**  
 chemotherapy and, synergy between, 900  
 palliation of bone pain, metastatic lesions, 84P(ab)  
 systemic, symptomatic osseous metastases, 245P(ab)  
 thrombocytopenia, cell kinetics model after, 1223
- Radiopharmaceuticals**  
 diagnostic, nuclear medicine market for, 20N(3), 2194(l)  
 Measurement Assurance Program (MAP), 18N(6)  
 molecular imaging with, atherosclerosis, 1819  
 multivalent, targeted with chemotactic peptides, 223P(ab)  
 PET and SPECT detection, breast cancer, 1424  
 placental binding and transfer, 1810  
 positron emitting, adverse reactions to, 2190  
 receptor-binding, factors influencing tumor imaging, 1036  
 regulation, FDA Modernization Act of 1997, 15N(1)  
<sup>99m</sup>Tc, pyridine analogs as coligands for, 215P(ab)  
 U. S. market, 14N(7)
- Radiosensitizer**, <sup>186</sup>Re HEDP and cisplatin combination, prostate cancer treatment, 183P(ab)
- Radiosurgery**  
 solid-state intraoperative beta probe for, 22P(ab)  
 X-knife, brain tumor, PET data utility in, 214P(ab)
- Radiosynthesis**, <sup>18</sup>F FLT, 22P(ab)
- Radiotoxicity**  
 after radioiodine therapy, thyroid cancer, 436  
 after <sup>89</sup>Sr therapy, bone metastases using micronucleus assay, 2077  
<sup>125</sup>I ODN, mammalian cells, 1412
- Ramsay Hunt syndrome**, peripheral facial nerve paralysis, prognosis using submandibular gland scintigraphy, 716
- Receptor gene**, herpes simplex virus type I thymidine, adenoviral-directed, imaging with ganciclovir, 2003
- Recombinant antibody**, CEA, <sup>99m</sup>Tc MET-labeled, cancer imaging, 47
- Reconstruction**  
 attenuation correction, whole-body FDG PET images, 98P(ab)  
 converging-beam SPECT, 22P(ab)  
 3D SPECT, with rotating slant hole collimators, 179P(ab)  
 iterative  
   attenuation correction and, PET, 179P(ab)  
   for attenuation correction in PET, 181P(ab)  
   filtered backprojection, <sup>15</sup>O water activation studies, 183P(ab)  
   helical SPECT with axially truncated data, 78P(ab)  
   noise reduction, myocardial SPECT, 160P(ab)  
   noise reduction by, oncology FDG PET, 80P(ab)  
   OSEM and ICD for SPECT brain images, 79P(ab)  
   for PET, Pentium systems and web-based interface, 8P(ab)  
   pinhole SPECT, 78P(ab)  
   SPECT, attenuation and depth-dependent resolution for, 79P(ab)  
   upper and lower bounds, SPECT transmission imaging, 180P(ab)  
 maximum-likelihood, Patlak-analysis and, <sup>18</sup> FDG PET, 107P(ab)
- oblique, DMSA studies, variability in pediatric urine infection, 27P(ab)
- ordered-subset algorithms, cardiac SPECT, 37P(ab)
- parametric, strategies in dynamic emission tomography, 176P(ab)
- partial volume correction, PET and SPECT, autoradiographic brain phantom for, 121P(ab)
- tomographic time activity curves from, from dynamic SPECT projections, 144P(ab)
- Red blood cell volume**, estimation, polycythemia, 30P(ab)
- Redifferentiation therapy**, retinoic acid  
 follicular thyroid cancer, 1555  
 thyroid cancer, 1903
- Reflux esophagitis**, salivary function, cisapride effects, 1449
- Region of interest**  
 2D and volumetric 3D brain SPECT data comparison, resting state, 106P(ab)  
 dual, left ventricular ejection fraction accuracy, 1857  
 fuzzy, automatic separation of renal parenchyma and pelvis, 198P(ab)  
 partial volume effects, correction for, PET, 904
- Registration**  
 automated, <sup>99m</sup>Tc HMPAO, mean regional cerebral blood flow images, 203  
 automatic 3-D matching SPECT, lung damage after radiotherapy, 1074  
 automatic 3D multimodality, radionuclide transmission CT attenuation maps in, 169P(ab)  
 3D correlation approach, multimodality body images, 163P(ab)  
 errors, SPECT system using sequential scanning, 365  
 intersubject, assessment by comparison of anatomic landmarks, 168P(ab)
- Reiter's syndrome**, whole body and pinhole bone scans in, pattern and early signs, 33P(ab)
- Remote synthesis device**  
<sup>64</sup>Cu, 240P(ab)  
 electrophilic fluorination, 240P(ab)
- Renal artery stenosis**, <sup>99m</sup>Tc EC and DTPA comparison, captopril scintigraphy, 199P(ab)
- Renal cell carcinoma**  
 adrenal metastases from, <sup>131</sup>I iodocholesterol accumulation in, 656
- <sup>131</sup>I G250, pharmacokinetic model, 484  
 metastasized, <sup>131</sup>I-labeled chimeric monoclonal antibody G-250, 247P(ab)
- <sup>99m</sup>Tc G-250 mAb preparations, immunoscintigraphy and biodistribution of, mice, 244P(ab)  
 tumor heterogeneity, monoclonal antibody G-250, 246P(ab)
- Renal cyst**, unsuspected, posttherapy localization, thyroid cancer, 2158
- Renography**  
 captopril  
   false-positive, calcium antagonists and, 1621  
   orthoiodohippurate and diethylenetriaminepentaacetic acid, 522  
 diuresis, quantitative gravity-assisted drainage in, 28P(ab)
- diuretic  
   adult patients, 198P(ab)  
   children, 2015(l)e
- exercise, supine position, hypertensive patients, 87P(ab)
- fuzzy ROI, automatic separation of renal parenchyma and pelvis, 198P(ab)
- before heart transplant, cardiomyopathy patients, 2153  
<sup>123</sup>I OIH and <sup>99m</sup>Tc MAG3, kidney transplant, 15P(ab)  
 radionuclide, hydronephrosis in infants, replacement by renal duplex Doppler ultrasound, 199P(ab)
- Renovascular hypertension**  
 captopril renography, OIH and DTPA, 522  
 diagnosis, procedure guidelines, 1297
- Repetitive transcranial magnetic stimulation**, synaptic activation induced by, FDG PET, 109P(ab)
- Reporter gene**, expression, adenovirus delivered dopamine receptor as, PET, 35P(ab)
- Respiratory distress syndrome**, acute, bleomycin-induced, <sup>111</sup>In-labeled antibody, rat, 723
- Respiratory motion**, list mode data acquisition for, cardiac gated PET, 93P(ab)
- Restenosis**, coronary, myocardial fatty acid metabolism after angioplasty, 933
- Retinoic acid**, redifferentiation therapy  
 follicular thyroid cancer, 1555  
 thyroid cancer, 1903
- Revascularization**  
 after CAD, prediction with SPECT and echocardiography, 18P(ab)  
 functional outcome, <sup>201</sup>Tl rest-redistribution prediction of, 60P(ab)  
 medical therapy and, serial changes on myocardial perfusion SPECT, 31P(ab)  
 transmyocardial laser, effects on regional myocardial blood flow, 32P(ab)
- Reverse transcription-polymerase chain reaction**, hematologic malignancy, P-glycoprotein expression, 1191
- Rhenium**, oxo complexes, single isomer <sup>99m</sup>Tc and, synthesis, 218P(ab)
- Rhenium-105**, bombesin analogs, targeting of prostate cancer, 222P(ab)
- Rhenium-186 APD**, synthesis and biodistribution, mice, 236P(ab)
- Rhenium-186 monoclonal antibody**, radiation absorbed dose from, bone marrow toxicity and, 1746
- Rhenium-188**  
 alpha-melanocyte stimulating hormone analogs, malignant melanoma bearing mice, 222P(ab)  
 beta ray-emitting paper, treatment of skin cancer, 234P(ab)
- biomolecules labeled with, novel N3S chelation system for preparation, 215P(ab)  
 colloidal entrapped chitosan, radionuclide therapy, 235P(ab)
- cyclic melanotropin peptide analogs labeled with, melanoma model, 77P(ab)
- liquid, balloon catheter filled with, radiation dose measurements of, 84P(ab)

- liquid-filled balloons, inhibition of coronary restenosis, swine model, 48P(ab)
- microspheres, direct injection in hepatoma, 1752
- microspheres labeled with, intraarterial tumor treatment, 246P(ab)
- Rhenium-188 HEDP**
- labeling and biodistribution, carrier effects on, 235P(ab)
  - treatment of osseous metastases, 659
- Rhenium-188 MAG2**, conjugate of amino-bis-phosphonates, bone seeking agents, 105P(ab)
- Rhenium-188 PTCA**,  $^{99m}$ Tc PTCA and, pharmacokinetics, 190P(ab)
- Rhenium-188 sulfur colloid**, suspended in lipiodol, targeting liver cancer, 235P(ab)
- Right ventricular function**, hypertrophy, impaired regional fatty acid uptake and, 1676
- Risperidone**, schizophrenia treatment,  $^{123}$ I IBZM SPECT in, 1138
- ROC analysis**, PET, effect of contrast, size, and SNR on lesion detectability, 9P(ab)
- Ross, Joseph F.**, nuclear medicine pioneer, 22N(4)
- Rotablation**, transient myocardial ischemia during,  $^{99m}$ Tc sestamibi SPECT, 157P(ab)
- S**
- Sacroiliac joint**, scintigraphy, age and gender effects, 1269
- Sacroilitis**, age and gender in, quantitative joint scintigraphy, 1269
- Salivary function**, reflux esophagitis, cisapride effects, 1449
- Salivary glands**
- pleomorphic adenoma,  $^{67}$ Ga uptake, 537
  - radioprotection of, amifostine, high-dose radioiodine therapy, 1237
  - scintigraphy, peripheral facial nerve paralysis, 716
  - variability of indices, 1260
- Samarium-153 EDTMP**
- quantifying radiation dose, individual skeletal lesions, 2110
  - University of Missouri Research Reactor (MURR), 13N(6)
- Sandler**, Martin P., new JNM editor, 9N(9), 29N(4)
- Saponins**, effect on binding of H-3 raclopride, dopamine D<sub>2</sub> receptors, 12P(ab)
- Sarcoidosis**
- $^{67}$ Ga uptake in, intense muscle, 1605
  - lymphadenopathy in,  $^{18}$ F FDG and and  $^{11}$ C Met PET evaluation, 1160
  - somatostatin receptor scintigraphy, comparison with  $^{67}$ Ga, 44P(ab)
- Sarcoma**
- bone and soft tissue, advanced, repeated  $^{18}$ F FDG in, 255P(ab)
  - murine model, tumor size effects on FDG uptake in, 255P(ab)
  - soft tissue, hypoxia, quantitative FMISO PET analysis, 190P(ab)
  - tumor metabolic rates in, FDG PET, 250
  - tumor response in,  $^{18}$ F FDG PET assessment of, 95P(ab)
- Scanning line source**,  $^{201}$ Tl and  $^{153}$ Gd, simultaneous SPECT, 73P(ab)
- Scatter correction**
- attenuation correction and, importance for quantitative brain SPECT, 8P(ab)
  - attenuation maps, simultaneous emission transmission imaging, 178P(ab)
  - backscatter material effects,  $^{99m}$ Tc and  $^{201}$ Tl SPECT, 170P(ab)
  - characterizing and correcting, brain SPECT, 182P(ab)
  - Compton scattering with NA(TL) detector, sensitivity for quantitative  $^{131}$ I imaging, 181P(ab)
- 3D acquisition PET, quantitative thorax measurement, 98P(ab)
- 3D transmission-map-based technique, SPECT, 182P(ab)
- effect on attenuation compensation,  $^{99m}$ Tc myocardial perfusion imaging, 74P(ab)
- effects,  $^{99m}$ Tc sestamibi myocardial perfusion imaging, 180P(ab)
- energy resolution, gamma cameras, photon energy recovery, 555
- fast iterative reconstruction-based compensation, attenuation, detector response blurring, 120P(ab)
- impact on planar scintimammography, 1590
- multi-isotope SPECT imaging, a priori information of spectral data, 176P(ab)
- photon energy recovery, calibration procedure and quantitative validation of, 175P(ab)
- quantitative assessment of regional cerebral blood flow and, SPECT, 181
- reconstruction-based, bias and noise properties for, 177P(ab)
- resolution compensation and attenuation correction, anthropomorphic phantom, 179P(ab)
- SPECT
- effects on regional distribution of CBF, 182P(ab)
  - OS-EM algorithm, 120P(ab)
  - transmission and emission data, quantitation in cardiac SPECT, 61P(ab)
  - transmission CT, uncollimated line array source in, 176P(ab)
- Schirmer test**, radioiodine secretion, tears, 1452
- Schizophrenia**
- antipsychotic receptor occupancy, SPECT study, 83P(ab)
  - benzodiazepine receptor imaging,  $^{123}$ I iomazenil SPECT, 82P(ab)
  - determination of regional cerebral blood flow, significance imaging, 425
  - Dopa decarboxylase activity in, fluorodopa PET study, 83P(ab)
  - resting dopamine synaptic release, SPECT imaging of, 82P(ab)
  - risperidone-treatment,  $^{123}$ I IBZM SPECT in, 1138
  - serotonergic receptor,  $^{11}$ C MDL 100,907 PET imaging of, 209
- Scintigraphy**, see also specific type
- anti CEA MoAb, primary mammary carcinoma and axillary lymphatic spread, 244P(ab)
  - bone
    - femoral neck stress fractures in endurance athletes, SPECT comparison, 128P(ab)
    - radiation-induced cytogenetic adaptive response, lymphocytes, 184P(ab)
    - screening test for painful joint replacements, 34P(ab)
    - value in chronic ankle pain, 196P(ab)  - bone marrow, anti-NCA-90 antibody MN-3, 113P(ab)
  - captopril,  $^{99m}$ Tc EC and DTPA comparison, renal artery stenosis, 199P(ab)
  - captopril renal, bilateral symmetrical induced changes in, 86P(ab)
  - double-nuclide, neuroendocrine tumors, 1155
  - dual-head pinhole, bone, 1444
  - hepatobiliary, infants, 311
  - intramedullary fat necrosis, multiple bones, with pancreatitis, 1401
  - lesional threshold detection, diffuse lung disease, 44P(ab)
  - limb salvage, findings in fibular donor sites, 1087
  - lung, segmental reference chart, 1095
  - lung perfusion, congenital heart disease, 202P(ab)
  - MIBG, long-term follow-up of neuroblastoma, 29P(ab)
  - myocardial
    - coronary vasculopathy after heart transplant, 153P(ab)
- heterogeneity with angiographically normal coronary arteries, 156P(ab)
- planar,  $^{99m}$ Tc DMSA, reproducibility in, 16P(ab)
- pulmonary aerosol, inhaled surfactant effects, 543
- reflux esophagitis, cisapride effects on salivary function, 1449
- renal, diuretic renography in adult patients, 198P(ab)
- salivary, characteristics of chronic sialadenitis, 273P(ab)
- screening, prior to visceral arteriography, acute lower gastrointestinal bleeding, 1081
- skeletal
- assessing the limping child, 1056
  - $^{99m}$ Tc MDP, primary malignant bone tumors, 1563
  - uptake of  $^{99m}$ Tc MDP, sites of heparin administration, 893
- static,  $^{99m}$ Tc DMSA, assessment of renal function, 17P(ab)
- $^{99m}$ Tc DMSA, after urinary tract infection, children, 1428
- $^{99m}$ Tc MAG3 study, AIDS nephropathy diagnosis, 28P(ab)
- ventilation, in ICU patients with suspected pulmonary embolism, 5P(ab)
- Scintillation camera**, first, nuclear medicine history, 15N(3)
- Scintimammography**
- emission tuned aperture CT, 24P(ab)
  - gamma camera, addition of medial view to routine breast imaging, 139P(ab)
  - image comparison, gamma camera, 23P(ab)
  - impact of scatter correction on, 1590
  - mammography combined with, ROC curves, suspected breast cancer, 138P(ab)
  - planar, iterative SPECT effects on detection of breast cancer, 318P(ab)
  - $^{99m}$ Tc MDP, male breast cancer, 28
  - $^{99m}$ Tc MIBI
    - benign and malignant breast lesions, 449
    - breast cancer recurrence, 319P(ab)
    - $^{123}$ I MIE2 complementary role in breast tumors, 319P(ab)
    - palpable and nonpalpable breast lesions, 86  - $^{99m}$ Tc sestamibi
    - breast cancer, planar and SPECT imaging comparison, 849
    - breast cancer response to neoadjuvant chemotherapy, 316P(ab)
    - $^{99m}$ Tc sestamibi, with dual-view pinhole collimators, 23P(ab)
    - uni- and multifocal breast cancer, 313P(ab)
- Seaborg**, Glenn T., nuclear medicine pioneer, 16N(6)
- Segmental reference chart**, lung, scintigraphy, 1095
- Segrè, Emilio**, discovery of technetium, 29N(12)
- Seizures**, intractable, evaluation for surgical resection, cost-effectiveness, 69P(ab)
- Semen**, analysis, diagnosis of clinical and subclinical varicocele, 1069
- Semiconductor detectors**, maximum-likelihood estimation, 64x64 CdZnTe array, 173P(ab)
- Sentinel node**
- advancing medical care in radioguided surgery, 13N(12)
  - identification
    - lymphoscintigraphic drainage patterns, melanoma, 25P(ab)
    - $^{99m}$ Tc albumin, in melanoma, 10P(ab)
    - $^{99m}$ Tc-labeled nanocolloid, squamous cell cancer, vulva, 1381
    - intraoperative localization, combined imaging and gamma probe, in breast cancer, 24P(ab)
    - localization
      - cutaneous melanoma, 245P(ab)
      - early breast cancer, 1388

- lymphatic mapping, for breast cancer, 24P(ab)  
 lymphoscintigraphy and radioguided biopsy, breast cancer, 24P(ab), 2080  
**Serial imaging**, acute renal allograft dysfunction, 197P(ab)  
**Serotonin**  
 level changes, <sup>18</sup>F labeled 5HT1A silent antagonists, 36P(ab)  
 maturational changes, children, PET studies, 124P(ab)  
 synthesis rate  
     capacity or, PET tracer <sup>11</sup>C alpha-MTrp, 137P(ab)  
     healthy controls with parametrical mapping and serotonin rate images, 136P(ab)  
     in psychiatric disorders, 83P(ab)  
**Serotonin antagonist**, MDL 100907, integrated synthetic route to precursors of, 119P(ab)  
**Serotonin receptors**  
 brain, <sup>11</sup>C as a radioligand for, 237P(ab)  
 carbonyl-carbon-11 WAY-100635 binding to, brain, 1965  
<sup>18</sup>F altanserin PET data, cerebellar data as input for, 165P(ab)  
<sup>18</sup>F FCWAY, evaluation for PET, 135P(ab)  
 H-2 and F-18 dual labeled altanserin, PET ligand for, 21P(ab)  
 5-HT<sub>4</sub>, <sup>125</sup>I SB-207710 as radioligand for, rat brain, 49P(ab)  
 imaging agents, SPECT, <sup>123</sup><sup>125</sup>I IBSP, 226P(ab)  
 kinetic derivation, binding potential with <sup>11</sup>C carbonyl-way 100635, PET, 167P(ab)  
 ligand <sup>11</sup>C MDL 100.907, kinetic analysis, 136P(ab)  
 PET imaging, <sup>11</sup>C MDL 100.907, 209  
 radiosynthesis, human postmortem autoradiography and, <sup>11</sup>C NAD-299, 237P(ab)  
**Serotonin transporters**  
 amphetamine effects, <sup>11</sup>C McN5652 binding, brain, 100P(ab)  
 availability, in alcohol addiction, gender and genetics effects, 100P(ab)  
 dopamine and, impact in <sup>123</sup>I beta-CIT SPECT, 42P(ab)  
 mapping specific binding sites of <sup>11</sup>C McN5652, dynamic PET data, 167P(ab)  
 precursor synthesis, radiolabeling and PET, monkey, 120P(ab)  
 reduced midbrain binding, <sup>123</sup>I beta-CIT SPECT, in major depression, 40P(ab)  
**Sex hormone binding globulin (SHBG)**, <sup>18</sup>F fluoroestradiol binding for, 34P(ab), 35P(ab)  
**Shalala, Donna**, letter from the Secretary of Health and Human Services re PET, 22N(1)  
**Sialadenitis**, chronic, scintigraphic characteristics of, 273P(ab)  
**Side effects**, long-term nonstochastic, radioiodine therapy for thyroid cancer, 1551  
**Sigma receptors**  
 detection of tumor proliferation, 227P(ab)  
<sup>18</sup>F FBnCND ligand for, PET, 229P(ab)  
**Sigmoidal curves**, 2196(l)  
**Silver-111**, labeling of therapeutic agents with, AZA-THIO (N2S4) crown ether ligand for, 92P(ab)  
**Simple model**, myocardial blood flow measurements, <sup>13</sup>N ammonia PET, 1123  
**Single photon emission computed tomography (SPECT)**  
 anthropomorphic phantom, attenuation correction, 180P(ab)  
 attenuation correction  
     CAD diagnosis accuracy and, 73P(ab)  
     data consistency conditions in, 177P(ab)  
     true effects of, 178P(ab)  
 automatic 3-D matching, lung damage after radiotherapy, 1074  
 automatic task-dependent filter selection, 79P(ab)  
 benzodiazepine receptor binding, anxiety disorders, 202P(ab)  
 bone, comparison to planar <sup>99m</sup>Tc MDP bone scanning, 130P(ab)  
 bone and gallium, osteomyelitis, 29P(ab)  
 brain  
     acetazolamide-induced myocardial ischemia, 408 after stroke, 149P(ab)  
     bone attenuation importance in, 190  
     characterizing and correcting for scatter, 182P(ab)  
     epilepsy, meta-analysis, 285  
     interictal, in temporal lobe epilepsy, 281  
     MRI and, mild neuropsychiatric manifestations, 204P(ab)  
     OSME and ICD for iterative reconstruction of, 79P(ab)  
     primary progressive aphasia, 96P(ab)  
     procedure guidelines for, 923  
     stereotaxic image orientation in six degrees of freedom, 503  
     <sup>99m</sup>Tc HMPAO, in anorexia nervosa, 304  
 brain perfusion  
     acute traumatic brain injury, 1357  
     depressive pseudodementia, 41P(ab)  
 cannabinoid receptor system, brain, 12P(ab)  
 cardiac  
     attenuation-compensated fanbeam, 166  
     attenuation-corrected, misalignment effects, 411  
     fast iterative reconstruction-based, 120P(ab)  
     fast sequential asymmetric fanbeam CT, 1335, 1344(ed)  
     noise reduction using gamma prior, 181P(ab)  
     quantitative accuracy, 179P(ab)  
     stress myocardial, abnormal, 3P(ab)  
 cardiac gated  
     evaluation of myocardial stunning, 102P(ab)  
     prognostic value of ejection fraction, 101P(ab)  
 cardiac stress, referral to catheterization after, 116P(ab)  
 cerebral blood flow  
     in ADHD, on and off Ritalin, 203P(ab)  
     changes, encephalitis, 2055  
     quantitative analysis, 3D-SSP, 164P(ab)  
     scatter correction effects, 182P(ab)  
 cerebral perfusion  
     age and gender differences in, 965  
     findings in mitochondrial encephalomyopathy, 961  
 cerebral perfusion and metabolism, focal epilepsy, 26P(ab)  
 cerebral perfusion impairment, with toluene abuse, 632  
 chronic recurrent multifocal osteomyelitis, 1778  
 collimator holes and photomultipliers, dual sampling, 169P(ab)  
 converging-beam, reconstruction, 22P(ab)  
 cranial bone graft, technique for survival, 99P(ab)  
 crossed cerebellar diaschisis, intracranial hematoma, 2044  
 diamox, occlusive carotid artery disease, 213P(ab)  
 DMSA  
     quantitative uptake, kidneys of children, 28P(ab)  
     use in first-time urinary tract infection, children, 28P(ab)  
 24h DMSA  
     <sup>51</sup>Cr EDTA comparison, kidney function, 198P(ab)  
     growth hormone effects, kidney, Turner syndrome, 198P(ab)  
 dopamine, dopa-untreated Parkinson's disease, 14P(ab)  
 3D transmission-map-based scatter correction technique, 182P(ab)  
 dual-head, new equipment in nuclear medicine, 15N(11)  
 dynamic  
     cardiac, kinetic parameters of, 144P(ab)  
     cardiac motion blurring, 121P(ab)  
     chronic intracranial artery occlusions, 149P(ab)  
     kinetic parameter estimation, 65P(ab)  
     parametric image reconstruction in, 176P(ab)  
     regional myocardial blood flow quantification with, 158P(ab)
- teboroxime, compartmental analysis, 182P(ab)  
 tomographic time activity curves from, 144P(ab)  
 ECG-gated, <sup>99m</sup>Tc sestamibi, follow-up to acute MI, 140P(ab)  
 energy resolution, gamma cameras, 555  
 FBP-reconstructed, detection of small lesions, 79P(ab)  
 FDG, assessment of myocardial viability, 2035  
 FDG 511 keV, intractable seizures, 212P(ab)  
 femoral neck fractures, bone scintigraphy comparison, 128P(ab)  
 fever of unknown origin patients, 1248  
<sup>18</sup>F FDG  
     <sup>123</sup>I BMIPP comparison, ischemic myocardium, 255  
     iterative reconstruction, 124  
     laryngeal cancer, 1385  
     Sjögren's syndrome, 1354  
<sup>18</sup>F FDG, viability vs improvement, heart failure, 18P(ab)  
 gated  
     beating bulls-eye plot for, 276P(ab)  
     left ventricular volume, phantom for, 175P(ab)  
 gated blood pool, 3D analysis, multiple reference models, 145P(ab)  
 gated myocardial, measurement of contractility, 103P(ab)  
 gated perfusion, left ventricular function, RNA comparison, 76P(ab)  
 gated TL, post-exercise stunning, 46P(ab)  
 helical, axially truncated data, 78P(ab)  
 hepatic, lesion detection, channelized hotelling, 169P(ab)  
 high-resolution, 3-D imaging of small animals, 9P(ab)  
 HMPAO, findings during transient global amnesia, 155  
<sup>123</sup>I, brain, nonuniform attenuation correction in, 37P(ab)  
<sup>123</sup>I beta CIT uptake, brain, technical factors in, 166P(ab)  
<sup>123</sup>I BMIPP  
     evaluation of myocardial perfusion, 1117  
     reduced uptake in jeopardized myocardium, 155P(ab)  
<sup>123</sup>I  $\beta$ -CIT and FPCIT, measurement of dopamine transporters, 1500  
 ictal  
     intractable childhood epilepsy, 212P(ab)  
     vs FDG PET, in partial epilepsy, 68P(ab)  
 ictal-interictal, seizure foci, 27P(ab)  
<sup>123</sup>I EPID, absolute quantitation, baboon, P(ab)  
<sup>123</sup>I FP-CIT, dopamine transporters in Parkinson's, 1879  
<sup>123</sup>I IBF, binding to dopamine receptors, aging effects, 1511  
<sup>123</sup>I IBF/IBZM/<sup>99m</sup>Tc TRODAT-1, dopaminergic system, 7P(ab)  
<sup>123</sup>I IBZM  
     hypoxic-ischemic brain injury, infants, 1703  
     risperidone-treated schizophrenic patients, 1138  
<sup>123</sup>I IMP  
     brain perfusion, 163P(ab)  
     bull's eye display, cerebral cortex, 107P(ab)  
<sup>123</sup>I IMT  
     diagnosis of recurrent glioma, 23  
     extracranial tumors, 1737  
<sup>123</sup>I IMZ  
     Alzheimer's disease, 927(l)e)  
     Machado-Joseph disease, 1518  
     major cerebral artery occlusive disease, 1348  
<sup>123</sup>I IPPA, coronary artery disease, 2019  
<sup>123</sup>I MIBG  
     after cardiac transplantation, 1862  
     Brugada syndrome, 1129  
<sup>131</sup>I NP-59, adrenocortical, 1460  
 iterative reconstruction, 79P(ab)  
 iterative reconstruction algorithm, upper and lower bounds, 180P(ab)

- knee, arthroscopy proven internal derangement, 130P(ab)
- low energy, prototype Compton camera, 173P(ab)
- lung, Takayasu's arteritis, 117P(ab)
- lung perfusion scintigraphy, quantitative analysis of, 1630
- lymphocyte distribution, divalent cobalt as a label for study of, 836
- MIBI/FDG, recovery after revascularization, CAD, 18P(ab)
- motion correction techniques, cardiac phantom study, 2027
- multi-pinhole, high-resolution small animal imaging, 174P(ab)
- myocardial.** see also **Myocardial perfusion imaging**
- attenuation compensation, 177P(ab)
  - background and dose effects, 62P(ab)
  - clearance of MIBI, metoclopramide and, 102P(ab)
  - infarct size and severity assessment, 62P(ab)
- myocardial perfusion, reorientation algorithm effects on, 1864
- normal, after transluminal coronary angioplasty, 115P(ab)
- OS-EM algorithm, 120P(ab)
- parallel-hole collimators, Compton scatter apertures and, 132P(ab)
- PET and, quantitation of benzodiazepine receptor binding, 209P(ab)
- PET and coincidence, quality control, 174P(ab)
- PET combination, LSO/Nal(Tl) phoswich detector, 9P(ab)
- PET comparison, breast cancer detection, 1424
- pinhole
- <sup>131</sup>I distribution in brain tumors, 856
  - normal and morbid ankles, 130
  - ordered subsets expectation maximization algorithm, 78P(ab)
- 21-pinhole system, cardiac imaging, 172P(ab)
- preclinical studies, <sup>123</sup>I HEPIE as lung cancer agent, 227P(ab)
- predictors for myocardial viability, before bypass surgery, 60P(ab)
- preictal, temporal lobe epilepsy, 978
- quadric-based object model for, 121P(ab)
- quantitative
- bone, delayed puberty and hypogonadism, males, 104
  - brain, subjective errors in, 106P(ab)
  - comparison of techniques, 102P(ab)
  - fanbeams with scanning point sources, 1996
  - validation and diagnostic yield, 103P(ab)
  - women, effects on accuracy of Wiener filtering, 46P(ab)
- quantitative bone, bone loss in primary hyperparathyroidism, 1614
- quantitative brain imaging, nonuniform attenuation correction, 1719
- reconstruction-based scatter compensation, bias and noise, 177P(ab)
- reduced GABA benzodiazepine receptor in alcoholism, gender, 204P(ab)
- resting synaptic dopamine release, schizophrenia, 82P(ab)
- right-angle dual-camera, attenuation correction, cardiac, 61P(ab)
- rotational atherectomy, transient regional ischemia during, 402
- scattering detector, Compton camera, 51P(ab)
- schizophrenia, antipsychotic receptor occupancy in, 83P(ab)
- stress <sup>99m</sup>Tc sestamibi, prone imaging with, 154P(ab)
- striatal dopamine release, amphetamine-induced, 207P(ab)
- subarachnoid hemorrhage, cerebral vasospasm after, 765
- <sup>99m</sup>Tc
- brain, attenuation correction, 181P(ab)
  - cardiac, acquisition orbits on, 61P(ab)
  - and <sup>201</sup>Tl SPECT, scatter response, 170P(ab)
- <sup>99m</sup>Tc ECD
- brain distribution, age effects, 200P(ab)
  - cerebral palsy, comparison with MRI, 619
  - herpes simplex encephalitis, 790
  - predictor of epileptogenic zone, 68P(ab)
  - stroke outcome, 213P(ab)
  - transient global amnesia, 1360
- <sup>99m</sup>Tc HMPAO
- acupuncture effects on CBF, 206P(ab)
  - Behcet's disease, 950
  - carbon dioxide poisoning, 769
  - and <sup>57</sup>Co labeled leukocytes, ischemia, 495
  - and ECD comparison, cerebral blood flow, 613
  - and ECD discord, herpes simplex encephalitis, 1508
  - effects of coronary artery bypass surgery, 587
  - hypoglycemic encephalopathy, neonate, 1711
  - leukocyte scan, bone infection, 34P(ab)
  - perfusion decreases in epilepsy, 212P(ab)
  - Sjögren's syndrome, 773
  - surgical outcome in epilepsy and, 68P(ab)
- <sup>99m</sup>Tc MIBI, diagnostic accuracy in men and women, 751, 756
- <sup>99m</sup>Tc pertechnetate, Meckel's diverticulum, 1458
- <sup>99m</sup>Tc sestamibi
- heart/lung uptake after exercise, 104P(ab)
  - left ventricular ejection fraction, 104P(ab)
  - viable myocardium after nitroglycerin, 59P(ab)
- <sup>99m</sup>Tc sestamibi, breast cancer, 849
- <sup>99m</sup>Tc tetrofosmin
- brain tumor imaging, 313P(ab)
  - lung lesions, 1830(ie)
  - primary breast cancer, 314P(ab)
  - pulmonary nodules, 2016(ie)
- <sup>99m</sup>Tc TRODAT-I
- binding, dopamine transporters, 214P(ab)
  - dopamine transporters, 2069
  - Parkinson's disease, 6P(ab)
- three-headed camera, transmission imaging, 1105
- <sup>201</sup>Tl, FDG comparison, viable myocardium, 1481
- <sup>201</sup>Tl and <sup>153</sup>Gd, lead x-ray compensation method, 177P(ab)
- <sup>201</sup>Tl/FDG, recovery after revascularization, CAD, 18P(ab)
- <sup>201</sup>Tl images, 180° and 360° acquisition for attenuation, 562
- <sup>201</sup>Tl myocardial gated, left ventricular function, 927(ie)
- <sup>201</sup>Tl rest-redistribution, myocardial viability, 384
- transmission and emission, registration errors, 365
- transmission measurement, scanning line source, 175P(ab)
- transmission scans, multiple line source array for, 2183
- V/Q lung, thromboembolic pulmonary hypertension, 6P(ab)
- V/Q lung scan, pulmonary embolism, 191P(ab)
- <sup>133</sup>Xe, obstructive lung disease, 889
- YSO/LSO phoswich detector, 52P(ab)
- Sjögren's syndrome**
- glucose metabolism, regional cerebral blood flow and, 1354
  - HMPAO brain SPECT in, 773
- Skeletal muscle**, free fatty acid uptake, after <sup>18</sup>F FTHA, 1320
- Skin cancer**, beta ray-emitting paper for treatment, 234P(ab)
- Society of Nuclear Medicine (SNM)**
- 1998 annual meeting, 10N(9), 13N(8)
  - 1998 annual meeting preview, 13N(5)
  - Archives, 16N(10)
  - Chinese, fifth national meeting, 30N(1)
  - Computer and Instrumentation Council, 10N(9)
  - Education and Research Foundation, 29N(4)
- decline in grant applications, 14N(5)
- 1999 elections, call for nominations, 36N(12)
- House of Delegates, 29N(4)
- is it time for a change?, 1649(ie)
- lines from the president, 28N(5)
- Manpower Committee, benchmarking physician workforce, 11N(7)
- Office of Government Relations, 33N(5)
- annual report, 34N(2)
  - committee meeting highlights, 27N(4)
  - mid-year report, 24N(6)
  - NRC activity, 16N(9)
  - pharmacy compounding, 26N(1)
  - update, 38N(11)
- Sodium.** dietary, manipulation, angiotensin II subtype I receptor regulation during, 196P(ab)
- Soft tissue masses**, dynamic response, <sup>18</sup>F FDG, 255P(ab)
- Soft-tissue tumors**
- malignant, <sup>99m</sup>Tc MIBI assessment of P-glycoprotein, 1179
  - prediction of tumor response, <sup>201</sup>Tl scintigraphy use in, 1600
- Software.** see Computers
- Solid-state detectors**, new equipment in nuclear medicine, 15N(11)
- Somatostatin analogs**
- <sup>67</sup>Cu TETA-octreotide, tumor-bearing rats, 1944
  - <sup>111</sup>In-labeled, tumor scintigraphy and radionuclide therapy, 261P(ab)
  - <sup>111</sup>In labeled DOTATOC, neuroendocrine tumors, 221P(ab)
- MAURITIUS, tumor diagnosis and therapy, 223P(ab)
- Somatostatin receptors**
- binding studies, rodent biodistribution and primate PET imaging, 63P(ab)
  - cardiac imaging, detection of allograft rejection, 3P(ab)
  - expression, Hürthle cell cancer of thyroid, 243
  - <sup>111</sup>In DOTA, tumor uptake, 1928
  - <sup>111</sup>In-DTPA, tissue distribution and metabolism, 264P(ab)
  - <sup>111</sup>In DTPA-D-Phe<sup>-1</sup>-octreotide, malignant thymic masses, 634
  - <sup>111</sup>In-labeled analogs, comparison, 39P(ab)
  - <sup>111</sup>In or <sup>125</sup>I radiolabel for, 233P(ab)
  - <sup>111</sup>In pentetreotide fusion imaging, neuroendocrine tumors, 38P(ab)
  - localization of <sup>64</sup>Cu TETA-octreotide, ovarian cancer xenografts, 63P(ab)
  - radiotherapy and dosimetry, <sup>64</sup>Cu in, 104P(ab)
  - radiotherapy mediated by, MAURITIUS, 246P(ab)
  - scintigraphy
    - false-positive, 2193(l)
    - limited Hodgkin's disease, 39P(ab)
    - postsurgical follow-up of meningioma, 38P(ab)
    - sarcoidosis, <sup>67</sup>Ga comparison, 44P(ab)
- scintigraphy, postsurgical exams in meningioma, 1913
- <sup>99m</sup>Tc and <sup>111</sup>In imaging comparison, 38P(ab)
- <sup>99m</sup>Tc P829, binding, 39P(ab)
- tumors, <sup>90</sup>Y DOTATOC treatment, 70P(ab)
- tumor targeting, metal coordination chemical aspects and, 63P(ab)
- <sup>90</sup>Y-DOTA-lanreotide treatment, metastatic gastrinoma, 2090
- Somatostatin receptor scintigraphy**, octreotide in small-cell lung cancer, 224, 2195(l)
- visualization of fibrous dysplasia during, 238
- Spatial relations**, encoding, PET investigations, 205P(ab)
- Spectral deconvolution**, photon energy recovery, 555
- Spermatozoa**, auger-emitting diagnostic radionuclides in, uptake and dosimetry in, 895
- Sphincter of Oddi**, dysfunction, quantitative cholescintigraphy test, 58P(ab)
- Spillover correction**, linear least square with, myocardial blood flow map, PET, 161P(ab)

- Spinal cord.** neoplasms, primitive neuroectodermal tumor, PET FDG imaging, 1207
- Spinal cord injury**  
gastric emptying in, 272P(ab)
- Spleen.** imaging  
procedure guidelines, 1114
- Squamous cell cancer**  
head and neck  
<sup>11</sup>C methionine uptake in, 1393
- preoperative lymph node staging with <sup>18</sup>F FDG, 122P(ab)
- vulva, serial lymph node identification with <sup>99m</sup>Tc-labeled nanocolloid, 1381
- Standardized uptake value.** characterization of brain tumors, FDG PET scan, 164P(ab)
- Statistical power.** PET studies, humans, 1826
- Stereoisomers.** CHX-DTPA-conjugated monoclonal antibodies, 829
- Steroids**  
nasal <sup>11</sup>C triamcinolone acetonide, biodistribution and kinetics in PET, 1972
- synthesis, adrenal cortex, <sup>11</sup>C etomidate and MET PET imaging, 982
- Stevens.** Ted (Sen.), U. S. Congress aid to nuclear medicine, 16N(11)
- Stomach.** PET FDG uptake, blood glucose level relations, 126P(ab)
- Strauss, H. William.** lines from the president, 28N(5)
- Streptavidin**  
antibody-based pretargeting, 228P(ab)
- anti-CEA antigen and <sup>90</sup>Y DOTA-peptide-biotin pretargeting, colorectal cancer, 245P(ab)
- radiolabeled  
improved intratumoral penetration, 30  
localization in tumor, 2017(1e)
- Stress testing.** myocardial perfusion imaging, glycogen phosphorylase-BB levels in, 32P(ab)
- Stroke**  
irreversible ischemic damage, <sup>11</sup>C FMZ visualization of benzodiazepine receptors, 148P(ab)
- outcome after 6 hours, <sup>99m</sup>Tc ECD SPECT prediction, 213P(ab)
- recovery, contralateral hemispheric cerebral reorganization, 149P(ab)
- subcortical, diaschisis in recovery, rest and Diamox rCBF brain SPECT, 148P(ab)
- Srontium-89.** therapy, bone metastases, radiotoxicity after, 2077
- Stupak.** Bart (Rep.), U. S. Congress aid to nuclear medicine, 16N(11)
- Subarachnoid hemorrhage.** cerebral vasospasm after, SPECT imaging, 765
- Subendocardial infarction.** myocardial stunning and, gated <sup>99m</sup>Tc sestamibi scintigraphy, 152P(ab)
- Submandibular glands.** scintigraphy, peripheral facial nerve paralysis, 716
- Superconducting supercollider.** new isotope production company, 17N(4)
- Surfactant.** inhaled, effect on pulmonary deposition of <sup>99m</sup>Tc DTPA, 543
- Sympathetic innervation.** noninvasive probe, coronary vasoconstriction, 89P(ab)
- Sympathetic nervous system**  
cardiac, quantitation with <sup>11</sup>C mHED, 1327  
with diabetes, <sup>123</sup>I MIBG lung uptake in, 334  
impaired innervation, in essential hypertension, 1486
- Symposia**  
Madrid PET, 23N(10)  
Taiwan Isotope and Radiation Applications, 23N(10)
- Syndrome X.** myocardial perfusion imaging, mathematical model for heterogeneity, 1312
- Synovectomy.** radiation agent, <sup>166</sup>Ho chitosan, 195P(ab)
- Systemic lupus erythematosus (SLE).** with CNS involvement, <sup>99m</sup>Tc HMPAO brain SPECT in, 930(1e)
- T**
- Takayasu's arteritis.** pulmonary involvement in, ventilation-perfusion lung scan in, 117P(ab)
- Taxol.** RIT and, synergistic therapy for breast cancer, 246P(ab)
- 10T-1/2 cells.** malignant transformation, <sup>99m</sup>Tc sestamibi and, 186P(ab)
- Tears.** radioiodine secretion in, 1452
- Technetium.** discovery of, 29N(12)
- Technetium-99m**  
alpha-melanocyte stimulating hormone analogs, malignant melanoma bearing mice, 222P(ab)
- anti-Fas ligand, imaging of adenoviral-mediated gene transfer of FAS ligand, 225P(ab)
- biomolecules labeled with, novel N3S chelation system for preparation, 215P(ab)
- bombesin analog, imaging of adenoviral-mediated gene transfer of GRPr, 224P(ab)
- chelates, cysteine-derived, renal imaging agents, 217P(ab)
- chemotactic peptides labeled with, acute focal infection, rat, 266P(ab)
- concentration, cation/anion exchange column system, 241P(ab)
- cyclic melanotropin peptide analogs labeled with, melanoma model, 77P(ab)
- IgG labeled with, nicotinyl hydrazine derivative, 119
- labeling, hydrazone-protected HYNIC derivatized peptides, 217P(ab)
- labeling of proteins and peptides, hyroxamide-based chelating agent for, 217P(ab)
- labeling peptides with, NHS-MAG3 chelator, 56
- leukotriene B4 antagonists, inflammation/infection sites, 215P(ab)
- liposome-encapsulated, intravascular brachytherapy, 219P(ab)
- mama-chrysamine G, imaging of beta-amyloid protein of Alzheimer's disease, 218P(ab)
- murine MAb labeled with, transient changes in white blood cell counts after, 265P(ab)
- peptides  
multiple HPLC peaks, 241P(ab)  
route and rate of clearance, 8P(ab)
- peptides and proteins labeled with, imaging of infection and inflammation, 268P(ab)
- practice guidelines, myocardial perfusion imaging, 918
- preparation, pyridine analogs as coligands for, 215P(ab)
- radiolabeled liposomes, imaging of experimental osteomyelitis, 1089
- single isomer, rhenium oxo complexes and, 218P(ab)
- site-specific receptor-avid peptides, cancer targeting in humans, 225P(ab)
- soluble TNF-alpha receptor, arthritis model, 225P(ab)
- <sup>201</sup>Tl perfusion SPECT comparison, during stress and at rest, 88P(ab)
- Technetium-99m AGAbs.** scintigraphy, chronic osteomyelitis, 2145
- Technetium-99m AGF-Fab.** imaging inflammation, nonspecific bowel activity, 30P(ab)
- Technetium-99m albumin.** identification of sentinel lymph nodes, melanoma, 10P(ab)
- Technetium-99m albumin colloid.** lymphoscintigraphic agents, cutaneous melanoma, 1185
- Technetium-99m alpha-fetoprotein.** scintigraphic imaging, prostate and breast cancer xenografts, 222P(ab)
- Technetium-99m analogs.** binding to bombesin receptor, prostate cancer cells, 7P(ab)
- Technetium-99m antiepidermal growth factor receptor antibody.** tumors of epithelial origin, 15, 1918
- Technetium-99m antigranulocyte antibody.** immunoscintigraphy, fever of unknown origin patients, 1248
- Technetium-99m anti-NCA-95.** bone marrow scintigraphy, for malignant osteoporosis, 1033
- Technetium-99m biotin.** analogs, infection imaging, 267P(ab)
- Technetium-99m BnAO.** hypoxia, in tumors, 216P(ab)
- Technetium-99m chemotactic peptide**  
accumulation, experimental pancreatitis, 58P(ab)  
FDG and, accumulation by sterile inflammation, rat, 266P(ab)
- Technetium-99m DISIDA.** segmental parenchymal excretion delay, hepatobiliary scan, 273P(ab)
- Technetium-99m DMP444.** platelet receptor, experimental endocarditis, 47P(ab)
- Technetium-99m DMSA**  
<sup>67</sup>Ga and, assessment of bone and joint infection, 2128  
high-purity, kinetic aspects, 143P(ab)  
interpretation variability, after urinary tract infection, children, 1428
- pentavalent, in renal osteodystrophy, 541
- planar scintigraphy, reproducibility in, 16P(ab)  
quantification study, congenital solitary kidney, renal function with, 199P(ab)
- renal cortical scarring, renal length and, 1280
- scanning, preoperative staging of medullary thyroid cancer, 1907
- scintigraphy  
hypoplastic dysplastic kidney with vaginal ectopic ureter, 113  
variability, pediatric urine infection, 27P(ab)
- SPECT**  
kidney functioning after radical nephrectomy, 16P(ab)  
quantitative uptake, kidneys of children, 28P(ab)  
vs TCT, renal volume determination, 16P(ab)
- Technetium-99m DTPA**  
aerosols, in ventilation scans, 2193(l)  
camera-based method of evaluation, glomerular filtration rate, 1784
- clearance, radiation lung damage effects, 374(1e)  
liver scintigraphy, CT/MRI attenuation/signal intensity differences, 529
- pulmonary deposition and clearance, inhaled surfactant effects, 543
- renal depth estimates, glomerular filtration rates, 1822
- single blood sampling, glomerular filtration rate estimation, 85P(ab)
- Technetium-99m EC.** DTPA captopril comparison, renal artery stenosis, 199P(ab)
- Technetium-99m ECD**  
brain distribution, age effects, SPECT, 200P(ab)  
brain SPECT, stereotaxic image orientation in six degrees of freedom for, 503
- cerebral perfusion impairment, with toluene abuse, 632
- dynamic SPECT, chronic intracranial artery occlusions, response to Diamox and, 149P(ab)
- SPECT**  
cerebral palsy, comparison with MRI, 619
- herpes simplex encephalitis, 790
- transient global amnesia, 1360
- <sup>99m</sup>Tc HMPAO comparison, imaging of cerebral blood flow, 613
- <sup>99m</sup>Tc HMPAO discordance, SPECT, herpes simplex encephalitis, 1508
- uptake, in ADHD, Ritalin effects, 203P(ab)
- uptake and retention, high grade glioma, 315P(ab)
- Technetium-99m endothelin derivative.** molecular imaging with, atherosclerosis, 1819
- Technetium-99m exametazime**  
radiolabeling of leukocytes, volume and plasma effects on, 243P(ab)

stabilized, use in radiolabeling leukocytes, 912

**Technetium-99m Fab fragment**  
bone and soft tissue infections, 34P(ab)  
osteomyelitis, semiquantitative analysis, 33P(ab)

**Technetium-99m furifosmin**, PET, differentiated thyroid cancer, 1536

**Technetium-99m glucarate**, marker of necrosis, adriamycin-induced apoptotic myocardial injury, 159P(ab)

**Technetium-99m GSA**  
liver asialoglycoprotein receptor imaging, 3-compartment model analysis, 57P(ab)  
<sup>99m</sup>Tc PMT comparison, hepatic function, dynamic SPECT, 126P(ab)  
uptake, dimethylnitrosamine or hepatocyte growth factor, 1463

**Technetium-99m HIDA**, scintigraphy, versus endoscopic retrograde cholangiopancreatography, for bile leaks, 1802

**Technetium-99m HIG**, <sup>99m</sup>Tc MDP and <sup>99m</sup>Tc WBC comparison, musculoskeletal inflammation, 516

**Technetium-99m HL91**  
tumor hypoxia identification, correlation with <sup>18</sup>F FDG, 99  
tumor marker, hypoxic tumors, 220P(ab)

**Technetium-99m HMDP**, skeletal uptake, bone mineral density relations, elderly women, 129P(ab)

**Technetium-99m HMPAO**  
binding and transfer, placental, 1810  
brain  
previous history of brain injury, 97P(ab)  
quantitative electroencephalography and, Alzheimer patients, 96P(ab)  
brain perfusion, effects of coronary artery bypass surgery, 587  
brain SPECT  
Behcet's disease, 950  
mean regional cerebral blood flow images, 203  
Sjögren's syndrome, 773  
systemic lupus erythematosus with CNS involvement, 930(le)

brain SPECT, acute carbon monoxide poisoning, 769

cerebral perfusion scanning, treatment in AIDS dementia, 298

<sup>57</sup>Co labeled leukocytes and, visualization of ischemic infarct, 495

labeled leukocyte scan, prosthetic vascular graft infection, 875

leukocytes, in surgery for mediastinitis after sternotomy, 29P(ab)

leukocyte scan, bone infection, 34P(ab)

perfusion patterns, Tourette's syndrome, neuroleptic therapy and after withdrawal, 624

regional cerebral blood flow scintigraphy, encephalitis, 2055

SPECT  
brain  
in anorexia nervosa, 304  
in neuro-Behcet's syndrome, 1707  
cerebral perfusion, age and gender differences in, 965  
findings during transient global amnesia, 155  
findings in cerebral microangiopathy, 147  
hypofrontality in major depressive disorder, 608  
hypoglycemic encephalopathy, neonate, 1711  
surgical outcome in epilepsy and, 68P(ab)

SPECT and angiography, WADA test, 212P(ab)

<sup>99m</sup>Tc ECD comparison, imaging of cerebral blood flow, 613

<sup>99m</sup>Tc ECD discordance, SPECT, herpes simplex encephalitis, 1508

uptake, discordance with <sup>18</sup>F FDG, traumatic brain injury, 1357

uptake and retention, high grade glioma, 315P(ab)

**Technetium-99m HSA**, lymphoscintigraphic agents, cutaneous melanoma, 1185

**Technetium-99m-labeled nanocolloid**, serial lymph node identification, squamous cell cancer, vulva, 1381

**Technetium-99m liposomes**  
compared with <sup>99m</sup>Tc HMPAO and <sup>99m</sup>Tc HYNIC-IgG, experimental colitis, 2172  
early image detection, rabbit colitis model, 125P(ab) versus <sup>99m</sup>Tc sulfur colloid, lymphoscintigraphy in rabbit model, 314P(ab)

**Technetium-99m MAA**, arteriovenous shunting, multiple myeloma and high-output failure patients, 1

**Technetium-99m MAG3**  
clearance studies, Bubeck method, 1066  
early identification of pyelonephritis, children, 1254  
hybrid oligonucleotide, antisense imaging, 219P(ab)  
postoperative function studies, kidney transplantation, 15P(ab)  
renal clearance  
proteinuria and transplant patients, 86P(ab)  
renography, normal parameters, 86P(ab)  
without blood sampling, 86P(ab)  
renography, pediatric patients, 201P(ab)  
scdsFv, renal clearance of, 76P(ab)  
survival of malfunctioning renal graft, in kidney transplantation, 16P(ab)  
urinary excretion, prediction, 1257

**Technetium-99m MAG3-biocytin**, uptake inhibition study, hepatobiliary imaging, 272P(ab)

**Technetium-99m MDP**  
extraskeletal uptake, sites of heparin administration, 893  
flare response, seen in therapy for osteomalacia, 2095  
scintigraphy, primary malignant bone tumors, 1563  
scintimammography, male breast cancer, 28  
<sup>99m</sup>Tc WBC and <sup>99m</sup>Tc HIG comparison, musculoskeletal inflammation, 516

**Technetium-99m Mebrofenin**, hepatic extraction efficacy, toxin-induced liver disease, 1286

**Technetium-99m meso-HMPAO**, glutathione and, diethyl maleate-treated mouse brain mitochondria, 2178

**Technetium-99m MET**, scFv labeled with, cancer imaging with, 47

**Technetium-99m metal complexes**, functional imaging, multidrug resistance P-glycoprotein, 77

**Technetium-99m MIBI**  
assessment of P-glycoprotein, malignant bone and soft tissue tumors, 1179  
assessment of thyroid malignancy, 215(le)  
comparison with <sup>99m</sup>Tc tetrofosmin, ultrasound and MRI, parathyroid glands, 320  
dual-phase scintigraphy, Hürthle cell tumor in thyroid nodules, 822  
immunohistological assessment, benign and malignant breast lesions, 449  
loss of accumulation, glutathione in, MDR protein expression in tumor cells, 1214  
metastatic axillary lymph node imaging, primary breast cancer, 459  
oxyphil cell content and, preoperative localization of lesions, hyperparathyroidism, 1441  
primary and recurrent head and neck tumors, 1166  
scintigraphy, hematologic malignancy, P-glycoprotein expression, 1191  
scintimammography, palpable and nonpalpable breast lesions, 86

**SPECT**, diagnostic accuracy in men and women, 751, 756

<sup>99m</sup>Tc tetrofosmin and <sup>201</sup>Tl uptake, myocardial cells, rat, 266

tumor response to chemotherapy and, bone lesions, 928(le)

uptake  
p-glycoprotein expression effects, breast cancer, 1021  
small cell lung cancer, 91

**Technetium-99m monoclonal AGA**, detection of bone metastases, breast cancer, 150P(ab)

**Technetium-99m NAC**, MIBI comparison, experimental tumor model, 221P(ab)

**Technetium-99m nitroimidazole**  
detection of myocardial ischemia, rabbits, 598  
hypoxia, tumors, 219P(ab)  
uptake, swine model of demand ischemia, 1468

**Technetium-99m NOET**  
image acquisition, initial and redistribution, 160P(ab)  
murine myoblast labeling with, biodistribution studies, 218P(ab)

**Technetium-99m P829**, binding, somatostatin receptor, 39P(ab)

**Technetium-99m PEG-liposomes**, detection of infection and inflammation, 30P(ab)

**Technetium-99m pertechnetate**  
lemon juice stimulation, evaluation of Warthin's tumor, 43  
<sup>188</sup>Rb pertechnetate and, pharmacokinetics, 190P(ab)  
scintigraphy, neonatal hypothyroidism, 201P(ab)  
SPECT, heterotopic gastric mucosa, Meckel's diverticulum, 1458

**Technetium-99m PET liposomes**, experimental chronic osteomyelitis, scintigraphic evaluation, 195P(ab)

**Technetium-99m PMT**, <sup>99m</sup>Tc GSA comparison, hepatic function, dynamic SPECT, 126P(ab)

**Technetium-99m Q64**  
kinetics, myocardial ischemia, dog model, 216P(ab)  
myocardial kinetics, perfused rat heart, 219P(ab)

**Technetium-99m Q12**, uptake, correlation with thallium-201 uptake, acute coronary reperfusion, 159

**Technetium-99m Q compounds**, uptake in laminin, cardiac myocytes, rat, 216P(ab)

**Technetium-99m RBC**  
combined bleeding scan and colonoscopy, active GI bleeding prior to surgery, 273P(ab)  
scintigraphy, acute lower gastrointestinal bleeding, 1081

**Technetium-99m rhenium**, synthesis, organo-hydrazino with thiolate coligands, 220P(ab)

**Technetium-99m RP128**  
imaging inflammatory lesions, Crohn's disease, 271P(ab)  
structural characterization, NMR spectroscopy, 7P(ab)

**Technetium-99m sestamibi**  
accumulation, tumor washout rates and, lung cancer, 228  
after coronary artery bypass graft, evaluation of ventricular function, 88P(ab)  
continuous infusion, regional myocardial blood flow quantification with, 158P(ab)  
delayed images, diagnosis of abnormal parathyroid tissue, 264P(ab)  
detectability, parathyroid scintigraphy, 19P(ab)  
diagnostic accuracy, metastatic melanoma, 137P(ab)  
dual- versus single-tracer scan for, parathyroid, 1100  
enhancement of flow heterogeneity, single coronary stenosis, 417  
factors affecting sensitivity of scintigraphy, parathyroid, 263P(ab)  
gated myocardial perfusion SPECT, gradation of interpreter confidence, value of, 101P(ab)  
P-glycoprotein expression by, chemosensitivity of lung cancer, 137P(ab)  
hepatobiliary clearance, metoclopramide effects, myocardial SPECT, 102P(ab)  
hyperparathyroidism, concomitant thyroid nodular disease and, 264P(ab)  
liposome-encapsulated, multidrug resistant human tumor cell lines, 313P(ab)  
MDR1 Pgp-mediated transport of, plasma membrane cholesterol, 317P(ab)  
mediastinal lymph node staging with, non small cell lung cancer, 316P(ab)

- myocardial perfusion imaging, cardiac sequelae of Kawasaki disease, 201P(ab)  
 myocardial SPECT, reproducibility of, with intravenous adenosine, 31P(ab)  
 myocardial uptake, after stress injection, 17P(ab)  
 nasopharyngeal cancer cell lines, 314P(ab)  
 parathyroid scintigraphy, P-glycoprotein effects, 1617  
 post-exercise, lung uptake, new automatic technique, 104P(ab)  
 pulmonary uptake, dipyridamole-based stress or exercise, 339  
 radiochemical purity of, three paper chromatography methods for, 241P(ab)  
 rotational atherectomy, transient regional ischemia during, 402  
 scans, gender-based differences in referral patterns, 155P(ab)  
 scintimammography, breast cancer, planar and SPECT imaging comparison, 849  
 solitary lung tumors, differentiation of malignant from benign, 43P(ab)  
**SPECT**  
 adenosine low-level treadmill, radionuclide angiography and, CAD, 102P(ab)  
 dobutamine stress, prognostic value, 115P(ab)  
 inferior wall defects, prone imaging, 154P(ab)  
 myocardial salvage in acute MI, 139P(ab)  
 prognostic value of quantitative indices, 115P(ab)  
 reduction of transient myocardial ischemia, 157P(ab)  
<sup>99m</sup>Tc tetrofosmin comparison  
 cardiac tomography of CAD, 17P(ab)  
 dipyridamole imaging of CAD, 17P(ab)  
<sup>201</sup>Tl comparative SPECT, prediction of chemotherapy response, small cell lung cancer, 1626  
<sup>201</sup>Tl comparison, CNS lymphoma, 315P(ab)  
 transformation of 10T1/2 cells by, 186P(ab)  
 whole-body scanning, multiple myeloma, 138P(ab)  
**Technetium-99m sulfur colloid**  
 diagnosis of rejection, renal transplant, 199P(ab)  
 versus <sup>111</sup>In leukocyte scintigraphy, Charcot joint, 346  
 lymphoscintigraphic agents, cutaneous melanoma, 1185  
 versus <sup>99m</sup>Tc liposomes, lymphoscintigraphy in rabbit model, 314P(ab)  
 sentinel lymph node identification, early breast cancer, 1388  
**Technetium-99m teboroxime**, SPECT, attenuation and point response correction, 182P(ab)  
**Technetium-99m tetrofosmin**  
 comparison with <sup>99m</sup>Tc MIBI, parathyroid glands, 320  
 detection of metastases, differentiated thyroid cancer, 1897  
 factors affecting sensitivity of scintigraphy, parathyroid, 263P(ab)  
<sup>18</sup>F FDG and, SPECT prediction of myocardial viability, 155P(ab)  
<sup>131</sup>I and, differentiated thyroid cancer, 870  
 myocardial tomography, with adenosine triphosphate, 582  
 myocardial uptake, after stress injection, 17P(ab)  
 parathyroid scintigraphy, 1433  
 scintigraphy  
 P-glycoprotein and lung cancer, 1830(le)  
 pulmonary tuberculosis, 2116  
**SPECT**  
 brain tumor imaging, 313P(ab)  
 comparison with FDG PET, detection of lung cancer, 44P(ab)  
 lung lesions, 1830(le)  
 primary breast cancer detection, 314P(ab)  
 pulmonary nodules, 2016(le)  
 uptake in brain tumors, <sup>201</sup>Tl comparison, 802  
<sup>99m</sup>Tc MIBI comparison, prediction of chemoresistance, 216P(ab)  
<sup>99m</sup>Tc sestamibi comparison  
 cardiac tomography of CAD, 17P(ab)  
 dipyridamole imaging of CAD, 17P(ab)  
<sup>99m</sup>Tc MIBI and <sup>201</sup>Tl uptake, myocardial cells, rat, 266  
<sup>201</sup>Tl dual SPECT, predictions, lung cancer, 191P(ab)  
**Technetium-99m TG**, imaging, tumors and ischemic imaging, 217P(ab)  
**Technetium-99m thrombospindon peptide**, imaging, deep venous thrombosis, 64P(ab)  
**Technetium-99m TRODAT-1**, biodistribution and dosimetry of, imaging of dopamine transporters, 221P(ab), 2069  
**Technetium-99m VIP analogs**  
 receptor imaging agent, development of, 225P(ab)  
 tumor imaging agent, synthesis and evaluation, 226P(ab)  
**Technetium-99m VIP receptor agonist**, tumor imaging, 64P(ab)  
**Technetium-99m WBC**, <sup>99m</sup>Tc MDP and <sup>99m</sup>Tc HIG comparison, musculoskeletal inflammation, 516  
**Testicular cancer**, staging, comparison of FDG PET, CT and tumor markers, 249P(ab)  
**Thallium-201**  
<sup>123</sup>BMP mismatch, preinfarction angina, 1492  
 bone marrow uptake, before and after therapy for multiple myeloma, 473  
 detection of metastases, differentiated thyroid cancer, 1897  
 dipyridamole, electron beam CT and, coronary artery stenosis, 156P(ab)  
 versus <sup>18</sup>F FDG PET, thyroid tumors, 453  
<sup>99m</sup>Tc sestamibi comparative SPECT, predicting chemotherapy response in lung cancer, 1626  
<sup>99m</sup>Tc sestamibi comparison, CNS lymphoma, 315P(ab)  
<sup>99m</sup>Tc tetrofosmin and <sup>99m</sup>Tc MIBI uptake, myocardial cells, rat, 266  
<sup>99m</sup>Tc tetrofosmin SPECT comparison, uptake in brain tumors, 802  
 myocardial gated SPECT, left ventricular function, 927(le)  
 perfusion agents, 180° and 360° acquisition for attenuation compensation, 562  
 practice guidelines, myocardial perfusion imaging, 918  
 prediction of outcome, <sup>131</sup>I therapy of metastatic thyroid cancer, 807  
 regional myocardial activity, left ventricular dysfunction and, CAD patients, 101P(ab)  
 rest-redistribution, functional outcome after revascularization, 60P(ab)  
 rest-redistribution tomography, identification of viable myocardium in coronary artery disease, 1869  
 retention index, focal intracranial lesions, AIDS patients, 1366  
 scintigraphy  
 detection of melanoma metastases, 799  
 tumor response in bone and soft-tissue tumors, 1600  
 severe fixed thallium defect, myocardial infarction patients, 154P(ab)  
**SPECT**  
 comparison with <sup>18</sup>F FDG PET, lung cancer evaluation, 9  
 computation of left ventricular ejection fraction from, 103P(ab)  
 disease activity of pulmonary tuberculosis, 31P(ab)  
 dynamic CT and, pulmonary masses, 45P(ab)  
 FDG comparison, viable myocardium, 1481  
 imaging of CNS lesions in HIV patient, 317P(ab)  
 life-threatening ventricular arrhythmias, 155P(ab)  
 linsidomim and myocardial viability, 156P(ab)  
 prediction of response to radiotherapy, head and neck tumors, 138P(ab)  
 reversible perfusion defects after balloon angioplasty, 59P(ab)  
 site of image-guided biopsy, thoracic tumor, 193P(ab)  
 women, effects on accuracy of Wiener filtering, 46P(ab)  
 subcellular localization and kinetics, myocardium, rat, 242P(ab)  
<sup>99m</sup>Tc perfusion SPECT comparison, during stress and at rest, 88P(ab)  
 tracer kinetics, detection of myocardial viability, 384 uptake correlation with <sup>99m</sup>Tc Q12 uptake, acute coronary reperfusion, 159  
 with negative <sup>131</sup>I scintigraphy, papillary thyroid cancer, 236  
**Thallium-201 chloride**  
 bone uptake, granulocyte colony-stimulating factor-producing lung cancer, 241  
 gated SPECT, post-exercise stunning, abnormal lung heart ratio, 46P(ab)  
**Thallium-technetium subtraction scan**, <sup>99m</sup>Tc tetrofosmin, parathyroid scintigraphy, 1433  
**Thio-D-glucose**, <sup>99m</sup>Tc labeled, tumors and ischemic imaging, 217P(ab)  
**Thoracic duct**, lymphatic leakage, localization of with oral administration of <sup>123</sup>I IPPA, 2141  
**Thrombocytopenia**, cell kinetics model, after radioimmunotherapy, 1223  
**Thrombolytic threshold**, platelet emboli, ischemic sensitivity of organs and, 265P(ab)  
**Thrombosis**, deep venous activated platelet imaging with MP-2026, 30P(ab)  
 DMP 444 diagnostic results, 218P(ab)  
<sup>99m</sup>Tc TP-1300 peptide imaging, 64P(ab)  
**Thymic tumor**, combination methionine PET and FDG PET, 258P(ab)  
**Thymidine**  
<sup>18</sup>F FLT, imaging of cell proliferation, 228P(ab)  
 PET, kinetic analysis, 1043  
**Thymidine kinase**, receptor gene expression, ganciclovir imaging, 2003  
**Thymoma**, <sup>111</sup>In DTPA-D-Phe<sup>1</sup>-octreotide scintigraphy, 634  
**Thyroglobulin**  
 initial whole-body scan and, role in differentiated thyroid cancer metastases, 1542  
 redifferentiation therapy with retinoic acid and, follicular thyroid cancer, 1555  
 serum, negative <sup>131</sup>I scintigraphy and, papillary thyroid cancer, 236  
**Thyroid adenoma**, autonomous, percutaneous ethanol injection treatment of, 1012  
**Thyroid cancer**  
 anaplastic cells, gene therapy, 259P(ab)  
 biologic dosimetry in, after repeated <sup>131</sup>I treatments, 825  
 breast cyst simulating metastases, <sup>131</sup>I imaging, 1910  
 childhood, differentiation, Chernobyl, 20P(ab)  
 differentiated functioning primary metastases, thyrotoxicosis from, 1202  
 glucose metabolism and Ki67 in, 19P(ab)  
 high activity radioiodine therapy, 260P(ab)  
 impact factors on prognosis, 259P(ab)  
 initial whole-body scan and thyroglobulin role in, 1542  
<sup>131</sup>I therapy for, radiotoxicity after, 436  
 metastatic tumors from, small dose radionuclide scintigraphy in, 261P(ab)  
 radiation absorbed doses and biological effects, 189P(ab)  
 recurrent or metastatic, detection by chromatographic analysis, 262P(ab)  
 surgery, scanning doses of <sup>131</sup>I effects, 1546  
<sup>99m</sup>Tc furifosmin PET follow-up, 1536  
 thyroglobulin and low-dose <sup>131</sup>I and <sup>99m</sup>Tc tetrofosmin in, 870  
<sup>201</sup>Tl, <sup>99m</sup>Tc tetrofosmin, and <sup>131</sup>I detection of metastases, 1897

- FDG uptake in, rheumatoid arthritis-associated lung cancer.** 234  
 $^{18}\text{F}$  FDG PET, versus  $^{201}\text{Tl}$ , 453  
 $^{18}\text{F}$  FDG PET scans, patients with negative  $^{131}\text{I}$  scans, 123P(ab)  
follicular, redifferentiation therapy with retinoic acid, 1555  
follicular cancer cell lines, initial characterization of, 262P(ab)  
high-dose radioiodine therapy, side effects, 1551  
high-risk patients, FDG PET evaluation after negative  $^{131}\text{I}$  scans, 19P(ab)  
Hürthle cell, somatostatin receptor expression in, 243  
incidence rates, iodine-deficiency area Unterfranken, 259P(ab)  
innovative strategies, 11N(9)  
 $^{131}\text{I}$  scan negative patients, FDG detection of metastatic sites in, 257P(ab)  
 $^{131}\text{I}$  therapy,  $^{201}\text{Tl}$  scintigraphy in prediction of outcome, 807  
medullary  
  biodistribution and dosimetry study, 1608  
  intraoperative gamma probe detection, 1155  
  preoperative staging,  $^{113}\text{In}$  DTPA and  $^{99m}\text{Tc}$  DMSA, 1907  
  pretargeted radioimmunodetection, 1172  
  suprasensitive calcitonin measurement, 268P(ab)  
  two-step targeting radioimmunotherapy in, 246P(ab)  
nonmedullary, familial, 260P(ab)  
papillary,  $^{201}\text{Tl}$  uptake with negative  $^{131}\text{I}$  scintigraphy, 236  
postoperative patients,  $^{131}\text{I}$  ablation dose for remnant thyroid tissue in, 261P(ab)  
posttherapy localization of large renal cyst,  $^{131}\text{I}$ , 2158  
pulmonary metastases in, children and adolescents, 1531  
radioiodine secretion, tears, 1452  
radioiodine uptake  
  gadolinium MRI contrast effects, 259P(ab)  
  redifferentiation therapy and, 1903  
  during therapy after tracer dosimetry, 188P(ab)  
  recurrent or metastatic,  $^{131}\text{I}$ -negative, FDG PET imaging of, 258P(ab)  
**Thyroid gland**  
  dysfunction, after anti-lymphocyte monoclonal antibody treatment of MS, 263P(ab)  
  fetal, radioiodine treatment of hyperthyroidism in pregnancy, 357, 2194(l)  
  function, after ethanol ablation, 1012  
 $^{131}\text{I}$  sodium iodide uptake, liquid vs capsule, hyperthyroid patients, 20P(ab)  
  malignancy, assessment with  $^{99m}\text{Tc}$  MIBI, 215(l)e  
  Memorial Sloan-Kettering protocol for treatment, worldwide dosimetry by internet, 278P(ab)  
nODULES  
  FNAB-indeterminate, FDG PET in, 123P(ab)  
  Hürthle cell tumor in,  $^{99m}\text{Tc}$  MIBI dual-phase scintigraphy, 822  
  radioiodine treatment outcomes, Graves' hyperthyroidism, 712  
**Thyroid hormone**, sulfated, increased excretion, thyroxine-treated patients, 270P(ab)  
**Thyroid-stimulating hormone**, levels, indication of relapse in thyrotoxicosis, 262P(ab)  
**Thyrotoxicosis**  
  functioning primary metastases, well-differentiated thyroid cancer, 1202  
  relapse, TSH levels as indication of relapse, 262P(ab)  
**Time-of-flight**, positron measuring system, noninvasive measurement of input function, 172P(ab)  
**Tirapazamine**, radioactive copper isotopes and hypoxic cytotoxin, targeted tumor therapy, 677  
**Tissue polypeptide antigen**, monoclonal or polyclonal radioimmunoassay, follow-up for bladder cancer, 269P(ab)  
**TNF-alpha**, see Tumor necrosis factor-alpha
- Toluene abuse**, cerebral perfusion with, 632  
**Tomography**, nonuniformity, quality assurance, 174P(ab)  
**Tonsils**, FDG uptake, PET, 256P(ab)  
**Tourette syndrome**  
  cerebral glucose metabolic rates, PET studies, 202P(ab)  
 $^{99m}\text{Tc}$  HMPAO perfusion patterns, neuroleptic therapy and after withdrawal, 624  
  presynaptic monoaminergic vesicles in,  $^{113}\text{C}$  DTBZ PET study, 202P(ab)  
**Toxoplasmosis**, in AIDS,  $^{201}\text{Tl}$  retention in diagnosis, 1366  
**Tracer kinetic modeling**  
  input function, blind estimation approach, 64P(ab)  
  PET, measuring reporter gene expression, 10P(ab)  
**Tracheal stenosis**, relapsing polychondritis, gallium uptake in, 1977  
**Transferrin receptors**  
  expression,  $^{67}\text{Ga}$  uptake in, 1405  
  transfected cells and tumors,  $^{67}\text{Ga}$  uptake in, 11P(ab)  
**Transient global amnesia**, cerebral perfusion during, HMPAO SPECT findings, 155  
**Transmission computed tomography (TCT)**  
  fan-beam, truncation artifacts in, 178P(ab)  
  gamma camera coincidence imaging system, 92P(ab)  
  scatter correction, accurate quantitation in SPECT, 61P(ab)  
 $^{201}\text{Tl}$  and  $^{153}\text{Gd}$ , lead x-ray compensation method, 177P(ab)  
  vs  $^{99m}\text{Tc}$  DMSA SPECT, renal volume determination, 16P(ab)  
**Transmission scan**  
  misalignment, effects on attenuation-corrected cardiac SPECT, 411  
  nonuniform attenuation correction, three-headed SPECT camera, 1105  
  registration errors, sequential scanning, 365  
**Transmission source**, SPECT, multiple line source array for, 2183  
**Transplantation**  
  bone, allogenic vascularized, 3-phase bone scans and SPECT in follow-up, 114P(ab)  
  bone marrow,  $^{99m}\text{Tc}$  anti-NCA-95 scintigraphy, for malignant osteoporosis, 1033  
  heart  
    apoptosis in, cyclosporine effects, 160P(ab)  
    cardiomyopathy patients, renography before, 2153  
    coronary vasculopathy, PET and intravascular ultrasound, 90P(ab)  
    coronary vasculopathy after, identification of, 153P(ab)  
    detection of allograft rejection by somatostatin receptor imaging, 3P(ab)  
    evaluation for, myocardial viability decision analysis model, 60P(ab)  
    experimental rejection,  $^{99m}\text{Tc}$  AVL investigation of, 8P(ab)  
     $^{67}\text{Ga}$  scintigraphy, children, 57P(ab)  
     $^{123}\text{I}$  MIBG serial SPECT images after, 1862  
    prognosis after myocardial perfusion SPECT, 116P(ab)  
    serial assessment of sympathetic reinnervation after, 161P(ab)  
  kidney  
     $^{123}\text{I}$  OIH and  $^{99m}\text{Tc}$  MAG3 renography in, 15P(ab)  
    postoperative function studies with  $^{99m}\text{Tc}$  MAG3, 15P(ab)  
    survival of malfunctioning graft, 16P(ab)  
     $^{99m}\text{Tc}$  sulfur colloid diagnosis of rejection, 199P(ab)  
    urinary excretion of  $^{99m}\text{Tc}$  MAG3, 1257  
  lung  
    bronchiolitis obliterans syndrome after, V/Q scan for, 192P(ab)  
    ventilation-perfusion mismatch in, 118P(ab)  
stem cell, survival, gated blood-pool imaging with exercise and, 76P(ab)  
**Trauma**, ectopic hematopoietic bone marrow, appendicular skeleton, 1980  
**Tritium**  
  medical isotope production, DOE consideration of FFTF, 21N(1)  
  production, source of medical radionuclides, 20N(4)  
**Truncated projections**, effect, in attenuation-compensated fanbeam cardiac SPECT, 166  
**Tuberculosis**, pulmonary  
 $^{99m}\text{Tc}$  tetrofosmin scintigraphy in, 2116  
 $^{201}\text{Tl}$  SPECT determination of disease activity, 31P(ab)  
**Tumor cell spheroids**, evaluation of metabolic changes after irradiation, 1762  
**Tumor detection**  
  brain, registered camera-based and dedicated PET images, 257P(ab)  
  carcinoma of unknown primary, FDG PET, 256P(ab)  
 $^{62}\text{Cu}$  ATSM for prediction, bioreductive drug activation, 90P(ab)  
 $^{67}\text{Ga}$  uptake, transferrin receptor, 1405  
  melanoma metastases, with  $^{201}\text{Tl}$  scintigraphy, 799  
  small lesions, FBP-reconstructed SPECT, 79P(ab)  
  use of beta probe, limits of, 171P(ab)  
**Tumor imaging**  
  factors effecting, 1036  
 $^{18}\text{F}$  FDG, procedure guidelines, 1302  
 $^{123}\text{I}$  IMT, extracranial tumors, 1737  
**Tumor markers**  
  melanoma, S100 in comparison to FDG, 269P(ab)  
  value as decision criteria, FDG PET scan in colorectal cancer, 135P(ab)  
**Tumor necrosis factor-alpha receptor**,  $^{99m}\text{Tc}$  labeled, arthritis model, 225P(ab)  
**Tumor necrosis treatment**,  $^{131}\text{I}$ -labeled chimeric monoclonal antibodies, radioimmunotherapy of solid tumors, 247P(ab)  
**Tumor proliferation**, imaging, thymidine analogs for, 237P(ab)  
**Tumor staging**  
  head and neck tumors,  $^{99m}\text{Tc}$  MIBI in, 1166  
  malignant melanoma, planar coincidence scintigraphy and PET, 1892  
  metastatic germ cell tumors,  $^{18}\text{F}$  FDG PET, 815  
**Tumor targeting**  
   $^{113}\text{In}$  DTPA-folate for, 1579  
 $^{99m}\text{Tc}$  MAG3 scdsFv, renal clearance of, 76P(ab)  
  two-step, bivalent chelate, RCC tumors, 78P(ab)  
**Tumor therapy**  
   $^{113}\text{In}$  DOTA, 1928  
  targeted, radioactive copper isotopes, hypoxic cytotoxin, and tirapazamine, 677  
**Turner syndrome**, kidney function, growth hormone treatment effects, 198P(ab)  
**beta-Tyrosinase**, with  $^{18}\text{F}$  fluoro-L-dopa, enzymatic synthesis, 230P(ab)

## U

- U. S. Congress**, aid to nuclear medicine, 16N(11)  
**Ultrasonography**  
  comparison with  $^{99m}\text{Tc}$  MIBI and  $^{99m}\text{Tc}$  tetrofosmin, parathyroid glands, 320  
 $^{99m}\text{Tc}$  DMSA, renal cortical scarring and renal length, 1280  
**University of Missouri Research Reactor (MURR)**, 13N(6)  
**Ureter**, ectopic, hypoplastic dysplastic kidney with,  $^{99m}\text{Tc}$  DMSA use in, 113  
**Urinary incontinence**, vaginal ectopic ureter, hypoplastic dysplastic kidney with,  $^{99m}\text{Tc}$  DMSA use in, 113

- Urinary tract infection**  
 first-time symptomatic,  $^{99m}\text{Tc}$  DMSA, children, 28P(ab)  
 $^{99m}\text{Tc}$  DMSA scintigraphy, interpretation variability, children, 1428  
 renal parenchymal changes with, infants,  $^{99m}\text{Tc}$  DMSA SPECT, 197P(ab)
- Uterine cervical cancer.** metastasis from, FDG PET, 2084
- V**
- Varicocele.** clinical and subclinical, gonadal venography and scrotal blood-pool index in diagnosis, 1069
- Vascular graft.** prosthetic, infection,  $^{99m}\text{Tc}$  HMPAO labeled leukocyte scan for, 875
- Vasculitis.** systemic, FDG PET diagnosis, 267P(ab)
- Vasoactive intestinal peptide**  
 $^{123}\text{I}$  receptor imaging  
 location of VIPoma, 1575  
 pancreatic cancer, 1570  
 $^{99m}\text{Tc}$ -labeled, tumor imaging, 64P(ab)
- Vasoactive intestinal peptide receptor**  
 analogs, synthesis, potential tumor imaging agents, 226P(ab)  
 imaging agent,  $^{99m}\text{Tc}$  1666, 225P(ab)
- Vasospasm**  
 acetazolamide SPECT prediction of, after subarachnoid hemorrhage, 149P(ab)  
 cerebral, after subarachnoid hemorrhage, SPECT, 765
- Venography.** gonadal, in varicocele diagnosis, 1069
- Ventilation**  
 improvement in aerosol delivery, standard nebulizer system, 117P(ab)  
 inertial changes in particle size, nebulizer systems, 118P(ab)
- Ventilation/perfusion imaging**  
 bronchiolitis obliterans syndrome, after lung transplant, 192P(ab)  
 with Doppler ultrasound of lower extremities, pulmonary embolism, 6P(ab)
- helical CT or, suspected acute pulmonary embolism, 193P(ab)  
 lung scan category, low probability subgroup, 192P(ab)  
 mismatch, lung transplant patients, 118P(ab)  
 reverse mismatch, lung cancer, 1986  
 screening requests for, 193P(ab)  
 SPECT, diagnosis of pulmonary embolism, 191P(ab)  
 stripe sign, pulmonary SPECT, 721  
 $^{99m}\text{Tc}$  DTPA aerosol usefulness in, 2193(l)  
 vs MRI, lung, 6P(ab)
- Vesicoureteral reflux.** small kidney, radionuclide cystography, children, 197P(ab)
- Vigabatrin effects.** GABAergic system,  $^{123}\text{I}$  iomazenil SPECT, 26P(ab)
- VIP.** see Vasoactive intestinal peptide
- VIPoma.** location,  $^{123}\text{I}$  VIP receptor imaging, 1575
- Viral vector.** in 9L gliosarcoma cells, HSV-1-tk and lacZ gene delivery and coexpression, 236P(ab)
- Volumes of interest.** 2D and volumetric 3D brain SPECT data comparison, resting state, 106P(ab)
- V/Q scan.** see Ventilation/perfusion imaging
- W**
- WADA test.** high-resolution  $^{99m}\text{Tc}$  HMPAO SPECT and angiography, correlation of, 212P(ab)
- Wagner, Henry N., Jr.** SNM 1998 annual meeting, 13N(8)
- Warthin's tumor.**  $^{99m}\text{Tc}$  pertechnetate scintigraphy with lemon juice, accuracy of, 43
- Wavelet transform.** ligand-receptor model, parametric imaging of, 65P(ab)
- World Federation of Nuclear Medicine and Biology (WFNMB).** lines from the president, 37N(2)
- World Wide Web**  
 multi-media procedure manual, 278P(ab)  
 nuclear medicine resident's cybermentor, web-based resource, 277P(ab)
- X**
- Xenon-133.** pulmonary SPECT, obstructive lung disease patients, 889
- Xenon clearance method.** muscle microcirculation, symptomatic Persian Gulf war veterans, 114P(ab)
- Y**
- Young Investigators Symposium.** Computer and Instrumentation Council, SNM, 10N(9)
- Yttrium.** CHX-DTPA-conjugated monoclonal antibodies labeled with, biodistribution, 829
- Yttrium-86**  
 improved separations in production, for PET, 232P(ab)  
 PET, distribution of  $^{90}\text{Y}$ -labeled pharmaceuticals, 174P(ab)
- Yttrium-90**  
 biotin-chelates, for pretargeting, 1813  
 CDR-grafted monoclonal antibody labeled with, radioimmunotherapy of non-Hodgkin's lymphoma, 105P(ab)  
 human monoclonal IgM labeled with, targeting of ovarian cancer, mice, 476  
 immunoconjugates, prevention of radiolysis, 243P(ab) incorporated, bone marrow, biological dosimetry for, 547
- Yttrium-90 DOTA.** immunoconjugates, chelation of, 2105
- Yttrium-90 DOTA-Biotin.** antibody streptavidin and, pretargeted radioimmunotherapy, 71P(ab)
- Yttrium-90 DOTA-lanreotide.** treatment, metastatic gastrinoma, 2090
- Yttrium-90 DOTA-peptide-chimeric L6.** efficacy, p53 mutant human breast cancer xenografts, 842
- Yttrium-90-DOTATOC.** treatment, somatostatin receptor positive tumors, 70P(ab)
- Yttrium-90 Lym-1.** antibody preparations, radiolysis effects on, 667
- Z**
- Zenker's diverticulum-esophagostomy.** transoral, radionuclide assessment before and after, 58P(ab)

# JNM

## DIRECT RESPONSE

Advertisers for December 1998

Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 20190, Fax: 703-708-9018. We will forward this information to the advertiser(s).

Reader Svc.No.	Advertiser	Telephone No.	Page(s)
1	ADAC Laboratories	800/538-8531	42A and Inside Back Cover
23	Capintec, Inc.	201/825-9500	2A
34	DuPont Pharma	800/343-7851	6A-8A
62	GE Medical Systems	414/544-3435	Back Cover
135	Nycomed Amersham	609/514-6472	17A-20A
181	Siemens Medical Systems	847/304-7700	Inside Front Cover and 1A

SNM Meetings

SNM Membership Information

SNM Book Order Information

YOUR NAME: \_\_\_\_\_ TITLE: \_\_\_\_\_

INSTITUTION: \_\_\_\_\_ DEPT: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

CITY: \_\_\_\_\_ STATE: \_\_\_\_\_ ZIP: \_\_\_\_\_

PHONE: \_\_\_\_\_ FAX: \_\_\_\_\_

PRIMARY SPECIALTY: \_\_\_\_\_ SECONDARY SPECIALTY: \_\_\_\_\_

### CHECK ONE ANSWER IN EACH CATEGORY

#### Employer

- Hospital
- 500 patients plus
- 300-499 patients
- 200-299 patients
- 100-199 patients

#### Employer

- Private Clinic
- R&D Commercial
- University
- Government
- Other \_\_\_\_\_

#### Purchase Authority

- Recommend
- Specify
- Purchase

#### Reason for Inquiry

- Immediate Purchase
- General Information
- Budgeting Information

#### SNM Member

- Yes
- No

#### JNM/JNMT Subscriber

- Yes
- No